<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004861" GROUP_ID="FERTILREG" ID="683699121619134496" MERGED_FROM="" MODIFIED="2011-03-25 11:40:51 +0100" MODIFIED_BY="Anja Helmerhorst" NOTES="&lt;p&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Short title (no longer in use): Acceptability of OCs with different progestins&lt;br&gt;24-09-2003: title changed from: Progestogens in combined oral contraceptives: effectiveness and acceptability to: Effectiveness and acceptability of progestagens in oral contraceptives for contraception&lt;br&gt;14-05-2004: title was changed according to the Cochrane Rules: Progestogens in combined oral contraceptives for contraception&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2011-03-25 11:13:11 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="0013" REVMAN_SUB_VERSION="5.1.0" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2011-03-24 12:42:59 +0100" MODIFIED_BY="Anja Helmerhorst">
<TITLE MODIFIED="2011-03-07 11:35:37 +0100" MODIFIED_BY="[Empty name]">Types of progestogens in combined oral contraception: effectiveness and side-effects</TITLE>
<CONTACT>
<PERSON ID="16495233707895187386090810093217" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Theresa</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Lawrie</LAST_NAME>
<SUFFIX>MBBCH, PhD</SUFFIX>
<POSITION>Researcher</POSITION>
<EMAIL_1>tess@lawrie.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+447826939464</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Effective Care Research Unit</DEPARTMENT>
<ORGANISATION>University of the Witwatersrand/University of Fort Hare/East London Hospital Complex</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>East London</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<PHONE_1>+00 44 1225 428021</PHONE_1>
<PHONE_2>+00 44 7826 939464</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2011-03-24 12:42:59 +0100" MODIFIED_BY="Anja Helmerhorst">
<PERSON ID="16495233707895187386090810093217" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Theresa</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Lawrie</LAST_NAME>
<SUFFIX>MBBCH, PhD</SUFFIX>
<POSITION>Researcher</POSITION>
<EMAIL_1>tess@lawrie.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+447826939464</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Effective Care Research Unit</DEPARTMENT>
<ORGANISATION>University of the Witwatersrand/University of Fort Hare/East London Hospital Complex</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>East London</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<PHONE_1>+00 44 1225 428021</PHONE_1>
<PHONE_2>+00 44 7826 939464</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5555" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Frans</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Helmerhorst</LAST_NAME>
<SUFFIX/>
<POSITION>Co-ordinating Editor, Cochrane Fertility Regulation Group</POSITION>
<EMAIL_1>f.m.helmerhorst@lumc.nl</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Gynaecology, Division of Reproductive Medicine and Dept. of Clinical Epidemiology</DEPARTMENT>
<ORGANISATION>Leiden University Medical Center</ORGANISATION>
<ADDRESS_1>PO Box 9600</ADDRESS_1>
<ADDRESS_2>Albinusdreef 2</ADDRESS_2>
<CITY>Leiden</CITY>
<ZIP>NL 2300 RC</ZIP>
<REGION/>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<PHONE_1>+31 71 5262871</PHONE_1>
<PHONE_2>+31 654661933</PHONE_2>
<FAX_1>+31 71 5248181</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13645" ROLE="AUTHOR">
<PREFIX>Dr.</PREFIX>
<FIRST_NAME>Nandita</FIRST_NAME>
<MIDDLE_INITIALS>K.</MIDDLE_INITIALS>
<LAST_NAME>Maitra</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>maitra_n@sify.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of OBGYN</DEPARTMENT>
<ORGANISATION>Medical College Baroda</ORGANISATION>
<ADDRESS_1>Race Coarse Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Baroda 390007</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="IN">India</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5770" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Regina</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Kulier</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>kulierr@who.int</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>World Health Organization</ORGANISATION>
<ADDRESS_1>Avenue Via Appia 20</ADDRESS_1>
<ADDRESS_2/>
<CITY>Geneva</CITY>
<ZIP>CH-1202</ZIP>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+ 41 22 7912744</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="18238" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Kitty</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Bloemenkamp</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>k.w.m.bloemenkamp@lumc.nl</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Obstetrics</DEPARTMENT>
<ORGANISATION>Leiden University Medical Center</ORGANISATION>
<ADDRESS_1>PO Box 9600</ADDRESS_1>
<ADDRESS_2/>
<CITY>Leiden</CITY>
<ZIP>2300 RC</ZIP>
<REGION/>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<PHONE_1>+31 71 526 3360</PHONE_1>
<PHONE_2/>
<FAX_1>+31 71 526 6741</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="15905" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>A Metin</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Gülmezoglu</LAST_NAME>
<SUFFIX/>
<POSITION>Scientist</POSITION>
<EMAIL_1>gulmezoglum@who.int</EMAIL_1>
<EMAIL_2/>
<URL>http://www.who.int/reproductive-health/rhl/index.html</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Department of Reproductive Health and Research</DEPARTMENT>
<ORGANISATION>World Health Organization</ORGANISATION>
<ADDRESS_1>20 Avenue Appia</ADDRESS_1>
<ADDRESS_2/>
<CITY>Geneva</CITY>
<ZIP>1211</ZIP>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+41 22 7913417</PHONE_1>
<PHONE_2/>
<FAX_1>+41 22 7914171</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2011-03-22 12:08:28 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="7" MONTH="3" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="28" MONTH="9" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="3" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2004"/>
</DATES>
<WHATS_NEW MODIFIED="2011-03-07 21:30:30 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2011-03-07 21:30:30 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="3" YEAR="2011"/>
<DESCRIPTION>
<P>Eight new trials included (<LINK REF="STD-Anttila-2009-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Anttila 2009 (DRSP-DSG)</LINK>, <LINK REF="STD-Gruber-2006-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Gruber 2006 (DRSP-DSG)</LINK>, <LINK REF="STD-Guang_x002d_Sheng2010_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Guang-Sheng2010(DRSP-DSG)</LINK>, <LINK REF="STD-Kelly-2010-_x0028_DRSP_x002d_LNG_x0029_" TYPE="STUDY">Kelly 2010 (DRSP-LNG)</LINK>, <LINK REF="STD-Kriplani-2010-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Kriplani 2010 (DRSP-DSG)</LINK>,<LINK REF="STD-Sangwathan-2005_x0028_DRSP_x002d_LNG_x0029_" TYPE="STUDY">Sangwathan 2005(DRSP-LNG)</LINK>, <LINK REF="STD-Suthipongse2004_x0028_DRSP_x002d_LNG_x0029_" TYPE="STUDY">Suthipongse2004(DRSP-LNG)</LINK>, <LINK REF="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_" TYPE="STUDY">Winkler 2004 (DSG-LNG)</LINK>), 17 excluded. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-11-02 10:48:16 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-11-02 10:48:16 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="28" MONTH="9" YEAR="2010"/>
<DESCRIPTION>
<P>New search identified 25 new trials for classification.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-10-01 12:13:15 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="14" MONTH="4" YEAR="2004"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>HRP - UNDP/UNFPA/WHO/World Bank Special Programme in Human Reproduction, Geneva</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-03-25 11:08:12 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2011-03-07 10:04:27 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2011-03-07 10:04:27 +0100" MODIFIED_BY="[Empty name]">Differences in effectiveness and adverse effects between different types of progestogens combined with ethinyl oestradiol (combined contraceptive pill)</TITLE>
<SUMMARY_BODY MODIFIED="2011-03-04 11:19:21 +0100" MODIFIED_BY="[Empty name]">
<P>Combined oral contraceptives (COC) have an oestrogen and a progestogen component. The type of progestogen and/or amount of oestrogen or progestogen can vary per pack of oral contraceptive pills. The objective of this review was to compare currently available low-dose COCs containing different progestogens in terms of pregnancy prevention, bleeding pattern, side effects and discontinuation rates.</P>
<P>Thirty trials were included in this review. All the pills studied were comparable with regard to preventing pregnancy. Women using levonorgestrel-containing pills were less likely to stop taking them than women using norethisterone-containing pills. Women using a gestodene-containing pill experienced less bleeding between periods than women using a levonorgestrel-containing pill but this needs further investigation. There is insufficient good quality evidence to draw any other conclusions.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-03-07 21:56:11 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2011-02-28 13:01:18 +0100" MODIFIED_BY="[Empty name]">
<P>The progestogen component of combined oral contraceptives (COC) has undergone changes since it was first recognised that it's chemical structure could influence the spectrum of minor adverse and beneficial effects. The major determinants of effectiveness are compliance and continuation which may be influenced by cycle control and common side effects. The rationale of this review is to provide a systematic comparison of COCs containing the progestogens currently in use worldwide.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2011-01-05 10:37:33 +0100" MODIFIED_BY="[Empty name]">
<P>To compare currently available low-dose COCs containing ethinyl estradiol and different progestogens in terms of contraceptive effectiveness, cycle control, side effects and continuation rates.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-03-04 11:09:22 +0100" MODIFIED_BY="[Empty name]">
<P>A search of PubMed, LILACS, EMBASE, Popline, CINAHL and the Cochrane Central Register of Controlled Trials databases was conducted in September 2010 to update the 2004 review.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-03-07 21:31:09 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised trials reporting clinical outcomes were considered for inclusion. We excluded studies comparing monophasic with multiphasic pills, crossover trials, trials in which the difference in total content of ethinyl estradiol between preparations exceeded 105 µg per cycle and those comparing continuous dosing regimens.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-03-04 11:10:49 +0100" MODIFIED_BY="[Empty name]">
<P>Two reviewers independently assessed methodological quality, applied inclusion criteria and extracted data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-03-07 21:56:11 +0100" MODIFIED_BY="[Empty name]">
<P>Thirty trials with a total of 13,923 participants were included, generating 16 comparisons. Overall the quality of trials was low. Only four trials were double-blind. At least twenty-three trials were sponsored by pharmaceutical companies. There was less discontinuation with second-generation compared with first-generation monophasic progestogens (3 trials, 2,709 women, Relative Risk (RR) 0.76, 95% Confidence Interval (CI) 0.67-0.86); this remained significant when only double-blind trials were considered (812 women, RR 0.79, 95% CI 0.66-0.94).</P>
<P>Women using monophasic COC's containing third-generation progestogens were less likely to discontinue than the second-generation group (3 trials, 1,815 women, RR 0.77, 95% CI 0.60-0.98) but this was not significant when only double-blind trials were considered (RR 0.79, 95% CI 0.50-1.26]. Women in the third-generation group experienced less intermenstrual bleeding than the second-generation group (one double-blind trial, 456 women, RR 0.71, 95% CI 0.55-0.91).</P>
<P>Compared to desogestrel (DSG), women in the drospirenone (DRSP) group were more likely to complain of breast tenderness (5 trials, 4,258 women, RR 1.39, 95% CI 1.04-1.86) and nausea (6 trials, 4,701 women, RR 1.46, 95% CI 0.96-2.21].</P>
<P>Pregnancy rates overall were comparable but the trials had insufficient power to find potentially important differences.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2011-03-07 10:04:19 +0100" MODIFIED_BY="[Empty name]">
<P>Women using COCs containing second-generation progestogens may be less likely to discontinue than those using COCs containing first-generation progestogens. Based on one small double-blind trial, third-generation progestogens may be preferable to second-generation preparations with regard to bleeding patterns but further evidence is needed. Without blinding as to treatment group, comparisons between the various "generations" of progestogens used in COCs cannot be made. Until this widespread methodological flaw is overcome in better trials conducted according to CONSORT guidelines and internationally accepted definitions, no further conclusions can be drawn.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-03-25 11:08:12 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2011-03-25 11:08:12 +0100" MODIFIED_BY="[Empty name]">
<INTERVENTION MODIFIED="2011-03-25 11:08:12 +0100" MODIFIED_BY="[Empty name]">
<P>Combined oral contraceptives (COCs) work by inhibiting ovulation and were first introduced for clinical use in the 1960s. The dose of oestrogen has been gradually reduced to 30 µg or less in order to decrease side effects and increase acceptability. It was thought that a similar goal could be reached by changing the biochemical structure rather than dosage of the progestogen component in the COC: all contraceptive progestogens have a similar 4-ring steroid skeleton and can be classified according to the time of introduction (first, second, third generation and other). Henzl classified progestogens according to three tetracyclic structures (<LINK REF="REF-Henzl-2000" TYPE="REFERENCE">Henzl 2000</LINK>): estranes (derivatives of testosterone), pregnanes (derived from the progesterone molecule), and gonanes; however a more recent spironolactone-derivative, drospirenone (DRSP), does not fall into Henzl's classification. Estranes correspond to first-generation progestogens, such as norethisterone (NE), norethindrone (NE), ethynodiol diacetate, lynestrenol (LYN) and norethynodrel as well as dienogest (DNG). Gonane progestogens correspond to second-generation e.g. levonorgestrel (LNG) and norgestrel (NG) and third-generation progestogens e.g. desogestrel (DSG), gestodene (GSD) and norgestimate (NGM). Examples of pregnanes in COCs are cyproterone acetate, chlormadinone acetate and nomegestrol (see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>Although norethynodrel was the progestogen component used in the very first COC, norethisterone (as it is known in Europe) or norethindrone (NE) can be considered the most important substance used during the early period of oral contraception. After the synthesis of norgestrel (NG) in 1963 by Hershel Smith (<LINK REF="REF-Smith-1963" TYPE="REFERENCE">Smith 1963</LINK>), the biologically active component levonorgestrel (LNG) was isolated (<LINK REF="REF-Lachnit_x002d_Fixon-1991" TYPE="REFERENCE">Lachnit-Fixon 1991</LINK>). These second-generation progestogens were introduced into the market in the 1970s. During the 1980s, three new third-generation progestogens (DSG, GSD and NGM) were developed by three different pharmaceutical companies. DSG and NGM are both pro-drugs: DSG is activated in the body by conversion into 3-keto-DSG, whereas NGM is converted by biotransformation into several metabolites, one of which is LNG. DRSP is a progestogen derived from 17-a spironolactone and possesses anti-mineralocorticoid and mild anti-androgenic activity (<LINK REF="REF-Krattenmacher-2000" TYPE="REFERENCE">Krattenmacher 2000</LINK>).</P>
<P>The lowest expected contraceptive failure rate with COCs is thought to be around 0.1% with perfect use (theoretical effectiveness) and the higher failure rates observed in typical users are considered to be largely attributed to problems with compliance (<LINK REF="REF-Hillard-1992" TYPE="REFERENCE">Hillard 1992</LINK>). In a recent report of a large U.S. cohort of COC users including 1,634 unintended pregnancies, the lowest pregnancy rate at one year was 2.1% and at three years was 3.5%; 86% of unintended pregnancies were attributed to non-compliance (<LINK REF="REF-Dinger-2011" TYPE="REFERENCE">Dinger 2011</LINK>).</P>
<P>Diminishing compliance due to poor cycle control will affect the method's effectiveness. Cycle control has often been attributed to the oestradiol component of a COC (<LINK REF="STD-GSD-Group-1999-_x0028_GSD_x002d_DSG_x0029_" TYPE="STUDY">GSD Group 1999 (GSD-DSG)</LINK>). Since progestogen steroids differ in their oestrogenic, progestogenic and androgenic properties (<LINK REF="REF-Speroff-2005" TYPE="REFERENCE">Speroff 2005</LINK>), variation in the oestrogenic potential of progestogens may explain some clinical phenomena such as spotting and breakthrough bleeding. In a well-conducted study of two continuous regimens, the occurrence of spotting seemed to depend more on the type of progestogen than the dose of oestradiol used (<LINK REF="STD-Edelman-2006" TYPE="STUDY">Edelman 2006</LINK>).</P>
<P>The common side-effects attributed to COC use are breast tenderness, headache, migraine, nausea, nervousness, vomiting, dizziness, weight gain, acne, tiredness, decline of libido and an increase in blood pressure. These non-specific effects may be no more common in COC users than placebo users (<LINK REF="REF-Grimes-2011" TYPE="REFERENCE">Grimes 2011</LINK>), may decrease after few months use (<LINK REF="REF-ACOG-1995" TYPE="REFERENCE">ACOG 1995</LINK>) and are difficult to attribute to either the oestrogen or progestogen component.</P>
<P>The effect of COCs on weight gain, acne and premenstrual syndrome have been reviewed separately (<LINK REF="REF-Gallo-2008" TYPE="REFERENCE">Gallo 2008</LINK>, <LINK REF="REF-Arowojolu-2009" TYPE="REFERENCE">Arowojolu 2009</LINK>, <LINK REF="REF-Lopez-2009" TYPE="REFERENCE">Lopez 2009</LINK>). The relationship between acute myocardial infarction, stroke and venous thromboembolism with COC use has been studied extensively, generating considerable controversy. However, because comparisons of rare long-term adverse events are not amenable to studies using randomised controlled trials, such events are not the focus of this review and will not be discussed further here.</P>
<P>In this review we adhere to the widely used categorisation of the progestogens according to their introduction sequence: first generation (NE, LYN), second generation (LNG, NG), third generation (DSG, GSD, NGM) and others (e.g. CPA, DRSP). We consider traditional (cyclical) regimens of oral contraception use only. Continuous dosing regimens and comparisons between monophasic and multiphasic regimens are the subjects of separate reviews (<LINK REF="REF-Van-Vliet-2006a" TYPE="REFERENCE">Van Vliet 2006a</LINK>, <LINK REF="REF-Van-Vliet-2006b" TYPE="REFERENCE">Van Vliet 2006b</LINK>, <LINK REF="REF-Edelman-2010" TYPE="REFERENCE">Edelman 2010</LINK>).</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2011-03-03 12:43:12 +0100" MODIFIED_BY="[Empty name]">
<P>It is not clear how the relative contraceptive effectiveness, discontinuation rates and side-effects profiles of the various progestogen-containing COCs compare.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2011-03-03 15:58:13 +0100" MODIFIED_BY="[Empty name]">
<P>The objective of this review is to compare the various low-dose progestogen-containing COCs and to assess their acceptability according to the following indicators:</P>
<OL>
<LI>Effectiveness</LI>
<LI>Discontinuation rates and reasons for discontinuation</LI>
<LI>Cycle control</LI>
<LI>Side-effects</LI>
</OL>
</OBJECTIVES>
<METHODS MODIFIED="2011-03-07 21:32:58 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2011-03-07 21:32:19 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2011-03-07 10:06:50 +0100" MODIFIED_BY="[Empty name]">
<P>All randomised clinical trials comparing low-dose oestrogen (&lt; 50 µg) combined oral contraceptive compounds were considered eligible.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2011-03-01 11:31:16 +0100" MODIFIED_BY="[Empty name]">
<P>Participants were women of reproductive age irrespective of the duration of past OC use, or of being new starters or switchers seeking contraception. Trials enrolling volunteers for biochemical change assessments or women who were prescribed COCs for non-contraceptive purposes (such as acne vulgaris) were not eligible.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2011-03-07 21:32:19 +0100" MODIFIED_BY="[Empty name]">
<P>We categorised the progestogens according to their introduction sequence. Only comparisons between the same phasic dosages were eligible. Trials comparing monophasic with multiphasic COCs were not eligible even if the progestogens fell within the scope of this review. In addition, trials were not eligible if the difference in ethinyl oestradiol content between interventions was greater than 5 &#956;g per day i.e. more than 105 &#956;g per cycle.</P>
<P>Interventions had to be applied for a minimum of 6 months for a trial to be considered for inclusion.</P>
<P>Interventions were grouped as follows:</P>
<OL>
<LI>Any monophasic low-dose oestrogen COC containing a second-generation progestogen versus any monophasic low-dose oestrogen COC containing a first-generation progestogen;</LI>
<LI>Any multiphasic low-dose oestrogen COC containing a second-generation progestogen versus any multiphasic low-dose oestrogen COC containing a first-generation progestogen;</LI>
<LI>Any monophasic low-dose oestrogen COC containing a third-generation progestogen versus any monophasic low-dose oestrogen COC containing a first-generation progestogen;</LI>
<LI>Any multiphasic low-dose oestrogen COC containing a third-generation progestogen versus any multiphasic low-dose oestrogen COC containing a first-generation progestogen;</LI>
<LI>Any monophasic low-dose oestrogen (&lt;50 µg) COC containing a third-generation progestogen versus any monophasic low-dose oestrogen COC containing a second-generation progestogen;</LI>
<LI>Any multiphasic low-dose oestrogen (&lt;50 µg) COC containing a third-generation progestogen versus any multiphasic low-dose oestrogen COC containing a second-generation progestogen;and</LI>
<LI>Comparisons between low-dose oestrogen OCs containing a certain type of progestogen.</LI>
</OL>
<P>Continuous dosing interventions are the subject of a separate review (<LINK REF="REF-Edelman-2010" TYPE="REFERENCE">Edelman 2010</LINK>).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-03-04 11:51:56 +0100" MODIFIED_BY="[Empty name]">
<P>To be eligible, trials had to report clinical outcomes. Trials focusing only on biochemical changes were not eligible for this review. For contraceptive effectiveness (incidence of pregnancy) we used authors' definitions and did not differentiate between method and user failure.</P>
<P>1. Contraceptive effectiveness</P>
<UL>
<LI>Pregnancy rate at 6 months and 1 year</LI>
</UL>
<P>2. Discontinuation rates and reasons for discontinuation</P>
<UL>
<LI>Discontinuation rate at 6 months and 1 year</LI>
<LI>Discontinuation rate due to side effects</LI>
<LI>Discontinuation rate due to cycle disturbances</LI>
</UL>
<P>3. Cycle control</P>
<UL>
<LI>Incidence of spotting or breakthrough bleeding (as defined by the authors) within 6 months and 1 year</LI>
<LI>Incidence of amenorrhoea (lack of withdrawal bleeding) within 6 months and 1 year</LI>
</UL>
<P>4. Side effects (reported during the course of the study but not necessarily causing discontinuation)</P>
<UL>
<LI>Breast tenderness</LI>
<LI>Headache</LI>
<LI>Migraine</LI>
<LI>Nausea/vomiting</LI>
<LI>Nervousness</LI>
<LI>Dizziness</LI>
<LI>Varicose veins</LI>
<LI>Chloasma</LI>
<LI>Oedema</LI>
<LI>Other</LI>
</UL>
<P>5. Women's satisfaction with the method (as defined by authors)</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-03-04 11:52:29 +0100" MODIFIED_BY="[Empty name]">
<P>For the methods used when assessing the trials identified in the previous version of this review,<I> see</I> <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. For this update, the Fertility Review Group's Trial Search Co-ordinator conducted electronic searches of the following databases in September 2010: PubMed, LILACS, EMBASE, Popline, CINAHL and the Cochrane Central Register of Controlled Trials (CENTRAL, <I>The Cochrane Library, 2010).</I> No language restrictions were applied. Reference lists of identified trials were searched.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-03-07 21:32:58 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2011-03-04 11:53:26 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors (TL and FH) independently assessed for inclusion all the potential studies identified as a result of the search strategy conducted for the update. We resolved any disagreement through discussion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2011-03-04 11:53:31 +0100" MODIFIED_BY="[Empty name]">
<P>We designed a new form to extract data. For eligible studies, FH and TL extracted the data using the agreed form. We resolved discrepancies through discussion. We entered data into Review Manager software (<LINK REF="REF-Revman-2008" TYPE="REFERENCE">Revman 2008</LINK>) and checked for accuracy. Where Information provided was unclear, we contacted authors of the original reports to provide further details.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2011-03-04 11:54:41 +0100" MODIFIED_BY="[Empty name]">
<P>FH and TL independently assessed the risk of bias for eligible studies using the criteria outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). We resolved any disagreement by discussion.</P>
<P>
<B>(1) Sequence generation (checking for possible selection bias)</B>
</P>
<P>We described for each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups.</P>
<P>We assessed the method as:</P>
<UL>
<LI>adequate (any truly random process, e.g. random number table; computer random number generator),</LI>
<LI>inadequate (any non-random process, e.g. odd or even date of birth; hospital or clinic record number) or,</LI>
<LI>unclear.   </LI>
</UL>
<P>
<B> (2) Allocation concealment (checking for possible selection bias)</B>
</P>
<P>We described for each included study the method used to conceal the allocation sequence and determined whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>adequate (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);</LI>
<LI>inadequate (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth);</LI>
<LI>unclear.   </LI>
</UL>
<P>
<B>(3) Blinding (checking for possible performance bias)</B>
</P>
<P>We described for each included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We considered that studies were at low risk of bias if they were blinded, or if we judged that the lack of blinding could not have affected the results.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>adequate, inadequate or unclear for participants;</LI>
<LI>adequate, inadequate or unclear for personnel;</LI>
<LI>adequate, inadequate or unclear for outcome assessors.</LI>
</UL>
<P>
<B>(4) Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol deviations)</B>
</P>
<P>We described for each included study, and for each outcome or class of outcomes, the completeness of data including attrition and exclusions from the analysis. We stated whether attrition and exclusions were reported, the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. We assessed methods as:</P>
<UL>
<LI>adequate;</LI>
<LI>inadequate;</LI>
<LI>unclear.</LI>
</UL>
<P>
<B>(5) Selective reporting bias</B>
</P>
<P>We described for each included study how we investigated the possibility of selective outcome reporting bias and what we found. We assessed the methods as:</P>
<UL>
<LI>adequate (where it is clear that all of the study&#8217;s pre-specified outcomes and all expected outcomes of interest to the review have been reported);</LI>
<LI>inadequate (where not all the study&#8217;s pre-specified outcomes have been reported; one or more reported primary outcomes were not pre-specified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported);</LI>
<LI>unclear.</LI>
</UL>
<P>
<B>(6) Other sources of bias</B>
</P>
<P>We described for each included study any important concerns we had about other possible sources of bias e.g. funding and conflict of interests, and assessed whether each study was free of other problems that could put it at risk of bias as follows:</P>
<UL>
<LI>yes;</LI>
<LI>no;</LI>
<LI>unclear.</LI>
</UL>
<P>
<B>(7) Overall risk of bias </B>
</P>
<P>We made explicit judgements about whether studies were at high risk of bias, according to the criteria given in the Handbook (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). With reference to (1) to (6) above, we assessed the likely magnitude and direction of the bias and whether we considered it likely to impact on the findings.  We explored the impact of the level of bias through undertaking sensitivity analyses - <I>see </I>
<LINK TAG="SENSITIVITY_ANALYSIS" TYPE="SECTION">Sensitivity analysis</LINK>. </P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2010-11-02 11:08:19 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Dichotomous data</B>
</P>
<P>For dichotomous data, we present results as the summary risk ratio with 95% confidence intervals.<I> </I>
</P>
<P>
<B>Continuous data</B>
</P>
<P>There was no continuous data included in this review.</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2010-10-29 11:11:58 +0200" MODIFIED_BY="[Empty name]">
<P>For included studies, we noted levels of attrition. We explored the impact of including studies with high levels of missing data in the overall assessment of treatment effect by using sensitivity analysis. Data from trials or outcomes with &gt;20% missing data were excluded from analysis.</P>
<P>For all outcomes, we carried out analyses, as far as possible, on an intention-to-treat basis, i.e. we attempted to include all participants randomised to each group in the analyses, and all participants were analysed in the group to which they were allocated, regardless of whether or not they received the allocated intervention. The denominator for each outcome in each trial was the number randomised minus any participants whose outcomes are known to be missing.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2011-03-04 11:56:06 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed statistical heterogeneity in each meta-analysis using the T², I² and Chi² statistics. We regarded heterogeneity as substantial if T² was greater than zero and either I² was greater than 30% or there was a low P value (&lt; 0.10) in the Chi² test for heterogeneity.<B> </B>
</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2011-03-04 11:56:54 +0100" MODIFIED_BY="[Empty name]">
<P>If there had been 10 or more studies in the meta-analysis we would have investigated reporting biases (such as publication bias) using funnel plots, however the maximum number of studies in any meta-analysis in this review was seven.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2010-10-29 11:20:57 +0200" MODIFIED_BY="[Empty name]">
<P>We carried out statistical analysis using the Review Manager software (RevMan 2008). We used fixed-effect meta-analysis for combining data where it was reasonable to assume that studies were estimating the same underlying treatment effect: i.e. where trials were examining the same intervention, and the trials&#8217; populations and methods were judged sufficiently similar. If there was clinical heterogeneity sufficient to expect that the underlying treatment effects differed between trials, or if substantial statistical heterogeneity was detected, we used random-effects meta-analysis to produce an overall summary if an average treatment effect across trials was considered clinically meaningful. If the average treatment effect was not clinically meaningful we did not combine trials.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2010-10-29 11:25:34 +0200" MODIFIED_BY="[Empty name]">
<P>If we identified substantial heterogeneity, we investigated it using subgroup analyses and sensitivity analyses. We considered whether an overall summary was meaningful used random-effects analysis to produce it. We carried out the following subgroup analyses:</P>
<P>1.      Monophasic pills</P>
<P>2.      Multiphasic pills</P>
<P>The following outcomes were used in subgroup analysis: pregnancy rates, discontinuation rates and side-effects.</P>
<P>For fixed-effect inverse variance meta-analyses we assessed differences between subgroups by interaction tests. For random-effects and fixed-effects meta-analyses using methods other than inverse variance, we assessed differences between subgroups by inspection of the subgroups&#8217; confidence intervals; non-overlapping confidence intervals indicated a statistically significant difference in treatment effect between the subgroups.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2011-03-07 21:32:58 +0100" MODIFIED_BY="[Empty name]">
<P>Sensitivity analyses was performed for aspects of the review that might affect the results, for example, where there was a risk of bias associated with the quality/sponsorship of some of the included trials. Specifically, we performed sensitivity analyses with respect to double-blinding as it is likely that the lack of blinding can greatly influence the results of contraceptive drug trials.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-03-25 11:08:12 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2011-03-04 12:20:11 +0100" MODIFIED_BY="[Empty name]">
<P>Twenty-five studies were identified by the updated search (September 2010), of which 17 were excluded and 8 (<LINK REF="STD-Anttila-2009-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Anttila 2009 (DRSP-DSG)</LINK>, <LINK REF="STD-Gruber-2006-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Gruber 2006 (DRSP-DSG)</LINK>, <LINK REF="STD-Guang_x002d_Sheng2010_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Guang-Sheng2010(DRSP-DSG)</LINK>, <LINK REF="STD-Kelly-2010-_x0028_DRSP_x002d_LNG_x0029_" TYPE="STUDY">Kelly 2010 (DRSP-LNG)</LINK>, <LINK REF="STD-Kriplani-2010-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Kriplani 2010 (DRSP-DSG)</LINK>, <LINK REF="STD-Sangwathan-2005_x0028_DRSP_x002d_LNG_x0029_" TYPE="STUDY">Sangwathan 2005(DRSP-LNG)</LINK>, <LINK REF="STD-Suthipongse2004_x0028_DRSP_x002d_LNG_x0029_" TYPE="STUDY">Suthipongse2004(DRSP-LNG)</LINK>, <LINK REF="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_" TYPE="STUDY">Winkler 2004 (DSG-LNG)</LINK>) were included. Thus, the total number of included studies in this review is thirty. Seven out of the eight new included studies compared DRSP with LNG or DSG; the other study compared monophasic DSG with LNG.</P>
<P>Overall, 15 trials were conducted in Europe, six in the United States and Canada, two in Latin America, and seven in Asia. The participants were usually described as women seeking contraception and those with contraindications to COC use were excluded. <LINK REF="STD-Kriplani-2010-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Kriplani 2010 (DRSP-DSG)</LINK> participants were women with Polycystic Ovarian Syndrome seeking contraception. Most studies included starters and switchers; four studies mention washout periods of one cycle (<LINK REF="STD-Huber-2000-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Huber 2000 (DRSP-DSG)</LINK>, <LINK REF="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_" TYPE="STUDY">Winkler 2004 (DSG-LNG)</LINK>) and three cycles (<LINK REF="STD-Guang_x002d_Sheng2010_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Guang-Sheng2010(DRSP-DSG)</LINK>, <LINK REF="STD-Sangwathan-2005_x0028_DRSP_x002d_LNG_x0029_" TYPE="STUDY">Sangwathan 2005(DRSP-LNG)</LINK>) amongst the switchers; in the study by <LINK REF="STD-Rossmanith-1997-_x0028_DSG_x002d_NE_x0029_" TYPE="STUDY">Rossmanith 1997 (DSG-NE)</LINK>, 40% of the switchers received the same OC that had been prescribed before due to double blinding and randomisation; <LINK REF="STD-Zichella-1999-_x0028_GSD_x002d_DSG_x0029_" TYPE="STUDY">Zichella 1999 (GSD-DSG)</LINK>, <LINK REF="STD-Suthipongse2004_x0028_DRSP_x002d_LNG_x0029_" TYPE="STUDY">Suthipongse2004(DRSP-LNG)</LINK> and <LINK REF="STD-Kriplani-2010-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Kriplani 2010 (DRSP-DSG)</LINK> trial only recruited starters defined as women who had not used hormonal contraception for 3 months or 6 months prior to the study respectively. The <LINK REF="STD-Gruber-2006-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Gruber 2006 (DRSP-DSG)</LINK> and <LINK REF="STD-Anttila-2009-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Anttila 2009 (DRSP-DSG)</LINK> trials excluded women who had used an OC containing either of the trial progestogens within one cycle of the study.</P>
<P>
<B>Pill composition and regimens </B>
</P>
<P>Twenty-five trials used COCs distributed as 28-day cycles with 21 active pills and 7 days of no tablet taking. Two trials (<LINK REF="STD-GSD-Group-1999-_x0028_GSD_x002d_DSG_x0029_" TYPE="STUDY">GSD Group 1999 (GSD-DSG)</LINK>, <LINK REF="STD-Anttila-2009-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Anttila 2009 (DRSP-DSG)</LINK>) distributed one COC as a 24-day preparation with all active pills compared to a 21-day cycle. <LINK REF="STD-Dunson-1993-_x0028_NG_x002d_NE_x0029_" TYPE="STUDY">Dunson 1993 (NG-NE)</LINK> used 21 active hormone tablets and 7 iron tablets for one group and inactive tablets for the other group. No information on the duration of COC dosing was available for two trials (<LINK REF="STD-Rabe-1989-_x0028_GSD_x002d_LNG_x0029_" TYPE="STUDY">Rabe 1989 (GSD-LNG)</LINK>; <LINK REF="STD-Rossmanith-1997-_x0028_DSG_x002d_NE_x0029_" TYPE="STUDY">Rossmanith 1997 (DSG-NE)</LINK>).</P>
<P>The day for starting the pill varied within and between studies to either a first-day start, first-Sunday start or fifth-day start: Fifteen trials had no information about which day the pill was started; the Shoupe study used a first-Sunday start for both OCs (<LINK REF="STD-Shoupe-1994-_x0028_DSG_x002d_NE_x0029_" TYPE="STUDY">Shoupe 1994 (DSG-NE)</LINK>; Day-1 start for both pill types was used in 12 trials (<LINK REF="STD-Serfaty-1998-_x0028_GSD_x002d_DSG_x0029_" TYPE="STUDY">Serfaty 1998 (GSD-DSG)</LINK>; <LINK REF="STD-Loudon-1990-_x0028_GSD_x002d_LNG_x0029_" TYPE="STUDY">Loudon 1990 (GSD-LNG)</LINK>; <LINK REF="STD-GSD-Group-1999-_x0028_GSD_x002d_DSG_x0029_" TYPE="STUDY">GSD Group 1999 (GSD-DSG)</LINK>; <LINK REF="STD-Affinito-1993-_x0028_GSD_x002d_NGM_x0029_" TYPE="STUDY">Affinito 1993 (GSD-NGM)</LINK>; <LINK REF="STD-Endrikat-1999-_x0028_GSD_x002d_DSG_x0029_" TYPE="STUDY">Endrikat 1999 (GSD-DSG)</LINK>, <LINK REF="STD-Anttila-2009-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Anttila 2009 (DRSP-DSG)</LINK>, <LINK REF="STD-Endrikat-2001-_x0028_LNG_x002d_NE_x0029_" TYPE="STUDY">Endrikat 2001 (LNG-NE)</LINK>, <LINK REF="STD-Gruber-2006-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Gruber 2006 (DRSP-DSG)</LINK>, <LINK REF="STD-Kelly-2010-_x0028_DRSP_x002d_LNG_x0029_" TYPE="STUDY">Kelly 2010 (DRSP-LNG)</LINK>, <LINK REF="STD-Suthipongse2004_x0028_DRSP_x002d_LNG_x0029_" TYPE="STUDY">Suthipongse2004(DRSP-LNG)</LINK>, <LINK REF="STD-Guang_x002d_Sheng2010_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Guang-Sheng2010(DRSP-DSG)</LINK>, <LINK REF="STD-Sangwathan-2005_x0028_DRSP_x002d_LNG_x0029_" TYPE="STUDY">Sangwathan 2005(DRSP-LNG)</LINK>; First-Sunday and day-1 start for two OC preparations was used in one trial (<LINK REF="STD-Reiter-1990-_x0028_NG_x002d_NE_x0029_" TYPE="STUDY">Reiter 1990 (NG-NE)</LINK>); Fifth-day start for both OC types was recommended in the study by <LINK REF="STD-Ramos-1989-_x0028_LNG_x002d_NE_x0029_" TYPE="STUDY">Ramos 1989 (LNG-NE)</LINK>.</P>
<P>
<B>Comparisons </B>
</P>
<P>Trials were only included if the difference in the total content of ethinyl estradiol did not exceed 105 µg/cycle. Twenty-four trials compared monophasic COCs and six (<LINK REF="STD-Droegem_x00fc_ller-1989-_x0028_LNG_x002d_NE_x0029_" TYPE="STUDY">Droegemüller 1989 (LNG-NE)</LINK>; <LINK REF="STD-Percival-1990-_x0028_NG_x002d_NE_x0029_" TYPE="STUDY">Percival 1990 (NG-NE)</LINK>; <LINK REF="STD-Reiter-1990-_x0028_NG_x002d_NE_x0029_" TYPE="STUDY">Reiter 1990 (NG-NE)</LINK>; <LINK REF="STD-Shoupe-1994-_x0028_DSG_x002d_NE_x0029_" TYPE="STUDY">Shoupe 1994 (DSG-NE)</LINK>; <LINK REF="STD-Singh-1996-_x0028_DSG_x002d_NE_x0029_" TYPE="STUDY">Singh 1996 (DSG-NE)</LINK>, <LINK REF="STD-Weber_x002d_Diehl-1993-_x0028_GSD_x002d_NE_x0029_" TYPE="STUDY">Weber-Diehl 1993 (GSD-NE)</LINK>) compared triphasic COCs. Except for seven trials using drospirenone (<LINK REF="STD-Foidart-2000-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Foidart 2000 (DRSP-DSG)</LINK>; <LINK REF="STD-Huber-2000-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Huber 2000 (DRSP-DSG)</LINK>, <LINK REF="STD-Anttila-2009-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Anttila 2009 (DRSP-DSG)</LINK>, <LINK REF="STD-Gruber-2006-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Gruber 2006 (DRSP-DSG)</LINK>, <LINK REF="STD-Kelly-2010-_x0028_DRSP_x002d_LNG_x0029_" TYPE="STUDY">Kelly 2010 (DRSP-LNG)</LINK>, <LINK REF="STD-Sangwathan-2005_x0028_DRSP_x002d_LNG_x0029_" TYPE="STUDY">Sangwathan 2005(DRSP-LNG)</LINK>, <LINK REF="STD-Kriplani-2010-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Kriplani 2010 (DRSP-DSG)</LINK> ) all other trials included progestogens categorised as first-, second- or third-generation. No included trials compared ethynodiol diacetate, lynestrenol, norethynodrel, cyproterone acetate or dienogest.</P>
<P>
<B>Duration of follow-up</B>
</P>
<P>Trials were conducted over periods of six to 26 months. All but four trials had follow-up confined to the course of the study with the final assessment at the end of the concluding study cycle. <LINK REF="STD-Foidart-2000-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Foidart 2000 (DRSP-DSG)</LINK> continued with follow-up for 3 months post-study, <LINK REF="STD-Huber-2000-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Huber 2000 (DRSP-DSG)</LINK> for 6 weeks, <LINK REF="STD-Kriplani-2010-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Kriplani 2010 (DRSP-DSG)</LINK> for 6 months and <LINK REF="STD-Singh-1996-_x0028_DSG_x002d_NE_x0029_" TYPE="STUDY">Singh 1996 (DSG-NE)</LINK> for 13 months in the desogestrel/ethinyl estradiol (CTR-05) arm.</P>
<P>
<B>Excluded trials</B>
</P>
<P>
<I>See </I>
<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.<BR/>
</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-03-25 11:08:12 +0100" MODIFIED_BY="[Empty name]">
<P>With some exceptions, the quality of these randomised trials was low. <I>See</I> <I>Risk of bias tables in</I> <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>, <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> and <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
<ALLOCATION MODIFIED="2011-03-04 12:26:19 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation concealment was not described in the majority of trials and was found to be adequate in only three trials (<LINK REF="STD-Kriplani-2010-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Kriplani 2010 (DRSP-DSG)</LINK>, <LINK REF="STD-Dunson-1993-_x0028_NG_x002d_NE_x0029_" TYPE="STUDY">Dunson 1993 (NG-NE)</LINK> and <LINK REF="STD-Shoupe-1994-_x0028_DSG_x002d_NE_x0029_" TYPE="STUDY">Shoupe 1994 (DSG-NE)</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2011-03-04 13:46:01 +0100" MODIFIED_BY="[Empty name]">
<P>Most of the trials were open-label i.e. unblinded. Two trials declared partial blinding (<LINK REF="STD-Kelly-2010-_x0028_DRSP_x002d_LNG_x0029_" TYPE="STUDY">Kelly 2010 (DRSP-LNG)</LINK>; <LINK REF="STD-Percival-1990-_x0028_NG_x002d_NE_x0029_" TYPE="STUDY">Percival 1990 (NG-NE)</LINK>) and four trials were reported as double-blind (<LINK REF="STD-Loudon-1990-_x0028_GSD_x002d_LNG_x0029_" TYPE="STUDY">Loudon 1990 (GSD-LNG)</LINK>; <LINK REF="STD-Shoupe-1994-_x0028_DSG_x002d_NE_x0029_" TYPE="STUDY">Shoupe 1994 (DSG-NE)</LINK>; <LINK REF="STD-Rossmanith-1997-_x0028_DSG_x002d_NE_x0029_" TYPE="STUDY">Rossmanith 1997 (DSG-NE)</LINK>; <LINK REF="STD-Ramos-1989-_x0028_LNG_x002d_NE_x0029_" TYPE="STUDY">Ramos 1989 (LNG-NE)</LINK>). Sensitivity analyses were performed to ascertain whether double-blinding altered the results.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2011-03-04 12:19:42 +0100" MODIFIED_BY="[Empty name]">
<P>Twenty-two out of 30 trials had clearly stated data on loss to follow-up. Post-randomisation exclusions occurred in 16 trials and were unclear in four others. Cycle control data were difficult to collate due to differences in reporting: some trials reported data on cycle control in terms of cycles rather than subjects, or the data were given graphically without denominators. For the purpose of this review, we entered the data on cycle control only where it had been given as subject numbers and excluded data when reported as number of cycles. Attempts to obtain additional unpublished data was successful in five of the studies identified for the update: <LINK REF="STD-Anttila-2009-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Anttila 2009 (DRSP-DSG)</LINK>, <LINK REF="STD-Kelly-2010-_x0028_DRSP_x002d_LNG_x0029_" TYPE="STUDY">Kelly 2010 (DRSP-LNG)</LINK>, <LINK REF="STD-Kriplani-2010-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Kriplani 2010 (DRSP-DSG)</LINK>, <LINK REF="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_" TYPE="STUDY">Winkler 2004 (DSG-LNG)</LINK> and <LINK REF="STD-Gruber-2006-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Gruber 2006 (DRSP-DSG)</LINK>. </P>
<P>
<LINK REF="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_" TYPE="STUDY">Winkler 2004 (DSG-LNG)</LINK> had greater than 20% missing cycle control data and so was excluded from this outcome.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2011-03-04 13:46:34 +0100" MODIFIED_BY="[Empty name]">
<P>Sixteen trials stated that analysis was by intention to treat, and the type of analysis was unclear in fourteen studies. <LINK REF="STD-Endrikat-1999-_x0028_GSD_x002d_DSG_x0029_" TYPE="STUDY">Endrikat 1999 (GSD-DSG)</LINK> reported both intention to treat as well as valid case analysis. In several trials, the reasons for discontinuation were sometimes unclear or incomplete, and rarely attributed to cycle disturbances (<LINK REF="STD-Anttila-2009-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Anttila 2009 (DRSP-DSG)</LINK>, <LINK REF="STD-Kelly-2010-_x0028_DRSP_x002d_LNG_x0029_" TYPE="STUDY">Kelly 2010 (DRSP-LNG)</LINK>, <LINK REF="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_" TYPE="STUDY">Winkler 2004 (DSG-LNG)</LINK>). </P>
<P>
<LINK REF="STD-Kelly-2010-_x0028_DRSP_x002d_LNG_x0029_" TYPE="STUDY">Kelly 2010 (DRSP-LNG)</LINK> failed to report key cycle control data. In <LINK REF="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_" TYPE="STUDY">Winkler 2004 (DSG-LNG)</LINK>, 210/998 women discontinued the trial, only 35 of these women discontinued due to side effects, 54 were 'not willing to continue', eleven discontinued due to 'poor compliance' and 83 women discontinued for 'other' reasons. This lack of detail suggests selective or under-reporting of side-effects.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2011-03-04 12:17:46 +0100" MODIFIED_BY="[Empty name]">
<P>Twenty three out of thirty trials were supported by pharmaceutical companies, one trial (<LINK REF="STD-Ramos-1989-_x0028_LNG_x002d_NE_x0029_" TYPE="STUDY">Ramos 1989 (LNG-NE)</LINK>) was jointly supported by a pharmaceutical company and an international organisation (UNFPA), and three studies (<LINK REF="STD-Dunson-1993-_x0028_NG_x002d_NE_x0029_" TYPE="STUDY">Dunson 1993 (NG-NE)</LINK>; <LINK REF="STD-Reiter-1990-_x0028_NG_x002d_NE_x0029_" TYPE="STUDY">Reiter 1990 (NG-NE)</LINK>, <LINK REF="STD-Kriplani-2010-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Kriplani 2010 (DRSP-DSG)</LINK>) were supported or conducted by international organisations (WHO), NGOs or university departments; five trials failed to declare any sponsorship or conflict of interest.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-03-07 10:29:20 +0100" MODIFIED_BY="[Empty name]">
<P>Twenty-two trials were included in the original review and an additional eight trials contributed data for the updated review.</P>
<P>
<B>1. SECOND- VS. FIRST-GENERATION PROGESTOGENS </B>
</P>
<P>Six trials compared levonorgestrel (LNG) or norgestrel (NG) to norethindrone/norethisterone (NE); 2709 women received monophasic preparations and 581 women received triphasic preparations. Pregnancies occurred in one of the two monophasic trials reporting on it (<LINK REF="STD-Dunson-1993-_x0028_NG_x002d_NE_x0029_" TYPE="STUDY">Dunson 1993 (NG-NE)</LINK>) with more pregnancies occurring in the group receiving first-generation progestogens (2,074 women, RR 0.12, 95% CI: 0.02-0.99) over a follow-up period of 1 year. No pregnancies occurred in the only double-blind trial (<LINK REF="STD-Ramos-1989-_x0028_LNG_x002d_NE_x0029_" TYPE="STUDY">Ramos 1989 (LNG-NE)</LINK>; 1,199 women) of this comparison.</P>
<P>There was less discontinuation with second-generation compared to first-generation monophasic progestogens (3 trials, 2709 women, RR 0.76, 95% CI 0.67-0.86); this remained significant when only the double-blind trial was considered (RR 0.79, 95% CI 0.66-0.94).</P>
<P>Cycle control was better when using second- compared to first-generation progestogens for both monophasic (1 trial, 875 women, RR 0.69; 95% CI 0.52-0.91) and multiphasic preparations (3 trials, 581 women, RR 0.61; 95% CI 0.43-0.85), however these trials were not double-blind.</P>
<P>Other side effects and the number of women who discontinued due to side effects were similar in both groups. As <LINK REF="STD-Dunson-1993-_x0028_NG_x002d_NE_x0029_" TYPE="STUDY">Dunson 1993 (NG-NE)</LINK> used iron tablets during the 7-day hormone-free interval in one group, the data from this trial on side effects such as headaches, nausea/vomiting and dizziness were not included in the meta-analysis.</P>
<P>
<B>2. NORGESTREL VS. NORETHINDRONE (MONOPHASIC)</B>
</P>
<P>One trial with 875 women was included in this comparison (<LINK REF="STD-Dunson-1993-_x0028_NG_x002d_NE_x0029_" TYPE="STUDY">Dunson 1993 (NG-NE)</LINK>). This trial was not double-blind. More pregnancies occurred with norethindrone (NE) (RR 0.12, 95% CI: 0.02-0.99) at 12 months of OC use. Cycle disturbances as a reason for discontinuation were less frequent in the NG group (RR 0.27, 95% CI 0.12-0.61). Intermenstrual bleeding (RR 0.69, 95% CI 0.52-0.91), absence of withdrawal bleeding (RR 0.29, 95% CI 0.16-0.54) and other menstrual complaints (RR 0.37, 95% CI 0.25-0.55) were reported less frequently in the NG group compared to NE. Side effects were similar in both groups.</P>
<P>
<B>3. NORGESTREL VS. NORETHINDRONE (TRIPHASIC)</B>
</P>
<P>Two open-label trials with 485 women were included in this comparison (<LINK REF="STD-Reiter-1990-_x0028_NG_x002d_NE_x0029_" TYPE="STUDY">Reiter 1990 (NG-NE)</LINK>; <LINK REF="STD-Percival-1990-_x0028_NG_x002d_NE_x0029_" TYPE="STUDY">Percival 1990 (NG-NE)</LINK>). No data on contraceptive effectiveness were reported. A similar number of women was satisfied with the treatment, reported intermenstrual bleeding and the absence of withdrawal bleeding in both groups.</P>
<P>
<B>4. LEVONORGESTREL VS. NORETHINDRONE (MONOPHASIC) </B>
</P>
<P>This comparison includes 1,834 women from two trials (<LINK REF="STD-Ramos-1989-_x0028_LNG_x002d_NE_x0029_" TYPE="STUDY">Ramos 1989 (LNG-NE)</LINK>, <LINK REF="STD-Endrikat-2001-_x0028_LNG_x002d_NE_x0029_" TYPE="STUDY">Endrikat 2001 (LNG-NE)</LINK>). No pregnancies occurred in either group at 12 months of OC use. Fewer women using LNG discontinued (RR: 0.75; 95% CI: 0.64-0.87); this result remained significant when only double blind trials were considered (1 trial, 1,199 women; RR 0.79; 95% CI 0.66-0.94) .</P>
<P>
<B>5. LEVONORGESTREL VS. NORETHINDRONE (TRIPHASIC) </B>
</P>
<P>This comparison is based on a single unblinded trial (<LINK REF="STD-Droegem_x00fc_ller-1989-_x0028_LNG_x002d_NE_x0029_" TYPE="STUDY">Droegemüller 1989 (LNG-NE)</LINK>), including 96 women. There are no data on contraceptive effectiveness. Fewer women had spotting (RR 0.44; 95% CI 0.20-0.97), breakthrough bleeding (RR 0.45; 95% CI 0.24-0.85) and intermenstrual bleeding (RR 0.53; 95% CI 0.34-0.84) in the LNG group.</P>
<P>
<B>6. THIRD- VS. SECOND-GENERATION PROGESTOGENS </B>
</P>
<P>Three trials with a total of 1,815 women were included: two compared monophasic GSD with monophasic LNG combined and 30 µg EE (<LINK REF="STD-Loudon-1990-_x0028_GSD_x002d_LNG_x0029_" TYPE="STUDY">Loudon 1990 (GSD-LNG)</LINK>; <LINK REF="STD-Rabe-1989-_x0028_GSD_x002d_LNG_x0029_" TYPE="STUDY">Rabe 1989 (GSD-LNG)</LINK>) and one compared monophasic DSG with monophasic LNG and 20µg EE (<LINK REF="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_" TYPE="STUDY">Winkler 2004 (DSG-LNG)</LINK>). Women using monophasic COC's containing third-generation progestogens were less likely to discontinue than the second-generation group (3 trials, 1815 women, RR 0.77, 95% CI 0.60-0.98); however, on sensitivity analysis, when only the double-blind trial (<LINK REF="STD-Loudon-1990-_x0028_GSD_x002d_LNG_x0029_" TYPE="STUDY">Loudon 1990 (GSD-LNG)</LINK> was considered, there was no significant difference between the groups (456 women, RR 0.79; 95% CI 0.50-1.26). Women in the third-generation group experienced less intermenstrual bleeding (one double-blind trial, GSD vs LNG, 456 women, RR 0.71, 95% CI 0.55-0.91).</P>
<P>
<B>7. GESTODENE VS. LEVONORGESTREL (MONOPHASIC)</B>
</P>
<P>See third- vs. second-generation comparison.</P>
<P>
<B>8. DESOGESTREL VS. LEVONORGESTREL (MONOPHASIC)</B>
</P>
<P>Only one trial of 998 women is included (<LINK REF="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_" TYPE="STUDY">Winkler 2004 (DSG-LNG)</LINK>. Discontinuation due to side-effects including cycle disturbances was more likely to occur in the LNG group (RR 0.40, 95% CI 0.19, 0.82) (see <LINK TAG="STUDY_QUALITY" TYPE="SECTION">Risk of bias in included studies</LINK>). There was no important difference in pregnancy rates.</P>
<P>
<B>9. THIRD- VS. FIRST-GENERATION PROGESTOGENS </B>
</P>
<P>Overall, three trials and 976 women were included in this comparison. Two trials used triphasic OCs (<LINK REF="STD-Shoupe-1994-_x0028_DSG_x002d_NE_x0029_" TYPE="STUDY">Shoupe 1994 (DSG-NE)</LINK>; <LINK REF="STD-Singh-1996-_x0028_DSG_x002d_NE_x0029_" TYPE="STUDY">Singh 1996 (DSG-NE)</LINK>; one trial used a monophasic preparation (<LINK REF="STD-Rossmanith-1997-_x0028_DSG_x002d_NE_x0029_" TYPE="STUDY">Rossmanith 1997 (DSG-NE)</LINK>). Except for two pregnancies in women receiving norethindrone (NE) in the <LINK REF="STD-Shoupe-1994-_x0028_DSG_x002d_NE_x0029_" TYPE="STUDY">Shoupe 1994 (DSG-NE)</LINK> trial, no other pregnancies were observed. The number of women who had side effects, breakthrough bleeding or discontinued usage was similar for the comparison groups, for mono and multiphasic preparations.</P>
<P>
<B>10. GESTODENE VS. NORETHINDRONE (TRIPHASIC)</B>
</P>
<P>One trial (229 women) was included in this comparison. Fewer women had spotting in the GSD group (RR 0.59; 95%CI 0.35-0.99).</P>
<P>
<B>11. DESOGESTREL VS. NORETHISTERONE (MONOPHASIC)</B>
</P>
<P>There is one double-blind trial included in this comparison (<LINK REF="STD-Rossmanith-1997-_x0028_DSG_x002d_NE_x0029_" TYPE="STUDY">Rossmanith 1997 (DSG-NE)</LINK>). No pregnancies were reported in either group after 6 cycles in a total of 118 women. Overall reported side effects were similar in both groups.</P>
<P>
<B>12. DESOGESTREL VS. NORETHINDRONE (TRIPHASIC)</B>
</P>
<P>Two trials, with a total number 858 women were included (<LINK REF="STD-Singh-1996-_x0028_DSG_x002d_NE_x0029_" TYPE="STUDY">Singh 1996 (DSG-NE)</LINK>; <LINK REF="STD-Shoupe-1994-_x0028_DSG_x002d_NE_x0029_" TYPE="STUDY">Shoupe 1994 (DSG-NE)</LINK>). No pregnancies occurred with desogestrel compared to two in the group receiving norethindrone. Both were described as user failures. Similar results for side effects, discontinuation and cycle disturbances were reported for both groups.</P>
<P>
<B>13. GESTODENE VS. DESOGESTREL (MONOPHASIC)</B>
</P>
<P>This comparison has the largest number of studies included (7 trials, 5624 women). Discontinuation rates were similar but occurred more frequently as a result of non-cycle related side-effects in the GSD group (5 trials, 3534 women, RR 1.81; 95% CI: 1.01-3.23). Regarding cycle control, trials were further stratified according to their oestrogen dose with effects similar between groups. In one trial (<LINK REF="STD-GSD-Group-1999-_x0028_GSD_x002d_DSG_x0029_" TYPE="STUDY">GSD Group 1999 (GSD-DSG)</LINK>) the oestrogen dose was 15 µg in GSD and 20 µg in the DSG group and so the data for cycle disturbances were not included in the meta-analysis.</P>
<P>
<B>14. GESTODENE VS. NORGESTIMATE (MONOPHASIC) </B>
</P>
<P>This comparison is based on the single study by <LINK REF="STD-Affinito-1993-_x0028_GSD_x002d_NGM_x0029_" TYPE="STUDY">Affinito 1993 (GSD-NGM)</LINK> of 174 women. No pregnancies were reported in either group after 6 months of OC use. Discontinuation, reasons for discontinuation and overall side effects were similar.</P>
<P>
<B>15. DROSPIRENONE VS. LEVONORGESTREL (MONOPHASIC)</B>
</P>
<P>Three trials compared COCs containing these progestogens (<LINK REF="STD-Sangwathan-2005_x0028_DRSP_x002d_LNG_x0029_" TYPE="STUDY">Sangwathan 2005(DRSP-LNG)</LINK>, <LINK REF="STD-Kelly-2010-_x0028_DRSP_x002d_LNG_x0029_" TYPE="STUDY">Kelly 2010 (DRSP-LNG)</LINK>, <LINK REF="STD-Suthipongse2004_x0028_DRSP_x002d_LNG_x0029_" TYPE="STUDY">Suthipongse2004(DRSP-LNG)</LINK>. There was no significant difference in any of the outcomes evaluated.</P>
<P>
<B>16. DROSPIRENONE VS. DESOGESTREL (MONOPHASIC) </B>
</P>
<P>Of the six trials included in this comparison (4415 participants), one was conducted over a period of 26 months (<LINK REF="STD-Foidart-2000-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Foidart 2000 (DRSP-DSG)</LINK>, two over 13 months (<LINK REF="STD-Huber-2000-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Huber 2000 (DRSP-DSG)</LINK>, <LINK REF="STD-Guang_x002d_Sheng2010_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Guang-Sheng2010(DRSP-DSG)</LINK>), two over 7 months (<LINK REF="STD-Anttila-2009-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Anttila 2009 (DRSP-DSG)</LINK>, <LINK REF="STD-Gruber-2006-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Gruber 2006 (DRSP-DSG)</LINK>) and one with a treatment phase of 6 months plus 6 months of follow-up (<LINK REF="STD-Kriplani-2010-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Kriplani 2010 (DRSP-DSG)</LINK>). The small trial by Kriplani et al featured only women with PCOS seeking contraception. Pregnancy and discontinuation rates were similar in both groups. Overall, a similar number of women in both groups reported side effects, except for breast tenderness which was more common in the DRSP group (5 trials, 4258 women, RR 1.39, 95% CI 1.04, 1.86). There was a trend towards more nausea and vomiting in the DRSP group (6 trials, 4701 women, RR 1.46, 95% CI 0.96, 2.21).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-03-07 21:42:46 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2011-03-07 21:42:46 +0100" MODIFIED_BY="[Empty name]">
<P>A significant difference in effectiveness between the different progestogens was not observed, however, the trials had insufficient power to find potentially important differences. Overall, trials with a follow-up period of up to one year or longer showed a failure/pregnancy rate ranging from 0.2% to 1.8%.</P>
<P>The use of second-generation progestogens showed less discontinuation than first-generation progestogens and third generation progestogens showed less discontinuation than second-generation preparations. On sensitivity analysis, when only double-blind trials were considered, there was no significant difference in discontinuation rates between the second and third generations. <I>See</I> <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK> and <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>.This difference suggests a bias towards the latest pharmaceutical development.</P>
<P>Discontinuation rates varied widely suggesting that COCs are not highly acceptable to all women. Discontinuation due to cycle disturbance was under-reported in trials included in this review and cyclical bleeding patterns were difficult to compare due to a lack of standardised reporting. Some trials reported the number of women experiencing spotting per cycle and others reported total number of spotting days per study period and so it was not always possible to include cycle control data in the review meta-analyses. Standardisation of methods for collecting and analysing cycle control data is considered by us and others as long overdue (<LINK REF="REF-Mishell-2007" TYPE="REFERENCE">Mishell 2007</LINK>). As women will have differing opinions as to whether any, and how much, cycle disturbance is acceptable, the outcome 'discontinuation due to cycle disturbance' is arguably a more useful indicator of acceptability than other more detailed measurements of cycle control.</P>
</SUMMARY_OF_RESULTS>
<POTENTIAL_BIASES MODIFIED="2011-03-07 10:32:47 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>The shortage of large, independent, well-conducted randomised trials impacts on the reliability of the review results (<I>see</I> <LINK TAG="STUDY_QUALITY" TYPE="SECTION">Risk of bias in included studies</LINK>). A large proportion of the trials were sponsored fully or partially by the relevant pharmaceutical company, most studies were open-label and methods of randomisation were frequently unclear. Even the double-blind trials had methodological flaws/omissions. However, without blinding as to treatment effect, interpretation of reported side-effects is difficult, if not impossible. Indeed, knowledge by the patient and investigator of the 'generation' of progestogen being used may account for the differences observed, not any difference in pharmacology. </LI>
<LI>Our selection criteria did not allow for all relevant types of comparisons, for example, monophasic versus multiphasic comparisons and so some otherwise relevant trials were excluded. These comparisons are reviewed elsewhere; see also other relevant Cochrane reviews (<LINK REF="REF-Van-Vliet-2006a" TYPE="REFERENCE">Van Vliet 2006a</LINK>, <LINK REF="REF-Van-Vliet-2006b" TYPE="REFERENCE">Van Vliet 2006b</LINK>).</LI>
<LI>The day on which the pill was started, recruitment of both starters and switchers, use of a washout period for the switchers, and the type of OC received by switchers, may all influence cycle control data and contraceptive outcomes. Determining the impact of these influences was beyond the scope of this review.</LI>
<LI>The trials included in this review did not have large enough sample sizes to detect rare outcomes, including pregnancy.</LI>
</OL>
</POTENTIAL_BIASES>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2011-03-04 12:55:44 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2011-03-03 11:37:42 +0100" MODIFIED_BY="[Empty name]">
<P>Overall the quality of trials reviewed here is poor and, in the absence of treatment blinding, they shed little light on the clinical differences, if any, between the various progestogens in COCs. Without blinding as to treatment group, comparisons cannot be made between various "generations" of progestogens used in COCs.  Until this widespread methodological flaw is overcome in better trials, no conclusions can be drawn.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2011-03-04 12:55:44 +0100" MODIFIED_BY="[Empty name]">
<P>Current areas of interest include the acceptability of traditional versus continuous dosing of COCs (<I>see Cochrane review, </I>
<LINK REF="REF-Edelman-2010" TYPE="REFERENCE">Edelman 2010</LINK>); and further double-blind comparisons of the side-effect and benefit profiles of new progestogens versus the earlier progestogens would be helpful. Reasons for discontinuation should be carefully recorded, including 'discontinuation due to cycle disturbance'.To minimise bias, all trials should comply with CONSORT guidelines (<LINK REF="REF-CONSORT-2010" TYPE="REFERENCE">CONSORT 2010</LINK>) and use internationally accepted definitions.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2011-03-04 12:19:42 +0100" MODIFIED_BY="[Empty name]">
<P>Carol Manion of FHI, USA, for the extensive, updated literature search; the investigators of the trials who provided additional unpublished information, particularly Prof. A Kriplani (<LINK REF="STD-Kriplani-2010-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Kriplani 2010 (DRSP-DSG)</LINK>), Dr. Susanne Parke (<LINK REF="STD-Gruber-2006-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Gruber 2006 (DRSP-DSG)</LINK>, Dr Paul Grob (<LINK REF="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_" TYPE="STUDY">Winkler 2004 (DSG-LNG)</LINK>), Dr J. Marr (<LINK REF="STD-Anttila-2009-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Anttila 2009 (DRSP-DSG)</LINK> Dr. Jan Endrikat, Prof. G. Benagiano and Prof. Lars Carlborg and also Dr. E. Barden who responded on behalf of Dr. Nancy Loudon; Anne Eisinga of the Cochrane Centre, UK, and Carol Manion for the original literature search; Olav Meirik for the early preparation phase of this review; Dr. Paul O'Brien for sharing the unpublished data on analysis of cycle control.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.<BR/> </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2011-01-05 11:29:19 +0100" MODIFIED_BY="[Empty name]">
<P>TL and FH selected trials and extracted data for the updated review and contributed to the updated text. NM, AMG, FH wrote the original protocol. NM, RK, KB, FH and AMG were involved in the data extraction of the original review; NM, RK, FH and AMG were involved in writing up the original review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-03-25 11:13:11 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2011-03-04 12:20:11 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2011-03-04 12:20:11 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Affinito-1993-_x0028_GSD_x002d_NGM_x0029_" MODIFIED="2011-03-04 12:11:26 +0100" MODIFIED_BY="[Empty name]" NAME="Affinito 1993 (GSD-NGM)" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Affinito P, Monterubbianesi M, Primizia M, Regina V, Di Carlo C, Farace MJ, Petrillo G, Nappi C</AU>
<TI>Efficacy, cycle control and side-effects of two monophasic combination oral contraceptives: gestodene/ethinyl estradiol and norgestimate/ethinylestradiol</TI>
<SO>Gynecological Endocrinolology</SO>
<YR>1993</YR>
<VL>7</VL>
<PG>259-266</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-03-04 12:11:11 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-03-04 12:11:11 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Anttila-2009-_x0028_DRSP_x002d_DSG_x0029_" MODIFIED="2011-03-04 12:12:03 +0100" MODIFIED_BY="[Empty name]" NAME="Anttila 2009 (DRSP-DSG)" YEAR="2009">
<REFERENCE MODIFIED="2010-10-01 13:40:47 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Anttila L, Kunz M, Marr J</AU>
<TI>Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel150 mcg+ ethinyl estradiol 20 mcg 21/7 combined oral contraceptive</TI>
<SO>Contraception</SO>
<YR>2009</YR>
<VL>80</VL>
<PG>445-451</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Droegem_x00fc_ller-1989-_x0028_LNG_x002d_NE_x0029_" MODIFIED="2011-03-04 12:13:15 +0100" MODIFIED_BY="[Empty name]" NAME="Droegemüller 1989 (LNG-NE)" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Droegemueller W, Rao Katta L, Bright TG, Bowes WA</AU>
<TI>Triphasic randomized clinical trial: Comparative frequency of intermenstrual bleeding</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1989</YR>
<VL>161</VL>
<PG>1407-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dunson-1993-_x0028_NG_x002d_NE_x0029_" MODIFIED="2011-03-04 12:13:38 +0100" MODIFIED_BY="[Empty name]" NAME="Dunson 1993 (NG-NE)" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dunson TR, McLaurin VL, Israngkura B</AU>
<TI>A comparative study of two low dose combined oral contraceptives: results from a multicenter trial</TI>
<SO>Contraception</SO>
<YR>1993</YR>
<VL>48</VL>
<PG>109-119</PG>
<PB>Butterworth-Heinemann</PB>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Endrikat-1999-_x0028_GSD_x002d_DSG_x0029_" MODIFIED="2011-03-04 12:13:58 +0100" MODIFIED_BY="[Empty name]" NAME="Endrikat 1999 (GSD-DSG)" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Dr. Endrikat had shared this data with us prior to it's official publication with a request that it not be used until the paper was published. &lt;br&gt;His gesture is much appreciated.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Endrikat J, Dusterberg B, Ruebig A, Gerlinger C, Strowitzki T</AU>
<TI>Comparison of efficacy, cycle control and tolerability of two low-dose oral contraceptives containing 20mcg Ethinylestradiol/75mcg Gestodene and 20mcg Ethinylestradiol/150mcg Desogestrel in a multicenter clinical study</TI>
<SO>Contraception</SO>
<YR>1999</YR>
<VL>60</VL>
<PG>269-274</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Endrikat-2001-_x0028_LNG_x002d_NE_x0029_" MODIFIED="2011-03-04 12:14:17 +0100" MODIFIED_BY="[Empty name]" NAME="Endrikat 2001 (LNG-NE)" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Endrikat J, Hite R, Bannemerschult R, Gerlinger C, Schmidt W</AU>
<TI>Multicenter, comparative study of cycle control, efficacy and tolerability of two low-dose oral contraceptives containing 20mcg ethinylestradiol/100mcg levonorgestrel and 20mcg ethinylestradiol/500mcg norethisterone</TI>
<SO>Contraception</SO>
<YR>2001</YR>
<VL>64</VL>
<PG>3-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Foidart-2000-_x0028_DRSP_x002d_DSG_x0029_" MODIFIED="2011-03-04 12:14:09 +0100" MODIFIED_BY="[Empty name]" NAME="Foidart 2000 (DRSP-DSG)" YEAR="2000">
<REFERENCE MODIFIED="2011-02-28 13:50:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Foidart JM, Wuttke W, Bouw GM, Gerlinger C, Heithecker R</AU>
<TI>A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel</TI>
<SO>European Journal of Contraception and Reproductive Health Care</SO>
<YR>2000</YR>
<VL>5</VL>
<PG>124-134</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Gruber-2006-_x0028_DRSP_x002d_DSG_x0029_" MODIFIED="2011-03-04 12:14:24 +0100" MODIFIED_BY="[Empty name]" NAME="Gruber 2006 (DRSP-DSG)" YEAR="2006">
<REFERENCE MODIFIED="2011-02-28 13:49:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gruber DM, Huber JC, Benedetto Melis G, Stagg C, Parke S, Marr J</AU>
<TI>A comparison of the cycle control, safety, and efficacy profile of a 21-day regimen of ethinyl estradiol and drospirenone 3mg with a 21-day regimen of ethinyl estradiol 20&#956;g and desogestrel 150&#956;g</TI>
<SO>Treatments in Endocrinology</SO>
<YR>2006</YR>
<VL>5</VL>
<NO>2</NO>
<PG>115-121</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-GSD-Group-1999-_x0028_GSD_x002d_DSG_x0029_" MODIFIED="2011-03-04 12:14:44 +0100" MODIFIED_BY="[Empty name]" NAME="GSD Group 1999 (GSD-DSG)" YEAR="1999">
<REFERENCE MODIFIED="2011-02-28 13:50:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gestodene Study Group</AU>
<TI>Cycle control, safety and efficacy of a 24- day regimen of gestodene 60mcg/ethinylestradiol 15mcg and a 21-day regimen of desogestrel 150mcg/ethinylestradiol 20mcg</TI>
<SO>European Journal of Contraception and Reproductive Health Care</SO>
<YR>1999</YR>
<VL>4</VL>
<NO>Supplement 2</NO>
<PG>17-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Guang_x002d_Sheng2010_x0028_DRSP_x002d_DSG_x0029_" MODIFIED="2011-03-04 12:15:30 +0100" MODIFIED_BY="[Empty name]" NAME="Guang-Sheng2010(DRSP-DSG)" YEAR="2010">
<REFERENCE MODIFIED="2011-02-28 13:51:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Guang-Sheng F, Mei-Lu B, Li-Nan C, Xiao-Ming C, Zi-Rong H, Zi-Yan H, Xiao-Ping J, Jian L, Shu-Ying W, Cheng-Liang X, Zheng-Ai X, Tian-Fu Y</AU>
<TI>Efficacy and Safety of the combined oral contraceptive ethinylestradiol/drospirenone (Yasmin) in healthy Chinese women</TI>
<SO>Clinical Drug Investigation</SO>
<YR>2010</YR>
<VL>30</VL>
<NO>6</NO>
<PG>387-396</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Halbe-1998-_x0028_GSD_x002d_DSG_x0029_" MODIFIED="2011-03-04 12:15:52 +0100" MODIFIED_BY="[Empty name]" NAME="Halbe 1998 (GSD-DSG)" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Halbe HW, de Melo NR, Bahamondes L, Petracco A, Lemgruber M, de Andrade RP, da Cunha DC, Guazelli CAF, Baracat EC</AU>
<TI>Efficacy and acceptability of two monophasic oral contraceptives containing ethinylestradiol and either desogestrel or gestodene</TI>
<SO>European Journal of Contraception and Reproductive Health Care</SO>
<YR>1998</YR>
<VL>3</VL>
<PG>113-120</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huber-2000-_x0028_DRSP_x002d_DSG_x0029_" MODIFIED="2011-03-04 12:16:00 +0100" MODIFIED_BY="[Empty name]" NAME="Huber 2000 (DRSP-DSG)" YEAR="2000">
<REFERENCE MODIFIED="2010-10-01 14:58:18 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huber J, Foidart JM, Wuttke W, Merki-Feld GS, The HS, Gerlinger C, Schellschmidt I, Heithecker R</AU>
<TI>Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone</TI>
<SO>European Journal of Contraception and Reproductive Health Care</SO>
<YR>2000</YR>
<VL>5</VL>
<PG>25-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Kelly-2010-_x0028_DRSP_x002d_LNG_x0029_" MODIFIED="2011-03-04 12:16:10 +0100" MODIFIED_BY="[Empty name]" NAME="Kelly 2010 (DRSP-LNG)" YEAR="2010">
<REFERENCE MODIFIED="2011-02-28 13:52:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kelly S, Davies E, Fearns S, McKinnon C, Carter R, Gerlinger C, Smithers A</AU>
<TI>Effects of oral contraceptives containing ethinyl estradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women</TI>
<SO>Clinical Drug Investigation</SO>
<YR>2010</YR>
<VL>30</VL>
<NO>5</NO>
<PG>325-336</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koetsawang-1995-_x0028_GSD_x002d_DSG_x0029_" MODIFIED="2011-03-04 12:16:19 +0100" MODIFIED_BY="[Empty name]" NAME="Koetsawang 1995 (GSD-DSG)" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;We had certain minor queries regarding side-effects leading to discontinuation, number of subjects reporting amenorrhea and normal cycle etc. for which we wrote to the authors however there has been no reply.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koetsawang S,Charoenvisal C, Banharnsupawat L, Singhakovin S, Kaewsuk O, Punnahitanont S</AU>
<TI>Oral contraceptives containing 30 mcg ethinylestradiol and either desogestrel or gestodene in Thai women</TI>
<SO>Contraception</SO>
<YR>1995</YR>
<VL>51</VL>
<PG>225-229</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Kriplani-2010-_x0028_DRSP_x002d_DSG_x0029_" MODIFIED="2011-03-04 12:16:30 +0100" MODIFIED_BY="[Empty name]" NAME="Kriplani 2010 (DRSP-DSG)" YEAR="2010">
<REFERENCE MODIFIED="2010-10-01 13:39:25 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kriplani A, Periyasamy AJ, Agarwal N, Kulshrestha V, Kumar A, Ammini AC</AU>
<TI>Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome</TI>
<SO>Contraception</SO>
<YR>2010</YR>
<VL>82</VL>
<PG>139-146</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-L.-America-1994-_x0028_GSD_x002d_DSG_x0029_" MODIFIED="2011-03-04 12:17:02 +0100" MODIFIED_BY="[Empty name]" NAME="L. America 1994 (GSD-DSG)" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Latin American Oral Contraceptive Study Group</AU>
<TI>Clinical comparison of monophasic oral contraceptive preparations of gestodene/ethinyl estradiol and desogestrel/ethinyl estradiol</TI>
<SO>Contraception</SO>
<YR>1994</YR>
<VL>50</VL>
<PG>201-214</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loudon-1990-_x0028_GSD_x002d_LNG_x0029_" MODIFIED="2011-03-04 12:17:11 +0100" MODIFIED_BY="[Empty name]" NAME="Loudon 1990 (GSD-LNG)" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;We had certain minor queries about the data for which we wrote to Dr. Loudon. However, we were informed that Dr. Loudon having retired more than 10 years ago the data would be difficult to acquire. We are grateful to the Chief Medical Officer of the Lothian Primary CareTrust, Edinburgh for the assistance extended.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loudon NB, Kirkman RJE, Dewsbury JA</AU>
<TI>A double-blind comparison of the efficacy and acceptability of Femodene and Microgynon-30</TI>
<SO>European Journal of Obstetrics and Gynaecology and Reproductive Biology</SO>
<YR>1990</YR>
<VL>34</VL>
<PG>257-266</PG>
<PB>Elsevier Science</PB>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Percival-1990-_x0028_NG_x002d_NE_x0029_" MODIFIED="2011-03-04 12:17:19 +0100" MODIFIED_BY="[Empty name]" NAME="Percival 1990 (NG-NE)" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Percival-Smith RKL, Yuzpe AA, Desrosiers JAJ, Rioux JE, Guilbert E</AU>
<TI>Cycle control on low-dose oral contraceptives: A comparative trial</TI>
<SO>Contraception</SO>
<YR>1990</YR>
<VL>42</VL>
<NO>3</NO>
<PG>253- 262</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rabe-1989-_x0028_GSD_x002d_LNG_x0029_" MODIFIED="2011-03-04 12:17:29 +0100" MODIFIED_BY="[Empty name]" NAME="Rabe 1989 (GSD-LNG)" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rabe T, Runnebaum B, Kohlmeier M, Harenberg J, Weicker H</AU>
<TI>Clinical and metabolic effects of gestodene and levonorgestrel</TI>
<SO>International Journal of Fertility</SO>
<YR>1989</YR>
<VL>32</VL>
<PG>29-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ramos-1989-_x0028_LNG_x002d_NE_x0029_" MODIFIED="2011-03-04 12:17:46 +0100" MODIFIED_BY="[Empty name]" NAME="Ramos 1989 (LNG-NE)" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ramos R, ApeloRuben, Osterja T, Vilar E</AU>
<TI>Comparative analysis of three different dose combinations of oral contraceptives</TI>
<SO>Contraception</SO>
<YR>1989</YR>
<VL>39</VL>
<NO>2</NO>
<PG>165-176</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reiter-1990-_x0028_NG_x002d_NE_x0029_" MODIFIED="2011-03-04 12:17:38 +0100" MODIFIED_BY="[Empty name]" NAME="Reiter 1990 (NG-NE)" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reiter SL, Baer LJ</AU>
<TI>Initial selection of oral contraceptives</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>1990</YR>
<VL>35</VL>
<NO>5</NO>
<PG>547-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rossmanith-1997-_x0028_DSG_x002d_NE_x0029_" MODIFIED="2011-03-04 12:17:56 +0100" MODIFIED_BY="[Empty name]" NAME="Rossmanith 1997 (DSG-NE)" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rossmanith WG, Ulrike W, Gasser S, Thun B, Steffens D</AU>
<TI>Comparative study on ovarian activity, cycle stability and tolerance during administration of two low-dose oral contraceptives</TI>
<TO>Ovarielle Aktivitat, Zyklusverhalten und Vertraeglichkeit bei niedrig-dosierten oralen Kontrazeptiva: eine Vergleichsstudie</TO>
<SO>Zentralb Gynakol</SO>
<YR>1997</YR>
<VL>119</VL>
<PG>538-544</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Sangwathan-2005_x0028_DRSP_x002d_LNG_x0029_" MODIFIED="2011-03-04 12:18:16 +0100" MODIFIED_BY="[Empty name]" NAME="Sangwathan 2005(DRSP-LNG)" YEAR="2005">
<REFERENCE MODIFIED="2010-10-01 14:47:08 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sangthawan M, Taneepanichskul S</AU>
<TI>A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 15&#956;g on premenstrual symptoms</TI>
<SO>Contraception</SO>
<YR>2005</YR>
<VL>71</VL>
<PG>1-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Serfaty-1998-_x0028_GSD_x002d_DSG_x0029_" MODIFIED="2011-03-04 12:18:32 +0100" MODIFIED_BY="[Empty name]" NAME="Serfaty 1998 (GSD-DSG)" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;We have written to authors with certain queries however there has been no reply.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Serfaty D, Vree ML</AU>
<TI>A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 20mcg ethinylestradiol and either 150mcg desogestrel or 75mcg gestodene</TI>
<SO>European Journal of Contraception and Reproductive Health Care</SO>
<YR>1998</YR>
<VL>3</VL>
<PG>179-189</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shoupe-1994-_x0028_DSG_x002d_NE_x0029_" MODIFIED="2011-03-04 12:18:44 +0100" MODIFIED_BY="[Empty name]" NAME="Shoupe 1994 (DSG-NE)" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shoupe D</AU>
<TI>Multicenter randomized comparative trial of two low-dose triphasic combined oral contraceptives containing desogestrel or norethindrone</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>1994</YR>
<VL>83</VL>
<NO>5</NO>
<PG>679-685</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Singh-1996-_x0028_DSG_x002d_NE_x0029_" MODIFIED="2011-03-04 12:18:55 +0100" MODIFIED_BY="[Empty name]" NAME="Singh 1996 (DSG-NE)" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Singh M, Thomas D, Singh R, Saxena BB, Ledger WJ</AU>
<TI>A triphasic oral contraceptive pill, CTR-05: clinical efficacy and safety</TI>
<SO>European Journal of Contraception and Reproductive Health Care</SO>
<YR>1996</YR>
<VL>1</VL>
<PG>285-292</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Suthipongse2004_x0028_DRSP_x002d_LNG_x0029_" MODIFIED="2011-03-04 12:19:16 +0100" MODIFIED_BY="[Empty name]" NAME="Suthipongse2004(DRSP-LNG)" YEAR="2004">
<REFERENCE MODIFIED="2010-10-01 14:50:50 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Suthipongse W, Taneepanichskul S</AU>
<TI>An open-label randomized comparative study of oral contraceptives between medications containing 3 mg drospirenone/30&#956;g ethinyl estradiol and 150&#956;g levonorgestrel/30&#956;g ethinyl estradiol inThai women</TI>
<SO>Contraception</SO>
<YR>2004</YR>
<VL>69</VL>
<PG>23-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weber_x002d_Diehl-1993-_x0028_GSD_x002d_NE_x0029_" MODIFIED="2011-03-04 12:19:32 +0100" MODIFIED_BY="[Empty name]" NAME="Weber-Diehl 1993 (GSD-NE)" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;We had some queries about side-effects leading to discontinuation and did contact the authors however there was no reply.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weber-Diehl F, Lehnert J, Lachnit U</AU>
<TI>Comparison of two triphasic oral contraceptives containing either gestodene or norethindrone: A randomized controlled trial</TI>
<SO>Contraception</SO>
<YR>1993</YR>
<VL>48</VL>
<PG>291-301</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_" MODIFIED="2011-03-04 12:19:42 +0100" MODIFIED_BY="[Empty name]" NAME="Winkler 2004 (DSG-LNG)" YEAR="2004">
<REFERENCE MODIFIED="2010-10-01 14:53:00 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Winkler UH, Ferguson H, Mulders JAPA</AU>
<TI>Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 g ethinyl estradiol</TI>
<SO>Contraception</SO>
<YR>2004</YR>
<VL>69</VL>
<PG>469-476</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zichella-1999-_x0028_GSD_x002d_DSG_x0029_" MODIFIED="2011-03-04 12:20:11 +0100" MODIFIED_BY="[Empty name]" NAME="Zichella 1999 (GSD-DSG)" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zichella L, Sbrignadello C, Tomassini A, Di Lieto A, Montoneri C, Zarbo G, Mancone M, Pietrobattista P, Bertoli G, Perrone G</AU>
<TI>Comparative study on the acceptability of two modern oral contraceptive preparations: 30mcg ethinyl estradiol combined with 150mcg desogestrel or 75mcg gestodene</TI>
<SO>Advances in Contraception</SO>
<YR>1999</YR>
<VL>15</VL>
<PG>191-200</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2011-02-28 13:55:18 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ahrendt-2009" MODIFIED="2010-09-14 14:13:21 +0200" MODIFIED_BY="[Empty name]" NAME="Ahrendt 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-09-14 14:13:16 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ahrendt H-J, Makalova D, PArke S, Mellinger U, Mansour D</AU>
<TI>Bleeding pattern and cycle control with an oestradiol-based oral contraceptive: a seven-cycle, randomised comparative trial estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel</TI>
<SO>Contraception</SO>
<YR>2009</YR>
<VL>80</VL>
<PG>436-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Akerlund-1993" NAME="Akerlund 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Akerlund M, Rode A, Westergaard J</AU>
<TI>Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 mcg desogestrel and either 30mcg or 20 mcg ethinyl estradiol</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1993</YR>
<VL>100</VL>
<NO>9</NO>
<PG>832-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anstee-1993" NAME="Anstee 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anstee P, Kovacs GT</AU>
<TI>A prospective randomized study comparing the clinical effects of a norethisterone and a levonorgestrel containing low dose oestrogen oral contraceptive pills</TI>
<SO>Australian and New Zealand Journal of Obstetrics and Gynaecology</SO>
<YR>1993</YR>
<VL>33</VL>
<NO>1</NO>
<PG>81-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ayangade-1989" NAME="Ayangade 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ayangade O, Akinyemi A</AU>
<TI>A comparative study of Norinyl 1/35 versus Lo-ovral in Ile-Ife Nigeria</TI>
<SO>International Journal of Gynecology and Obstetrics</SO>
<YR>1989</YR>
<VL>30</VL>
<PG>165-170</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bassol-2000" NAME="Bassol 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bassol S, Alvarado A, Celis C, Cravioto MC, Peralta O, Novelli J, Albornoz H, Kesseru E, Soares A, Petracco A, Isaia B, Mendes J, Bahamondes L, de Melo NR, Reyes-Marquez R, Albrecht G</AU>
<TI>Latin American experience with two low-dose oral contraceptives containing 30 mcg ethinylestradiol/75 mcg gestodene and 20 mcg ethinyl estradiol/150mcg desogestrel</TI>
<SO>Contraception</SO>
<YR>2000</YR>
<VL>62</VL>
<PG>131-135</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Benagiano-1989" MODIFIED="2011-01-04 16:26:53 +0100" MODIFIED_BY="[Empty name]" NAME="Benagiano 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;This study is the data from an interim analysis. We corresponded with authors regarding final report on complete data. In a letter dated 29/05/2001, Professor Benagiano has been kind to mention that he has double checked with Wyeth the sponsors of the study who confirmed that no final report was ever published. We appreciate Dr. Benagiano's help in clearing this matter.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benagiano G</AU>
<TI>Comparison of two monophasic oral contraceptives: Gestodene/Ethinyl Estradiol versus Desogestrel/Ethinyl Estradiol</TI>
<SO>International Journal of Fertility</SO>
<YR>1989</YR>
<VL>(supplement)</VL>
<PG>31-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boschitsch-2000" MODIFIED="2011-02-28 13:53:11 +0100" MODIFIED_BY="[Empty name]" NAME="Boschitsch 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-02-28 13:53:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boschitsch E, Skarabis H, Wuttke W, Heithecker R</AU>
<TI>The acceptability of a novel oral contraceptive containing drospirenone and it's effect on well-being</TI>
<SO>European Journal of Contraception and Reproductive Health Care</SO>
<YR>2000</YR>
<VL>5</VL>
<NO>supplement 3</NO>
<PG>34-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bounds-1979" NAME="Bounds 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bounds W, Vessey M, Wiggins P</AU>
<TI>A randomized double-blind trial of two low dose combine oral contraceptives</TI>
<SO>British Journal of Obstetrics and Gynaecology.</SO>
<YR>1979</YR>
<VL>86</VL>
<PG>325-329</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bruni-2000" NAME="Bruni 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bruni V, Croxatto H, De La Cruz , Dhont M, Durlot F, Fernandes MTMS, Andrade RP, Weisberg E, Rhoa M</AU>
<TI>A comparison of cycle control and effect on well-being of monophasic gestodene-, triphasic gestodene - and monophasic desogestrel- containing oral contraceptives</TI>
<SO>Gynecological Endocrinology</SO>
<YR>2000</YR>
<VL>14</VL>
<PG>90-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burkman-2007" MODIFIED="2010-09-14 12:45:26 +0200" MODIFIED_BY="[Empty name]" NAME="Burkman 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-09-14 12:45:19 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burkman RT, Fisher AC, LaGuardia KD</AU>
<TI>Effects of low-dose oral contraceptives on body weight: Results of a randomised study of up to 13 cycles of use.</TI>
<SO>The Journal of Reproductive Medicine</SO>
<YR>2007</YR>
<VL>52</VL>
<PG>1030-1034</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burkman-2009" MODIFIED="2010-09-14 12:54:24 +0200" MODIFIED_BY="[Empty name]" NAME="Burkman 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-09-14 12:54:17 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burkman RT, Fisher AC, Wan GJ, Barnowski CE, LaGuardia KD</AU>
<TI>Association between efficacy and body weight or mass index for two low-dose oral contraceptives</TI>
<SO>Contraception</SO>
<YR>2009</YR>
<VL>79</VL>
<PG>424-427</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cagnacci-2009" MODIFIED="2010-09-14 14:25:44 +0200" MODIFIED_BY="[Empty name]" NAME="Cagnacci 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-09-14 14:25:40 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cagnacci A, Ferrari S, Tirelli A, Zanin R, Volpe A</AU>
<TI>Route of administration of contraceptives containing desogestrel/etonorgestrel and insulin sensitivity: a prospective randomised study</TI>
<SO>Contraception</SO>
<YR>2009</YR>
<VL>80</VL>
<NO>1</NO>
<PG>34-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carlborg-1983" NAME="Carlborg 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carlborg L</AU>
<TI>Comparison of contraceptive acceptability of levonorgestrel and ethinyl estradiol administered in one three-phasic (TRIONETTA) and one monophasic (NEOVLETTA) version</TI>
<SO>Contraception</SO>
<YR>1983</YR>
<VL>27</VL>
<NO>5</NO>
<PG>439-451</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cislo-1986" MODIFIED="2011-02-28 13:53:45 +0100" MODIFIED_BY="[Empty name]" NAME="Cislo 1986" YEAR="1986">
<REFERENCE MODIFIED="2011-02-28 13:53:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cislo M, Palczynski B, Blok K</AU>
<TI>Comparative assessment of certain side-effects of the estrogen-progestin combined preparations</TI>
<SO>Ginekologica Polska</SO>
<YR>1986</YR>
<VL>57(supplement)</VL>
<PG>135-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cullberg-1982" NAME="Cullberg 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cullberg G, Samsoie G, Andersen RF, Bredesgaard P</AU>
<TI>Two oral contraceptives, efficacy, serum proteins and lipid metabolism. A comparative multicentre study on a triphasic and a fixed dose combination</TI>
<SO>Contraception</SO>
<YR>1982</YR>
<VL>26</VL>
<NO>3</NO>
<PG>229-243</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dickerson-1989" NAME="Dickerson 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dickerson JK</AU>
<TI>Study design for the triphasic randomized clinical trial</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1989</YR>
<VL>161</VL>
<PG>1392-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dunson-1993a" NAME="Dunson 1993a" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dunson TR, McLaurin VL, Aguayo EL</AU>
<TI>A multicenter comparative trial of triphasic and monophasic low-dose combined oral contraceptives</TI>
<SO>Contraception</SO>
<YR>1993</YR>
<VL>47</VL>
<PG>515-525</PG>
<PB>Butterworth-Heinemann</PB>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Edelman-2006" MODIFIED="2011-01-04 16:22:56 +0100" MODIFIED_BY="[Empty name]" NAME="Edelman 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-01-04 16:22:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Edelman AB, Koontz SL, Nichols MD, Jensen JT</AU>
<TI>Continuous oral contraceptives. Are bleeding patterns dependent on the hormones given?</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2006</YR>
<VL>107</VL>
<NO>3</NO>
<PG>657-665</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Edgren-1989" MODIFIED="2011-01-04 16:27:06 +0100" MODIFIED_BY="[Empty name]" NAME="Edgren 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Edgren RA, Nelson JH, Gordon RT, Keifer WS</AU>
<TI>Bleeding patterns with low-dose monophasic oral contraceptives</TI>
<SO>Contraception</SO>
<YR>1989</YR>
<VL>40</VL>
<NO>3</NO>
<PG>285-295</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garza-Flores-1992" NAME="Garza Flores 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garza-Flores J, Martinez M, Valles De Bourges V, Vazquez-Estrada L, McMullen S, Dunson R, Perez-Palacios G</AU>
<TI>Comparative assessment of two low-dose oral contraceptives, Lo-Femenal and Lo-estrin, in Mexican women</TI>
<SO>Advances in Contraception</SO>
<YR>1992</YR>
<VL>8</VL>
<PG>291-301</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hampton-2001" MODIFIED="2010-10-01 13:04:31 +0200" MODIFIED_BY="[Empty name]" NAME="Hampton 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-10-01 13:04:26 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hampton RM, Short M, Bieber E, Bouchard C, Ayotte N, Shangold G, Fisher AC, Creasy GW</AU>
<TI>Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20</TI>
<SO>Contraception</SO>
<YR>2001</YR>
<VL>63</VL>
<PG>289-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hampton-2008" MODIFIED="2010-09-14 12:17:10 +0200" MODIFIED_BY="[Empty name]" NAME="Hampton 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-09-14 12:17:03 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hampton MR, Zhang HF, Barnowski C, Wan GJ</AU>
<TI>Bleeding patterns with monophasic and triphasic low-dose ethinyl estradiol combined oral contraceptives</TI>
<SO>Contraception</SO>
<YR>2008</YR>
<VL>77</VL>
<PG>415-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kashanian-2010" MODIFIED="2010-09-14 13:29:47 +0200" MODIFIED_BY="[Empty name]" NAME="Kashanian 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-09-14 13:29:44 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kashanian M, Shahpourian F, Zare O</AU>
<TI>A comparison between monophasic levonorgestrel-ethinyl estradiol 150/30 and triphasic levonorgestrel-ethinyl estradiol 50-75-125/30-40-30 contraceptive pills for side effects and patient satisfaction: a study in Iran</TI>
<SO>European Journal of Obstetrics, Gynecology, and Reproductive Biology</SO>
<YR>2010</YR>
<VL>150</VL>
<NO>1</NO>
<PG>47-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaunitz-2000" NAME="Kaunitz 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaunitz AM</AU>
<TI>Efficacy, cycle control, and safety of two triphasic oral contraceptives: Cyclessa (Desogestrel/Ethinyl Estradiol) and Ortho-Novum 7/7/7 (Norethindrone/Ethinyl Estradiol): A randomized clinical trial</TI>
<SO>Contraception</SO>
<YR>2000</YR>
<VL>61</VL>
<PG>295-302</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaunitz-2009" MODIFIED="2010-09-14 13:35:43 +0200" MODIFIED_BY="[Empty name]" NAME="Kaunitz 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-09-14 13:35:40 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaunitz AM, Burkman RT, Fisher AC, LaGuardia KD</AU>
<TI>Cycle control with a 21-day compared with a 24-day oral contraceptive pill: A randomised controlled rial</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2009</YR>
<VL>114</VL>
<NO>6</NO>
<PG>1205-1212</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kirkman-1994" NAME="Kirkman 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kirkman RJE, Pedersen JH, Fioretti P, Roberts HE</AU>
<TI>Clinical comparison of two low dose oral contraceptives, Minulet and Mercilon in women over 30 years of age.</TI>
<SO>Contraception</SO>
<YR>1994</YR>
<VL>49</VL>
<PG>33-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koetsawang-1977" NAME="Koetsawang 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koetsawang S, Srisupandit S, Srivannaboon S, Bhiraleus P</AU>
<TI>Comparative clinical trial of two oral contraceptives with a low-estrogen content</TI>
<SO>Journal of Medical Association of Thailand</SO>
<YR>1977</YR>
<VL>60</VL>
<NO>8</NO>
<PG>368-373</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kovacs-1986" NAME="Kovacs 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kovacs L, Bartfai G, Apro G, Annus J, Bulpitt C, Belsey E, Pinol A</AU>
<TI>The effect of the contraceptive pill on blood pressure: a randomized controlled trial of three progestogen oestrogen combinations in Szeged, Hungary</TI>
<SO>Contraception</SO>
<YR>1986</YR>
<VL>33</VL>
<NO>1</NO>
<PG>69-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-London-1992" MODIFIED="2011-02-28 13:54:01 +0100" MODIFIED_BY="[Empty name]" NAME="London 1992" YEAR="1992">
<REFERENCE MODIFIED="2011-02-28 13:54:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>London RS, Chapdelaine A, Upmalis D, Olson W, Smith J</AU>
<TI>Comparative contraceptive efficacy and mechanism of action of the norgestimate containing triphasic oral contraceptive</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>1992</YR>
<VL>71</VL>
<NO>supplement 156</NO>
<PG>9-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oranratanaphan-2006" MODIFIED="2011-02-28 13:54:31 +0100" MODIFIED_BY="[Empty name]" NAME="Oranratanaphan 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-02-28 13:54:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oranratanaphan S, Taneepanichskul S</AU>
<TI>A double blind randomised control trial, comparing effect of drospirenone and gestodene to sexual desire and libido</TI>
<SO>Journal of the Medical Association of Thailand</SO>
<YR>2006</YR>
<VL>89</VL>
<NO>Suppl 4</NO>
<PG>S17-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Otolorin-1990" MODIFIED="2011-01-04 16:27:18 +0100" MODIFIED_BY="[Empty name]" NAME="Otolorin 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Otolorin EO, Falase EAO, Lapido OA</AU>
<TI>A comparative study of three oral contraceptives in Ibadan: Norinyl 1/35, Lo-ovral and Noriday 1/50</TI>
<SO>African Journal of Medical Science</SO>
<YR>1990</YR>
<VL>19</VL>
<PG>15-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perrone-1987" MODIFIED="2010-10-14 15:19:13 +0200" MODIFIED_BY="[Empty name]" NAME="Perrone 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-10-14 15:19:13 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perrone G, Calzolari E.</AU>
<TI>Oral contraceptives and their minor side effects.</TI>
<SO>Patologia e Clinica Obstetrica e Ginekologica</SO>
<YR>1987</YR>
<VL>15</VL>
<NO>1</NO>
<PG>6-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Refn-1990" NAME="Refn 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Refn H, Kjaer A, Lebech AM, Borgaard B, Schierup L</AU>
<TI>Clinical and hormonal effects of two contraceptives: Correlation to serum concentrations of levonorgestrel and gestodene</TI>
<SO>Contraception</SO>
<YR>1990</YR>
<VL>41</VL>
<NO>3</NO>
<PG>259-269</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosenberg-1996" NAME="Rosenberg 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosenberg MJ, Waugh MS, Higgins JE</AU>
<TI>The effect of Desogestrel, Gestodene and other factors on spotting and bleeding</TI>
<SO>Contraception</SO>
<YR>1996</YR>
<VL>53</VL>
<PG>85-90</PG>
<PB>Elsevier Science Inc.</PB>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sabatini-2006" MODIFIED="2010-09-14 12:37:33 +0200" MODIFIED_BY="[Empty name]" NAME="Sabatini 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-09-14 12:37:23 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sabatin R, Cagiano R</AU>
<TI>Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives</TI>
<SO>Contraception</SO>
<YR>2006</YR>
<VL>74</VL>
<PG>220-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanhueza-1979" NAME="Sanhueza 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanhueza H, Sivin I, Kumar S, Kessler M, Carrasco A, Yee J</AU>
<TI>A randomized double blind Study of two oral contraceptives</TI>
<SO>Contraception</SO>
<YR>1979</YR>
<VL>20</VL>
<NO>1</NO>
<PG>29-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schilling-1989" NAME="Schilling 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schilling LH, Bolding T, Chenault B, Chong AP, Fleury F, Forrest K, Glick HI, Hasson HM, Heil CG, London RS</AU>
<TI>Evaluation of the clinical performance of three triphasic oral contraceptives: A multicenter randomized comparative trial.</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1989</YR>
<VL>160</VL>
<PG>1264-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Teichmann-2009" MODIFIED="2010-09-14 13:41:02 +0200" MODIFIED_BY="[Empty name]" NAME="Teichmann 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-09-14 13:40:58 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Teichmann A, Apter D, Emerich J</AU>
<TI>Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial</TI>
<SO>Contraception</SO>
<YR>2009</YR>
<VL>80</VL>
<NO>6</NO>
<PG>504-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Uchikova-2008" MODIFIED="2010-09-14 14:07:09 +0200" MODIFIED_BY="[Empty name]" NAME="Uchikova 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-09-14 14:07:06 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Uchikova E, Pehlivanov B</AU>
<TI>Effect of two low-dose gestodene containing monophasic oral contraceptives on haemostasis in Bulgarian women</TI>
<SO>Expert Opinion on Pharmacology</SO>
<YR>2008</YR>
<VL>9</VL>
<NO>1</NO>
<PG>1839-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vartiainen-2001" NAME="Vartiainen 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vartiainen M, de Gezelle H, Broekmuelen CJH</AU>
<TI>Comparison of the effect on acne with a combigesic desogestrel- containing oral contraceptive and a preparation containing cyproterone acetate</TI>
<SO>European Journal of Contraception and Reproductive Health Care</SO>
<YR>2001</YR>
<VL>6</VL>
<PG>46-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Westhoff-2010" MODIFIED="2010-09-14 13:04:58 +0200" MODIFIED_BY="[Empty name]" NAME="Westhoff 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-09-14 13:04:51 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Westhoff CL, Torgal AH, Mayeda ER, Stanczyk FZ, Lerner JP, Benn EK, Paik M</AU>
<TI>Ovarian suppression in normal-weight and obese women during oral contraceptive use: a randomised controlled trial</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2010</YR>
<VL>116</VL>
<NO>2.1</NO>
<PG>275-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-WHO-_x0028_LNG_x002d_NE_x0029_" NAME="WHO (LNG-NE)" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Task Force on Oral Contraceptives</AU>
<TI>A randomized double-blind study of six combined oral contraceptives</TI>
<SO>Contraception</SO>
<YR>1982</YR>
<VL>25</VL>
<PG>231-241</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Winkler-2009" MODIFIED="2010-09-14 13:12:35 +0200" MODIFIED_BY="[Empty name]" NAME="Winkler 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-09-14 13:12:32 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Winkler UH, Sudik R</AU>
<TI>The effects of two monophasic oral contraceptives containing 30mcg of ethinyl estradiol and either 2mg of chlormadinone acetate or 0.15mg of desogestrel on lipid, hormone and metabolic parameters</TI>
<SO>Contraception</SO>
<YR>2009</YR>
<VL>79</VL>
<PG>15-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Winkler-2010" MODIFIED="2010-09-14 13:17:17 +0200" MODIFIED_BY="[Empty name]" NAME="Winkler 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-09-14 13:17:10 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Winkler UH, Rohm P, Hoschen K</AU>
<TI>An open-label, comparative study of the effects of a dose-reduced oral contraceptive containing 0.02 mg ethinylestradiol/2 mg chlormadinone acetate on hemostatic parameters and lipid and carbohydrate metabolism variables</TI>
<SO>Contraception</SO>
<YR>2010</YR>
<VL>81</VL>
<NO>5</NO>
<PG>391-400</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yildezhan-2009" MODIFIED="2010-10-01 13:12:52 +0200" MODIFIED_BY="[Empty name]" NAME="Yildezhan 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-10-01 13:12:52 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yildezhan R, Yildezhan B, Adali E, Yoruk P, Birol F, Suer N</AU>
<TI>Effects of two combined oral contraceptives containing ethinyl estradiol 30&#956;g combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure</TI>
<SO>Arch Gynecol Obstet</SO>
<YR>2009</YR>
<VL>280</VL>
<PG>255-261</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zrubek-1986" MODIFIED="2011-02-28 13:55:18 +0100" MODIFIED_BY="[Empty name]" NAME="Zrubek 1986" YEAR="1986">
<REFERENCE MODIFIED="2011-02-28 13:55:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zrubek HK, Czajka R, Lopucka M</AU>
<TI>Clinical assessment of the contraceptive preparations Angravid, Gravistat and Triquilar</TI>
<SO>Ginekologia Polska</SO>
<YR>1986</YR>
<VL>57 (supplement)</VL>
<PG>139-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2010-10-14 15:19:13 +0200" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-03-25 11:13:11 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2011-03-25 11:13:11 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-ACOG-1995" NAME="ACOG 1995" TYPE="JOURNAL_ARTICLE">
<AU>ACOG Technical Bulletin</AU>
<TI>Hormonal contraception</TI>
<SO>International Journal of Gynecology and Obstetrics,</SO>
<YR>1995</YR>
<VL>48</VL>
<PG>115-126</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Arowojolu-2009" MODIFIED="2011-03-25 10:46:14 +0100" MODIFIED_BY="[Empty name]" NAME="Arowojolu 2009" TYPE="COCHRANE_REVIEW">
<AU>Arowojolu AO, Gallo MF, Lopez LM, Grimes DA, Garner SE</AU>
<TI>Combined oral contraceptive pills for treatment of acne</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009 Jul 8</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2011-03-25 10:46:14 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-03-25 10:46:14 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004425"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-CONSORT-2010" MODIFIED="2010-10-22 16:55:12 +0200" MODIFIED_BY="[Empty name]" NAME="CONSORT 2010" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Altman DG, Moher D, for the CONSORT Group</AU>
<TI>CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials.</TI>
<SO>BMJ</SO>
<YR>2010</YR>
<VL>340</VL>
<PG>c332</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dinger-2011" MODIFIED="2011-02-28 12:31:31 +0100" MODIFIED_BY="[Empty name]" NAME="Dinger 2011" TYPE="JOURNAL_ARTICLE">
<AU>Dinger J, Minh TD, Buttmann N, Bardenheuer K</AU>
<TI>Effectiveness of oral contraceptive pills in a large US cohort comparing progestogen and regimen</TI>
<SO>Obstet Gynecol</SO>
<YR>2011</YR>
<VL>117</VL>
<NO>1</NO>
<PG>1-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Edelman-2010" MODIFIED="2011-03-25 11:13:11 +0100" MODIFIED_BY="[Empty name]" NAME="Edelman 2010" TYPE="COCHRANE_REVIEW">
<AU>Edelman A, Gallo MF, Jensen JT, Nichols MD, Grimes DA</AU>
<TI>Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>8</NO>
<IDENTIFIERS MODIFIED="2011-03-25 11:13:11 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-03-25 11:13:11 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004695"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gallo-2008" MODIFIED="2011-03-25 11:04:46 +0100" MODIFIED_BY="[Empty name]" NAME="Gallo 2008" TYPE="COCHRANE_REVIEW">
<AU>Gallo MF, Lopez LM, Grimes DA, Schulz KF, Helmerhorst FM</AU>
<TI>Combination contraceptives: effects on weight</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2011-03-25 11:04:46 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-03-25 11:04:46 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003987"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Grimes-2011" MODIFIED="2011-02-28 12:26:27 +0100" MODIFIED_BY="[Empty name]" NAME="Grimes 2011" TYPE="JOURNAL_ARTICLE">
<AU>Grimes DA, Schulz KF</AU>
<TI>Nonspecific side effects of oral contraceptives: nocebo or noise?</TI>
<SO>Contraception</SO>
<YR>2011</YR>
<VL>83</VL>
<PG>5-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Henzl-2000" NAME="Henzl 2000" TYPE="BOOK_SECTION">
<AU>Henzl MR, Edwards JA</AU>
<TI>Pharmacology of Progestin:17 alpha Hydroxyprogesterone Derivatives and Progestins of the First and Second Generation</TI>
<SO>Progestins and Antiprogestins in Clinical Practice</SO>
<YR>2000</YR>
<PG>101-132</PG>
<EN>1</EN>
<ED>Sitruk-Ware R, Mishell DR</ED>
<PB>Marcel Dekker Inc.</PB>
<CY>United states of America</CY>
<MD>English</MD>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="ISBN: 0-8247-8291-7"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2010-10-29 10:49:43 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="BOOK">
<AU>Higgins JPT, Green S, editors</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1</SO>
<YR>[updated September 2008]</YR>
<PB>The Cochrane Collaboration, 2008.</PB>
<CY>Available from www.cochrane-handbook.org.</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hillard-1992" NAME="Hillard 1992" NOTES="&lt;p&gt;Hilllard PJ. Oral contraception noncompliance: the extent of the problem. Advances in Contraception, 1992;8(Suppl. 1):13-20.&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Hilllard PJ</AU>
<TI>Oral contraception noncompliance: the extent of the problem.</TI>
<SO>Advances in contraception</SO>
<YR>1992</YR>
<VL>8</VL>
<NO>Suppl. 1</NO>
<PG>13-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Krattenmacher-2000" MODIFIED="2010-10-14 11:42:54 +0200" MODIFIED_BY="[Empty name]" NAME="Krattenmacher 2000" TYPE="JOURNAL_ARTICLE">
<AU>Krattenmacher R</AU>
<TI>Drospirenone: pharmacology and pharmacokinetics of a unique progestogen</TI>
<SO>Contraception</SO>
<YR>2000</YR>
<VL>62</VL>
<PG>29&#8211;38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lachnit_x002d_Fixon-1991" NAME="Lachnit-Fixon 1991" NOTES="&lt;p&gt;Lachnit-Fixon U . The role of oral contraception in fertility regulation. Advances in Contraception, 1991;7(suppl 12):9-17.&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Lachnit-Fixon U</AU>
<TI>The role of oral contraception in fertility regulation</TI>
<SO>Advances in Contraception,</SO>
<YR>1991</YR>
<VL>7</VL>
<NO>suppl 12</NO>
<PG>9-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lopez-2009" MODIFIED="2011-03-24 21:38:22 +0100" MODIFIED_BY="[Empty name]" NAME="Lopez 2009" TYPE="COCHRANE_REVIEW">
<AU>Lopez LM, Kaptein AA, Helmerhorst FM.</AU>
<TI>Oral contraceptives containing drospirenone for premenstrual syndrome.</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009 Apr 15</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2011-03-24 21:38:22 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-03-24 21:38:22 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006586"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mishell-2007" MODIFIED="2011-02-15 10:26:21 +0100" MODIFIED_BY="[Empty name]" NAME="Mishell 2007" TYPE="JOURNAL_ARTICLE">
<AU>Mishell DR, Guillebaud J, Westhoff C, Nelson AL, Kaunitz AM, Trussel J, Davis AJ</AU>
<TI>Combined hormonal contraceptive trials: variable data collection and bleeding assessment methodologies influence study outcomes and physician perception</TI>
<SO>Contraception</SO>
<YR>2007</YR>
<VL>75</VL>
<NO>1</NO>
<PG>4-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Revman-2008" MODIFIED="2011-01-31 11:56:25 +0100" MODIFIED_BY="[Empty name]" NAME="Revman 2008" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2008</YR>
<EN>5.0</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-1963" NAME="Smith 1963" TYPE="JOURNAL_ARTICLE">
<AU>Smith H, Hughes GA, Douglas GH, Hartley D, McLoughlin BJ</AU>
<TI>Totally synthetic (+-) 13-alkyl-3-hydroxy and methoxy -gona-1,3,5 (10)-trien-17-ones and related compounds</TI>
<SO>Experientia,</SO>
<YR>1963</YR>
<VL>9</VL>
<PG>394-396</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Speroff-2005" MODIFIED="2011-01-31 12:25:21 +0100" MODIFIED_BY="[Empty name]" NAME="Speroff 2005" TYPE="BOOK">
<AU>Speroff L, Darney PD</AU>
<SO>A clinical guide for contraception</SO>
<YR>2001</YR>
<EN>Third</EN>
<PB>Lippincott Williams &amp; Wilkins</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Vliet-2006a" MODIFIED="2011-03-24 21:40:06 +0100" MODIFIED_BY="[Empty name]" NAME="Van Vliet 2006a" TYPE="COCHRANE_REVIEW">
<AU>van Vliet HA, Grimes DA, Lopez LM, Schulz KF, Helmerhorst FM</AU>
<TI>Triphasic versus monophasic oral contraceptives for contraception</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2011-03-24 21:40:06 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-03-24 21:40:06 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003553"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Van-Vliet-2006b" MODIFIED="2011-03-24 21:40:37 +0100" MODIFIED_BY="[Empty name]" NAME="Van Vliet 2006b" TYPE="COCHRANE_REVIEW">
<AU>Van Vliet HA, Grimes DA, Helmerhorst FM, Schulz KF</AU>
<TI>Biphasic versus monophasic oral contraceptives for contraception</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2011-03-24 21:40:37 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-03-24 21:40:37 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002032"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2011-03-07 11:59:45 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Maitra-2004" MODIFIED="2011-03-07 11:59:45 +0100" MODIFIED_BY="[Empty name]" NAME="Maitra 2004" TYPE="JOURNAL_ARTICLE">
<AU>Maitra N, Kulier R, Bloemenkamp K, Helmerhorst F, Gulmezoglu M</AU>
<TI>Progestogens in combined oral contraceptives for contraception</TI>
<SO>Reproductive Health</SO>
<YR>2004</YR>
<VL>1</VL>
<NO>1</NO>
<PG>.</PG>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-03-22 12:20:29 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2011-03-22 12:20:29 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2011-03-22 12:09:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Affinito-1993-_x0028_GSD_x002d_NGM_x0029_">
<CHAR_METHODS>
<P>Randomized trial. Total enrolled 189, no exclusions. Intention to treat analysis not clear. No blinding.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-18 13:22:24 +0200" MODIFIED_BY="[Empty name]">
<P>189 women in the age group 16 to 38 using standard inclusion criteria, history of at least 3 regular cycles, if smokers then less than 35 years. Study location: Italy. Setting not mentioned.<BR/>Exclusion criteria: excessive alcohol consumption, PAP smear &gt; grade 3, SBP &gt; 140 mm Hg, DBP &gt; 90, drug abuse, abnormal blood tests. Work-up at admission included gynaecological history, breast and cervical smear examination, medical and gynaecological examination.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A) Monophasic gestodene 75 mcg+ EE 30 mcg versus B) monophasic norgestimate 250 mcg+ EE 35 mcg. Duration of study: 6 cycles.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Contraceptive effectiveness, discontinuation rate and reasons for discontinuation, cycle control analysis overall side-effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-22 12:09:16 +0100" MODIFIED_BY="[Empty name]">
<P>Cycle control analysis is not included in the review as it uses the number of cycles in the denominator. Sponsored by WYETH-AYERST.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-25 11:54:04 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anttila-2009-_x0028_DRSP_x002d_DSG_x0029_">
<CHAR_METHODS MODIFIED="2010-10-18 11:44:57 +0200" MODIFIED_BY="[Empty name]">
<P>Multicentred open-label RCT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-18 11:56:14 +0200" MODIFIED_BY="[Empty name]">
<P>453 healthy women aged 18-35 years (30 years for smokers) from centres in Austria, Finland, Lithuania and Estonia. Excluded criteria were: contraindication to COC use, pregnancy, BMI&gt;30, lactation or abortion within 3 months, hypersensitivity to study drug, suspicious cervical smear within 6 months, use of DSG, DRSP or IUS/IUD within 1 cycle of treatment, use of depot contraception within last 6 cycles before start of treatment. Approximately 55% were switchers. Participants were started on the first day of menses or scheduled bleed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-19 12:10:59 +0200" MODIFIED_BY="[Empty name]">
<P>Monophasic DRSP 3mg/EE 20&#956;g (24 active tablets and 4 placebos) versus monophasic DSG 150&#956;g/EE 20&#956;g (21 active /7 placebos) for 7 cycles.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-18 11:56:36 +0200" MODIFIED_BY="[Empty name]">
<P>Cycle control, bleeding pattern and efficacy.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-10-25 11:54:04 +0200" MODIFIED_BY="[Empty name]">
<P>200/230 in the DRSP group versus 194/223 in the DSG group completed the study. There were 4 post-randomisation withdrawals, 1 in the DRSP group (participant lost to follow-up before receiving medication) and 3 in the DSG group (1 lost to follow-up before starting, 1 withdrew due to pregnancy and 1 withdrew due to weight gain). For this review, we have re-included the latter two into the data analysis. Discontinuation due to poor cycle control was not reported, suggestive of selective reporting bias. Authors contacted and provided some additional data. Funded by BAYER-SCHERING.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-22 12:09:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Droegem_x00fc_ller-1989-_x0028_LNG_x002d_NE_x0029_">
<CHAR_METHODS>
<P>Randomized multicentre open label study on 157 subjects with three triphasic OCs. Technique of allocation concealment unclear. Analysis by intention to treat.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>157 women in outpatient setting were randomized to three groups. Age group, inclusion and exclusion criteria are not mentioned. It is not clear how many of these subjects were starters or switchers and which day the pill was started.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A) triphasic LNG 50/75/125 +EE 30/40/30 (Trilevlen) versus B) triphasic norethindrone 500/1000/500 +EE35 mcg (Trinorinyl) versus C) triphasic norethindrone 500/750/1000 + EE 35 mcg (OrthoNovum7/7/7). Both formulations were given in 28 day packs with 21 active tablets and 7 placebos. Study duration 6 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Study mentions only cycle control analysis. There is no information on contraceptive effectiveness, discontinuation rate and side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-22 12:09:55 +0100" MODIFIED_BY="[Empty name]">
<P>No sponsorship/conflict of interest declared.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-22 12:10:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dunson-1993-_x0028_NG_x002d_NE_x0029_">
<CHAR_METHODS MODIFIED="2010-11-02 14:23:25 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation by use of pre- printed sealed envelopes. No blinding. Analysis not by intention to treat. There were no post randomisation exclusions.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>892 women 18-35 years age group, in good health, desiring to use OCs, &gt; 42 days post-partum, no known contraindications to OC use, if breast feeding, then at least &gt;4 months post-partum, at least one normal period since termination of pregnancy. 42% had past history of OC use. The study was conducted across various centres in Malaysia, Egypt, Thailand and Mexico.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A) Monophasic norgestrel 0.3 mg/EE 30 mcg (Lo-femenal)<BR/>vs<BR/>B) monophasic norethindrone acetate 1.5 mg/ EE 30 mcg (Lo-estrin).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Contraceptive effectiveness, <BR/>discontinuation rate and reasons for discontinuation<BR/>cycle control analysis<BR/>overall side-effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-22 12:10:44 +0100" MODIFIED_BY="[Empty name]">
<P>User failure defined as missing 2 or more pills. In norgestrel group, 4 pregnancies due to method failure, 4 due to user failure. In norethindrone group pregnancy was due to user failure. Trial organised by FHI<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Endrikat-1999-_x0028_GSD_x002d_DSG_x0029_">
<CHAR_METHODS>
<P>Randomized trial, no blinding; allocation concealment unclear. Analysis both by intention to treat and valid case analysis. 1,563 enrolled and 87 excluded for protocol violations therefore not included in efficacy analysis.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1,563 women age group 18 to 35 years willing for contraception for at least 12 months. Conducted in 123 centres across 6 European countries. Exclusion criteria: previous use of DSG/EE in this dose; known contraindication to OC use; use of injectables with in 6 months; genital pathology, bleeding not diagnosed, and migraine with menses and specific concomitant pathology.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A) Monophasic gestodene 75 mcg+EE20 mcg versus B) monophasic desogestrel 150 mcg+EE20 mcg; studied over 12 cycles of treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Contraceptive effectiveness, discontinuation rate, cycle control analysis and side-effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Supported by SCHERING AG.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Endrikat-2001-_x0028_LNG_x002d_NE_x0029_">
<CHAR_METHODS>
<P>Multicentre randomized trial; no blinding was used; intention to treat analysis<BR/>3 arms - 2 arms included in the review</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>767 women between 18 and 35 years; exclusion criteria: use of depot contraception 6 months before study begin, concurrent diseases, contraindications for oral contraceptives, unexplained vaginal bleeding, menstruation associated with migraine</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A) Monophasic levonorgestrel 100 mcg+EE 20 mcg<BR/>B) Monophasic norethisterone 500 mcg+EE 20 mcg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Discontinuation rate, side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Sponsored by SCHERING AG.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-25 11:54:26 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Foidart-2000-_x0028_DRSP_x002d_DSG_x0029_">
<CHAR_METHODS>
<P>Randomized open label multicentre trial across 26 study centres. Allocation concealment unclear. Analysis was not by intention to treat. There were 13 post randomisation exclusions.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>900 women between 18 to 35 years, healthy, menstruating and seeking OC use. Both starters and switchers were included. Women were recruited from outpatient clinics across 26 centres in Europe (Belgium, Germany, NL).<BR/>Exclusion Criteria: obesity, liver, vascular and metabolic disease, genital infection, use of diuretics or drugs known to affect hepatic enzymes.<BR/>Regular follow-up during study and for 3 months after completion.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A) Monophasic drospirenone 3 mg+EE30 mcg (Yasmin) versus B) monophasic desogestrel 150 mcg +EE30 mcg for 21 days days over 26 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Contraceptive effectiveness, cycle control, discontinuation rate and overall side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-10-25 11:54:26 +0200" MODIFIED_BY="[Empty name]">
<P>Cycle control is given in terms of cycles rather than subjects and has therefore not been included. Study supported by SCHERING.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-25 09:11:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gruber-2006-_x0028_DRSP_x002d_DSG_x0029_">
<CHAR_METHODS MODIFIED="2010-10-19 11:40:52 +0200" MODIFIED_BY="[Empty name]">
<P>Multicentred open-label randomised clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-19 12:00:51 +0200" MODIFIED_BY="[Empty name]">
<P>445 healthy women aged 15-35 years (excluding smokers over 30 years) in Italy, Belgium, the Czech Republic and the United Kingdom. Excluded if there were contraindications to COC use, use if depot contraceptives within 6 months of study, use of DSG or DRSP OC within one cycle of study; childbirth, abortion or lactation within three cycles of study or a suspicious cervical smear result.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-19 12:12:33 +0200" MODIFIED_BY="[Empty name]">
<P>Monophasic DRSP 3mg/EE 20&#956;g versus monophasic DSG 150&#956;g/EE 20&#956;g.Treatment started on first day of menses or withdrawal bleed. Both had 21 active tablets and 7 placebos.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-19 12:06:04 +0200" MODIFIED_BY="[Empty name]">
<P>Cycle control, contraceptive efficacy, safety, discontinuation and satisfaction.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-10-25 09:11:30 +0200" MODIFIED_BY="[Empty name]">
<P>Weight decreased in the DRSP group (-0.22kg (SD 2.25) vs +0.45kg (2.94) in the DSG group. Baseline characteristics comparable. Intention to treat analysis. Four post randomisation exclusions, two in each group received no treatment, no other details given. Sponsored by Schering.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-19 12:57:37 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-GSD-Group-1999-_x0028_GSD_x002d_DSG_x0029_">
<CHAR_METHODS>
<P>Multicentre open label randomized trial on 1074 women. Allocation concealment is unclear. There were no post randomisation exclusions. Analysis was by intent to treat.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-19 12:57:37 +0200" MODIFIED_BY="[Empty name]">
<P>1074 women aged &gt;18 years, healthy, menstruating regularly and not breast feeding were enrolled from 61 centres in Europe. Exclusion Criteria: smokers&gt;36 years, history of thromboembolic disease, cardiovascular or cerebrovascular disease, abnormal pap smear, breast feeding and using concomitant medication which would interfere with study. There were comparable number of starters and switchers in each group. There is no mention of a washout period.<BR/>Work up at admission involved medical, obstetric and gynaecological history and examination, and pap smear testing.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A) Monophasic gestodene 60 mcg/EE15 mcg given for 24 days versus B) monophasic desogestrel 150 mcg/ EE20 mcg (Mercilon) given for 21 days. Both pill types were started on day 1 of menses. Study duration 6 cycles.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Contraceptive effectiveness, cycle control, discontinuation rate and reasons, side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Supported by WYETH AYERST. Cycle control for spotting and breakthrough bleeding is given in terms of cycles.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-25 11:54:43 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guang_x002d_Sheng2010_x0028_DRSP_x002d_DSG_x0029_">
<CHAR_METHODS MODIFIED="2010-10-22 09:40:27 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial in ratio DRSP3:DSG1. 12 centres in China from December 2003 to March 2006</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-21 14:30:36 +0200" MODIFIED_BY="[Empty name]">
<P>786 healthy Chinese women aged 20 to 35 years. Included if: three normal cycles before study; willingness to use no other forms of hormonal treatment; normal smear; normal breast and gynaecological examination; at least 3 normal cycles since abortion or delivery; no systemic diseases. Included first time users or past COC user with wash-out of 3 months.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-22 11:30:10 +0200" MODIFIED_BY="[Empty name]">
<P>Monophasic DRSP 3mg/EE 30&#956;g vs. monophasic DSG 150&#956;g/EE 30&#956;g over 13 cycles. Both treatments had 21 active days and 7 placebos. Started on first day of menses.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-22 09:43:01 +0200" MODIFIED_BY="[Empty name]">
<P>Efficacy, bleeding patterns and side-effects at baseline, cycle 4, cycle 10 and cycle 13.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-10-25 11:54:43 +0200" MODIFIED_BY="[Empty name]">
<P>No exclusions. Baseline characteristics similar. Satisfaction reported: 478/573 (83.4%) DRSP participants satisfied vs. 130/195 (66.7%) DSG participants. Higher loss to follow-up in the DRSP group. No discontinuation due to cycle disturbance reported. Cycle control data reported as mean (SD) for pre-specified 90 day reference periods. Translation and editorial support provided by BAYER. Unpublished information sought but not obtained from authors.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-25 11:54:50 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Halbe-1998-_x0028_GSD_x002d_DSG_x0029_">
<CHAR_METHODS MODIFIED="2010-10-22 09:51:14 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised trial on 595 women over 6 cycles of OC use. Technique of allocation concealment is unclear. Analysis by intention to treat.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>595 women at reproductive age and with regular menstrual cycles. Multicentre trial across centres in Brazil. Study setting is not mentioned. Exclusion criteria: Contraindication OC use, complete breast feeding and women on medication known to interact with OCs. <BR/>Both starters (65%) and switchers(35%) were included. Work-up at admission included detailed medical history and examination. Follow up was at 1, 3 and 6 cycles. No details available on day of starting the pill. No period of washout was given for the switchers.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A) Monophasic desogestrel 150 mcg+EE 30 mcg vs B) monophasic gestodene 75 mcg+EE30 mcg given for 6 cycles.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Contraceptive effectiveness, cycle control and discontinuation rate, reasons for discontinuation.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-10-25 11:54:50 +0200" MODIFIED_BY="[Empty name]">
<P>Supported by ORGANON NV.<BR/>The data on cycle control is expressed as subjects per cycle, rather than as overall subjects experiencing menstrual irregularities; therefore these data has not been included.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-02 14:38:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huber-2000-_x0028_DRSP_x002d_DSG_x0029_">
<CHAR_METHODS>
<P>Randomized open label multicentre trial. Allocation concealment unclear. There were 29 post randomisation exclusions. Analysis was by intention to treat.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-02 14:38:19 +0100" MODIFIED_BY="[Empty name]">
<P>2098 women aged 18 to 35 years were enrolled from 80 centres across 8 countries in Europe. Both starters and switchers were included with switchers being given one cycle of wash out. Exclusion criteria: pregnancy, lactation, liver disease, metabolic or vascular diseases, tumours, genital infections, drug/alcohol abuse, on medication such as diuretics or those causing interaction with OCs.<BR/>Work up at admission included physical and gynaecological examination, cervical smear and general blood tests. The follow up was at 2 or 3, 6, 9 13 cycles and 6 weeks.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-25 11:55:03 +0200" MODIFIED_BY="[Empty name]">
<P>A) Monophasic drospirenone 3 mg/EE30 mcg (Yasmin) versus B) monophasic desogestrel 150 mcg/EE30 mcg (Marvelon) over 13 cycles. 1680 women were given drospirenone and 418 were given desogestrel containing OC. Pills were given in 28 day packs. There is no information on day of pill start.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Contraceptive effectiveness, cycle control, BP, body weight, side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Supported by SCHERING AG.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-25 11:55:15 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kelly-2010-_x0028_DRSP_x002d_LNG_x0029_">
<CHAR_METHODS MODIFIED="2010-10-19 14:03:20 +0200" MODIFIED_BY="[Empty name]">
<P>Multicentred randomised clinical trial. Randomised in 2DRSP:1LNG ratio.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-20 11:21:30 +0200" MODIFIED_BY="[Empty name]">
<P>424 women aged 16-40 (35yrs maximum for smokers) having regular cycles and requesting contraception; on no other hormonal treatment during the study (except for thyroxin and insulin). Excluded if there were contraindications to COC including a history of herpes, obesity or concurrent treatment with hepatic enzyme-inducing drugs. Two thirds of participants were COC switchers.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-20 14:41:44 +0200" MODIFIED_BY="[Empty name]">
<P>Monophasic DRSP 3mg/EE 30&#956;g versus monophasic LNG 150&#956;g/EE 30&#956;g over 7 cycles.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-19 14:37:21 +0200" MODIFIED_BY="[Empty name]">
<P>PMS, acne, menstrual symptoms, cycle control and well-being.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-10-25 11:55:15 +0200" MODIFIED_BY="[Empty name]">
<P>Intention to treat analysis. Baseline characteristics similar. HIgher proportion lost to follow-up in the LNG group (14/282 DSRP vs 13/142 LNG). No post-randomisation exclusions. Some unpublished data from authors included. Funded and coordinated by BAYER-SCHERING.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-19 14:35:48 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koetsawang-1995-_x0028_GSD_x002d_DSG_x0029_">
<CHAR_METHODS MODIFIED="2010-10-19 14:35:48 +0200" MODIFIED_BY="[Empty name]">
<P>Randomized trial; no post-randomisation exclusions. Intention to treat analysis not clear. Allocation concealment unclear. No blinding.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>783 women with mean age of 26 years, healthy women with regular menstrual cycles of at least 24 days. Study conducted across Family Health centres in Thailand. Exclusion criteria: known contraindications to OC use, use of medication and currently breast feeding. Work up included detailed medical history and physical exam. Follow-up at 1,3 and 6 cycles.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A) Monophasic desogestrel 150 mcg+EE 30 mcg versus B) monophasic gestodene 75 mcg+EE 30 mcg.<BR/>Duration of study 6 cycles.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Contraceptive effectiveness, discontinuation and reasons for discontinuation, cycle control, side-effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>This study was sponsored by ORGANON.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-31 13:13:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kriplani-2010-_x0028_DRSP_x002d_DSG_x0029_">
<CHAR_METHODS MODIFIED="2010-10-25 09:19:34 +0200" MODIFIED_BY="[Empty name]">
<P>A randomised clinical trial conducted in New Delhi, India. Randomisation by means of a computer generated table.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-25 09:14:36 +0200" MODIFIED_BY="[Empty name]">
<P>60 women with PCOS defined by the presence of any two of the following: oligomenorrhoea and/or anovulation, clinical or biochemical signs of hyperandrogenism, PCO morphology on ultrasound (12 or more follicles in each ovary or increased ovarian volume&gt;10ml), <I>and requesting contraception</I>. Excluded if they had hypothyroidism, hyperprolactinaemia, hormonal treatment within 6 months, smoking, alcohol, recent surgery for PCOS, contraindications to COC or adrenal insufficiency on ACE inhibitors or ATII blockers.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-25 09:40:07 +0200" MODIFIED_BY="[Empty name]">
<P>Monophasic DRSP 3mg/EE 30&#956;g versus monophasic DSG 150&#956;g/EE 30&#956;g for 6 cycles.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-25 09:40:42 +0200" MODIFIED_BY="[Empty name]">
<P>Acne, hirsutism, bodyweight, BMI, cycle control, BP, ultrasound parameters, biochemical parameters assessed at 1, 3 and 6 months during treatment and 3 and 6 months after treatment.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-31 13:13:33 +0100" MODIFIED_BY="[Empty name]">
<P>Baseline difference in weight was 68.3kg [±12.4 SD] in the DRSP group vs. 60.44kg [±7.56 SD] (p=0.04) in the DSG group. At 6 months, the DRSP group had mean weight loss of -1.25 kg vs mean weight gain in the DSG group of +1.11kg no SDs given). More acne experienced in the DSG group. No funding/conflict of interest. Unpublished data provided by primary author.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-02 14:40:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-L.-America-1994-_x0028_GSD_x002d_DSG_x0029_">
<CHAR_METHODS>
<P>Randomized trial, allocation concealment unclear. Randomized in blocks of 12, analysis was by intention to treat. No post randomisation exclusions.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-02 14:40:45 +0100" MODIFIED_BY="[Empty name]">
<P>352 women age group 18-41 years seeking contraception, sexually active, non-nursing, 12 women in the gestodene group and 24 in the desogestrel group were switchers from other OCs.<BR/>Location: Argentina, Brazil, Chile, Columbia, Venezuela.<BR/>Exclusion criteria: women with thromboembolic disease, liver disease, oestrogen dependant neoplasia, disorders of lipid metabolism, other known contraindication to OCs.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A) monophasic gestodene 75mcg / EE 30 mcg vs B) monophasic desogestrel 150mcg/ EE 30 mcg.<BR/>Follow-up at 6 months, check BP and weight at 3 and 6 cycles of treatment. Also 20 women randomly selected for laboratory tests.<BR/>Study duration 6 cycles.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>effectiveness,<BR/>discontinuation rate and reasons for discontinuation<BR/>cycle control, side effects and <BR/>side-effects leading to discontinuation.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>The study was supported by grants from WYETH-AYERST.<BR/>Some of the side-effects have been mentioned in graphical format (figure 3) and these have not been included in the analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-22 12:15:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Loudon-1990-_x0028_GSD_x002d_LNG_x0029_">
<CHAR_METHODS MODIFIED="2010-10-29 11:36:23 +0200" MODIFIED_BY="[Empty name]">
<P>Randomized double blind trial, 456 were randomised, 31 post randomisation exclusions. Analysis was not by intention to treat.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-29 11:36:27 +0200" MODIFIED_BY="[Empty name]">
<P>Women aged 16-35 years requesting oral contraception studied over 6 cycles, standard contraindications being applied. Post-partum women excluded unless menstruation established for at least 2 cycles. 54% reported past OC use in each group.<BR/>Exclusion criteria: women less than 16 years, DBP &gt; 90 mm amenorrhoea, medical contraindications to OC use.<BR/>This study was conducted in Family Planning centres in the UK.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A) Monophasic gestodene 75mcg / EE 30mcg (Femodene)<BR/>vs<BR/>B) monophasic levonorgestrel 150mcg /EE 30mcg (Microgynon).<BR/>Study duration 6 cycles.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Contraceptive effectiveness<BR/>discontinuation rate and reasons for discontinuation,<BR/>cycle control, side-effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-22 12:15:43 +0100" MODIFIED_BY="[Empty name]">
<P>Sponsorship not stated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-25 11:56:20 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Percival-1990-_x0028_NG_x002d_NE_x0029_">
<CHAR_METHODS>
<P>Randomized trial on 469 women. Randomization was based on randomized code list provided by Parke-Davis. Allocation concealment adequate. Analysis not by intention to treat. Intervention giver was blinded to the medication given.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-25 11:56:20 +0200" MODIFIED_BY="[Empty name]">
<P>469 women in the age group 15 to 35 years, menstruating regularly for at least 2 months prior to enrolment and with no known contraindication to OC use. Classified into pre-study users and nonusers. 53% were non-users. Study conducted across 4 University centres in Canada.<BR/>Exclusion criteria not clearly elucidated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A) triphasic Norgestrel 0.1/.15/25+EE 30/40/30 (Triphasil) vs B) triphasic Norethindrone500/750/1000+EE 35mcg (Ortho7/7/7) over a duration of 6 cycles. Work-up at admission included a history and physical exam. Follow-up was at 3 and 6 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Discontinuation rate, reasons for discontinuation, cycle control, side-effects Intermenstrual bleeding recorded as cycles and not subjects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Supported by PARKE-DAVIS division of Warner-Lambert, Canada.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rabe-1989-_x0028_GSD_x002d_LNG_x0029_">
<CHAR_METHODS>
<P>Randomized clinical trial. No blinding used. Allocation concealment unclear. Analysis by intention to treat. There were no post randomisation exclusions.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>361 women randomized to either gestodene or LNG containing pill for 6 cycles. Characteristics of participants, inclusion and exclusion criteria not mentioned. Study conducted across 5 European countries.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A) Monophasic gestodene 75 mcg/EE30 mcg vs B) monophasic levonorgestrel 150 mcg/EE30 mcg.<BR/>Study was conducted in three phases A, B, and C.<BR/>In phase A, cycle control and contraceptive efficacy was evaluated over 6 cycles. In phase B 707 women including those from phase A were given the gestodene pill over 24 cycles. In phase C 30 women from either group on gestodene and LNG were studied for metabolic effects. Only Study A is included for purpose of this review.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Contraceptive effectiveness, cycle control.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Sponsored by SCHERING AG. Data for spotting and break through bleeding is presented according to cycles.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-29 11:37:36 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ramos-1989-_x0028_LNG_x002d_NE_x0029_">
<CHAR_METHODS MODIFIED="2010-10-29 11:37:31 +0200" MODIFIED_BY="[Empty name]">
<P>Randomized trial, double-blind. Allocation concealment unclear. Analysis by intent to treat. No post randomisation exclusions.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-29 11:37:36 +0200" MODIFIED_BY="[Empty name]">
<P>1800 women seeking family planning, with a mean age of 26 years were enrolled from Health centres and Family Planning clinics in the Philippines. Inclusion and exclusion criteria not stated. Physical and pelvic exam prior to study. Follow up was at 1, 4, 7 and 11 months.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A) monophasic NE 0.4 mg + EE 35mcg vs B) monophasic LNG 150mcg+ EE 30mcg.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Contraceptive effectiveness, cycle control, side-effects leading to discontinuation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Project was supported by UNFPA. Some OC pills were provided by WYETH.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-22 12:18:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reiter-1990-_x0028_NG_x002d_NE_x0029_">
<CHAR_METHODS MODIFIED="2010-10-29 11:38:03 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised trial across 3 pill groups over 12 months, allocation concealment unclear, analysis was not by intention to treat, post randomisation exclusions are not mentioned.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>477 women &gt; 18 years of age were enrolled from Planned Parenthood Centres in the US. Mean age was 20.3 years. Inclusion and exclusion criteria are not clearly stated. No information is available on the work up at admission. Follow- up every 2/3 months.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A) triphasic norethindrone 500/750/1000+ EE 35mcg (Ortho Novum 7/7/7) vs B) triphasic norgestrel 0.1/0.15/0.25 mg +EE 30/40/30 mcg(Triphasil) . Pills were given in 28 day packs. Ortho Novum had a Sunday start whereas Triphasil had a first day start.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Cycle control.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-22 12:18:01 +0100" MODIFIED_BY="[Empty name]">
<P>Support not stated.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-22 12:18:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rossmanith-1997-_x0028_DSG_x002d_NE_x0029_">
<CHAR_METHODS>
<P>Randomized multicentre trial, double blind, allocation concealment unclear. Analysis was by intent to treat.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Women aged 18 to 35, both starters and switchers were included. Pre trial work-up included physical and gynaecological. examination and biochemical tests. <BR/>Inclusion and exclusion criteria not clearly stated. Study conducted across 10 centres in Germany.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A) monophasic norethisterone 500 mcg/ EE20 mcg (EVE 20) vs B) monophasic desogestrel 150 mcg/ EE20<BR/>mcg (Lovelle).<BR/>Study duration 6 cycles. For first 3 treatment cycles participants underwent estimation of LH, FSH, sex steroids and vaginal US for ovarian follicular activity.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Contraceptive effectiveness, cycle control, side-effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-22 12:18:16 +0100" MODIFIED_BY="[Empty name]">
<P>Original paper in German. Data on cycle control analysis given in cycles. Study supported by GRUNENTHAL GmBH Ltd.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-21 14:05:09 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sangwathan-2005_x0028_DRSP_x002d_LNG_x0029_">
<CHAR_METHODS MODIFIED="2010-10-21 13:44:54 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised trial stated but no details given. Conducted in Bangkok, Thailand.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-21 13:45:35 +0200" MODIFIED_BY="[Empty name]">
<P>104 women 18-35 years requesting COC for at least 6 months, included if regular cycles lasting 21-35 days, no injectables within 6 months and no OCs within 3 months of the study, 3 consecutive normal periods after the removal of contraceptive implant or IUD or post-abortion or delivery. Excluded if pregnancy or suspected pregnancy, breastfeeding, smokers, and if contraindications according to WHO categories 2, 3, 4.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-21 13:45:48 +0200" MODIFIED_BY="[Empty name]">
<P>Monophasic DRSP 3mg/EE 30&#956;g vs. monophasic LNG/EE 30&#956;g for 6 cycles.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-21 14:05:09 +0200" MODIFIED_BY="[Empty name]">
<P>Premenstrual symptoms.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-10-21 14:02:48 +0200" MODIFIED_BY="[Empty name]">
<P>No sponsor declared. Enrolled 104, analysed 99 (three lost to follow-up, 2 withdrawn). Little usable data. Additional unpublished information sought but not obtained.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-22 12:18:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Serfaty-1998-_x0028_GSD_x002d_DSG_x0029_">
<CHAR_METHODS MODIFIED="2010-11-02 14:54:21 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, multicentre trial. </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1026 sexually active healthy women aged 18-45, with regular cycles, with normal lipid and carbohydrate profiles and a BMI within 18 to 29. Exclusion criteria: known contraindication to OC use, smokers &gt;35 years, less than 2 months postpartum, use of injectable contraceptive within 6 months prior to study.<BR/>Both starters and switchers were included. Study conducted across 52 centres in France.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-02 14:54:32 +0100" MODIFIED_BY="[Empty name]">
<P>A) monophasic desogestrel 150 mcg/ EE20mcg (Mercilon) vs B) monophasic gestodene 75 mcg/ EE20mcg (Harmonet).<BR/>Study duration 6 cycles. Follow-up was at 3 and 6 cycles.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Contraceptive efficacy and cycle control analysis. This data on cycle control is in graphical format from which it is not possible to deduce figures.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-22 12:18:46 +0100" MODIFIED_BY="[Empty name]">
<P>Only data on contraceptive efficacy included in review. Sponsored by ORGANON.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-22 12:19:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shoupe-1994-_x0028_DSG_x002d_NE_x0029_">
<CHAR_METHODS MODIFIED="2010-11-02 14:57:05 +0100" MODIFIED_BY="[Empty name]">
<P>Multicentre randomized trial using computer generated random number tables.<BR/>Double blinding. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>812 women aged 18 to 35, healthy volunteers, sexually active. Both starters and switchers included. Inclusion criteria not specified. Exclusion criteria : known contraindication to OC, on medication, BMI &gt; 95 th percentile, breast feeding, use of progestogen containing IUD in past 3 months, injectable contraceptive within 12 months., irregular cycles. Setting: FP and Ob-Gyn. clinics, across USA and Canada. Work-up included complete physical exam, pap smears and biochemical tests. Follow-up at 3 and 6 months.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A) Triphasic desogestrel 50/100/150 mcg+ EE 35/30/30 mcg versus B) triphasic norethindrone 500/750/1000 mcg+ EE 35 mcg.<BR/>Duration 6 cycles.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Contraceptive efficacy, discontinuation rate, side-effects and cycle- control analysis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-22 12:19:08 +0100" MODIFIED_BY="[Empty name]">
<P>Cycle control figures given as % in graphic form, therefore not used. Study supported by ORGANON and FHI.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-22 12:19:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Singh-1996-_x0028_DSG_x002d_NE_x0029_">
<CHAR_METHODS>
<P>Randomized trial, allocation concealment unclear. Analysis was by intention to treat.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>46 healthy sexually active women aged 19 to 35 years, study setting (in New York) not mentioned. Exclusion Criteria: known contraindications to OC use, &lt;80% or &gt;130% of ideal body weight, pregnancy, current breast feeding, irregular menstrual cycles, diabetes, hypertension, alcohol/drug abuse, abnormal breast or physical examination, on medication known to interact with OCs.<BR/>At work up a complete physical examination, pap smear, blood tests were performed. The women in CTR-05 group were followed for additional 13 cycles. No information on starters and switchers.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A) Triphasic desogestrel 50/100/150 +EE 35/30/30 mcg (CTR-05) versus B) triphasic norethindrone 500/750/1000 mcg +EE35/35/35 mcg (Ortho Novum 7/7/7). Both pill types were supplied as 28 day packets with 21 active pills and 7 placebos. Study duration 6 cycles.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Contraceptive effectiveness, cycle control, discontinuation rate and reasons for discontinuation, side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-22 12:19:19 +0100" MODIFIED_BY="[Empty name]">
<P>This study was funded by a grant from ORGANON.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-22 11:30:21 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Suthipongse2004_x0028_DRSP_x002d_LNG_x0029_">
<CHAR_METHODS MODIFIED="2010-10-22 11:21:42 +0200" MODIFIED_BY="[Empty name]">
<P>Reported as "randomly allocated" but no details given.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-22 11:28:04 +0200" MODIFIED_BY="[Empty name]">
<P>120 women aged 16-35 in Thailand, requesting contraception. Included if no injectables or OCs within 6 months of study; minimum of three normal regular cycles following implant or IUD removal or abortion or delivery. Excluded if suspected pregnancy; breastfeeding or contraindication to COCs. All pill starters, no switchers. Started on the first day of menses.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-22 11:27:45 +0200" MODIFIED_BY="[Empty name]">
<P>Monophasic DRSP 3mg/EE 30&#956;g versus monophasic LNG 150&#956;g/EE 30&#956;g over 7 cycles.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-22 11:20:41 +0200" MODIFIED_BY="[Empty name]">
<P>Cycle control, efficacy, adverse effects and body weight at baseline, cycle 1, cycle 3 and cycle 6.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-10-22 11:30:21 +0200" MODIFIED_BY="[Empty name]">
<P>No conflict of interests declared. Five post-randomisation exclusions. Baseline characteristics similar. Little data to contribute. Unpublished information requested from authors but not obtained.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-22 12:19:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weber_x002d_Diehl-1993-_x0028_GSD_x002d_NE_x0029_">
<CHAR_METHODS MODIFIED="2010-11-02 14:58:52 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized study, allocation concealment unclear, no blinding used.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>254 women aged 16 to 50 years were enrolled. Inclusion, exclusion criteria not mentioned. Total randomised 229, with 25 post-randomisation exclusions. Study location: Germany.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A) Triphasic Gestodene 50/70/100 mcg+EE 30/40/30mcg vs B) triphasic Norethindrone 500/750/1000 mcg+ EE 35/35/35 mcg.Total duration of treatment 12 cycles.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Contraceptive effectiveness, discontinuation and reasons for discontinuation; cycle control, side-effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-22 12:19:50 +0100" MODIFIED_BY="[Empty name]">
<P>Figures for side-effects given as % in graphic form. Study sponsored by SCHERING AG.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-22 12:20:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_">
<CHAR_METHODS MODIFIED="2010-10-22 12:50:27 +0200" MODIFIED_BY="[Empty name]">
<P>Multicentred randomised clinical trial conducted in Germany and the Netherlands</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-22 12:52:18 +0200" MODIFIED_BY="[Empty name]">
<P>1027 healthy women aged 18-45 with BMI between 18 and 29kg/m2. Excluded if: menses &lt;24 days or &gt;35 days; &gt;35 and a smoker; use of concomitant or addictive drugs; mental disorder including depression; use of OC, IUD or implant within 1 month or depot injection within 6 months of enrolment. Overall, more pill switchers (59%) than pill starters (41%).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-22 13:39:35 +0200" MODIFIED_BY="[Empty name]">
<P>Monophasic DSG 150&#956;g/EE20&#956;g vs. monophasic LNG/EE 100&#956;g/EE 20&#956;g for 6 cycles.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-22 12:53:05 +0200" MODIFIED_BY="[Empty name]">
<P>Cycle control, bleeding/spotting, dysmenorrhoea, PMS, acne and discontinuation. Assessment at baseline, cycle 1, 3 and 6.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-22 12:20:29 +0100" MODIFIED_BY="[Empty name]">
<P>There were 29 post-randomisation exclusions/withdrawals (17 DSG and 12 LNG). Published data and unpublished data/information obtained from authors. Funded by NV ORGANON.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-22 12:20:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zichella-1999-_x0028_GSD_x002d_DSG_x0029_">
<CHAR_METHODS MODIFIED="2010-11-02 15:00:21 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized open parallel group study, allocation concealment is unclear. </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-22 13:04:02 +0200" MODIFIED_BY="[Empty name]">
<P>241 women aged 18 to 40 were enrolled in a University setting across 5 centres in Italy. The women had regular cycles with no contraindication to OC use. All women were starters. Exclusion Criteria: history of thromboembolic disease, thrombophlebitis, jaundice in pregnancy, oestrogen dependant carcinomas, Diabetes Mellitus or impaired glucose tolerance, breast feeding and no history of OC use in preceding 3 months.<BR/>A baseline history and medical examination was performed. Follow up was at 1, 3 and 6 cycles.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>A) Monophasic desogestrel 150 mcg/EE30mcg (Marvelon) versus B) monophasic gestodene 75 mcg/EE30mcg (Femodene) over 6 cycles <BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Contraceptive effectiveness, cycle control, discontinuation rate and reasons for discontinuation, side effects leading to discontinuation.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-22 12:20:09 +0100" MODIFIED_BY="[Empty name]">
<P>The data on cycle control is given in graphical form. Similarly the side effects are reported as percentages for cycles 1, 3 and 6 and have not been included in review. Study was supported by ORGANON NV.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2011-03-03 13:21:47 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2010-09-14 14:18:40 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ahrendt-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-14 14:18:40 +0200" MODIFIED_BY="[Empty name]">
<P>A RCT comparing oral OC preparations with different oestradiols (Estradiol valerate with EE) and different progestogens (DNG and LNG). Also 'dynamic dosing' is used in the E2V preparation vs monophasic dosing in the EE preparation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Akerlund-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study compares two monophasic OCs containing one progestogen desogestrel with oestrogen in two doses of 30 and 20 mcg.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Anstee-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study compares two monophasic contraceptives NET 500/EE 35 mcg and LNG 150/EE 30 mcg. There appear to be some problems in the study methodology.<BR/>1) Of the 240 women enrolled, 140 only were available for follow-up between 1 and 16 months, giving a post randomisation exclusion rate of 42%.<BR/>2) Of these 140 women, at the end of 15 cycles, 34/80 and 14/60 respectively were available for follow up i.e. 46 women in either group discontinued for reasons that are not entirely clear.<BR/>3) Randomisation was performed according to hospital record numbers.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ayangade-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study compares a monophasic norethindrone 1mg + EE 35 mcg OC (Norinyl 1/35) with a norgestrel 0.3 mg + EE 30 mcg OC (Lo-Ovral) over a 12 cycle study period. Fifty subjects were enrolled in the study . Allocation concealment was by pre printed and sealed envelopes. The study was excluded due to an imbalance in loss to follow-up (26% vs 18%).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bassol-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Compares a 30 mcg EE pill containing gestodene with a 20 mcg EE pill containing desogestrel. The difference in the oestrogen content of the two formulations is &gt; than 105 mcg.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Benagiano-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>This is an interim analysis of a multicenter study, and presents selected data, no data on follow up.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Boschitsch-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>This is not an original study. This study was based on asking women who were involved in two major clinical trials how they felt after the trials had ended.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bounds-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>This is a randomised double blind trial of two combined OCs containing NE 1.0 mg +EE 20 mcg and LNG 150 mcg+EE 30 mcg. 133 sexually active women in the 16 to 39 age group studied over 12 cycles. There were 23 post randomisation exclusions. Study only mentions contraceptive efficacy with 2 /55 pregnancies in NE group and 1/55 in LNG group. No details obtained on number discontinued and reasons for discontinuation, cycle control and side-effects. Analysis not by intention to treat. Incomplete study data. Study supported by Parke-Davis. No correspondence with authors attempted.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bruni-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study compares three oral contraceptives: 1) monophasic gestodene + EE 30 mcg 2) triphasic gestodene + triphasic EE and monophasic desogestrel + EE 20 mcg. The monophasic pill is compared with triphasic pill. Also the two monophasic pills have 30 and 20 mcg EE respectively.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-14 12:55:00 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burkman-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-14 12:55:00 +0200" MODIFIED_BY="[Empty name]">
<P>An RCT comparing a monophasic OC containing norethindrone acetate with a triphasic OC containing norgestimate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-14 12:59:48 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burkman-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-14 12:59:48 +0200" MODIFIED_BY="[Empty name]">
<P>Secondary analysis of data from an RCT comparing a monophasic OC containing NETA with a triphasic OC containing NGM.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-14 14:26:50 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cagnacci-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-14 14:26:50 +0200" MODIFIED_BY="[Empty name]">
<P>A RCT of monophasic OCs (DSG vs CMA) over 6 cycles reporting biochemical outcomes only (insulin sensitivity, C-peptide and lipid studies).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Carlborg-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Compares monophasic LNG containing OC with an LNG containing triphasic OC.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cislo-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>This paper in Polish compares two OC pills with an EE content of 50 mcg/pill.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-14 12:50:31 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cullberg-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-14 12:50:31 +0200" MODIFIED_BY="[Empty name]">
<P>Compares monophasic desogestrel containing OC with triphasic LNG containing OC.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dickerson-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>This is only a study design. There is no data available. Medline search did not reveal any other full text article.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dunson-1993a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Compares triphasic LNG containing OC with monophasic LNG containing OC</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-02-28 13:12:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Edelman-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-02-28 13:12:57 +0100" MODIFIED_BY="[Empty name]">
<P>A four-arm RCT comparing continuous regimens of LNG-EE and NE-EE, and two EE doses. This trial is included in the review on continuous dosing vs. cyclic regimens (<LINK REF="REF-Edelman-2010" TYPE="REFERENCE">Edelman 2010</LINK>).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-14 12:31:14 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Edgren-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-14 12:31:14 +0200" MODIFIED_BY="[Empty name]">
<P>Unclear number of women included in the analyses; loss-to-follow up&gt;60%</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-14 12:31:52 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garza-Flores-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-14 12:31:52 +0200" MODIFIED_BY="[Empty name]">
<P>The data from this study appears to have been included in the multicentric trial of Dunson 1993. In this Dunson study 17% women were from Mexico (=151). We have excluded this study to avoid duplication of data. We wrote to FHI and Dr. Garza-Flores for a clarification but received no response.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-01 13:17:15 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hampton-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-01 13:17:15 +0200" MODIFIED_BY="[Empty name]">
<P>Compares monophasic preparation with triphasic preparation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-14 12:57:52 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hampton-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-14 12:57:52 +0200" MODIFIED_BY="[Empty name]">
<P>Secondary analysis of an RCT comparing a monophasic combined OC (NETA) with a triphasic OC containing norgestimate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-14 13:31:56 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kashanian-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-14 13:31:56 +0200" MODIFIED_BY="[Empty name]">
<P>A RCT comparing a monophasic LNG OC to a triphasic LNG OC.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kaunitz-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>This randomised trial compares two triphasic oral contraceptives. Cyclessa contains 25 mcg EE combined with desogestrel in a triphasic combination and Ortho-novum 7/7/7 contains 35 mcg EE with NET in a triphasic combination. The difference in the oestrogen content of the formulations is 210 mcg over 21 pill taking days.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-14 13:37:43 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kaunitz-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-14 13:37:43 +0200" MODIFIED_BY="[Empty name]">
<P>A RCT comparing a monophasic OC containing DRSP with a triphasic OC containing NGM.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kirkman-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>This is a randomised trial comparing a 30 mcg EE pill containing gestodene (Minulet) with a 20 mcg EE pill containing desogestrel (Mercilon).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Koetsawang-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study compares the same progestin lynestrenol in two doses of 1 and 2 mg with 40 mcg ethinyl estradiol in 300 women at the Mahidol University, Bangkok.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kovacs-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study compares three oral contraceptives two of which contain EE in the standard dose of 50 mcg. The trial also looks only at Blood Pressure as major outcome variable which is not pertinent to the objectives of this review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-14 13:38:10 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-London-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-14 13:38:10 +0200" MODIFIED_BY="[Empty name]">
<P>This study set in USA compares two triphasic OCs containing either Norgestimate and fixed dose EE (35 mcg) or LNG. The study duration was 6 cycles. The trial studied 2115 women in the NGM arm and 2132 women in the LNG arm. The outcomes studied were contraceptive efficacy, discontinuation rate and overall side effects. This trial was excluded due to high loss to follow-up rate of 32.23% ( 715/2115 and 654/2132 in each group respectively).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-29 09:35:40 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oranratanaphan-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-29 09:35:40 +0200" MODIFIED_BY="[Empty name]">
<P>Double blind RCT comparing DRSP-containing COC with GSD-containing COC with the difference in EE component between the two pills of &gt; 105&#956;g per cycle.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Otolorin-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>The loss to follow up was 26% and 40% in the 2 groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-14 15:22:09 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Perrone-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-14 15:22:09 +0200" MODIFIED_BY="[Empty name]">
<P>Not randomised. 40 women received monophasic LNG/EE, 32 women received triphasic LNG/EE and 34 women received monophasic DSG/EE.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-14 15:20:59 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Refn-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-14 15:20:59 +0200" MODIFIED_BY="[Empty name]">
<P>This study comparing a gestodene containing OC with another LNG containing OC looks predominantly at biochemical outcomes. Data on cycle control is scarce. This is a double publication ( Am J Obstet Gynecol 1990;163:374-7</P>
<P>Two triphasic oral contraceptives containing levonorgestrel and gestodene are compared in this trial. The study looks at predominantly biochemical outcomes. There is scarce data on clinical outcomes. Double publication : (Am. J. Obstet Gynecol 1990;163:374-7)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-14 15:21:48 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rosenberg-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-14 15:21:48 +0200" MODIFIED_BY="[Empty name]">
<P>This is not an original study. It compares pooled data from two independent studies- one by G. Benagiano and the other paper is not referenced. We wrote to Dr. Rosenberg seeking clarification but received no reply.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-14 12:41:29 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sabatini-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-14 12:41:29 +0200" MODIFIED_BY="[Empty name]">
<P>Three arm open label RCT comparing two combined OCs (EE/LNG, EE/GSD) and a vaginal ring. No details regarding the method of randomisation (possibly quasi-randomisation) and 26 post-randomisation exclusions reported without giving details. Denominators absent in reporting. Possible high risk of bias.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sanhueza-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study compares Norinyl 1+50 which contains 0.05 mg of mestranol with Ovral which contains 50 mcg of ethinyl estradiol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schilling-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>This is a comparative study of three triphasic oral contraceptives given for 4 cycles, which does not fit into review protocol; the inclusion criteria for trials is 6 months minimum.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-14 13:42:13 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Teichmann-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-14 13:42:13 +0200" MODIFIED_BY="[Empty name]">
<P>A Phase 3 RCT comparing continuous EE/LNG with cyclical EE/LNG.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-14 14:08:16 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Uchikova-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-14 14:08:16 +0200" MODIFIED_BY="[Empty name]">
<P>A RCT comparing two monophasic OCs with different oestrogen doses and the same progestogen (GSD)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vartiainen-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>The pills in this study were given for therapeutic effects and not for contraceptive purposes. Also the study compares a combigesic pill with a monophasic pill.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-14 13:08:58 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Westhoff-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-14 13:08:58 +0200" MODIFIED_BY="[Empty name]">
<P>A RCT comparing monophasic 30EE/150LNG vs monophasic 20EE/100LNG i.e. different doses of the same progestogen in both preparations.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-14 13:06:34 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-WHO-_x0028_LNG_x002d_NE_x0029_">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-14 13:06:34 +0200" MODIFIED_BY="[Empty name]">
<P>Unclear number of women included in the analysis; loss-to-follow-up &gt;50%</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-14 13:13:12 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Winkler-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-14 13:13:12 +0200" MODIFIED_BY="[Empty name]">
<P>RCT of monophasic OCs (DSG vs CMA) over 6 cycles looking at biochemical (lipid, hormone and metabolic) parameters only.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-14 13:19:07 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Winkler-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-14 13:19:07 +0200" MODIFIED_BY="[Empty name]">
<P>A Phase 2 open-label RCT comparing 20EE/2CMA vs 30EE/150LNG vs 20EE/150DSG. 165 subjects randomised. Outcomes are biochemical parameters only.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-01 13:16:26 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yildezhan-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-01 13:16:26 +0200" MODIFIED_BY="[Empty name]">
<P>RCT of mono GSD vs mono DRSP over 12 cycles but only biochemical data reported. Attempts to obtain unpublished data unsuccessful.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-14 13:09:06 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zrubek-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-14 13:09:06 +0200" MODIFIED_BY="[Empty name]">
<P>This article in Polish compares three OC preparations.<BR/>A) monophasic Mestranol 0.05 mg+Ethynodiol 1.0 mg in 21 tablets (Angravid)<BR/>B) monophasic EE 50 mcg + LNG 125 mcg in 21 tablets (Gravistat)<BR/>C) Triphasic LNG 50/75/125 mcg +EE30/40/30 mcg (Triquilar)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2010-10-14 15:19:13 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2011-03-22 12:20:18 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2011-03-22 12:16:35 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:18:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Affinito-1993-_x0028_GSD_x002d_NGM_x0029_">
<DESCRIPTION>
<P>'Randomized' - insufficient details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-18 12:34:49 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anttila-2009-_x0028_DRSP_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Computer generated in balanced blocks.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:19:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Droegem_x00fc_ller-1989-_x0028_LNG_x002d_NE_x0029_">
<DESCRIPTION>
<P>randomised multicentre study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:22:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dunson-1993-_x0028_NG_x002d_NE_x0029_">
<DESCRIPTION>
<P>Method of randomisation not clearly described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:28:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Endrikat-1999-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION>
<P>randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:27:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Endrikat-2001-_x0028_LNG_x002d_NE_x0029_">
<DESCRIPTION>
<P>multicentre randomised trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:30:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Foidart-2000-_x0028_DRSP_x002d_DSG_x0029_">
<DESCRIPTION>
<P>multicentre trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:33:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-GSD-Group-1999-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Multicentre trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-19 12:13:37 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gruber-2006-_x0028_DRSP_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Yes, computer generated sequence, balanced blocks</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-21 14:32:29 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guang_x002d_Sheng2010_x0028_DRSP_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Computer-generated sequence in ratio 3DRSP:1DSG</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:34:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Halbe-1998-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Multicentre trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:35:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huber-2000-_x0028_DRSP_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Multicentre trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-19 14:04:19 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kelly-2010-_x0028_DRSP_x002d_LNG_x0029_">
<DESCRIPTION>
<P>Centrally coordinated, multicentre randomisation in 2DRSP:1LNG ratio</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:39:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koetsawang-1995-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION>
<P>'Randomised'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-25 09:20:36 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kriplani-2010-_x0028_DRSP_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Randomisation by means of a computer generated table.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:41:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L.-America-1994-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Randomized in blocks of 12</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-22 12:16:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loudon-1990-_x0028_GSD_x002d_LNG_x0029_">
<DESCRIPTION>
<P>Stated 'randomised', no details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:44:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Percival-1990-_x0028_NG_x002d_NE_x0029_">
<DESCRIPTION>
<P>Randomization was based on randomized code list provided by Parke-Davis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rabe-1989-_x0028_GSD_x002d_LNG_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:48:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ramos-1989-_x0028_LNG_x002d_NE_x0029_">
<DESCRIPTION>
<P>'randomised'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:49:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reiter-1990-_x0028_NG_x002d_NE_x0029_">
<DESCRIPTION>
<P>'randomised'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:51:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rossmanith-1997-_x0028_DSG_x002d_NE_x0029_">
<DESCRIPTION>
<P>Multicentre trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-20 14:59:24 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sangwathan-2005_x0028_DRSP_x002d_LNG_x0029_">
<DESCRIPTION>
<P>Stated as 'randomised' but no details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:53:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Serfaty-1998-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Randomisation in blocks of 4.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:55:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shoupe-1994-_x0028_DSG_x002d_NE_x0029_">
<DESCRIPTION>
<P>Computer generated random number tables.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Singh-1996-_x0028_DSG_x002d_NE_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-22 11:26:07 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Suthipongse2004_x0028_DRSP_x002d_LNG_x0029_">
<DESCRIPTION>
<P>No details given - &#8220;subjects were randomly allocated", could be quasi-randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Weber_x002d_Diehl-1993-_x0028_GSD_x002d_NE_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-22 12:53:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_">
<DESCRIPTION>
<P>Centrally controlled computer-generated randomisation, sequential numbers given to subjects in order of enrolment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Zichella-1999-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-03-22 12:13:31 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-28 15:26:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Affinito-1993-_x0028_GSD_x002d_NGM_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-18 13:24:32 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anttila-2009-_x0028_DRSP_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Unpublished information provided stated that the study treatments were packaged in such that it was not possible for the investigators or subjects to know which treatment was allocated before opening the pack.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-28 15:27:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Droegem_x00fc_ller-1989-_x0028_LNG_x002d_NE_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:21:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dunson-1993-_x0028_NG_x002d_NE_x0029_">
<DESCRIPTION>
<P>Adequate, sealed envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:25:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Endrikat-1999-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:28:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Endrikat-2001-_x0028_LNG_x002d_NE_x0029_">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-03 11:39:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Foidart-2000-_x0028_DRSP_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:32:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-GSD-Group-1999-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-19 12:13:41 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gruber-2006-_x0028_DRSP_x002d_DSG_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-21 14:32:40 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guang_x002d_Sheng2010_x0028_DRSP_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-22 12:13:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Halbe-1998-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-03 11:39:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huber-2000-_x0028_DRSP_x002d_DSG_x0029_">
<DESCRIPTION>
<P>not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-19 14:52:09 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kelly-2010-_x0028_DRSP_x002d_LNG_x0029_">
<DESCRIPTION>
<P>Allocation concealed with the use of envelopes but not from the principle investigator.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-03 11:40:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koetsawang-1995-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-25 09:20:23 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kriplani-2010-_x0028_DRSP_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Sequential opaque envelopes (unpublished information obtained from authors).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-03 11:40:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-L.-America-1994-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION>
<P>not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-03 11:40:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loudon-1990-_x0028_GSD_x002d_LNG_x0029_">
<DESCRIPTION>
<P>not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:45:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Percival-1990-_x0028_NG_x002d_NE_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-03 11:40:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rabe-1989-_x0028_GSD_x002d_LNG_x0029_">
<DESCRIPTION>
<P>not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-03 11:40:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ramos-1989-_x0028_LNG_x002d_NE_x0029_">
<DESCRIPTION>
<P>not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-03 11:40:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reiter-1990-_x0028_NG_x002d_NE_x0029_">
<DESCRIPTION>
<P>not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-03 11:41:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rossmanith-1997-_x0028_DSG_x002d_NE_x0029_">
<DESCRIPTION>
<P>not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-21 13:48:52 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sangwathan-2005_x0028_DRSP_x002d_LNG_x0029_">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-03 11:41:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Serfaty-1998-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION>
<P>not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-03 11:41:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shoupe-1994-_x0028_DSG_x002d_NE_x0029_">
<DESCRIPTION>
<P>not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-03 11:41:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Singh-1996-_x0028_DSG_x002d_NE_x0029_">
<DESCRIPTION>
<P>not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-22 11:22:15 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Suthipongse2004_x0028_DRSP_x002d_LNG_x0029_">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-03 11:41:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weber_x002d_Diehl-1993-_x0028_GSD_x002d_NE_x0029_">
<DESCRIPTION>
<P>not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-22 13:39:59 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-03 11:42:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zichella-1999-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION>
<P>not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-01-04 16:22:35 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-02 14:20:01 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Affinito-1993-_x0028_GSD_x002d_NGM_x0029_">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-18 12:36:58 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Anttila-2009-_x0028_DRSP_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Inadequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-02 14:19:52 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Droegem_x00fc_ller-1989-_x0028_LNG_x002d_NE_x0029_">
<DESCRIPTION>
<P>Open label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-02 14:21:52 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dunson-1993-_x0028_NG_x002d_NE_x0029_">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-02 14:25:29 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Endrikat-1999-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Open label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-02 14:28:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Endrikat-2001-_x0028_LNG_x002d_NE_x0029_">
<DESCRIPTION>
<P>open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-02 14:30:49 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Foidart-2000-_x0028_DRSP_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-02 14:33:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-GSD-Group-1999-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Open label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-19 12:13:55 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gruber-2006-_x0028_DRSP_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Open label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-21 14:33:39 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Guang_x002d_Sheng2010_x0028_DRSP_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Open-label.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Halbe-1998-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-02 14:35:27 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Huber-2000-_x0028_DRSP_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-19 14:52:52 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kelly-2010-_x0028_DRSP_x002d_LNG_x0029_">
<DESCRIPTION>
<P>Single/partial blinding - patients and caregiver were blind to intervention, not the principle investigator.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-02 14:40:10 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Koetsawang-1995-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Open label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-25 09:41:14 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kriplani-2010-_x0028_DRSP_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Open label.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-02 14:41:52 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-L.-America-1994-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Open label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-02 14:43:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loudon-1990-_x0028_GSD_x002d_LNG_x0029_">
<DESCRIPTION>
<P>Double-blind (no details).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-02 14:45:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Percival-1990-_x0028_NG_x002d_NE_x0029_">
<DESCRIPTION>
<P>Intervention giver was blinded to the medication given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-02 14:46:56 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rabe-1989-_x0028_GSD_x002d_LNG_x0029_">
<DESCRIPTION>
<P>Open label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-02 14:47:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ramos-1989-_x0028_LNG_x002d_NE_x0029_">
<DESCRIPTION>
<P>Double blind (no details)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-02 14:50:23 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Reiter-1990-_x0028_NG_x002d_NE_x0029_">
<DESCRIPTION>
<P>Open label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-02 14:51:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rossmanith-1997-_x0028_DSG_x002d_NE_x0029_">
<DESCRIPTION>
<P>Double blind (no details)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-21 13:49:20 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sangwathan-2005_x0028_DRSP_x002d_LNG_x0029_">
<DESCRIPTION>
<P>Open-label.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-02 14:55:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Serfaty-1998-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Open label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-02 14:57:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shoupe-1994-_x0028_DSG_x002d_NE_x0029_">
<DESCRIPTION>
<P>Double-blind (no details)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Singh-1996-_x0028_DSG_x002d_NE_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-22 11:24:07 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Suthipongse2004_x0028_DRSP_x002d_LNG_x0029_">
<DESCRIPTION>
<P>Open label.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-02 14:59:01 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Weber_x002d_Diehl-1993-_x0028_GSD_x002d_NE_x0029_">
<DESCRIPTION>
<P>Open label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-22 12:58:49 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_">
<DESCRIPTION>
<P>open label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-02 15:00:09 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zichella-1999-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Open label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2011-01-04 16:22:35 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-02 14:18:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Affinito-1993-_x0028_GSD_x002d_NGM_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-18 12:37:51 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Anttila-2009-_x0028_DRSP_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Denominators of data reported not clear. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Droegem_x00fc_ller-1989-_x0028_LNG_x002d_NE_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Dunson-1993-_x0028_NG_x002d_NE_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-02 14:27:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Endrikat-1999-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION>
<P>87 women excluded for protocol violations.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Endrikat-2001-_x0028_LNG_x002d_NE_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-02 14:30:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Foidart-2000-_x0028_DRSP_x002d_DSG_x0029_">
<DESCRIPTION>
<P>13 post-randomisation exclusions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-02 14:33:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-GSD-Group-1999-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION>
<P>No post randomisation exclusions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-02 15:03:47 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gruber-2006-_x0028_DRSP_x002d_DSG_x0029_">
<DESCRIPTION>
<P>&gt; 20% of cycle control data missing and so is not included in this review. Four post-randomisation exclusions.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-22 10:32:58 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guang_x002d_Sheng2010_x0028_DRSP_x002d_DSG_x0029_">
<DESCRIPTION>
<P>No post-randomisation exclusions. Higher proportion of loss to follow-up in the DRSP group 31/573 vs 6/195. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Halbe-1998-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Huber-2000-_x0028_DRSP_x002d_DSG_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-21 14:19:56 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kelly-2010-_x0028_DRSP_x002d_LNG_x0029_">
<DESCRIPTION>
<P>High drop out rate: 89/282 in DRSP group and 55/142 in the LNG group. HIgher proportion lost to follow-up in the LNG group (14/282 DSRP vs 13/142 LNG). Side effects resulting in discontinuation (37 vs. 25) are not fully reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Koetsawang-1995-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-25 09:46:01 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kriplani-2010-_x0028_DRSP_x002d_DSG_x0029_">
<DESCRIPTION>
<P>No loss to follow-up, two withdrawn (one in the DRSP group for jaundice and one in the DSG group for severe lower limb pain which turned out not to be a DVT).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-02 14:42:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-L.-America-1994-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION>
<P>No post randomisation exclusions. Denominators not always clear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-02 14:44:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loudon-1990-_x0028_GSD_x002d_LNG_x0029_">
<DESCRIPTION>
<P>31 post randomisation exclusions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Percival-1990-_x0028_NG_x002d_NE_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-02 14:46:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rabe-1989-_x0028_GSD_x002d_LNG_x0029_">
<DESCRIPTION>
<P>There were no post randomisation exclusions.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-02 14:48:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ramos-1989-_x0028_LNG_x002d_NE_x0029_">
<DESCRIPTION>
<P>No post randomisation exclusions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-02 14:48:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reiter-1990-_x0028_NG_x002d_NE_x0029_">
<DESCRIPTION>
<P>Post randomisation exclusions not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Rossmanith-1997-_x0028_DSG_x002d_NE_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-21 14:03:30 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sangwathan-2005_x0028_DRSP_x002d_LNG_x0029_">
<DESCRIPTION>
<P>Enrolled 104, analysed 99 (three lost to follow-up, 2 withdrawn).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-02 14:53:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Serfaty-1998-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION>
<P>10 post randomisation exclusions.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-02 14:56:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shoupe-1994-_x0028_DSG_x002d_NE_x0029_">
<DESCRIPTION>
<P>23 post-randomisation exclusions. Cycle control denominators unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Singh-1996-_x0028_DSG_x002d_NE_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-22 11:24:39 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Suthipongse2004_x0028_DRSP_x002d_LNG_x0029_">
<DESCRIPTION>
<P>115 women analysed. Five post-randomisation exclusions: 2 in each group did not return after baseline visit, one planned a pregnancy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-02 14:59:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weber_x002d_Diehl-1993-_x0028_GSD_x002d_NE_x0029_">
<DESCRIPTION>
<P>Figures for side-effects given as % in graphic form.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-22 14:02:35 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_">
<DESCRIPTION>
<P>Denominators not clearly stated. More than 20% of cycle control data is missing and so is excluded form analysis. Also, &#8220;There were 29 subjects who were randomized but not treated. The majority of these subjects withdrew consent (10 DSG, 9 LNG). Three subjects randomized to LNG were pregnant, 3 subjects randomized to  DSG had a protocol violation, and &#8216;other&#8217; reasons for  not starting medication were given for 4 subjects randomized to receive DSG .&#8221; (Quoted from authors' correspondence).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-02 15:00:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zichella-1999-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION>
<P>The data on cycle control is given in graphical form.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-01-04 16:22:35 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:16:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Affinito-1993-_x0028_GSD_x002d_NGM_x0029_">
<DESCRIPTION>
<P>Intention to treat analysis not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-18 13:01:51 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Anttila-2009-_x0028_DRSP_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Discontinuation data not reported. Cycle control data presented in such a way that comparisons cannot be made and so were not used for this review. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Droegem_x00fc_ller-1989-_x0028_LNG_x002d_NE_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:24:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dunson-1993-_x0028_NG_x002d_NE_x0029_">
<DESCRIPTION>
<P>Not analysed by intention to treat.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:26:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Endrikat-1999-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Intention to treat analysis and VCA.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Endrikat-2001-_x0028_LNG_x002d_NE_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:31:30 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Foidart-2000-_x0028_DRSP_x002d_DSG_x0029_">
<DESCRIPTION>
<P>No intention to treat analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:33:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-GSD-Group-1999-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Analysis was by intent to treat.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-19 12:15:33 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gruber-2006-_x0028_DRSP_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Data on side-effects not published but obtained after contacting the authors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-22 10:33:05 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guang_x002d_Sheng2010_x0028_DRSP_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Intention to treat analysis not described. Acne not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Halbe-1998-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:36:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huber-2000-_x0028_DRSP_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Analysis by intention to treat</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-21 14:10:04 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kelly-2010-_x0028_DRSP_x002d_LNG_x0029_">
<DESCRIPTION>
<P>Report fails to include key cycle control data. Limited unpublished cycle control data obtained from authors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:39:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koetsawang-1995-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Intention to treat analysis not clear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-25 09:47:11 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kriplani-2010-_x0028_DRSP_x002d_DSG_x0029_">
<DESCRIPTION>
<P>All pre-specified outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:42:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-L.-America-1994-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Denominators not clear. Intention to treat analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:43:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loudon-1990-_x0028_GSD_x002d_LNG_x0029_">
<DESCRIPTION>
<P>No intention to treat analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:45:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Percival-1990-_x0028_NG_x002d_NE_x0029_">
<DESCRIPTION>
<P>Analysis not by intention to treat.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:46:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rabe-1989-_x0028_GSD_x002d_LNG_x0029_">
<DESCRIPTION>
<P>Analysis by intention to treat. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:47:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ramos-1989-_x0028_LNG_x002d_NE_x0029_">
<DESCRIPTION>
<P>Analysis by intention to treat</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:49:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reiter-1990-_x0028_NG_x002d_NE_x0029_">
<DESCRIPTION>
<P>No intention to treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:53:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rossmanith-1997-_x0028_DSG_x002d_NE_x0029_">
<DESCRIPTION>
<P>There was an unequal number of women who had switched preparations and those who were starters. 40 % of women on desogestrel were assigned the same preparation. Analysis was by intent to treat.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-21 13:47:58 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sangwathan-2005_x0028_DRSP_x002d_LNG_x0029_">
<DESCRIPTION>
<P>Intention to treat analysis not described. Five post-randomisation exclusions not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:54:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Serfaty-1998-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Analysis not by intent to treat.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:57:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shoupe-1994-_x0028_DSG_x002d_NE_x0029_">
<DESCRIPTION>
<P>Cycle control figures given as % in graphic form. Analysis not by intention to treat.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Singh-1996-_x0028_DSG_x002d_NE_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-22 11:23:55 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Suthipongse2004_x0028_DRSP_x002d_LNG_x0029_">
<DESCRIPTION>
<P>Intention to treat analysis not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:58:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weber_x002d_Diehl-1993-_x0028_GSD_x002d_NE_x0029_">
<DESCRIPTION>
<P>Analysis not by intention to treat.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-22 13:03:34 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_">
<DESCRIPTION>
<P>Possible selective reporting of reasons for discontinuation. Bulk of reasons given in unpublished data are very vague, i.e. not willing to continue (27 vs 27); poor compliance (7 vs 4); protocol violations (13 vs 9); and other (38 vs 45). Intention to treat analysis not clear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 15:00:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zichella-1999-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Analysis was by intention to treat. The data on cycle control is given in graphical form.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2011-03-22 12:20:18 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-22 12:09:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Affinito-1993-_x0028_GSD_x002d_NGM_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-22 12:09:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anttila-2009-_x0028_DRSP_x002d_DSG_x0029_">
<DESCRIPTION>
<P>Assessed as moderate to high risk of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-22 12:09:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Droegem_x00fc_ller-1989-_x0028_LNG_x002d_NE_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-22 12:10:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dunson-1993-_x0028_NG_x002d_NE_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-22 12:11:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Endrikat-1999-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-22 12:11:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Endrikat-2001-_x0028_LNG_x002d_NE_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-22 12:11:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Foidart-2000-_x0028_DRSP_x002d_DSG_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-22 12:13:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-GSD-Group-1999-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-22 12:12:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gruber-2006-_x0028_DRSP_x002d_DSG_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-22 12:13:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guang_x002d_Sheng2010_x0028_DRSP_x002d_DSG_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-22 12:13:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Halbe-1998-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-22 12:14:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huber-2000-_x0028_DRSP_x002d_DSG_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-21 14:16:56 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kelly-2010-_x0028_DRSP_x002d_LNG_x0029_">
<DESCRIPTION>
<P>Funded and coordinated by Bayer Schering. Eleven subjects became pregnant during the study. Five became pregnant before starting treatment and so did not start, two subjects started the treatment but were found to have conceived prior to the start of the study. (6 were in the DRSP group, 3 in the LNG group and 2 are not accounted). Only four (two in each group) are described in the trial report. Pregnancy data is therefore not included in this review.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-22 12:14:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koetsawang-1995-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-28 15:29:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kriplani-2010-_x0028_DRSP_x002d_DSG_x0029_">
<DESCRIPTION>
<P>No funding received (unpublished information). Moderate risk of bias due to unblinded study design.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-22 12:15:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-L.-America-1994-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-22 12:15:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loudon-1990-_x0028_GSD_x002d_LNG_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-22 12:16:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Percival-1990-_x0028_NG_x002d_NE_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-22 12:17:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rabe-1989-_x0028_GSD_x002d_LNG_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-22 12:17:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ramos-1989-_x0028_LNG_x002d_NE_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-22 12:17:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reiter-1990-_x0028_NG_x002d_NE_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-22 12:18:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rossmanith-1997-_x0028_DSG_x002d_NE_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-22 12:18:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sangwathan-2005_x0028_DRSP_x002d_LNG_x0029_">
<DESCRIPTION>
<P>Overall moderate to high risk of bias as unblinded and no details of randomisation provided (could be quasi-randomisation). </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-22 12:18:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Serfaty-1998-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-22 12:19:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shoupe-1994-_x0028_DSG_x002d_NE_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-22 12:19:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Singh-1996-_x0028_DSG_x002d_NE_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-22 12:19:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Suthipongse2004_x0028_DRSP_x002d_LNG_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-22 12:19:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weber_x002d_Diehl-1993-_x0028_GSD_x002d_NE_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-22 12:20:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_">
<DESCRIPTION>
<P>Moderate to high risk of bias. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-22 12:20:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zichella-1999-_x0028_GSD_x002d_DSG_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2011-03-04 12:59:19 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2011-03-04 12:59:11 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-03-03 13:15:48 +0100" MODIFIED_BY="[Empty name]">Second- vs. first-generation findings: double-blind trials only</TITLE>
<TABLE COLS="6" ROWS="6">
<TR>
<TD>
<P>Outcome</P>
</TD>
<TD>
<P>monophasic</P>
</TD>
<TD>
<P>multiphasic</P>
</TD>
<TD>
<P>Number of participants</P>
</TD>
<TD>
<P>RR [95% CI]</P>
</TD>
<TD>
<P>Conclusions</P>
</TD>
</TR>
<TR>
<TD>
<P>Pregnancy</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>1,199</P>
</TD>
<TD>
<P>not estimable; no pregnancies</P>
</TD>
<TD>
<P>NS**</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>1,199</P>
</TD>
<TD>
<P>0.79 [0.66- 0.94]</P>
</TD>
<TD>
<P>Significant but needs corroboration</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation due to side-effects (cycle-unrelated)</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>1,199</P>
</TD>
<TD>
<P>0.81 [0.48- 1.35]</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Headache</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>1,199</P>
</TD>
<TD>
<P>0.87 [0.43- 1.77]</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Nausea</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>1,199</P>
</TD>
<TD>
<P>0.73 [0.34- 1.58]</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*LNG vs. NE</P>
<P>**NS= no significant difference</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2011-03-04 12:59:19 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2011-03-03 14:25:52 +0100" MODIFIED_BY="[Empty name]">Third vs. second generation findings: double-blind trials only*</TITLE>
<TABLE COLS="6" ROWS="5">
<TR>
<TD>
<P>Outcome</P>
</TD>
<TD>
<P>monophasic</P>
</TD>
<TD>
<P>multiphasic</P>
</TD>
<TD>
<P>Number of participants</P>
</TD>
<TD>
<P>RR [95% CI]</P>
</TD>
<TD>
<P>Conclusions</P>
</TD>
</TR>
<TR>
<TD>
<P>Pregnancy</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>456</P>
</TD>
<TD>
<P>not estimable, no pregnancies</P>
</TD>
<TD>
<P>NS**</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>456</P>
</TD>
<TD>
<P>0.79 [0.50- 1.26]</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation due to side-effects (cycle unrelated)</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>456</P>
</TD>
<TD>
<P>0.88 [0.46- 1.68]</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Intermenstrual bleeding</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>456</P>
</TD>
<TD>
<P>0.71 [0.55- 0.91]</P>
</TD>
<TD>
<P>Significant but needs corroboration</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*LNG vs. GSD</P>
<P>**NS= no significant difference</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2011-03-03 14:54:56 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2011-03-03 14:54:30 +0100" MODIFIED_BY="[Empty name]">Third vs. first generation findings: double-blind trials only*</TITLE>
<TABLE COLS="6" ROWS="5">
<TR>
<TD>
<P>Outcome</P>
</TD>
<TD>
<P>monophasic</P>
</TD>
<TD>
<P>multiphasic</P>
</TD>
<TD>
<P>Number of participants</P>
</TD>
<TD>
<P>RR [95% CI]</P>
</TD>
<TD>
<P>Conclusions</P>
</TD>
</TR>
<TR>
<TD>
<P>Pregnancy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>812</P>
</TD>
<TD>
<P>0.20 [0.01-4.13]</P>
</TD>
<TD>
<P>**NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>812</P>
</TD>
<TD>
<P>1.14 [0.90-1.44]</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Headache</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>812</P>
</TD>
<TD>
<P>1.12 [0.78-1.60]</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Breast tenderness</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>812</P>
</TD>
<TD>
<P>0.90 [0.55-1.47]</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*DSG vs. NE</P>
<P>**NS= no significant difference</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2011-03-25 11:08:12 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2011-03-25 11:08:12 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Classification of Progestogens</TITLE>
<TABLE COLS="5" ROWS="5">
<TR>
<TH>
<P>Pregnanes</P>
<P/>
</TH>
<TH>
<P>Estranes</P>
<P>1st generation</P>
</TH>
<TH>
<P>Gonanes</P>
<P>2nd generation</P>
</TH>
<TH>
<P>Gonanes</P>
<P>3rd generation</P>
</TH>
<TH>
<P>Other/unclassified</P>
</TH>
</TR>
<TR>
<TD>
<P>Medroxyprogesterone acetate</P>
</TD>
<TD>
<P>Norethindrone acetate</P>
</TD>
<TD>
<P>dl-Norgestrel</P>
</TD>
<TD>
<P>Desogestrel</P>
</TD>
<TD>
<P>Drospirenone</P>
</TD>
</TR>
<TR>
<TD>
<P>Cyproterone acetate</P>
</TD>
<TD>
<P>Ethynodiol diacetate</P>
</TD>
<TD>
<P>Levonorgestrel</P>
</TD>
<TD>
<P>Gestodene</P>
</TD>
<TD>
<P>Cyproterone acetate</P>
</TD>
</TR>
<TR>
<TD>
<P>Chlormadinone acetate</P>
</TD>
<TD>
<P>Lynestrenol</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Norgestimate</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Nomegestrol, Nestorone</P>
</TD>
<TD>
<P>Norethynodrel</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2011-03-25 11:08:12 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE>Methodological Assessment of Included Studies</TITLE>
<TABLE COLS="7" ROWS="31">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Allocation Concealm</P>
</TH>
<TH>
<P>Blinding</P>
</TH>
<TH>
<P>Post Rand. Excl.</P>
</TH>
<TH>
<P>Analysis by ITT</P>
</TH>
<TH>
<P>Loss to Follow-up</P>
</TH>
<TH>
<P>Sponsorship</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Affinito-1993-_x0028_GSD_x002d_NGM_x0029_" TYPE="STUDY">Affinito 1993 (GSD-NGM)</LINK>
</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>7.93%</P>
</TD>
<TD>
<P>WYETH-AYERST</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Anttila-2009-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Anttila 2009 (DRSP-DSG)</LINK>
</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>4/453</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>1.1%</P>
</TD>
<TD>
<P>BAYER-SCHERING</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Droegem_x00fc_ller-1989-_x0028_LNG_x002d_NE_x0029_" TYPE="STUDY">Droegemüller 1989 (LNG-NE)</LINK>
</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>unknown</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>13.4%</P>
</TD>
<TD>
<P>None declared</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Dunson-1993-_x0028_NG_x002d_NE_x0029_" TYPE="STUDY">Dunson 1993 (NG-NE)</LINK>
</P>
</TD>
<TD>
<P>adequate</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>17/892</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>9%</P>
</TD>
<TD>
<P>FHI</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Endrikat-1999-_x0028_GSD_x002d_DSG_x0029_" TYPE="STUDY">Endrikat 1999 (GSD-DSG)</LINK>
</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>87/1563</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>SCHERING AG</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Endrikat-2001-_x0028_LNG_x002d_NE_x0029_" TYPE="STUDY">Endrikat 2001 (LNG-NE)</LINK>
</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>unknown</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>SCHERING AG</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Foidart-2000-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Foidart 2000 (DRSP-DSG)</LINK>
</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>13/900</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>SCHERING</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Guang_x002d_Sheng2010_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Guang-Sheng2010(DRSP-DSG)</LINK>
</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>4.7%</P>
</TD>
<TD>
<P>None declared. BAYER gave editorial financial support.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Gruber-2006-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Gruber 2006 (DRSP-DSG)</LINK>
</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>4/445</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>2.9%</P>
</TD>
<TD>
<P>BAYER</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-GSD-Group-1999-_x0028_GSD_x002d_DSG_x0029_" TYPE="STUDY">GSD Group 1999 (GSD-DSG)</LINK>
</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>1.86%</P>
</TD>
<TD>
<P>WYETH AYERST</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Halbe-1998-_x0028_GSD_x002d_DSG_x0029_" TYPE="STUDY">Halbe 1998 (GSD-DSG)</LINK>
</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>2.68%</P>
</TD>
<TD>
<P>ORGANON NV</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Huber-2000-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Huber 2000 (DRSP-DSG)</LINK>
</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>29/2098</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>0.9%</P>
</TD>
<TD>
<P>SCHERING AG</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kelly-2010-_x0028_DRSP_x002d_LNG_x0029_" TYPE="STUDY">Kelly 2010 (DRSP-LNG)</LINK>
</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>single-blinding (participant)</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>6.4%</P>
</TD>
<TD>
<P>BAYER-SCHERING</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Koetsawang-1995-_x0028_GSD_x002d_DSG_x0029_" TYPE="STUDY">Koetsawang 1995 (GSD-DSG)</LINK>
</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>5.5%</P>
</TD>
<TD>
<P>ORGANON</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kriplani-2010-_x0028_DRSP_x002d_DSG_x0029_" TYPE="STUDY">Kriplani 2010 (DRSP-DSG)</LINK>
</P>
</TD>
<TD>
<P>adequate</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>None</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-L.-America-1994-_x0028_GSD_x002d_DSG_x0029_" TYPE="STUDY">L. America 1994 (GSD-DSG)</LINK>
</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>WYETH-AYERST</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Loudon-1990-_x0028_GSD_x002d_LNG_x0029_" TYPE="STUDY">Loudon 1990 (GSD-LNG)</LINK>
</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>double-blinding</P>
</TD>
<TD>
<P>32/488</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>1.97%</P>
</TD>
<TD>
<P>None declared</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Percival-1990-_x0028_NG_x002d_NE_x0029_" TYPE="STUDY">Percival 1990 (NG-NE)</LINK>
</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>single - blinding (intervention giver)</P>
</TD>
<TD>
<P>78/469 (16%)</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>PARKE-DAVIS</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Rabe-1989-_x0028_GSD_x002d_LNG_x0029_" TYPE="STUDY">Rabe 1989 (GSD-LNG)</LINK>
</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>10.52%</P>
</TD>
<TD>
<P>SCHERING AG</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ramos-1989-_x0028_LNG_x002d_NE_x0029_" TYPE="STUDY">Ramos 1989 (LNG-NE)</LINK>
</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>double-blind</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>2.08%</P>
</TD>
<TD>
<P>UNFPA and WYETH</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Reiter-1990-_x0028_NG_x002d_NE_x0029_" TYPE="STUDY">Reiter 1990 (NG-NE)</LINK>
</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>None declared</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Rossmanith-1997-_x0028_DSG_x002d_NE_x0029_" TYPE="STUDY">Rossmanith 1997 (DSG-NE)</LINK>
</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>double-blinding</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>GRUNENTHAL</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Sangwathan-2005_x0028_DRSP_x002d_LNG_x0029_" TYPE="STUDY">Sangwathan 2005(DRSP-LNG)</LINK>
</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>3/104</P>
</TD>
<TD>
<P>None declared</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Serfaty-1998-_x0028_GSD_x002d_DSG_x0029_" TYPE="STUDY">Serfaty 1998 (GSD-DSG)</LINK>
</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>10/1026</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>ORGANON</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Shoupe-1994-_x0028_DSG_x002d_NE_x0029_" TYPE="STUDY">Shoupe 1994 (DSG-NE)</LINK>
</P>
</TD>
<TD>
<P>adequate</P>
</TD>
<TD>
<P>double-blind</P>
</TD>
<TD>
<P>23/812</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>8.25%</P>
</TD>
<TD>
<P>ORGANON and FHI</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Singh-1996-_x0028_DSG_x002d_NE_x0029_" TYPE="STUDY">Singh 1996 (DSG-NE)</LINK>
</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>3/23 and 7/23</P>
</TD>
<TD>
<P>ORGANON</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Suthipongse2004_x0028_DRSP_x002d_LNG_x0029_" TYPE="STUDY">Suthipongse2004(DRSP-LNG)</LINK>
</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>5/120</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>4/120</P>
</TD>
<TD>
<P>None declared</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Weber_x002d_Diehl-1993-_x0028_GSD_x002d_NE_x0029_" TYPE="STUDY">Weber-Diehl 1993 (GSD-NE)</LINK>
</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>25/254</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>10.1% and 9.5%</P>
</TD>
<TD>
<P>SCHERING AG</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_" TYPE="STUDY">Winkler 2004 (DSG-LNG)</LINK>
</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>29/1027</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>3/998</P>
</TD>
<TD>
<P>ORGANON NV</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Zichella-1999-_x0028_GSD_x002d_DSG_x0029_" TYPE="STUDY">Zichella 1999 (GSD-DSG)</LINK>
</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>ORGANON NV</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-03-03 15:42:48 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2011-03-03 13:30:53 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Second versus first generation OCs</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9929256097982943" CI_START="0.015664551564522233" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.12471461187214614" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.0030832877224551696" LOG_CI_START="-1.805082033328787" LOG_EFFECT_SIZE="-0.9040826605256213" METHOD="MH" MODIFIED="2011-03-03 12:59:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.04922113740363047" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1038" TOTAL_2="1036" WEIGHT="100.0" Z="1.966671128931493">
<NAME>pregnancy</NAME>
<GROUP_LABEL_1>2nd gen.</GROUP_LABEL_1>
<GROUP_LABEL_2>1st gen.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2nd</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1st</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9929256097982943" CI_START="0.015664551564522233" DF="0" EFFECT_SIZE="0.12471461187214614" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-0.0030832877224551696" LOG_CI_START="-1.805082033328787" LOG_EFFECT_SIZE="-0.9040826605256213" MODIFIED="2011-03-03 12:59:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.04922113740363047" STUDIES="2" TAU2="0.0" TOTAL_1="1038" TOTAL_2="1036" WEIGHT="100.0" Z="1.966671128931493">
<NAME>monophasic</NAME>
<DICH_DATA CI_END="0.9929256097982943" CI_START="0.015664551564522233" EFFECT_SIZE="0.12471461187214612" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.0030832877224551696" LOG_CI_START="-1.805082033328787" LOG_EFFECT_SIZE="-0.9040826605256213" MODIFIED="2011-03-03 12:59:35 +0100" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="1.0585029832068107" STUDY_ID="STD-Dunson-1993-_x0028_NG_x002d_NE_x0029_" TOTAL_1="438" TOTAL_2="437" VAR="1.120428565457718" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2" O_E="0.0" SE="0.0" STUDY_ID="STD-Ramos-1989-_x0028_LNG_x002d_NE_x0029_" TOTAL_1="600" TOTAL_2="599" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.316383690408067" CI_END="0.9025375700604231" CI_START="0.7117802722649011" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8015038598452975" ESTIMABLE="YES" EVENTS_1="369" EVENTS_2="429" I2="52.50446858452029" I2_Q="80.3883482873221" ID="CMP-001.02" LOG_CI_END="-0.04453471060754789" LOG_CI_START="-0.14765405309140783" LOG_EFFECT_SIZE="-0.09609438184947787" METHOD="MH" MODIFIED="2011-03-03 13:30:53 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.09719216035998801" P_Q="0.023939544307623017" P_Z="2.593108173775022E-4" Q="5.099009581908662" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.01752016335389453" TOTALS="SUB" TOTAL_1="1537" TOTAL_2="1408" WEIGHT="200.0" Z="3.65288457053719">
<NAME>discontinuation</NAME>
<GROUP_LABEL_1>2nd gen.</GROUP_LABEL_1>
<GROUP_LABEL_2>1st gen.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2nd</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1st</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.2085131807223253" CI_END="0.8647506035348491" CI_START="0.6713196610947565" DF="2" EFFECT_SIZE="0.7619213096485102" ESTIMABLE="YES" EVENTS_1="323" EVENTS_2="390" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="-0.0631091262066184" LOG_CI_START="-0.1730706333455098" LOG_EFFECT_SIZE="-0.11808987977606412" MODIFIED="2011-03-03 13:30:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5464807926665318" P_Z="2.5572166954759125E-5" STUDIES="3" TAU2="0.0" TOTAL_1="1418" TOTAL_2="1291" WEIGHT="100.0" Z="4.209689687272216">
<NAME>monophasic</NAME>
<DICH_DATA CI_END="1.0010726036932163" CI_START="0.63383482278919" EFFECT_SIZE="0.7965642951833849" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="124" LOG_CI_END="4.6557622045847536E-4" LOG_CI_START="-0.19802390441718412" LOG_EFFECT_SIZE="-0.09877916409836285" MODIFIED="2011-03-03 13:30:52 +0100" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.11659370346532659" STUDY_ID="STD-Dunson-1993-_x0028_NG_x002d_NE_x0029_" TOTAL_1="438" TOTAL_2="437" VAR="0.01359409168776051" WEIGHT="30.69067050242714"/>
<DICH_DATA CI_END="0.9405976357886623" CI_START="0.6553883215830525" EFFECT_SIZE="0.7851475694444444" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="192" LOG_CI_END="-0.02659611719660359" LOG_CI_START="-0.1835013016128213" LOG_EFFECT_SIZE="-0.10504870940471243" MODIFIED="2011-03-03 13:30:38 +0100" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.09216688201927552" STUDY_ID="STD-Ramos-1989-_x0028_LNG_x002d_NE_x0029_" TOTAL_1="600" TOTAL_2="599" VAR="0.008494734141155052" WEIGHT="49.11416671035594"/>
<DICH_DATA CI_END="0.8773905347740111" CI_START="0.4994620593100596" EFFECT_SIZE="0.6619843527738265" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="74" LOG_CI_END="-0.056807055043439546" LOG_CI_START="-0.30149749654331087" LOG_EFFECT_SIZE="-0.17915227579337523" MODIFIED="2011-03-03 13:30:53 +0100" MODIFIED_BY="[Empty name]" ORDER="1288" O_E="0.0" SE="0.14373237657424445" STUDY_ID="STD-Endrikat-2001-_x0028_LNG_x002d_NE_x0029_" TOTAL_1="380" TOTAL_2="255" VAR="0.020658996075680412" WEIGHT="20.195162787216923"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6323634997285978" CI_START="0.8238485369693652" DF="0" EFFECT_SIZE="1.1596638655462186" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="39" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.21281687521929046" LOG_CI_START="-0.08415262520187888" LOG_EFFECT_SIZE="0.06433212500870579" NO="2" P_CHI2="1.0" P_Z="0.3957872642632688" STUDIES="1" TAU2="0.0" TOTAL_1="119" TOTAL_2="117" WEIGHT="100.0" Z="0.8491690081787516">
<NAME>multiphasic</NAME>
<DICH_DATA CI_END="1.6323634997285978" CI_START="0.8238485369693652" EFFECT_SIZE="1.1596638655462186" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="39" LOG_CI_END="0.21281687521929046" LOG_CI_START="-0.08415262520187888" LOG_EFFECT_SIZE="0.06433212500870579" ORDER="1290" O_E="0.0" SE="0.1744413545701302" STUDY_ID="STD-Percival-1990-_x0028_NG_x002d_NE_x0029_" TOTAL_1="119" TOTAL_2="117" VAR="0.030429786184261887" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.794818419765022" CI_END="1.0532178015684388" CI_START="0.37370176944110134" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6273670026810402" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="97" I2="65.48640776769845" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.022518190974864016" LOG_CI_START="-0.42747484580386236" LOG_EFFECT_SIZE="-0.20247832741449923" METHOD="MH" MODIFIED="2011-03-03 10:16:36 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.055166036726380874" P_Q="1.0" P_Z="0.07776463182341962" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.13661632941163301" TOTALS="SUB" TOTAL_1="1418" TOTAL_2="1291" WEIGHT="99.99999999999999" Z="1.7638060900816537">
<NAME>discontinuation due to side-effects (cycle-unrelated)</NAME>
<GROUP_LABEL_1>2nd gen.</GROUP_LABEL_1>
<GROUP_LABEL_2>1st gen.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2nd</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1st</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.794818419765022" CI_END="1.0532178015684388" CI_START="0.37370176944110134" DF="2" EFFECT_SIZE="0.6273670026810402" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="97" I2="65.48640776769845" ID="CMP-001.03.01" LOG_CI_END="0.022518190974864016" LOG_CI_START="-0.42747484580386236" LOG_EFFECT_SIZE="-0.20247832741449923" MODIFIED="2011-03-03 10:16:36 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.055166036726380874" P_Z="0.07776463182341962" STUDIES="3" TAU2="0.13661632941163301" TOTAL_1="1418" TOTAL_2="1291" WEIGHT="99.99999999999999" Z="1.7638060900816537">
<NAME>monophasic</NAME>
<DICH_DATA CI_END="1.596845864704295" CI_START="0.4503907955173657" EFFECT_SIZE="0.8480593607305936" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="20" LOG_CI_END="0.20326299795502703" LOG_CI_START="-0.34641049359379694" LOG_EFFECT_SIZE="-0.07157374781938496" ORDER="1" O_E="0.0" SE="0.32288092986344497" STUDY_ID="STD-Dunson-1993-_x0028_NG_x002d_NE_x0029_" TOTAL_1="438" TOTAL_2="437" VAR="0.10425209486948285" WEIGHT="29.007274149697277"/>
<DICH_DATA CI_END="1.346851590481615" CI_START="0.48126915721264707" EFFECT_SIZE="0.8051075268817204" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="31" LOG_CI_END="0.1293197434692167" LOG_CI_START="-0.3176119697823514" LOG_EFFECT_SIZE="-0.09414611315656735" MODIFIED="2011-03-03 10:16:36 +0100" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.262529900711632" STUDY_ID="STD-Ramos-1989-_x0028_LNG_x002d_NE_x0029_" TOTAL_1="600" TOTAL_2="599" VAR="0.06892194876765938" WEIGHT="33.993358701940565"/>
<DICH_DATA CI_END="0.6164276739573208" CI_START="0.2516766385895333" EFFECT_SIZE="0.39387871853546913" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="46" LOG_CI_END="-0.2101178722619088" LOG_CI_START="-0.5991570951489746" LOG_EFFECT_SIZE="-0.4046374837054417" ORDER="1292" O_E="0.0" SE="0.22852356529907422" STUDY_ID="STD-Endrikat-2001-_x0028_LNG_x002d_NE_x0029_" TOTAL_1="380" TOTAL_2="255" VAR="0.05222301989700024" WEIGHT="36.99936714836215"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0229857698340987" CI_END="1.0576018367959983" CI_START="0.7226915965802456" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8742539447896707" ESTIMABLE="YES" EVENTS_1="166" EVENTS_2="189" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.024322196405628674" LOG_CI_START="-0.14104699520595543" LOG_EFFECT_SIZE="-0.05836239940016333" METHOD="MH" MODIFIED="2011-01-31 12:06:40 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.7956903334128917" P_Q="0.7958425615625135" P_Z="0.1665336112180898" Q="1.0223565717765963" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2076" TOTAL_2="2072" WEIGHT="400.0" Z="1.383428191925071">
<NAME>side effects (monophasic)</NAME>
<GROUP_LABEL_1>2nd gen.</GROUP_LABEL_1>
<GROUP_LABEL_2>1st gen.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2nd</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1st</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7737289244611103" CI_START="0.430209505454512" DF="0" EFFECT_SIZE="0.8735416666666667" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.24888724818667438" LOG_CI_START="-0.3663199981307125" LOG_EFFECT_SIZE="-0.058716374972019016" NO="1" P_CHI2="1.0" P_Z="0.7083118653749405" STUDIES="1" TAU2="0.0" TOTAL_1="600" TOTAL_2="599" WEIGHT="100.0" Z="0.37412426767332074">
<NAME>headache</NAME>
<DICH_DATA CI_END="1.7737289244611103" CI_START="0.430209505454512" EFFECT_SIZE="0.8735416666666667" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" LOG_CI_END="0.24888724818667438" LOG_CI_START="-0.3663199981307125" LOG_EFFECT_SIZE="-0.058716374972019016" ORDER="1294" O_E="0.0" SE="0.3613757818118167" STUDY_ID="STD-Ramos-1989-_x0028_LNG_x002d_NE_x0029_" TOTAL_1="600" TOTAL_2="599" VAR="0.13059245568010175" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5807835304123377" CI_START="0.33906393171526594" DF="0" EFFECT_SIZE="0.7321111111111112" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.1988724025166417" LOG_CI_START="-0.46971840630021844" LOG_EFFECT_SIZE="-0.1354230018917884" NO="2" P_CHI2="1.0" P_Z="0.4272064875270407" STUDIES="1" TAU2="0.0" TOTAL_1="600" TOTAL_2="599" WEIGHT="100.0" Z="0.793981020636225">
<NAME>nausea/vomiting</NAME>
<DICH_DATA CI_END="1.5807835304123374" CI_START="0.33906393171526594" EFFECT_SIZE="0.7321111111111112" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" LOG_CI_END="0.19887240251664165" LOG_CI_START="-0.46971840630021844" LOG_EFFECT_SIZE="-0.1354230018917884" ORDER="1295" O_E="0.0" SE="0.39273355067690346" STUDY_ID="STD-Ramos-1989-_x0028_LNG_x002d_NE_x0029_" TOTAL_1="600" TOTAL_2="599" VAR="0.15423964182728792" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4687082380683925" CI_START="0.7051466801785453" DF="0" EFFECT_SIZE="1.0176712328767124" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="50" I2="0.0" ID="CMP-001.04.03" LOG_CI_END="0.16693553086053936" LOG_CI_START="-0.15172053440405966" LOG_EFFECT_SIZE="0.0076074982282398765" NO="3" P_CHI2="1.0" P_Z="0.9254402784564546" STUDIES="1" TAU2="0.0" TOTAL_1="438" TOTAL_2="437" WEIGHT="100.0" Z="0.09358317110594726">
<NAME>breast tenderness</NAME>
<DICH_DATA CI_END="1.4687082380683925" CI_START="0.7051466801785453" EFFECT_SIZE="1.0176712328767124" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="50" LOG_CI_END="0.16693553086053936" LOG_CI_START="-0.15172053440405966" LOG_EFFECT_SIZE="0.0076074982282398765" ORDER="1296" O_E="0.0" SE="0.18718015010938807" STUDY_ID="STD-Dunson-1993-_x0028_NG_x002d_NE_x0029_" TOTAL_1="438" TOTAL_2="437" VAR="0.035036408594973055" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0636943491913728" CI_START="0.6498831977539871" DF="0" EFFECT_SIZE="0.8314307458143074" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="108" I2="0.0" ID="CMP-001.04.04" LOG_CI_END="0.026816852085521422" LOG_CI_START="-0.18716469124812646" LOG_EFFECT_SIZE="-0.08017391958130253" MODIFIED="2011-01-31 12:06:40 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.14191253265270837" STUDIES="1" TAU2="0.0" TOTAL_1="438" TOTAL_2="437" WEIGHT="100.0" Z="1.4687060615667051">
<NAME>other minor (vaginal discharge)</NAME>
<DICH_DATA CI_END="1.0636943491913728" CI_START="0.6498831977539871" EFFECT_SIZE="0.8314307458143074" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="108" LOG_CI_END="0.026816852085521422" LOG_CI_START="-0.18716469124812646" LOG_EFFECT_SIZE="-0.08017391958130253" ORDER="1297" O_E="0.0" SE="0.12569381777990724" STUDY_ID="STD-Dunson-1993-_x0028_NG_x002d_NE_x0029_" TOTAL_1="438" TOTAL_2="437" VAR="0.01579893582808852" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.1331839624527755" CI_END="0.8120591676598126" CI_START="0.5246067340347357" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6526957237403813" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="155" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-0.09041232635979442" LOG_CI_START="-0.2801661389546697" LOG_EFFECT_SIZE="-0.18528923265723202" METHOD="MH" MODIFIED="2010-11-01 12:41:00 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.5452287106785401" P_Q="0.5916835630310361" P_Z="1.2934689019225652E-4" Q="0.2877228489022099" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="737" TOTAL_2="719" WEIGHT="200.0" Z="3.8276988247565322">
<NAME>cycle disturbance</NAME>
<GROUP_LABEL_1>2nd gen.</GROUP_LABEL_1>
<GROUP_LABEL_2>1st gen.</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours 2nd</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours 1st</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9112159185829055" CI_START="0.5163435541906621" DF="0" EFFECT_SIZE="0.6859303652968036" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="96" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="-0.0403787019092804" LOG_CI_START="-0.2870612401534745" LOG_EFFECT_SIZE="-0.16371997103137745" NO="1" P_CHI2="1.0" P_Z="0.009278869022030903" STUDIES="1" TAU2="0.0" TOTAL_1="438" TOTAL_2="437" WEIGHT="100.0" Z="2.601604872849107">
<NAME>Monophasic</NAME>
<DICH_DATA CI_END="0.9112159185829055" CI_START="0.5163435541906621" EFFECT_SIZE="0.6859303652968036" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="96" LOG_CI_END="-0.0403787019092804" LOG_CI_START="-0.2870612401534745" LOG_EFFECT_SIZE="-0.16371997103137745" ORDER="2" O_E="0.0" SE="0.14490254406289754" STUDY_ID="STD-Dunson-1993-_x0028_NG_x002d_NE_x0029_" TOTAL_1="438" TOTAL_2="437" VAR="0.020996747275899966" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.8637480219576985" CI_END="0.8549371777902213" CI_START="0.4314902013399303" DF="2" EFFECT_SIZE="0.607368928228712" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="59" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="-0.06806579678227877" LOG_CI_START="-0.36502906217893805" LOG_EFFECT_SIZE="-0.21654742948060843" NO="2" P_CHI2="0.39381506328590044" P_Z="0.004257357160842664" STUDIES="3" TAU2="0.0" TOTAL_1="299" TOTAL_2="282" WEIGHT="100.0" Z="2.8584354509963186">
<NAME>Multiphasic</NAME>
<DICH_DATA CI_END="0.8415987966789108" CI_START="0.3379810493633185" EFFECT_SIZE="0.5333333333333333" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="30" LOG_CI_END="-0.07489489414575749" LOG_CI_START="-0.47110764998171784" LOG_EFFECT_SIZE="-0.27300127206373764" ORDER="1299" O_E="0.0" SE="0.2327373340628157" STUDY_ID="STD-Droegem_x00fc_ller-1989-_x0028_LNG_x002d_NE_x0029_" TOTAL_1="48" TOTAL_2="48" VAR="0.05416666666666667" WEIGHT="56.17570785275905"/>
<DICH_DATA CI_END="2.9991816265270996" CI_START="0.4209775417751855" EFFECT_SIZE="1.1236494597839135" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.4770027668632356" LOG_CI_START="-0.37574107220060027" LOG_EFFECT_SIZE="0.05063084733131762" ORDER="1300" O_E="0.0" SE="0.5009059522161784" STUDY_ID="STD-Percival-1990-_x0028_NG_x002d_NE_x0029_" TOTAL_1="119" TOTAL_2="117" VAR="0.25090677296559644" WEIGHT="12.127416115792437"/>
<DICH_DATA CI_END="1.1092093614227796" CI_START="0.32926645756048956" EFFECT_SIZE="0.6043388429752066" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="22" LOG_CI_END="0.04501352624760151" LOG_CI_START="-0.482452508700028" LOG_EFFECT_SIZE="-0.21871949122621326" ORDER="1301" O_E="0.0" SE="0.30983615992722024" STUDY_ID="STD-Reiter-1990-_x0028_NG_x002d_NE_x0029_" TOTAL_1="132" TOTAL_2="117" VAR="0.09599844599844601" WEIGHT="31.696876031448518"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2011-01-31 12:20:55 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Norgestrel vs Norethindrone (monophasic)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9929256097982943" CI_START="0.015664551564522233" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.12471461187214614" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.0030832877224551696" LOG_CI_START="-1.805082033328787" LOG_EFFECT_SIZE="-0.9040826605256213" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.04922113740363047" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="438" TOTAL_2="437" WEIGHT="100.0" Z="1.966671128931493">
<NAME>Pregnancy</NAME>
<GROUP_LABEL_1>NG</GROUP_LABEL_1>
<GROUP_LABEL_2>NE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NE</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9929256097982943" CI_START="0.015664551564522233" EFFECT_SIZE="0.12471461187214612" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.0030832877224551696" LOG_CI_START="-1.805082033328787" LOG_EFFECT_SIZE="-0.9040826605256213" ORDER="1462" O_E="0.0" SE="1.0585029832068107" STUDY_ID="STD-Dunson-1993-_x0028_NG_x002d_NE_x0029_" TOTAL_1="438" TOTAL_2="437" VAR="1.120428565457718" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0010726036932163" CI_START="0.63383482278919" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7965642951833849" ESTIMABLE="NO" EVENTS_1="99" EVENTS_2="124" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="4.6557622045847536E-4" LOG_CI_START="-0.19802390441718412" LOG_EFFECT_SIZE="-0.09877916409836285" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0510844816437994" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="438" TOTAL_2="437" WEIGHT="0.0" Z="1.9507694154251027">
<NAME>Discontinuation</NAME>
<GROUP_LABEL_1>NG</GROUP_LABEL_1>
<GROUP_LABEL_2>NE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NE</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0010726036932163" CI_START="0.63383482278919" EFFECT_SIZE="0.7965642951833849" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="124" LOG_CI_END="4.6557622045847536E-4" LOG_CI_START="-0.19802390441718412" LOG_EFFECT_SIZE="-0.09877916409836285" ORDER="1463" O_E="0.0" SE="0.11659370346532659" STUDY_ID="STD-Dunson-1993-_x0028_NG_x002d_NE_x0029_" TOTAL_1="438" TOTAL_2="437" VAR="0.01359409168776051" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.479771379951" CI_END="1.1163460829786076" CI_START="0.664020758137685" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8609744318872019" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="124" I2="70.32590622457174" I2_Q="69.54824812542459" ID="CMP-002.03" LOG_CI_END="0.04779885287004269" LOG_CI_START="-0.1778183438191252" LOG_EFFECT_SIZE="-0.06500974547454125" METHOD="MH" NO="3" P_CHI2="0.009154613863194494" P_Q="0.010632227638822545" P_Z="0.25868905140560194" Q="13.135533273997467" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.2874831600661243" TOTALS="SUB" TOTAL_1="2190" TOTAL_2="2185" WEIGHT="500.0" Z="1.129495106259638">
<NAME>Reasons for discontinuation</NAME>
<GROUP_LABEL_1>NG</GROUP_LABEL_1>
<GROUP_LABEL_2>NE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NE</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6123339952290626" CI_START="0.11783536895887343" DF="0" EFFECT_SIZE="0.2686160871092378" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="26" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="-0.21301162896773412" LOG_CI_START="-0.9287243340127435" LOG_EFFECT_SIZE="-0.5708679814902389" NO="1" P_CHI2="1.0" P_Z="0.0017682856724403246" STUDIES="1" TAU2="0.0" TOTAL_1="438" TOTAL_2="437" WEIGHT="100.0" Z="3.1266195940383166">
<NAME>cycle disturbances</NAME>
<DICH_DATA CI_END="0.6123339952290626" CI_START="0.11783536895887343" EFFECT_SIZE="0.2686160871092378" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="26" LOG_CI_END="-0.21301162896773412" LOG_CI_START="-0.9287243340127435" LOG_EFFECT_SIZE="-0.5708679814902389" ORDER="1464" O_E="0.0" SE="0.4204131857784666" STUDY_ID="STD-Dunson-1993-_x0028_NG_x002d_NE_x0029_" TOTAL_1="438" TOTAL_2="437" VAR="0.17674724677639947" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9929256097982943" CI_START="0.015664551564522233" DF="0" EFFECT_SIZE="0.12471461187214614" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="-0.0030832877224551696" LOG_CI_START="-1.805082033328787" LOG_EFFECT_SIZE="-0.9040826605256213" NO="2" P_CHI2="1.0" P_Z="0.04922113740363047" STUDIES="1" TAU2="0.0" TOTAL_1="438" TOTAL_2="437" WEIGHT="100.0" Z="1.966671128931493">
<NAME>pregnancy</NAME>
<DICH_DATA CI_END="0.9929256097982943" CI_START="0.015664551564522233" EFFECT_SIZE="0.12471461187214612" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.0030832877224551696" LOG_CI_START="-1.805082033328787" LOG_EFFECT_SIZE="-0.9040826605256213" ORDER="1465" O_E="0.0" SE="1.0585029832068107" STUDY_ID="STD-Dunson-1993-_x0028_NG_x002d_NE_x0029_" TOTAL_1="438" TOTAL_2="437" VAR="1.120428565457718" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.596845864704295" CI_START="0.4503907955173657" DF="0" EFFECT_SIZE="0.8480593607305936" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="20" I2="0.0" ID="CMP-002.03.03" LOG_CI_END="0.20326299795502703" LOG_CI_START="-0.34641049359379694" LOG_EFFECT_SIZE="-0.07157374781938496" NO="3" P_CHI2="1.0" P_Z="0.6097577695452278" STUDIES="1" TAU2="0.0" TOTAL_1="438" TOTAL_2="437" WEIGHT="100.0" Z="0.5104192584192916">
<NAME>side -effects (other than cycle disturbances)</NAME>
<DICH_DATA CI_END="1.596845864704295" CI_START="0.4503907955173657" EFFECT_SIZE="0.8480593607305936" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="20" LOG_CI_END="0.20326299795502703" LOG_CI_START="-0.34641049359379694" LOG_EFFECT_SIZE="-0.07157374781938496" ORDER="1466" O_E="0.0" SE="0.32288092986344497" STUDY_ID="STD-Dunson-1993-_x0028_NG_x002d_NE_x0029_" TOTAL_1="438" TOTAL_2="437" VAR="0.10425209486948285" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8637566437797974" CI_START="0.38240548598368446" DF="0" EFFECT_SIZE="0.8442219880576045" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" I2="0.0" ID="CMP-002.03.04" LOG_CI_END="0.2703892046041829" LOG_CI_START="-0.4174758859687618" LOG_EFFECT_SIZE="-0.07354334068228942" NO="4" P_CHI2="1.0" P_Z="0.6751426920525874" STUDIES="1" TAU2="0.0" TOTAL_1="438" TOTAL_2="437" WEIGHT="100.0" Z="0.419100492278176">
<NAME>other medical reasons</NAME>
<DICH_DATA CI_END="1.8637566437797974" CI_START="0.38240548598368446" EFFECT_SIZE="0.8442219880576045" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.2703892046041829" LOG_CI_START="-0.4174758859687618" LOG_EFFECT_SIZE="-0.07354334068228942" ORDER="1467" O_E="0.0" SE="0.404055359189661" STUDY_ID="STD-Dunson-1993-_x0028_NG_x002d_NE_x0029_" TOTAL_1="438" TOTAL_2="437" VAR="0.163260733289886" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5382985394852424" CI_START="0.7905064408147318" DF="0" EFFECT_SIZE="1.1027397260273972" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="57" I2="0.0" ID="CMP-002.03.05" LOG_CI_END="0.18704062770806287" LOG_CI_START="-0.10209458721323766" LOG_EFFECT_SIZE="0.0424730202474126" NO="5" P_CHI2="1.0" P_Z="0.5647337223028219" STUDIES="1" TAU2="0.0" TOTAL_1="438" TOTAL_2="437" WEIGHT="100.0" Z="0.5758246363883953">
<NAME>method unrelated</NAME>
<DICH_DATA CI_END="1.5382985394852424" CI_START="0.7905064408147318" EFFECT_SIZE="1.1027397260273972" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="57" LOG_CI_END="0.18704062770806287" LOG_CI_START="-0.10209458721323766" LOG_EFFECT_SIZE="0.0424730202474126" ORDER="1468" O_E="0.0" SE="0.16983945648716858" STUDY_ID="STD-Dunson-1993-_x0028_NG_x002d_NE_x0029_" TOTAL_1="438" TOTAL_2="437" VAR="0.028845440979856828" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.9598067831947" CI_END="0.635599870544238" CI_START="0.4136849467589769" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5127749005227398" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="223" I2="79.9192891635747" I2_Q="79.63207226549643" ID="CMP-002.04" LOG_CI_END="-0.19681619991954916" LOG_CI_START="-0.383330282001404" LOG_EFFECT_SIZE="-0.2900732409604766" METHOD="MH" MODIFIED="2011-01-31 12:16:14 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.006874743664366134" P_Q="0.007374863877921967" P_Z="1.084773579335189E-9" Q="9.81935926948509" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.16880484610897153" TOTALS="SUB" TOTAL_1="1314" TOTAL_2="1311" WEIGHT="300.0" Z="6.0964094379944225">
<NAME>Cycle control</NAME>
<GROUP_LABEL_1>NG</GROUP_LABEL_1>
<GROUP_LABEL_2>NE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NE</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9112159185829055" CI_START="0.5163435541906621" DF="0" EFFECT_SIZE="0.6859303652968036" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="96" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="-0.0403787019092804" LOG_CI_START="-0.2870612401534745" LOG_EFFECT_SIZE="-0.16371997103137745" NO="1" P_CHI2="1.0" P_Z="0.009278869022030903" STUDIES="1" TAU2="0.0" TOTAL_1="438" TOTAL_2="437" WEIGHT="100.0" Z="2.601604872849107">
<NAME>Intermenstrual bleeding</NAME>
<DICH_DATA CI_END="0.9112159185829055" CI_START="0.5163435541906621" EFFECT_SIZE="0.6859303652968036" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="96" LOG_CI_END="-0.0403787019092804" LOG_CI_START="-0.2870612401534745" LOG_EFFECT_SIZE="-0.16371997103137745" ORDER="1469" O_E="0.0" SE="0.14490254406289754" STUDY_ID="STD-Dunson-1993-_x0028_NG_x002d_NE_x0029_" TOTAL_1="438" TOTAL_2="437" VAR="0.020996747275899966" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5394670004215292" CI_START="0.16107610555873986" DF="0" EFFECT_SIZE="0.2947799916977999" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="44" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="-0.2680351162695991" LOG_CI_START="-0.7929688791564576" LOG_EFFECT_SIZE="-0.5305019977130284" MODIFIED="2011-01-31 12:16:14 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="7.447769759771757E-5" STUDIES="1" TAU2="0.0" TOTAL_1="438" TOTAL_2="437" WEIGHT="100.0" Z="3.9615086045368018">
<NAME>absence of withdrawal bleed</NAME>
<DICH_DATA CI_END="0.5394670004215292" CI_START="0.16107610555873986" EFFECT_SIZE="0.2947799916977999" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="44" LOG_CI_END="-0.2680351162695991" LOG_CI_START="-0.7929688791564576" LOG_EFFECT_SIZE="-0.5305019977130284" ORDER="1470" O_E="0.0" SE="0.3083486907837745" STUDY_ID="STD-Dunson-1993-_x0028_NG_x002d_NE_x0029_" TOTAL_1="438" TOTAL_2="437" VAR="0.0950789151080678" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5507645765047434" CI_START="0.25212496786113625" DF="0" EFFECT_SIZE="0.3726412499312318" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="83" I2="0.0" ID="CMP-002.04.03" LOG_CI_END="-0.2590340000114145" LOG_CI_START="-0.5983841441395433" LOG_EFFECT_SIZE="-0.42870907207547887" MODIFIED="2011-01-31 12:16:14 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="7.340258721303075E-7" STUDIES="1" TAU2="0.0" TOTAL_1="438" TOTAL_2="437" WEIGHT="100.0" Z="4.95213781784203">
<NAME>other menstrual complaints</NAME>
<DICH_DATA CI_END="0.5507645765047433" CI_START="0.25212496786113625" EFFECT_SIZE="0.37264124993123177" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="83" LOG_CI_END="-0.2590340000114146" LOG_CI_START="-0.5983841441395433" LOG_EFFECT_SIZE="-0.4287090720754789" ORDER="1471" O_E="0.0" SE="0.1993359544711679" STUDY_ID="STD-Dunson-1993-_x0028_NG_x002d_NE_x0029_" TOTAL_1="438" TOTAL_2="437" VAR="0.039734822744931515" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8066084843257411" CI_END="1.0862502831085012" CI_START="0.7215805314543402" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8853344320525774" ESTIMABLE="YES" EVENTS_1="141" EVENTS_2="158" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.03592990264654461" LOG_CI_START="-0.14171519275548627" LOG_EFFECT_SIZE="-0.05289264505447082" METHOD="MH" MODIFIED="2011-01-31 12:20:55 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.36912491194966435" P_Q="0.37000225290715316" P_Z="0.2431568978653631" Q="0.8036571062469078" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="876" TOTAL_2="874" WEIGHT="200.0" Z="1.1671324684671058">
<NAME>Side-effects</NAME>
<GROUP_LABEL_1>NG</GROUP_LABEL_1>
<GROUP_LABEL_2>NE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NE</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4687082380683925" CI_START="0.7051466801785453" DF="0" EFFECT_SIZE="1.0176712328767124" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="50" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="0.16693553086053936" LOG_CI_START="-0.15172053440405966" LOG_EFFECT_SIZE="0.0076074982282398765" NO="1" P_CHI2="1.0" P_Z="0.9254402784564546" STUDIES="1" TAU2="0.0" TOTAL_1="438" TOTAL_2="437" WEIGHT="100.0" Z="0.09358317110594726">
<NAME>breast tenderness</NAME>
<DICH_DATA CI_END="1.4687082380683925" CI_START="0.7051466801785453" EFFECT_SIZE="1.0176712328767124" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="50" LOG_CI_END="0.16693553086053936" LOG_CI_START="-0.15172053440405966" LOG_EFFECT_SIZE="0.0076074982282398765" ORDER="1472" O_E="0.0" SE="0.18718015010938807" STUDY_ID="STD-Dunson-1993-_x0028_NG_x002d_NE_x0029_" TOTAL_1="438" TOTAL_2="437" VAR="0.035036408594973055" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0636943491913728" CI_START="0.6498831977539871" DF="0" EFFECT_SIZE="0.8314307458143074" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="108" I2="0.0" ID="CMP-002.05.02" LOG_CI_END="0.026816852085521422" LOG_CI_START="-0.18716469124812646" LOG_EFFECT_SIZE="-0.08017391958130253" MODIFIED="2011-01-31 12:20:55 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.14191253265270837" STUDIES="1" TAU2="0.0" TOTAL_1="438" TOTAL_2="437" WEIGHT="100.0" Z="1.4687060615667051">
<NAME>other</NAME>
<DICH_DATA CI_END="1.0636943491913728" CI_START="0.6498831977539871" EFFECT_SIZE="0.8314307458143074" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="108" LOG_CI_END="0.026816852085521422" LOG_CI_START="-0.18716469124812646" LOG_EFFECT_SIZE="-0.08017391958130253" ORDER="1473" O_E="0.0" SE="0.12569381777990724" STUDY_ID="STD-Dunson-1993-_x0028_NG_x002d_NE_x0029_" TOTAL_1="438" TOTAL_2="437" VAR="0.01579893582808852" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.936459396710395" CI_START="0.0582873962613839" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5882352941176471" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.77352750172791" LOG_CI_START="-1.2344253444844577" LOG_EFFECT_SIZE="-0.2304489213782739" METHOD="MH" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.6527950509429759" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="17" TOTAL_2="20" WEIGHT="100.00000000000001" Z="0.4498826623638244">
<NAME>Side-effects leading to discontinuation</NAME>
<GROUP_LABEL_1>NG</GROUP_LABEL_1>
<GROUP_LABEL_2>NE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NE</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.936459396710395" CI_START="0.0582873962613839" DF="0" EFFECT_SIZE="0.5882352941176471" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="0.77352750172791" LOG_CI_START="-1.2344253444844577" LOG_EFFECT_SIZE="-0.2304489213782739" NO="1" P_CHI2="1.0" P_Z="0.6527950509429759" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="20" WEIGHT="100.00000000000001" Z="0.4498826623638244">
<NAME>serious adverse events</NAME>
<DICH_DATA CI_END="5.936459396710395" CI_START="0.0582873962613839" EFFECT_SIZE="0.5882352941176471" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.77352750172791" LOG_CI_START="-1.2344253444844577" LOG_EFFECT_SIZE="-0.2304489213782739" ORDER="1474" O_E="0.0" SE="1.1794814413920363" STUDY_ID="STD-Dunson-1993-_x0028_NG_x002d_NE_x0029_" TOTAL_1="17" TOTAL_2="20" VAR="1.3911764705882352" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2011-01-31 12:15:17 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Norgestrel vs Norethindrone (triphasic)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6323634997285978" CI_START="0.8238485369693652" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1596638655462186" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="39" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.21281687521929046" LOG_CI_START="-0.08415262520187888" LOG_EFFECT_SIZE="0.06433212500870579" METHOD="MH" MODIFIED="2011-01-31 12:15:17 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.3957872642632688" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="119" TOTAL_2="117" WEIGHT="100.0" Z="0.8491690081787516">
<NAME>Discontinuation</NAME>
<GROUP_LABEL_1>NG</GROUP_LABEL_1>
<GROUP_LABEL_2>NE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NE</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6323634997285978" CI_START="0.8238485369693652" EFFECT_SIZE="1.1596638655462186" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="39" LOG_CI_END="0.21281687521929046" LOG_CI_START="-0.08415262520187888" LOG_EFFECT_SIZE="0.06433212500870579" ORDER="1475" O_E="0.0" SE="0.1744413545701302" STUDY_ID="STD-Percival-1990-_x0028_NG_x002d_NE_x0029_" TOTAL_1="119" TOTAL_2="117" VAR="0.030429786184261887" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.9991816265270996" CI_START="0.4209775417751855" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1236494597839135" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.4770027668632356" LOG_CI_START="-0.37574107220060027" LOG_EFFECT_SIZE="0.05063084733131762" METHOD="MH" MODIFIED="2011-01-31 12:15:17 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.8159617827177477" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="119" TOTAL_2="117" WEIGHT="100.0" Z="0.23274196242817957">
<NAME>Reasons for discontinuation</NAME>
<GROUP_LABEL_1>NG</GROUP_LABEL_1>
<GROUP_LABEL_2>NE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NE</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.9991816265270996" CI_START="0.4209775417751855" DF="0" EFFECT_SIZE="1.1236494597839135" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.4770027668632356" LOG_CI_START="-0.37574107220060027" LOG_EFFECT_SIZE="0.05063084733131762" NO="1" P_CHI2="1.0" P_Z="0.8159617827177477" STUDIES="1" TAU2="0.0" TOTAL_1="119" TOTAL_2="117" WEIGHT="100.0" Z="0.23274196242817957">
<NAME>cycle disturbances</NAME>
<DICH_DATA CI_END="2.9991816265270996" CI_START="0.4209775417751855" EFFECT_SIZE="1.1236494597839135" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.4770027668632356" LOG_CI_START="-0.37574107220060027" LOG_EFFECT_SIZE="0.05063084733131762" ORDER="1476" O_E="0.0" SE="0.5009059522161784" STUDY_ID="STD-Percival-1990-_x0028_NG_x002d_NE_x0029_" TOTAL_1="119" TOTAL_2="117" VAR="0.25090677296559644" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4936305804712067" CI_END="1.0153586476466943" CI_START="0.30922008166352954" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5603296207975104" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="26" I2="33.04904083548406" I2_Q="29.979726782467264" ID="CMP-003.03" LOG_CI_END="0.006619471985113569" LOG_CI_START="-0.5097323094740979" LOG_EFFECT_SIZE="-0.2515564187444921" METHOD="MH" MODIFIED="2011-01-31 12:15:17 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.2216543683898825" P_Q="0.23206557378100434" P_Z="0.05617034288857737" Q="1.4281578092294631" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.5682248979931389" TOTALS="SUB" TOTAL_1="264" TOTAL_2="234" WEIGHT="200.0" Z="1.9097117063322397">
<NAME>Cycle control</NAME>
<GROUP_LABEL_1>NG</GROUP_LABEL_1>
<GROUP_LABEL_2>NE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NE</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1092093614227796" CI_START="0.32926645756048956" DF="0" EFFECT_SIZE="0.6043388429752066" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="22" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="0.04501352624760151" LOG_CI_START="-0.482452508700028" LOG_EFFECT_SIZE="-0.21871949122621326" NO="1" P_CHI2="1.0" P_Z="0.10406873403259723" STUDIES="1" TAU2="0.0" TOTAL_1="132" TOTAL_2="117" WEIGHT="100.0" Z="1.6254404913971945">
<NAME>intermenstrual bleeding</NAME>
<DICH_DATA CI_END="1.1092093614227796" CI_START="0.32926645756048956" EFFECT_SIZE="0.6043388429752066" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="22" LOG_CI_END="0.04501352624760151" LOG_CI_START="-0.482452508700028" LOG_EFFECT_SIZE="-0.21871949122621326" ORDER="1477" O_E="0.0" SE="0.30983615992722024" STUDY_ID="STD-Reiter-1990-_x0028_NG_x002d_NE_x0029_" TOTAL_1="132" TOTAL_2="117" VAR="0.09599844599844601" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.811798178895096" CI_START="0.005363717486961442" DF="0" EFFECT_SIZE="0.09857978279030909" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="0.25810981879676337" LOG_CI_START="-2.270534104997334" LOG_EFFECT_SIZE="-1.0062121431002853" NO="2" P_CHI2="1.0" P_Z="0.11879777247218463" STUDIES="1" TAU2="0.0" TOTAL_1="132" TOTAL_2="117" WEIGHT="100.0" Z="1.5598396774855754">
<NAME>absence of withdrawal bleed</NAME>
<DICH_DATA CI_END="1.811798178895096" CI_START="0.005363717486961442" EFFECT_SIZE="0.0985797827903091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.25810981879676337" LOG_CI_START="-2.270534104997334" LOG_EFFECT_SIZE="-1.0062121431002853" ORDER="1478" O_E="0.0" SE="1.4853379578259471" STUDY_ID="STD-Reiter-1990-_x0028_NG_x002d_NE_x0029_" TOTAL_1="132" TOTAL_2="117" VAR="2.206228848958555" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1417375246122066" CI_START="0.9173818910251049" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0234301780693533" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="97" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.057566274912996186" LOG_CI_START="-0.03744983702449908" LOG_EFFECT_SIZE="0.010058218944248534" METHOD="MH" MODIFIED="2011-01-31 12:15:17 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.6781742071346167" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="132" TOTAL_2="117" WEIGHT="100.0" Z="0.41495587384829996">
<NAME>women satisfied</NAME>
<GROUP_LABEL_1>NG</GROUP_LABEL_1>
<GROUP_LABEL_2>NE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NE</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1417375246122066" CI_START="0.9173818910251049" EFFECT_SIZE="1.0234301780693533" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="97" LOG_CI_END="0.057566274912996186" LOG_CI_START="-0.03744983702449908" LOG_EFFECT_SIZE="0.010058218944248534" ORDER="1479" O_E="0.0" SE="0.05581293448942431" STUDY_ID="STD-Reiter-1990-_x0028_NG_x002d_NE_x0029_" TOTAL_1="132" TOTAL_2="117" VAR="0.0031150836563207697" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2011-01-31 12:14:33 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Levonorgestrel vs Norethindrone (monophasic)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="600" TOTAL_2="599" WEIGHT="0.0" Z="0.0">
<NAME>Pregnancy</NAME>
<GROUP_LABEL_1>LNG</GROUP_LABEL_1>
<GROUP_LABEL_2>NE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LNG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NE</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1448" O_E="0.0" SE="0.0" STUDY_ID="STD-Ramos-1989-_x0028_LNG_x002d_NE_x0029_" TOTAL_1="600" TOTAL_2="599" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9988342720953116" CI_END="0.8697618979863387" CI_START="0.641679276898259" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.74706638645674" ESTIMABLE="YES" EVENTS_1="224" EVENTS_2="266" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-0.06059962156919814" LOG_CI_START="-0.19268198606966247" LOG_EFFECT_SIZE="-0.12664080381943033" METHOD="MH" NO="2" P_CHI2="0.317592995878495" P_Q="1.0" P_Z="1.709802317934764E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="980" TOTAL_2="854" WEIGHT="100.0" Z="3.7584338438825173">
<NAME>Discontinuation</NAME>
<GROUP_LABEL_1>LNG</GROUP_LABEL_1>
<GROUP_LABEL_2>NE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LNG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NE</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8773905347740111" CI_START="0.4994620593100596" EFFECT_SIZE="0.6619843527738265" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="74" LOG_CI_END="-0.056807055043439546" LOG_CI_START="-0.30149749654331087" LOG_EFFECT_SIZE="-0.17915227579337523" ORDER="1449" O_E="0.0" SE="0.14373237657424445" STUDY_ID="STD-Endrikat-2001-_x0028_LNG_x002d_NE_x0029_" TOTAL_1="380" TOTAL_2="255" VAR="0.020658996075680412" WEIGHT="29.13772638346492"/>
<DICH_DATA CI_END="0.9405976357886623" CI_START="0.6553883215830525" EFFECT_SIZE="0.7851475694444444" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="192" LOG_CI_END="-0.02659611719660359" LOG_CI_START="-0.1835013016128213" LOG_EFFECT_SIZE="-0.10504870940471243" ORDER="1450" O_E="0.0" SE="0.09216688201927552" STUDY_ID="STD-Ramos-1989-_x0028_LNG_x002d_NE_x0029_" TOTAL_1="600" TOTAL_2="599" VAR="0.008494734141155052" WEIGHT="70.86227361653508"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.720855868888531" CI_END="0.9788520652191313" CI_START="0.6233189984664349" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7811127248606249" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="163" I2="30.080391961052246" I2_Q="30.068121469707727" ID="CMP-004.03" LOG_CI_END="-0.009282938547874356" LOG_CI_START="-0.20528963581714013" LOG_EFFECT_SIZE="-0.10728628718250725" METHOD="MH" NO="3" P_CHI2="0.2209873994998478" P_Q="0.22106959551862326" P_Z="0.0319038673700776" Q="5.719852067562187" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.03247230742776247" TOTALS="SUB" TOTAL_1="3600" TOTAL_2="3594" WEIGHT="500.0" Z="2.1456130003952407">
<NAME>Reasons for discontinuation</NAME>
<GROUP_LABEL_1>LNG</GROUP_LABEL_1>
<GROUP_LABEL_2>NE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LNG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NE</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.173479783774059" CI_START="0.14745280835090166" DF="0" EFFECT_SIZE="0.41597222222222224" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" I2="0.0" ID="CMP-004.03.01" LOG_CI_END="0.06947561215276388" LOG_CI_START="-0.8313469515646404" LOG_EFFECT_SIZE="-0.3809356697059383" NO="1" P_CHI2="1.0" P_Z="0.0973899555327411" STUDIES="1" TAU2="0.0" TOTAL_1="600" TOTAL_2="599" WEIGHT="100.0" Z="1.6576409675379888">
<NAME>cycle disturbances</NAME>
<DICH_DATA CI_END="1.173479783774059" CI_START="0.14745280835090166" EFFECT_SIZE="0.41597222222222224" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="0.06947561215276388" LOG_CI_START="-0.8313469515646404" LOG_EFFECT_SIZE="-0.3809356697059383" ORDER="1451" O_E="0.0" SE="0.5291476330712098" STUDY_ID="STD-Ramos-1989-_x0028_LNG_x002d_NE_x0029_" TOTAL_1="600" TOTAL_2="599" VAR="0.2799972175848637" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="600" TOTAL_2="599" WEIGHT="0.0" Z="0.0">
<NAME>pregnancy</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1452" O_E="0.0" SE="0.0" STUDY_ID="STD-Ramos-1989-_x0028_LNG_x002d_NE_x0029_" TOTAL_1="600" TOTAL_2="599" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.346851590481615" CI_START="0.48126915721264707" DF="0" EFFECT_SIZE="0.8051075268817204" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="31" I2="0.0" ID="CMP-004.03.03" LOG_CI_END="0.1293197434692167" LOG_CI_START="-0.3176119697823514" LOG_EFFECT_SIZE="-0.09414611315656735" NO="3" P_CHI2="1.0" P_Z="0.40895593435865984" STUDIES="1" TAU2="0.0" TOTAL_1="600" TOTAL_2="599" WEIGHT="100.0" Z="0.8257323685036446">
<NAME>side-effects</NAME>
<DICH_DATA CI_END="1.346851590481615" CI_START="0.48126915721264707" EFFECT_SIZE="0.8051075268817204" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="31" LOG_CI_END="0.1293197434692167" LOG_CI_START="-0.3176119697823514" LOG_EFFECT_SIZE="-0.09414611315656735" ORDER="1453" O_E="0.0" SE="0.262529900711632" STUDY_ID="STD-Ramos-1989-_x0028_LNG_x002d_NE_x0029_" TOTAL_1="600" TOTAL_2="599" VAR="0.06892194876765938" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2543029212457566" CI_START="0.5020452747957247" DF="0" EFFECT_SIZE="0.7935470085470085" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="39" I2="0.0" ID="CMP-004.03.04" LOG_CI_END="0.09840243373418861" LOG_CI_START="-0.2992571161073061" LOG_EFFECT_SIZE="-0.10042734118655877" NO="4" P_CHI2="1.0" P_Z="0.3221925827882284" STUDIES="1" TAU2="0.0" TOTAL_1="600" TOTAL_2="599" WEIGHT="100.0" Z="0.9899622522191577">
<NAME>other medical reasons</NAME>
<DICH_DATA CI_END="1.2543029212457564" CI_START="0.5020452747957248" EFFECT_SIZE="0.7935470085470085" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="39" LOG_CI_END="0.09840243373418854" LOG_CI_START="-0.29925711610730604" LOG_EFFECT_SIZE="-0.10042734118655877" ORDER="1454" O_E="0.0" SE="0.23358718802341236" STUDY_ID="STD-Ramos-1989-_x0028_LNG_x002d_NE_x0029_" TOTAL_1="600" TOTAL_2="599" VAR="0.054562974408685" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.9847050212697788" CI_START="0.7905146328453608" DF="0" EFFECT_SIZE="1.7748148148148148" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="9" I2="0.0" ID="CMP-004.03.05" LOG_CI_END="0.6003961770805737" LOG_CI_START="-0.10209008663603841" LOG_EFFECT_SIZE="0.24915304522226767" NO="5" P_CHI2="1.0" P_Z="0.16443981222546972" STUDIES="1" TAU2="0.0" TOTAL_1="600" TOTAL_2="599" WEIGHT="100.00000000000001" Z="1.390293363717985">
<NAME>loss to follow up</NAME>
<DICH_DATA CI_END="3.9847050212697788" CI_START="0.7905146328453608" EFFECT_SIZE="1.7748148148148148" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="9" LOG_CI_END="0.6003961770805737" LOG_CI_START="-0.10209008663603841" LOG_EFFECT_SIZE="0.24915304522226767" ORDER="1455" O_E="0.0" SE="0.41264390867022555" STUDY_ID="STD-Ramos-1989-_x0028_LNG_x002d_NE_x0029_" TOTAL_1="600" TOTAL_2="599" VAR="0.17027499536264143" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9938934404657443" CI_START="0.503137490156383" DF="0" EFFECT_SIZE="0.7071527777777777" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="72" I2="0.0" ID="CMP-004.03.06" LOG_CI_END="-0.002660175661514482" LOG_CI_START="-0.2983133209938143" LOG_EFFECT_SIZE="-0.15048674832766437" NO="6" P_CHI2="1.0" P_Z="0.046017362221884156" STUDIES="1" TAU2="0.0" TOTAL_1="600" TOTAL_2="599" WEIGHT="100.0" Z="1.9952340201979415">
<NAME>method unrelated</NAME>
<DICH_DATA CI_END="0.9938934404657443" CI_START="0.503137490156383" EFFECT_SIZE="0.7071527777777777" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="72" LOG_CI_END="-0.002660175661514482" LOG_CI_START="-0.2983133209938143" LOG_EFFECT_SIZE="-0.15048674832766437" ORDER="1456" O_E="0.0" SE="0.17366812107486543" STUDY_ID="STD-Ramos-1989-_x0028_LNG_x002d_NE_x0029_" TOTAL_1="600" TOTAL_2="599" VAR="0.03016061627767412" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.10952881923822165" CI_END="1.3566630974476608" CI_START="0.47836226100817647" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.805590731526511" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.13247201193001115" LOG_CI_START="-0.32024309006144874" LOG_EFFECT_SIZE="-0.0938855390657188" METHOD="MH" MODIFIED="2011-01-31 12:14:33 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.7406812457173427" P_Q="0.7406870551758877" P_Z="0.4162596412011542" Q="0.10952372864176071" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1200" TOTAL_2="1198" WEIGHT="200.0" Z="0.8129274876339706">
<NAME>Side-effects leading to discontinuation</NAME>
<GROUP_LABEL_1>LNG</GROUP_LABEL_1>
<GROUP_LABEL_2>NE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LNG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NE</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7737289244611103" CI_START="0.430209505454512" DF="0" EFFECT_SIZE="0.8735416666666667" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" I2="0.0" ID="CMP-004.04.01" LOG_CI_END="0.24888724818667438" LOG_CI_START="-0.3663199981307125" LOG_EFFECT_SIZE="-0.058716374972019016" NO="1" P_CHI2="1.0" P_Z="0.7083118653749405" STUDIES="1" TAU2="0.0" TOTAL_1="600" TOTAL_2="599" WEIGHT="100.0" Z="0.37412426767332074">
<NAME>headache</NAME>
<DICH_DATA CI_END="1.7737289244611103" CI_START="0.430209505454512" EFFECT_SIZE="0.8735416666666667" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" LOG_CI_END="0.24888724818667438" LOG_CI_START="-0.3663199981307125" LOG_EFFECT_SIZE="-0.058716374972019016" ORDER="1457" O_E="0.0" SE="0.3613757818118167" STUDY_ID="STD-Ramos-1989-_x0028_LNG_x002d_NE_x0029_" TOTAL_1="600" TOTAL_2="599" VAR="0.13059245568010175" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5807835304123377" CI_START="0.33906393171526594" DF="0" EFFECT_SIZE="0.7321111111111112" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" I2="0.0" ID="CMP-004.04.02" LOG_CI_END="0.1988724025166417" LOG_CI_START="-0.46971840630021844" LOG_EFFECT_SIZE="-0.1354230018917884" MODIFIED="2010-10-25 11:31:15 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4272064875270407" STUDIES="1" TAU2="0.0" TOTAL_1="600" TOTAL_2="599" WEIGHT="100.0" Z="0.793981020636225">
<NAME>nausea/vomiting</NAME>
<DICH_DATA CI_END="1.5807835304123374" CI_START="0.33906393171526594" EFFECT_SIZE="0.7321111111111112" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" LOG_CI_END="0.19887240251664165" LOG_CI_START="-0.46971840630021844" LOG_EFFECT_SIZE="-0.1354230018917884" ORDER="1458" O_E="0.0" SE="0.39273355067690346" STUDY_ID="STD-Ramos-1989-_x0028_LNG_x002d_NE_x0029_" TOTAL_1="600" TOTAL_2="599" VAR="0.15423964182728792" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2011-01-31 12:14:02 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Levonorgestrel vs Norethindrone (triphasic)</NAME>
<DICH_OUTCOME CHI2="0.27143840939858255" CI_END="0.6880520383986986" CI_START="0.3519983362480419" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4921312556304626" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="68" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-0.1623787141849176" LOG_CI_START="-0.4534593892491482" LOG_EFFECT_SIZE="-0.3079190517170329" METHOD="MH" MODIFIED="2011-01-31 12:14:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8730877647392649" P_Q="0.8760153431351346" P_Z="3.3732043122890385E-5" Q="0.26474336164075096" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="144" TOTAL_2="144" WEIGHT="300.0" Z="4.146687177951191">
<NAME>Cycle control</NAME>
<GROUP_LABEL_1>LNG</GROUP_LABEL_1>
<GROUP_LABEL_2>NE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LNG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NE</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9668585970363047" CI_START="0.197967159403365" DF="0" EFFECT_SIZE="0.4375" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="16" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="-0.014637036793192875" LOG_CI_START="-0.703406848490143" LOG_EFFECT_SIZE="-0.359021942641668" NO="1" P_CHI2="1.0" P_Z="0.041026082306312085" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="48" WEIGHT="100.0" Z="2.0432663141946183">
<NAME>spotting</NAME>
<DICH_DATA CI_END="0.9668585970363047" CI_START="0.197967159403365" EFFECT_SIZE="0.4375" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="16" LOG_CI_END="-0.014637036793192875" LOG_CI_START="-0.703406848490143" LOG_EFFECT_SIZE="-0.359021942641668" ORDER="1459" O_E="0.0" SE="0.4045867968563435" STUDY_ID="STD-Droegem_x00fc_ller-1989-_x0028_LNG_x002d_NE_x0029_" TOTAL_1="48" TOTAL_2="48" VAR="0.16369047619047616" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8546759485210013" CI_START="0.24174258162461557" DF="0" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="22" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="-0.06819851737183295" LOG_CI_START="-0.6166468442725795" LOG_EFFECT_SIZE="-0.3424226808222063" NO="2" P_CHI2="1.0" P_Z="0.014389118779373532" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="48" WEIGHT="100.0" Z="2.4473996509160107">
<NAME>breakthrough bleeding</NAME>
<DICH_DATA CI_END="0.8546759485210013" CI_START="0.24174258162461557" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="22" LOG_CI_END="-0.06819851737183295" LOG_CI_START="-0.6166468442725795" LOG_EFFECT_SIZE="-0.3424226808222063" ORDER="1460" O_E="0.0" SE="0.3221612620845014" STUDY_ID="STD-Droegem_x00fc_ller-1989-_x0028_LNG_x002d_NE_x0029_" TOTAL_1="48" TOTAL_2="48" VAR="0.10378787878787879" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8415987966789108" CI_START="0.3379810493633185" DF="0" EFFECT_SIZE="0.5333333333333333" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="30" I2="0.0" ID="CMP-005.01.03" LOG_CI_END="-0.07489489414575749" LOG_CI_START="-0.47110764998171784" LOG_EFFECT_SIZE="-0.27300127206373764" NO="3" P_CHI2="1.0" P_Z="0.006914462880846777" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="48" WEIGHT="100.0" Z="2.7009360657741013">
<NAME>Intermenstrual bleeding</NAME>
<DICH_DATA CI_END="0.8415987966789108" CI_START="0.3379810493633185" EFFECT_SIZE="0.5333333333333333" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="30" LOG_CI_END="-0.07489489414575749" LOG_CI_START="-0.47110764998171784" LOG_EFFECT_SIZE="-0.27300127206373764" ORDER="1461" O_E="0.0" SE="0.2327373340628157" STUDY_ID="STD-Droegem_x00fc_ller-1989-_x0028_LNG_x002d_NE_x0029_" TOTAL_1="48" TOTAL_2="48" VAR="0.05416666666666667" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2011-03-03 14:25:21 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Third versus second generation OCs</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.87937124518184" CI_START="0.062471994935000996" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.996" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="1.2008333022375497" LOG_CI_START="-1.204314625390152" LOG_EFFECT_SIZE="-0.0017406615763012698" METHOD="MH" MODIFIED="2010-10-22 15:56:21 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.9977364498769866" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="905" TOTAL_2="910" WEIGHT="100.0" Z="0.0028369431747911206">
<NAME>pregnancy</NAME>
<GROUP_LABEL_1>3rd gen.</GROUP_LABEL_1>
<GROUP_LABEL_2>2nd gen.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3rd</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 2nd</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.87937124518184" CI_START="0.062471994935000996" DF="0" EFFECT_SIZE="0.996" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="1.2008333022375497" LOG_CI_START="-1.204314625390152" LOG_EFFECT_SIZE="-0.0017406615763012698" MODIFIED="2010-10-22 13:44:36 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9977364498769866" STUDIES="3" TAU2="0.0" TOTAL_1="905" TOTAL_2="910" WEIGHT="100.0" Z="0.0028369431747911206">
<NAME>monophasic</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1256" O_E="0.0" SE="0.0" STUDY_ID="STD-Loudon-1990-_x0028_GSD_x002d_LNG_x0029_" TOTAL_1="229" TOTAL_2="227" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1257" O_E="0.0" SE="0.0" STUDY_ID="STD-Rabe-1989-_x0028_GSD_x002d_LNG_x0029_" TOTAL_1="176" TOTAL_2="185" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="15.87937124518184" CI_START="0.062471994935000996" EFFECT_SIZE="0.996" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2008333022375497" LOG_CI_START="-1.204314625390152" LOG_EFFECT_SIZE="-0.0017406615763012698" MODIFIED="2010-10-22 13:44:36 +0200" MODIFIED_BY="[Empty name]" ORDER="586" O_E="0.0" SE="1.4127957983627661" STUDY_ID="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_" TOTAL_1="500" TOTAL_2="498" VAR="1.995991967871486" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.3930231843772534" CI_END="0.9842878063294426" CI_START="0.603996287669946" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7710422692834538" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="175" I2="16.423709847154342" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="-0.00687789503920419" LOG_CI_START="-0.21896573066597433" LOG_EFFECT_SIZE="-0.11292181285258926" METHOD="MH" MODIFIED="2010-10-22 15:56:27 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.30224679536732024" P_Q="1.0" P_Z="0.03688043804789666" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.009391203476498255" TOTALS="SUB" TOTAL_1="905" TOTAL_2="910" WEIGHT="100.0" Z="2.087085151357086">
<NAME>discontinuation</NAME>
<GROUP_LABEL_1>3rd gen.</GROUP_LABEL_1>
<GROUP_LABEL_2>2nd gen.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3rd</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 2nd</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.3930231843772534" CI_END="0.9842878063294426" CI_START="0.603996287669946" DF="2" EFFECT_SIZE="0.7710422692834538" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="175" I2="16.423709847154342" ID="CMP-006.02.01" LOG_CI_END="-0.00687789503920419" LOG_CI_START="-0.21896573066597433" LOG_EFFECT_SIZE="-0.11292181285258926" MODIFIED="2010-10-22 13:45:39 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.30224679536732024" P_Z="0.03688043804789666" STUDIES="3" TAU2="0.009391203476498255" TOTAL_1="905" TOTAL_2="910" WEIGHT="100.0" Z="2.087085151357086">
<NAME>monophasic</NAME>
<DICH_DATA CI_END="1.2584464668033528" CI_START="0.4997191331162649" EFFECT_SIZE="0.7930131004366813" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="35" LOG_CI_END="0.09983474577520783" LOG_CI_START="-0.30127402208485116" LOG_EFFECT_SIZE="-0.10071963815482167" ORDER="1258" O_E="0.0" SE="0.23561327576142163" STUDY_ID="STD-Loudon-1990-_x0028_GSD_x002d_LNG_x0029_" TOTAL_1="229" TOTAL_2="227" VAR="0.05551361571502771" WEIGHT="23.91276411637339"/>
<DICH_DATA CI_END="0.9312905488027512" CI_START="0.2527253006047341" EFFECT_SIZE="0.48513986013986016" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="26" LOG_CI_END="-0.030914804457985428" LOG_CI_START="-0.5973512782106729" LOG_EFFECT_SIZE="-0.3141330413343291" ORDER="1259" O_E="0.0" SE="0.3327275885880944" STUDY_ID="STD-Rabe-1989-_x0028_GSD_x002d_LNG_x0029_" TOTAL_1="176" TOTAL_2="185" VAR="0.11070764820764821" WEIGHT="12.923134647653775"/>
<DICH_DATA CI_END="1.0678291680905745" CI_START="0.6587940387156002" EFFECT_SIZE="0.8387368421052631" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="114" LOG_CI_END="0.028501779574684246" LOG_CI_START="-0.18125033932109522" LOG_EFFECT_SIZE="-0.07637427987320547" MODIFIED="2010-10-22 13:45:39 +0200" MODIFIED_BY="[Empty name]" ORDER="587" O_E="0.0" SE="0.12320943292911468" STUDY_ID="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_" TOTAL_1="500" TOTAL_2="498" VAR="0.015180564362714009" WEIGHT="63.16410123597284"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.5828914001818672" CI_END="1.3133981016322949" CI_START="0.2763718203398521" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6024833808322212" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="43" I2="61.28369934835093" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="0.11839638422870737" LOG_CI_START="-0.5585062409462019" LOG_EFFECT_SIZE="-0.22005492835874738" METHOD="MH" MODIFIED="2010-10-22 15:56:32 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.10802455870457839" P_Q="1.0" P_Z="0.20254539117993153" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.19412218034053907" TOTALS="SUB" TOTAL_1="729" TOTAL_2="725" WEIGHT="100.0" Z="1.2743331704238559">
<NAME>discontinuation due to side-effects (cycle-unrelated)</NAME>
<GROUP_LABEL_1>3rd gen.</GROUP_LABEL_1>
<GROUP_LABEL_2>2nd gen.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3rd</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 2nd</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.5828914001818672" CI_END="1.3133981016322949" CI_START="0.2763718203398521" DF="1" EFFECT_SIZE="0.6024833808322212" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="43" I2="61.28369934835093" ID="CMP-006.03.01" LOG_CI_END="0.11839638422870737" LOG_CI_START="-0.5585062409462019" LOG_EFFECT_SIZE="-0.22005492835874738" MODIFIED="2010-10-22 13:53:40 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.10802455870457839" P_Z="0.20254539117993153" STUDIES="2" TAU2="0.19412218034053907" TOTAL_1="729" TOTAL_2="725" WEIGHT="100.0" Z="1.2743331704238559">
<NAME>monophasic</NAME>
<DICH_DATA CI_END="1.6843349923852633" CI_START="0.4609430100447858" EFFECT_SIZE="0.881125667151868" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="18" LOG_CI_END="0.22642847129419255" LOG_CI_START="-0.33635276648248563" LOG_EFFECT_SIZE="-0.05496214759414656" ORDER="1260" O_E="0.0" SE="0.33058048488207675" STUDY_ID="STD-Loudon-1990-_x0028_GSD_x002d_LNG_x0029_" TOTAL_1="229" TOTAL_2="227" VAR="0.10928345698486898" WEIGHT="52.10794607337791"/>
<DICH_DATA CI_END="0.8207628271498135" CI_START="0.19338419668831858" EFFECT_SIZE="0.3984" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="25" LOG_CI_END="-0.08578232124942765" LOG_CI_START="-0.7135790192472502" LOG_EFFECT_SIZE="-0.3996806702483389" MODIFIED="2010-10-22 13:47:03 +0200" MODIFIED_BY="[Empty name]" ORDER="588" O_E="0.0" SE="0.3687708880476955" STUDY_ID="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_" TOTAL_1="500" TOTAL_2="498" VAR="0.13599196787148596" WEIGHT="47.89205392662209"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0792267396771225" CI_START="0.0827272311902787" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2988" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="0.03311269718122772" LOG_CI_START="-1.0823515108945052" LOG_EFFECT_SIZE="-0.5246194068566388" METHOD="MH" MODIFIED="2010-10-22 14:24:21 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.06524139431577887" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="500" TOTAL_2="498" WEIGHT="100.00000000000001" Z="1.8436004231880596">
<NAME>Discontinuation due to cycle disturbance</NAME>
<GROUP_LABEL_1>3rd gen</GROUP_LABEL_1>
<GROUP_LABEL_2>2nd gen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0792267396771225" CI_START="0.0827272311902787" DF="0" EFFECT_SIZE="0.2988" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" I2="0.0" ID="CMP-006.04.01" LOG_CI_END="0.03311269718122772" LOG_CI_START="-1.0823515108945052" LOG_EFFECT_SIZE="-0.5246194068566388" MODIFIED="2010-10-22 14:24:21 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.06524139431577887" STUDIES="1" TAU2="0.0" TOTAL_1="500" TOTAL_2="498" WEIGHT="100.00000000000001" Z="1.8436004231880596">
<NAME>monophasic</NAME>
<DICH_DATA CI_END="1.0792267396771225" CI_START="0.0827272311902787" EFFECT_SIZE="0.2988" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.03311269718122772" LOG_CI_START="-1.0823515108945052" LOG_EFFECT_SIZE="-0.5246194068566388" MODIFIED="2010-10-22 14:24:21 +0200" MODIFIED_BY="[Empty name]" ORDER="591" O_E="0.0" SE="0.6552291974605674" STUDY_ID="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_" TOTAL_1="500" TOTAL_2="498" VAR="0.42932530120481927" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.994344414168265" CI_END="1.5905783009693528" CI_START="0.911038830177296" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2037768043206807" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="86" I2="0.0" I2_Q="18.061339130842345" ID="CMP-006.05" LOG_CI_END="0.2015550534131327" LOG_CI_START="-0.040463112190180665" LOG_EFFECT_SIZE="0.08054597061147604" METHOD="MH" MODIFIED="2011-01-31 12:06:24 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.40677199521576035" P_Q="0.300439907788025" P_Z="0.19203260172918507" Q="3.6612753591256495" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2229" TOTAL_2="2219" WEIGHT="400.0" Z="1.3045896873466212">
<NAME>side effects (monophasic)</NAME>
<GROUP_LABEL_1>3rd gen.</GROUP_LABEL_1>
<GROUP_LABEL_2>2nd gen.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3rd</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 2nd</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.1808454427286685" CI_START="0.03465242244069709" DF="0" EFFECT_SIZE="0.332" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-006.05.01" LOG_CI_END="0.5025425672523451" LOG_CI_START="-1.4602663998442726" LOG_EFFECT_SIZE="-0.47886191629596364" MODIFIED="2010-10-22 14:30:06 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3389026885039632" STUDIES="1" TAU2="0.0" TOTAL_1="500" TOTAL_2="498" WEIGHT="100.0" Z="0.9563356651016599">
<NAME>breast tenderness</NAME>
<DICH_DATA CI_END="3.1808454427286685" CI_START="0.03465242244069709" EFFECT_SIZE="0.332" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5025425672523451" LOG_CI_START="-1.4602663998442726" LOG_EFFECT_SIZE="-0.47886191629596364" MODIFIED="2010-10-22 14:27:39 +0200" MODIFIED_BY="[Empty name]" ORDER="594" O_E="0.0" SE="1.1529637033336388" STUDY_ID="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_" TOTAL_1="500" TOTAL_2="498" VAR="1.3293253012048192" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.5255405098850874" CI_START="0.8837854674132939" DF="0" EFFECT_SIZE="1.4940000000000002" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="22" I2="0.0" ID="CMP-006.05.02" LOG_CI_END="0.402354339024752" LOG_CI_START="-0.053653144065991934" LOG_EFFECT_SIZE="0.17435059747938003" MODIFIED="2010-10-22 14:31:04 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.13393817681232795" STUDIES="1" TAU2="0.0" TOTAL_1="500" TOTAL_2="498" WEIGHT="100.0" Z="1.4987512460387564">
<NAME>headaches</NAME>
<DICH_DATA CI_END="2.5255405098850874" CI_START="0.8837854674132939" EFFECT_SIZE="1.494" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="22" LOG_CI_END="0.402354339024752" LOG_CI_START="-0.053653144065991934" LOG_EFFECT_SIZE="0.17435059747937998" MODIFIED="2010-10-22 14:26:10 +0200" MODIFIED_BY="[Empty name]" ORDER="592" O_E="0.0" SE="0.2678610528409491" STUDY_ID="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_" TOTAL_1="500" TOTAL_2="498" VAR="0.0717495436290617" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.043825728259733" CI_START="0.07765953711481473" DF="0" EFFECT_SIZE="0.3984" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-006.05.03" LOG_CI_END="0.3104438618727529" LOG_CI_START="-1.1098052023694307" LOG_EFFECT_SIZE="-0.3996806702483389" MODIFIED="2011-01-31 12:06:24 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.2699707051285477" STUDIES="1" TAU2="0.0" TOTAL_1="500" TOTAL_2="498" WEIGHT="100.0" Z="1.1031300617987858">
<NAME>other minor</NAME>
<DICH_DATA CI_END="2.043825728259733" CI_START="0.07765953711481473" EFFECT_SIZE="0.3984" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3104438618727529" LOG_CI_START="-1.1098052023694307" LOG_EFFECT_SIZE="-0.3996806702483389" MODIFIED="2010-10-22 14:32:07 +0200" MODIFIED_BY="[Empty name]" ORDER="596" O_E="0.0" SE="0.8342613306821106" STUDY_ID="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_" TOTAL_1="500" TOTAL_2="498" VAR="0.6959919678714859" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.3285433798943278" CI_END="1.667400909369387" CI_START="0.8457932571836244" DF="1" EFFECT_SIZE="1.1875506078338183" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="56" I2="0.0" ID="CMP-006.05.04" LOG_CI_END="0.22204003401719824" LOG_CI_START="-0.07273578144924742" LOG_EFFECT_SIZE="0.07465212628397543" MODIFIED="2011-01-31 12:06:24 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5665182067790128" P_Z="0.3208446027140235" STUDIES="2" TAU2="0.0" TOTAL_1="729" TOTAL_2="725" WEIGHT="100.0" Z="0.9927237663944846">
<NAME>all</NAME>
<DICH_DATA CI_END="3.0383624619847804" CI_START="0.6842199972071537" EFFECT_SIZE="1.4418420007939659" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="11" LOG_CI_END="0.4826395818539818" LOG_CI_START="-0.16480423715211284" LOG_EFFECT_SIZE="0.15891767235093446" ORDER="1261" O_E="0.0" SE="0.38031170418277205" STUDY_ID="STD-Loudon-1990-_x0028_GSD_x002d_LNG_x0029_" TOTAL_1="229" TOTAL_2="227" VAR="0.14463699233840432" WEIGHT="20.729055804687427"/>
<DICH_DATA CI_END="1.652561840402473" CI_START="0.7710388857155736" EFFECT_SIZE="1.1288" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="45" LOG_CI_END="0.2181577201655692" LOG_CI_START="-0.11292371867298627" LOG_EFFECT_SIZE="0.05261700074629142" MODIFIED="2010-10-22 14:00:38 +0200" MODIFIED_BY="[Empty name]" ORDER="590" O_E="0.0" SE="0.1944788760533212" STUDY_ID="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_" TOTAL_1="500" TOTAL_2="498" VAR="0.03782203323096307" WEIGHT="79.27094419531257"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9052690691890504" CI_START="0.5537924065166934" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7080474111041797" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="98" I2="0.0" I2_Q="0.0" ID="CMP-006.06" LOG_CI_END="-0.043222318147124926" LOG_CI_START="-0.25665300350288167" LOG_EFFECT_SIZE="-0.1499376608250033" METHOD="MH" MODIFIED="2010-11-01 12:41:21 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.005890825251969822" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="229" TOTAL_2="227" WEIGHT="100.0" Z="2.7537972307341625">
<NAME>intermenstrual bleeding</NAME>
<GROUP_LABEL_1>3rd gen.</GROUP_LABEL_1>
<GROUP_LABEL_2>2nd gen.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3r</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 2nd</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9052690691890504" CI_START="0.5537924065166934" DF="0" EFFECT_SIZE="0.7080474111041797" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="98" I2="0.0" ID="CMP-006.06.01" LOG_CI_END="-0.043222318147124926" LOG_CI_START="-0.25665300350288167" LOG_EFFECT_SIZE="-0.1499376608250033" NO="1" P_CHI2="1.0" P_Z="0.005890825251969822" STUDIES="1" TAU2="0.0" TOTAL_1="229" TOTAL_2="227" WEIGHT="100.0" Z="2.7537972307341625">
<NAME>monophasic</NAME>
<DICH_DATA CI_END="0.9052690691890504" CI_START="0.5537924065166934" EFFECT_SIZE="0.7080474111041797" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="98" LOG_CI_END="-0.043222318147124926" LOG_CI_START="-0.25665300350288167" LOG_EFFECT_SIZE="-0.1499376608250033" ORDER="1262" O_E="0.0" SE="0.125370241076903" STUDY_ID="STD-Loudon-1990-_x0028_GSD_x002d_LNG_x0029_" TOTAL_1="229" TOTAL_2="227" VAR="0.015717697347680776" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6115579800646291" CI_START="0.7635402745139128" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.109274277396548" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="42" I2="0.0" I2_Q="0.0" ID="CMP-006.07" LOG_CI_END="0.20724593502313285" LOG_CI_START="-0.11716805024102947" LOG_EFFECT_SIZE="0.04503894239105169" METHOD="MH" MODIFIED="2010-11-01 12:41:21 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.5862968143754137" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="229" TOTAL_2="227" WEIGHT="100.0" Z="0.5442102313582796">
<NAME>spotting</NAME>
<GROUP_LABEL_1>3rd gen.</GROUP_LABEL_1>
<GROUP_LABEL_2>2nd gen.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3rd</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 2nd</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6115579800646291" CI_START="0.7635402745139128" DF="0" EFFECT_SIZE="1.109274277396548" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="42" I2="0.0" ID="CMP-006.07.01" LOG_CI_END="0.20724593502313285" LOG_CI_START="-0.11716805024102947" LOG_EFFECT_SIZE="0.04503894239105169" NO="1" P_CHI2="1.0" P_Z="0.5862968143754137" STUDIES="1" TAU2="0.0" TOTAL_1="229" TOTAL_2="227" WEIGHT="100.0" Z="0.5442102313582796">
<NAME>monophasic</NAME>
<DICH_DATA CI_END="1.6115579800646291" CI_START="0.7635402745139128" EFFECT_SIZE="1.109274277396548" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="42" LOG_CI_END="0.20724593502313285" LOG_CI_START="-0.11716805024102947" LOG_EFFECT_SIZE="0.04503894239105169" ORDER="1263" O_E="0.0" SE="0.19056238081929522" STUDY_ID="STD-Loudon-1990-_x0028_GSD_x002d_LNG_x0029_" TOTAL_1="229" TOTAL_2="227" VAR="0.036314020983518096" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3401148682405457" CI_START="0.3258788732136039" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.660844250363901" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-006.08" LOG_CI_END="0.12714202560729387" LOG_CI_START="-0.48694379401218685" LOG_EFFECT_SIZE="-0.1799008842024465" METHOD="MH" MODIFIED="2010-11-01 12:41:21 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.25081535151531675" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="229" TOTAL_2="227" WEIGHT="100.0" Z="1.148371261991344">
<NAME>breakthrough bleeding</NAME>
<GROUP_LABEL_1>3rd gen.</GROUP_LABEL_1>
<GROUP_LABEL_2>2nd gen.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3rd</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 2nd</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3401148682405457" CI_START="0.3258788732136039" DF="0" EFFECT_SIZE="0.660844250363901" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" I2="0.0" ID="CMP-006.08.01" LOG_CI_END="0.12714202560729387" LOG_CI_START="-0.48694379401218685" LOG_EFFECT_SIZE="-0.1799008842024465" NO="1" P_CHI2="1.0" P_Z="0.25081535151531675" STUDIES="1" TAU2="0.0" TOTAL_1="229" TOTAL_2="227" WEIGHT="100.0" Z="1.148371261991344">
<NAME>monophasic</NAME>
<DICH_DATA CI_END="1.3401148682405457" CI_START="0.3258788732136039" EFFECT_SIZE="0.660844250363901" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" LOG_CI_END="0.12714202560729387" LOG_CI_START="-0.48694379401218685" LOG_EFFECT_SIZE="-0.1799008842024465" ORDER="1264" O_E="0.0" SE="0.3607170502183149" STUDY_ID="STD-Loudon-1990-_x0028_GSD_x002d_LNG_x0029_" TOTAL_1="229" TOTAL_2="227" VAR="0.1301167903182023" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.43392243843272615" CI_END="1.5897051939856515" CI_START="0.3812081933792049" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7784655708538487" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-006.09" LOG_CI_END="0.20131659319079048" LOG_CI_START="-0.4188377735606353" LOG_EFFECT_SIZE="-0.10876059018492247" METHOD="MH" MODIFIED="2010-11-01 12:41:21 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.5100705389270572" P_Q="1.0" P_Z="0.49179050793643386" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="405" TOTAL_2="412" WEIGHT="100.0" Z="0.6874638029766914">
<NAME>absence of withdrawal bleed</NAME>
<GROUP_LABEL_1>3rd gen.</GROUP_LABEL_1>
<GROUP_LABEL_2>2nd gen.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3rd</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 2nd</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.43392243843272615" CI_END="1.5897051939856515" CI_START="0.3812081933792049" DF="1" EFFECT_SIZE="0.7784655708538487" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="17" I2="0.0" ID="CMP-006.09.01" LOG_CI_END="0.20131659319079048" LOG_CI_START="-0.4188377735606353" LOG_EFFECT_SIZE="-0.10876059018492247" NO="1" P_CHI2="0.5100705389270572" P_Z="0.49179050793643386" STUDIES="2" TAU2="0.0" TOTAL_1="405" TOTAL_2="412" WEIGHT="100.0" Z="0.6874638029766914">
<NAME>monophasic</NAME>
<DICH_DATA CI_END="2.0800286636552827" CI_START="0.3904146084428668" EFFECT_SIZE="0.9011512504962287" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.3180693197615825" LOG_CI_START="-0.4084739403715631" LOG_EFFECT_SIZE="-0.0452023103049903" ORDER="1265" O_E="0.0" SE="0.4267751074493501" STUDY_ID="STD-Loudon-1990-_x0028_GSD_x002d_LNG_x0029_" TOTAL_1="229" TOTAL_2="227" VAR="0.18213699233840433" WEIGHT="72.85790103506628"/>
<DICH_DATA CI_END="2.069229898522471" CI_START="0.13349020035758474" EFFECT_SIZE="0.5255681818181818" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.31580874494945393" LOG_CI_START="-0.8745506150996885" LOG_EFFECT_SIZE="-0.27937093507511723" ORDER="1266" O_E="0.0" SE="0.6992229804667295" STUDY_ID="STD-Rabe-1989-_x0028_GSD_x002d_LNG_x0029_" TOTAL_1="176" TOTAL_2="185" VAR="0.4889127764127764" WEIGHT="27.142098964933716"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2011-02-15 10:47:49 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Gestodene vs Levonorgestrel (monophasic)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="405" TOTAL_2="412" WEIGHT="0.0" Z="0.0">
<NAME>Pregnancy</NAME>
<GROUP_LABEL_1>GSD</GROUP_LABEL_1>
<GROUP_LABEL_2>LNG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LNG</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1302" O_E="0.0" SE="0.0" STUDY_ID="STD-Loudon-1990-_x0028_GSD_x002d_LNG_x0029_" TOTAL_1="229" TOTAL_2="227" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1303" O_E="0.0" SE="0.0" STUDY_ID="STD-Rabe-1989-_x0028_GSD_x002d_LNG_x0029_" TOTAL_1="176" TOTAL_2="185" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4576126382752617" CI_END="1.049217302700423" CI_START="0.4101082780353738" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6559669971083835" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="61" I2="31.394667297666786" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="0.020865443951631476" LOG_CI_START="-0.3871014643901549" LOG_EFFECT_SIZE="-0.18311801021926175" METHOD="MH" NO="2" P_CHI2="0.22731065473343426" P_Q="1.0" P_Z="0.07849610003286185" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.03803247556055215" TOTALS="YES" TOTAL_1="405" TOTAL_2="412" WEIGHT="100.00000000000001" Z="1.759479495085457">
<NAME>Discontinuation</NAME>
<GROUP_LABEL_1>GSD</GROUP_LABEL_1>
<GROUP_LABEL_2>LNG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LNG</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2584464668033528" CI_START="0.4997191331162649" EFFECT_SIZE="0.7930131004366813" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="35" LOG_CI_END="0.09983474577520783" LOG_CI_START="-0.30127402208485116" LOG_EFFECT_SIZE="-0.10071963815482167" ORDER="1304" O_E="0.0" SE="0.23561327576142163" STUDY_ID="STD-Loudon-1990-_x0028_GSD_x002d_LNG_x0029_" TOTAL_1="229" TOTAL_2="227" VAR="0.05551361571502771" WEIGHT="61.390254390380235"/>
<DICH_DATA CI_END="0.9312905488027512" CI_START="0.2527253006047341" EFFECT_SIZE="0.48513986013986016" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="26" LOG_CI_END="-0.030914804457985428" LOG_CI_START="-0.5973512782106729" LOG_EFFECT_SIZE="-0.3141330413343291" ORDER="1305" O_E="0.0" SE="0.3327275885880944" STUDY_ID="STD-Rabe-1989-_x0028_GSD_x002d_LNG_x0029_" TOTAL_1="176" TOTAL_2="185" VAR="0.11070764820764821" WEIGHT="38.60974560961978"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.39634011001426545" CI_END="1.2958251545510078" CI_START="0.4905812999492749" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.797312729627844" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="0.1125464062133083" LOG_CI_START="-0.3092890103155774" LOG_EFFECT_SIZE="-0.0983713020511345" METHOD="MH" MODIFIED="2010-11-01 12:41:59 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9409975126929755" P_Q="0.9410955951454572" P_Z="0.36065352183196575" Q="0.39586390868375176" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="916" TOTAL_2="908" WEIGHT="400.0" Z="0.9141205388539599">
<NAME>Reasons for discontinuation</NAME>
<GROUP_LABEL_1>GSD</GROUP_LABEL_1>
<GROUP_LABEL_2>LNG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LNG</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6843349923852633" CI_START="0.4609430100447858" DF="0" EFFECT_SIZE="0.881125667151868" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="18" I2="0.0" ID="CMP-007.03.01" LOG_CI_END="0.22642847129419255" LOG_CI_START="-0.33635276648248563" LOG_EFFECT_SIZE="-0.05496214759414656" MODIFIED="2010-11-01 12:41:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7018482962429016" STUDIES="1" TAU2="0.0" TOTAL_1="229" TOTAL_2="227" WEIGHT="100.0" Z="0.38282665649294023">
<NAME>side-effects (other than cycle disturbances)</NAME>
<DICH_DATA CI_END="1.6843349923852633" CI_START="0.4609430100447858" EFFECT_SIZE="0.881125667151868" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="18" LOG_CI_END="0.22642847129419255" LOG_CI_START="-0.33635276648248563" LOG_EFFECT_SIZE="-0.05496214759414656" ORDER="1306" O_E="0.0" SE="0.33058048488207675" STUDY_ID="STD-Loudon-1990-_x0028_GSD_x002d_LNG_x0029_" TOTAL_1="229" TOTAL_2="227" VAR="0.10928345698486898" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.915351225926099" CI_START="0.21570978202272326" DF="0" EFFECT_SIZE="0.7930131004366813" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-007.03.02" LOG_CI_END="0.4646908837238176" LOG_CI_START="-0.666130160033461" LOG_EFFECT_SIZE="-0.10071963815482167" MODIFIED="2010-11-01 12:41:59 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7269849606328296" STUDIES="1" TAU2="0.0" TOTAL_1="229" TOTAL_2="227" WEIGHT="100.0" Z="0.34913899844567886">
<NAME>other medical reasons</NAME>
<DICH_DATA CI_END="2.915351225926099" CI_START="0.21570978202272326" EFFECT_SIZE="0.7930131004366813" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4646908837238176" LOG_CI_START="-0.666130160033461" LOG_EFFECT_SIZE="-0.10071963815482167" ORDER="1307" O_E="0.0" SE="0.6642498787574699" STUDY_ID="STD-Loudon-1990-_x0028_GSD_x002d_LNG_x0029_" TOTAL_1="229" TOTAL_2="227" VAR="0.44122790142931345" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.915351225926099" CI_START="0.21570978202272326" DF="0" EFFECT_SIZE="0.7930131004366813" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-007.03.03" LOG_CI_END="0.4646908837238176" LOG_CI_START="-0.666130160033461" LOG_EFFECT_SIZE="-0.10071963815482167" MODIFIED="2010-11-01 12:41:59 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.7269849606328296" STUDIES="1" TAU2="0.0" TOTAL_1="229" TOTAL_2="227" WEIGHT="100.0" Z="0.34913899844567886">
<NAME>lost to follow-up</NAME>
<DICH_DATA CI_END="2.915351225926099" CI_START="0.21570978202272326" EFFECT_SIZE="0.7930131004366813" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4646908837238176" LOG_CI_START="-0.666130160033461" LOG_EFFECT_SIZE="-0.10071963815482167" ORDER="1308" O_E="0.0" SE="0.6642498787574699" STUDY_ID="STD-Loudon-1990-_x0028_GSD_x002d_LNG_x0029_" TOTAL_1="229" TOTAL_2="227" VAR="0.44122790142931345" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.908451099345783" CI_START="0.16812163926423895" DF="0" EFFECT_SIZE="0.5664379288833438" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" I2="0.0" ID="CMP-007.03.04" LOG_CI_END="0.2806810364064855" LOG_CI_START="-0.7743763840726049" LOG_EFFECT_SIZE="-0.24684767383305967" MODIFIED="2010-11-01 12:41:59 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.3590743894816495" STUDIES="1" TAU2="0.0" TOTAL_1="229" TOTAL_2="227" WEIGHT="100.0" Z="0.917130273650117">
<NAME>method unrelated</NAME>
<DICH_DATA CI_END="1.908451099345783" CI_START="0.16812163926423895" EFFECT_SIZE="0.5664379288833438" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2806810364064855" LOG_CI_START="-0.7743763840726049" LOG_EFFECT_SIZE="-0.24684767383305967" ORDER="1309" O_E="0.0" SE="0.6197459514078784" STUDY_ID="STD-Loudon-1990-_x0028_GSD_x002d_LNG_x0029_" TOTAL_1="229" TOTAL_2="227" VAR="0.3840850442864563" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.013095271505182" CI_END="0.9570563673815612" CI_START="0.7194797478099157" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8298088176463057" ESTIMABLE="YES" EVENTS_1="232" EVENTS_2="277" I2="0.26122127739355516" I2_Q="12.652563766488468" ID="CMP-007.04" LOG_CI_END="-0.019062482994461172" LOG_CI_START="-0.1429814262418822" LOG_EFFECT_SIZE="-0.08102195461817169" METHOD="MH" NO="4" P_CHI2="0.41428429124839794" P_Q="0.33323485692791455" P_Z="0.010378175828882834" Q="4.579413171677463" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.0324261805926011E-4" TOTALS="SUB" TOTAL_1="1321" TOTAL_2="1320" WEIGHT="500.0" Z="2.5629675148470117">
<NAME>Cycle control</NAME>
<GROUP_LABEL_1>GSD</GROUP_LABEL_1>
<GROUP_LABEL_2>LNG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LNG</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9052690691890504" CI_START="0.5537924065166934" DF="0" EFFECT_SIZE="0.7080474111041797" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="98" I2="0.0" ID="CMP-007.04.01" LOG_CI_END="-0.043222318147124926" LOG_CI_START="-0.25665300350288167" LOG_EFFECT_SIZE="-0.1499376608250033" NO="1" P_CHI2="1.0" P_Z="0.005890825251969822" STUDIES="1" TAU2="0.0" TOTAL_1="229" TOTAL_2="227" WEIGHT="100.0" Z="2.7537972307341625">
<NAME>intermenstrual bleeding</NAME>
<DICH_DATA CI_END="0.9052690691890504" CI_START="0.5537924065166934" EFFECT_SIZE="0.7080474111041797" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="98" LOG_CI_END="-0.043222318147124926" LOG_CI_START="-0.25665300350288167" LOG_EFFECT_SIZE="-0.1499376608250033" ORDER="1310" O_E="0.0" SE="0.125370241076903" STUDY_ID="STD-Loudon-1990-_x0028_GSD_x002d_LNG_x0029_" TOTAL_1="229" TOTAL_2="227" VAR="0.015717697347680776" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6115579800646291" CI_START="0.7635402745139128" DF="0" EFFECT_SIZE="1.109274277396548" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="42" I2="0.0" ID="CMP-007.04.02" LOG_CI_END="0.20724593502313285" LOG_CI_START="-0.11716805024102947" LOG_EFFECT_SIZE="0.04503894239105169" NO="2" P_CHI2="1.0" P_Z="0.5862968143754137" STUDIES="1" TAU2="0.0" TOTAL_1="229" TOTAL_2="227" WEIGHT="100.0" Z="0.5442102313582796">
<NAME>spotting</NAME>
<DICH_DATA CI_END="1.6115579800646291" CI_START="0.7635402745139128" EFFECT_SIZE="1.109274277396548" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="42" LOG_CI_END="0.20724593502313285" LOG_CI_START="-0.11716805024102947" LOG_EFFECT_SIZE="0.04503894239105169" ORDER="1311" O_E="0.0" SE="0.19056238081929522" STUDY_ID="STD-Loudon-1990-_x0028_GSD_x002d_LNG_x0029_" TOTAL_1="229" TOTAL_2="227" VAR="0.036314020983518096" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3401148682405457" CI_START="0.3258788732136039" DF="0" EFFECT_SIZE="0.660844250363901" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" I2="0.0" ID="CMP-007.04.03" LOG_CI_END="0.12714202560729387" LOG_CI_START="-0.48694379401218685" LOG_EFFECT_SIZE="-0.1799008842024465" NO="3" P_CHI2="1.0" P_Z="0.25081535151531675" STUDIES="1" TAU2="0.0" TOTAL_1="229" TOTAL_2="227" WEIGHT="100.0" Z="1.148371261991344">
<NAME>breakthrough bleeding</NAME>
<DICH_DATA CI_END="1.3401148682405457" CI_START="0.3258788732136039" EFFECT_SIZE="0.660844250363901" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" LOG_CI_END="0.12714202560729387" LOG_CI_START="-0.48694379401218685" LOG_EFFECT_SIZE="-0.1799008842024465" ORDER="1312" O_E="0.0" SE="0.3607170502183149" STUDY_ID="STD-Loudon-1990-_x0028_GSD_x002d_LNG_x0029_" TOTAL_1="229" TOTAL_2="227" VAR="0.1301167903182023" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.43392243843272615" CI_END="1.5897051939856515" CI_START="0.3812081933792049" DF="1" EFFECT_SIZE="0.7784655708538487" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="17" I2="0.0" ID="CMP-007.04.04" LOG_CI_END="0.20131659319079048" LOG_CI_START="-0.4188377735606353" LOG_EFFECT_SIZE="-0.10876059018492247" NO="4" P_CHI2="0.5100705389270572" P_Z="0.49179050793643386" STUDIES="2" TAU2="0.0" TOTAL_1="405" TOTAL_2="412" WEIGHT="100.0" Z="0.6874638029766914">
<NAME>absence of withdrawal bleed</NAME>
<DICH_DATA CI_END="2.0800286636552827" CI_START="0.3904146084428668" EFFECT_SIZE="0.9011512504962287" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.3180693197615825" LOG_CI_START="-0.4084739403715631" LOG_EFFECT_SIZE="-0.0452023103049903" ORDER="1313" O_E="0.0" SE="0.4267751074493501" STUDY_ID="STD-Loudon-1990-_x0028_GSD_x002d_LNG_x0029_" TOTAL_1="229" TOTAL_2="227" VAR="0.18213699233840433" WEIGHT="72.85790103506628"/>
<DICH_DATA CI_END="2.069229898522471" CI_START="0.13349020035758474" EFFECT_SIZE="0.5255681818181818" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.31580874494945393" LOG_CI_START="-0.8745506150996885" LOG_EFFECT_SIZE="-0.27937093507511723" ORDER="1314" O_E="0.0" SE="0.6992229804667295" STUDY_ID="STD-Rabe-1989-_x0028_GSD_x002d_LNG_x0029_" TOTAL_1="176" TOTAL_2="185" VAR="0.4889127764127764" WEIGHT="27.142098964933716"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0855025586222302" CI_START="0.7047491708690501" DF="0" EFFECT_SIZE="0.8746468019522219" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="102" I2="0.0" ID="CMP-007.04.05" LOG_CI_END="0.035630851460826944" LOG_CI_START="-0.15196542639954294" LOG_EFFECT_SIZE="-0.05816728746935798" NO="5" P_CHI2="1.0" P_Z="0.22419924237480326" STUDIES="1" TAU2="0.0" TOTAL_1="229" TOTAL_2="227" WEIGHT="100.0" Z="1.2154376389406352">
<NAME>abnormal cycles</NAME>
<DICH_DATA CI_END="1.0855025586222302" CI_START="0.7047491708690501" EFFECT_SIZE="0.8746468019522219" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="102" LOG_CI_END="0.035630851460826944" LOG_CI_START="-0.15196542639954294" LOG_EFFECT_SIZE="-0.05816728746935798" ORDER="1315" O_E="0.0" SE="0.1101949822317332" STUDY_ID="STD-Loudon-1990-_x0028_GSD_x002d_LNG_x0029_" TOTAL_1="229" TOTAL_2="227" VAR="0.012142934109051994" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2011-02-15 10:47:49 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Desogestrel vs Levonorgestrel (monophasic)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.87937124518184" CI_START="0.062471994935000996" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.996" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="1.2008333022375497" LOG_CI_START="-1.204314625390152" LOG_EFFECT_SIZE="-0.0017406615763012698" METHOD="MH" MODIFIED="2010-10-22 14:41:19 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.9977364498769866" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="500" TOTAL_2="498" WEIGHT="100.0" Z="0.0028369431747911206">
<NAME>Pregnancy</NAME>
<GROUP_LABEL_1>DSG</GROUP_LABEL_1>
<GROUP_LABEL_2>LNG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DSG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LNG</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.87937124518184" CI_START="0.062471994935000996" EFFECT_SIZE="0.996" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2008333022375497" LOG_CI_START="-1.204314625390152" LOG_EFFECT_SIZE="-0.0017406615763012698" MODIFIED="2010-10-22 14:40:28 +0200" MODIFIED_BY="[Empty name]" ORDER="612" O_E="0.0" SE="1.4127957983627661" STUDY_ID="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_" TOTAL_1="500" TOTAL_2="498" VAR="1.995991967871486" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.268681386521861E-30" CI_END="1.0678291680905745" CI_START="0.6587940387156002" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8387368421052631" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="114" I2="100.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="0.028501779574684246" LOG_CI_START="-0.18125033932109522" LOG_EFFECT_SIZE="-0.07637427987320547" METHOD="MH" MODIFIED="2010-10-22 14:42:07 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="1.0" P_Z="0.15349003890635013" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="500" TOTAL_2="498" WEIGHT="100.0" Z="1.4273118067621784">
<NAME>Discontinuation</NAME>
<GROUP_LABEL_1>DSG</GROUP_LABEL_1>
<GROUP_LABEL_2>LNG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DSG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LNG</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0678291680905745" CI_START="0.6587940387156002" EFFECT_SIZE="0.8387368421052631" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="114" LOG_CI_END="0.028501779574684246" LOG_CI_START="-0.18125033932109522" LOG_EFFECT_SIZE="-0.07637427987320547" MODIFIED="2010-10-22 14:42:07 +0200" MODIFIED_BY="[Empty name]" ORDER="613" O_E="0.0" SE="0.12320943292911468" STUDY_ID="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_" TOTAL_1="500" TOTAL_2="498" VAR="0.015180564362714009" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0425950183050572" CI_END="0.6829937605123686" CI_START="0.20514771073928773" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.374318856616027" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="39" I2="0.0" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="-0.1655832637963968" LOG_CI_START="-0.6879333249990047" LOG_EFFECT_SIZE="-0.42675829439770074" METHOD="MH" MODIFIED="2010-10-22 14:45:46 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7909467559495574" P_Q="0.7923670761553274" P_Z="0.0013620797248356008" Q="1.0367229595300083" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2000" TOTAL_2="1992" WEIGHT="100.0" Z="3.202568351183948">
<NAME>Reasons for discontinuation</NAME>
<GROUP_LABEL_1>DSG</GROUP_LABEL_1>
<GROUP_LABEL_2>LNG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DSG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LNG</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.87937124518184" CI_START="0.062471994935000996" DF="0" EFFECT_SIZE="0.996" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-008.03.01" LOG_CI_END="1.2008333022375497" LOG_CI_START="-1.204314625390152" LOG_EFFECT_SIZE="-0.0017406615763012698" MODIFIED="2010-10-22 14:43:52 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9977364498769866" STUDIES="1" TAU2="0.0" TOTAL_1="500" TOTAL_2="498" WEIGHT="4.716715859090622" Z="0.0028369431747911206">
<NAME>Pregnancy or desire for pregnancy</NAME>
<DICH_DATA CI_END="15.87937124518184" CI_START="0.062471994935000996" EFFECT_SIZE="0.996" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2008333022375497" LOG_CI_START="-1.204314625390152" LOG_EFFECT_SIZE="-0.0017406615763012698" MODIFIED="2010-10-22 14:43:52 +0200" MODIFIED_BY="[Empty name]" ORDER="614" O_E="0.0" SE="1.4127957983627661" STUDY_ID="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_" TOTAL_1="500" TOTAL_2="498" VAR="1.995991967871486" WEIGHT="4.716715859090622"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.7474767070433983" CI_START="0.0073687791472570804" DF="0" EFFECT_SIZE="0.14228685486170517" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-008.03.02" LOG_CI_END="0.43893401918637415" LOG_CI_START="-2.1326044597025997" LOG_EFFECT_SIZE="-0.8468352202581126" MODIFIED="2010-10-22 14:45:03 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.19674725066833074" STUDIES="1" TAU2="0.0" TOTAL_1="500" TOTAL_2="498" WEIGHT="4.126076211398757" Z="1.2908743510328826">
<NAME>loss to follow-up</NAME>
<DICH_DATA CI_END="2.7474767070433983" CI_START="0.0073687791472570804" EFFECT_SIZE="0.14228685486170517" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.43893401918637415" LOG_CI_START="-2.1326044597025997" LOG_EFFECT_SIZE="-0.8468352202581126" MODIFIED="2010-10-22 14:44:24 +0200" MODIFIED_BY="[Empty name]" ORDER="615" O_E="0.0" SE="1.5105344318201495" STUDY_ID="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_" TOTAL_1="500" TOTAL_2="498" VAR="2.2817142697142216" WEIGHT="4.126076211398757"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8207628271498135" CI_START="0.19338419668831858" DF="0" EFFECT_SIZE="0.3984" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="25" I2="0.0" ID="CMP-008.03.03" LOG_CI_END="-0.08578232124942765" LOG_CI_START="-0.7135790192472502" LOG_EFFECT_SIZE="-0.3996806702483389" MODIFIED="2010-10-22 14:45:03 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.012574995357242063" STUDIES="1" TAU2="0.0" TOTAL_1="500" TOTAL_2="498" WEIGHT="69.22855163309187" Z="2.4955840688613846">
<NAME>side effects (including cycle disturbance)</NAME>
<DICH_DATA CI_END="0.8207628271498135" CI_START="0.19338419668831858" EFFECT_SIZE="0.3984" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="25" LOG_CI_END="-0.08578232124942765" LOG_CI_START="-0.7135790192472502" LOG_EFFECT_SIZE="-0.3996806702483389" MODIFIED="2010-10-22 14:44:52 +0200" MODIFIED_BY="[Empty name]" ORDER="616" O_E="0.0" SE="0.3687708880476955" STUDY_ID="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_" TOTAL_1="500" TOTAL_2="498" VAR="0.13599196787148596" WEIGHT="69.22855163309187"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0792267396771225" CI_START="0.0827272311902787" DF="0" EFFECT_SIZE="0.2988" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" I2="0.0" ID="CMP-008.03.04" LOG_CI_END="0.03311269718122772" LOG_CI_START="-1.0823515108945052" LOG_EFFECT_SIZE="-0.5246194068566388" MODIFIED="2010-10-22 14:45:46 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.06524139431577887" STUDIES="1" TAU2="0.0" TOTAL_1="500" TOTAL_2="498" WEIGHT="21.92865629641875" Z="1.8436004231880596">
<NAME>cycle disturbance</NAME>
<DICH_DATA CI_END="1.0792267396771225" CI_START="0.0827272311902787" EFFECT_SIZE="0.2988" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.03311269718122772" LOG_CI_START="-1.0823515108945052" LOG_EFFECT_SIZE="-0.5246194068566388" MODIFIED="2010-10-22 14:45:46 +0200" MODIFIED_BY="[Empty name]" ORDER="617" O_E="0.0" SE="0.6552291974605674" STUDY_ID="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_" TOTAL_1="500" TOTAL_2="498" VAR="0.42932530120481927" WEIGHT="21.92865629641875"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.998137166755179" CI_END="2.0982158996436517" CI_START="0.7810198413846426" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2801360275886389" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-008.04" LOG_CI_END="0.32185017365721" LOG_CI_START="-0.10733793296724826" LOG_EFFECT_SIZE="0.1072561203449809" METHOD="MH" MODIFIED="2011-02-15 10:47:34 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.3919126724973341" P_Q="0.3943037543982021" P_Z="0.32727947930976475" Q="2.982678233010507" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2000" TOTAL_2="1992" WEIGHT="100.00000000000001" Z="0.9796083803487043">
<NAME>Side-effects</NAME>
<GROUP_LABEL_1>DSG</GROUP_LABEL_1>
<GROUP_LABEL_2>LNG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DSG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LNG</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.1808454427286685" CI_START="0.03465242244069709" DF="0" EFFECT_SIZE="0.332" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-008.04.01" LOG_CI_END="0.5025425672523451" LOG_CI_START="-1.4602663998442726" LOG_EFFECT_SIZE="-0.47886191629596364" MODIFIED="2010-10-22 14:48:05 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3389026885039632" STUDIES="1" TAU2="0.0" TOTAL_1="500" TOTAL_2="498" WEIGHT="4.781226196842433" Z="0.9563356651016599">
<NAME>breast tenderness</NAME>
<DICH_DATA CI_END="3.1808454427286685" CI_START="0.03465242244069709" EFFECT_SIZE="0.332" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5025425672523451" LOG_CI_START="-1.4602663998442726" LOG_EFFECT_SIZE="-0.47886191629596364" MODIFIED="2010-10-22 14:48:05 +0200" MODIFIED_BY="[Empty name]" ORDER="618" O_E="0.0" SE="1.1529637033336388" STUDY_ID="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_" TOTAL_1="500" TOTAL_2="498" VAR="1.3293253012048192" WEIGHT="4.781226196842433"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.5255405098850874" CI_START="0.8837854674132939" DF="0" EFFECT_SIZE="1.4940000000000002" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="22" I2="0.0" ID="CMP-008.04.02" LOG_CI_END="0.402354339024752" LOG_CI_START="-0.053653144065991934" LOG_EFFECT_SIZE="0.17435059747938003" MODIFIED="2010-10-22 14:48:28 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.13393817681232795" STUDIES="1" TAU2="0.0" TOTAL_1="500" TOTAL_2="498" WEIGHT="88.58321088570048" Z="1.4987512460387564">
<NAME>headache</NAME>
<DICH_DATA CI_END="2.5255405098850874" CI_START="0.8837854674132939" EFFECT_SIZE="1.494" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="22" LOG_CI_END="0.402354339024752" LOG_CI_START="-0.053653144065991934" LOG_EFFECT_SIZE="0.17435059747937998" MODIFIED="2010-10-22 14:48:28 +0200" MODIFIED_BY="[Empty name]" ORDER="619" O_E="0.0" SE="0.2678610528409491" STUDY_ID="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_" TOTAL_1="500" TOTAL_2="498" VAR="0.0717495436290617" WEIGHT="88.58321088570048"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.474448041756264" CI_START="0.04530210134580757" DF="0" EFFECT_SIZE="0.498" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-008.04.03" LOG_CI_END="0.7383403382147082" LOG_CI_START="-1.343881652695273" LOG_EFFECT_SIZE="-0.30277065724028246" MODIFIED="2011-01-31 12:08:10 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.5686866152842805" STUDIES="1" TAU2="0.0" TOTAL_1="500" TOTAL_2="498" WEIGHT="4.248555534217908" Z="0.5699868566916215">
<NAME>migraine</NAME>
<DICH_DATA CI_END="5.474448041756264" CI_START="0.04530210134580757" EFFECT_SIZE="0.498" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7383403382147082" LOG_CI_START="-1.343881652695273" LOG_EFFECT_SIZE="-0.30277065724028246" MODIFIED="2010-10-22 14:48:56 +0200" MODIFIED_BY="[Empty name]" ORDER="620" O_E="0.0" SE="1.2231075046256097" STUDY_ID="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_" TOTAL_1="500" TOTAL_2="498" VAR="1.495991967871486" WEIGHT="4.248555534217908"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.130269923584375" CI_START="0.013557454817058475" DF="0" EFFECT_SIZE="0.3320026613439787" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-008.04.04" LOG_CI_END="0.9101049643366588" LOG_CI_START="-1.8678218342636952" LOG_EFFECT_SIZE="-0.4788584349635182" MODIFIED="2010-10-25 11:30:44 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.49922075413109535" STUDIES="1" TAU2="0.0" TOTAL_1="500" TOTAL_2="498" WEIGHT="2.387007383239188" Z="0.6757163555890627">
<NAME>nausea/vomiting</NAME>
<DICH_DATA CI_END="8.130269923584375" CI_START="0.013557454817058475" EFFECT_SIZE="0.3320026613439787" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9101049643366588" LOG_CI_START="-1.8678218342636952" LOG_EFFECT_SIZE="-0.4788584349635182" MODIFIED="2010-10-22 14:49:24 +0200" MODIFIED_BY="[Empty name]" ORDER="621" O_E="0.0" SE="1.6317679524572735" STUDY_ID="STD-Winkler-2004-_x0028_DSG_x002d_LNG_x0029_" TOTAL_1="500" TOTAL_2="498" VAR="2.6626666506666026" WEIGHT="2.387007383239188"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2011-02-15 10:46:55 +0100" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Third versus first generation OCs</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.132576778902093" CI_START="0.009584529562342233" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.19901960784313727" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="0.6162209310502" LOG_CI_START="-2.0184291987476093" LOG_EFFECT_SIZE="-0.7011041338487046" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.29688896192297687" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="489" TOTAL_2="487" WEIGHT="100.0" Z="1.0431281453382701">
<NAME>pregnancy</NAME>
<GROUP_LABEL_1>3rd gen.</GROUP_LABEL_1>
<GROUP_LABEL_2>1st gen.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3rd</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1st</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-009.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>monophasic</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1267" O_E="0.0" SE="0.0" STUDY_ID="STD-Rossmanith-1997-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="59" TOTAL_2="59" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.132576778902093" CI_START="0.009584529562342233" DF="0" EFFECT_SIZE="0.19901960784313727" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-009.01.02" LOG_CI_END="0.6162209310502" LOG_CI_START="-2.0184291987476093" LOG_EFFECT_SIZE="-0.7011041338487046" NO="2" P_CHI2="1.0" P_Z="0.29688896192297687" STUDIES="2" TAU2="0.0" TOTAL_1="430" TOTAL_2="428" WEIGHT="100.0" Z="1.0431281453382701">
<NAME>multiphasic</NAME>
<DICH_DATA CI_END="4.132576778902093" CI_START="0.009584529562342233" EFFECT_SIZE="0.19901960784313724" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6162209310502" LOG_CI_START="-2.0184291987476093" LOG_EFFECT_SIZE="-0.7011041338487047" ORDER="1" O_E="0.0" SE="1.54760652797171" STUDY_ID="STD-Shoupe-1994-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="407" TOTAL_2="405" VAR="2.395085965420651" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2" O_E="0.0" SE="0.0" STUDY_ID="STD-Singh-1996-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="23" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.05254949248953015" CI_END="1.4286252327647873" CI_START="0.8994430521145026" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1335638666108547" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="101" I2="0.0" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="0.1549183164827235" LOG_CI_START="-0.04602632863345411" LOG_EFFECT_SIZE="0.05444599392463465" METHOD="MH" MODIFIED="2011-02-15 10:46:55 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.818684903676697" P_Q="1.0" P_Z="0.28818789600577754" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="430" TOTAL_2="428" WEIGHT="100.0" Z="1.0621053089827217">
<NAME>discontinuation</NAME>
<GROUP_LABEL_1>3rd gen.</GROUP_LABEL_1>
<GROUP_LABEL_2>1st gen.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3rd</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1st</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.05254949248953015" CI_END="1.4286252327647873" CI_START="0.8994430521145026" DF="1" EFFECT_SIZE="1.1335638666108547" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="101" I2="0.0" ID="CMP-009.02.01" LOG_CI_END="0.1549183164827235" LOG_CI_START="-0.04602632863345411" LOG_EFFECT_SIZE="0.05444599392463465" MODIFIED="2011-02-15 10:46:55 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.818684903676697" P_Z="0.28818789600577754" STUDIES="2" TAU2="0.0" TOTAL_1="430" TOTAL_2="428" WEIGHT="100.0" Z="1.0621053089827217">
<NAME>multiphasic</NAME>
<DICH_DATA CI_END="1.44466694674789" CI_START="0.8999044424579214" EFFECT_SIZE="1.1402027027027026" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="96" LOG_CI_END="0.1597677364619111" LOG_CI_START="-0.04580360424570083" LOG_EFFECT_SIZE="0.05698206610810512" ORDER="1" O_E="0.0" SE="0.12075362312619926" STUDY_ID="STD-Shoupe-1994-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="407" TOTAL_2="405" VAR="0.014581437498104166" WEIGHT="95.5493502487975"/>
<DICH_DATA CI_END="2.993985681946091" CI_START="0.3340029332905827" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.4762497190976571" LOG_CI_START="-0.4762497190976571" LOG_EFFECT_SIZE="0.0" ORDER="1271" O_E="0.0" SE="0.5595028849441883" STUDY_ID="STD-Singh-1996-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="23" TOTAL_2="23" VAR="0.31304347826086965" WEIGHT="4.4506497512025"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.23904342725417563" CI_END="1.5550604433043627" CI_START="0.677064086315033" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0260972557270185" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-009.03" LOG_CI_END="0.1917472741881872" LOG_CI_START="-0.16937022198585652" LOG_EFFECT_SIZE="0.011188526101165322" METHOD="MH" MODIFIED="2011-01-31 12:09:04 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9710530710237578" P_Q="0.9710633712578716" P_Z="0.9033335267725164" Q="0.23898391199635113" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="236" TOTAL_2="236" WEIGHT="400.0" Z="0.12145137486111432">
<NAME>side effects (monophasic)</NAME>
<GROUP_LABEL_1>3rd gen.</GROUP_LABEL_1>
<GROUP_LABEL_2>1st gen.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3rd</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1st</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.425737107439599" CI_START="0.35304853453077006" DF="0" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-009.03.01" LOG_CI_END="0.6459856128946216" LOG_CI_START="-0.45216558687850894" LOG_EFFECT_SIZE="0.09691001300805642" NO="1" P_CHI2="1.0" P_Z="0.7293974950745757" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="59" WEIGHT="100.0" Z="0.34592710962996515">
<NAME>breast tenderness</NAME>
<DICH_DATA CI_END="4.425737107439599" CI_START="0.35304853453077006" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6459856128946216" LOG_CI_START="-0.45216558687850894" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="1272" O_E="0.0" SE="0.6450594506828454" STUDY_ID="STD-Rossmanith-1997-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="59" TOTAL_2="59" VAR="0.4161016949152542" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9097318097332177" CI_START="0.5236337348015878" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" I2="0.0" ID="CMP-009.03.02" LOG_CI_END="0.2809723820482649" LOG_CI_START="-0.2809723820482649" LOG_EFFECT_SIZE="0.0" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="59" WEIGHT="100.0" Z="0.0">
<NAME>headache</NAME>
<DICH_DATA CI_END="1.9097318097332177" CI_START="0.5236337348015878" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.2809723820482649" LOG_CI_START="-0.2809723820482649" LOG_EFFECT_SIZE="0.0" ORDER="1273" O_E="0.0" SE="0.3300891361017461" STUDY_ID="STD-Rossmanith-1997-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="59" TOTAL_2="59" VAR="0.10895883777239708" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.258022214704372" CI_START="0.33906885194229064" DF="0" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="0.0" ID="CMP-009.03.03" LOG_CI_END="0.3537282102532838" LOG_CI_START="-0.4697121042086574" LOG_EFFECT_SIZE="-0.057991946977686754" NO="3" P_CHI2="1.0" P_Z="0.7824970191920849" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="59" WEIGHT="100.0" Z="0.27606646279856356">
<NAME>nausea/vomiting</NAME>
<DICH_DATA CI_END="2.258022214704372" CI_START="0.33906885194229064" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3537282102532838" LOG_CI_START="-0.4697121042086574" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="1274" O_E="0.0" SE="0.4836929168102393" STUDY_ID="STD-Rossmanith-1997-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="59" TOTAL_2="59" VAR="0.23395883777239707" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.391540705632641" CI_START="0.5059499916309872" DF="0" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" I2="0.0" ID="CMP-009.03.04" LOG_CI_END="0.37867777725531304" LOG_CI_START="-0.29589240693886293" LOG_EFFECT_SIZE="0.04139268515822507" MODIFIED="2011-01-31 12:09:04 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.8099171366309398" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="59" WEIGHT="100.0" Z="0.24053293203416748">
<NAME>other minor effects</NAME>
<DICH_DATA CI_END="2.391540705632641" CI_START="0.5059499916309872" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.37867777725531304" LOG_CI_START="-0.29589240693886293" LOG_EFFECT_SIZE="0.04139268515822507" ORDER="1276" O_E="0.0" SE="0.39624586537192424" STUDY_ID="STD-Rossmanith-1997-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="59" TOTAL_2="59" VAR="0.15701078582434513" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8308831044984166" CI_END="1.2543282205453465" CI_START="0.8289132785097746" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0196711811263348" ESTIMABLE="YES" EVENTS_1="155" EVENTS_2="154" I2="0.0" I2_Q="0.0" ID="CMP-009.04" LOG_CI_END="0.09841119336889559" LOG_CI_START="-0.08149090326727271" LOG_EFFECT_SIZE="0.008460145050811413" METHOD="MH" MODIFIED="2011-01-31 12:09:08 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8720155788007576" P_Q="0.8920607142336934" P_Z="0.8537467069266598" Q="0.22844217313865486" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1269" TOTAL_2="1275" WEIGHT="300.0" Z="0.18434003731606988">
<NAME>side effects (multiphasic)</NAME>
<GROUP_LABEL_1>3rd gen.</GROUP_LABEL_1>
<GROUP_LABEL_2>1st gen.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3rd</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1st</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.11447867255496981" CI_END="1.4780091944190152" CI_START="0.5710046670903608" DF="1" EFFECT_SIZE="0.9186675938639188" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="33" I2="0.0" ID="CMP-009.04.01" LOG_CI_END="0.16967713573202917" LOG_CI_START="-0.24336034204608392" LOG_EFFECT_SIZE="-0.03684160315702738" NO="1" P_CHI2="0.7351017780225733" P_Z="0.7266052413943339" STUDIES="2" TAU2="0.0" TOTAL_1="423" TOTAL_2="425" WEIGHT="100.00000000000001" Z="0.34964485890687935">
<NAME>breast tenderness</NAME>
<DICH_DATA CI_END="1.470229685755489" CI_START="0.5494506804386855" EFFECT_SIZE="0.8987873504002536" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="31" LOG_CI_END="0.1673851874447643" LOG_CI_START="-0.2600712844499742" LOG_EFFECT_SIZE="-0.04634304850260496" ORDER="1277" O_E="0.0" SE="0.25109004753463077" STUDY_ID="STD-Shoupe-1994-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="407" TOTAL_2="405" VAR="0.06304621197094315" WEIGHT="93.36737013130401"/>
<DICH_DATA CI_END="7.921424913226403" CI_START="0.19724986566382696" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8988033099089441" LOG_CI_START="-0.7049832838928313" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="1278" O_E="0.0" SE="0.9420721840708386" STUDY_ID="STD-Singh-1996-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="16" TOTAL_2="20" VAR="0.8875" WEIGHT="6.632629868695999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9795586519986222" CI_END="1.453887468875551" CI_START="0.7476513376254857" DF="1" EFFECT_SIZE="1.0425933583433848" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="58" I2="0.0" ID="CMP-009.04.02" LOG_CI_END="0.16253079336092932" LOG_CI_START="-0.12630088535369585" LOG_EFFECT_SIZE="0.01811495400361678" NO="2" P_CHI2="0.3223080112981377" P_Z="0.8057982254119513" STUDIES="2" TAU2="0.0" TOTAL_1="423" TOTAL_2="425" WEIGHT="100.0" Z="0.2458501614967809">
<NAME>headache</NAME>
<DICH_DATA CI_END="1.600306639472845" CI_START="0.779563038766724" EFFECT_SIZE="1.1169332597904027" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="49" LOG_CI_END="0.2042032070755821" LOG_CI_START="-0.10814876016522468" LOG_EFFECT_SIZE="0.04802722345517872" ORDER="1279" O_E="0.0" SE="0.18347709172442403" STUDY_ID="STD-Shoupe-1994-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="407" TOTAL_2="405" VAR="0.03366384318765271" WEIGHT="85.50689923100681"/>
<DICH_DATA CI_END="1.6633450143020254" CI_START="0.28992967921457746" EFFECT_SIZE="0.6944444444444444" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.220982340780942" LOG_CI_START="-0.5377073249714415" LOG_EFFECT_SIZE="-0.15836249209524966" ORDER="1280" O_E="0.0" SE="0.4456580652373646" STUDY_ID="STD-Singh-1996-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="16" TOTAL_2="20" VAR="0.19861111111111113" WEIGHT="14.493100768993187"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.515834072320047" CI_END="1.4399732496736704" CI_START="0.7612494832614819" DF="1" EFFECT_SIZE="1.0469856217849596" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="63" I2="0.0" ID="CMP-009.04.03" LOG_CI_END="0.15835442429870622" LOG_CI_START="-0.11847298915941393" LOG_EFFECT_SIZE="0.019940717569646157" MODIFIED="2011-01-31 12:09:08 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.47262424245743295" P_Z="0.7776641928480793" STUDIES="2" TAU2="0.0" TOTAL_1="423" TOTAL_2="425" WEIGHT="100.0" Z="0.28236429170194327">
<NAME>other minor</NAME>
<DICH_DATA CI_END="1.4103815326065328" CI_START="0.726077690389048" EFFECT_SIZE="1.0119518594094865" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="59" LOG_CI_END="0.14933661272037355" LOG_CI_START="-0.13901690725847768" LOG_EFFECT_SIZE="0.00515985273094795" ORDER="1282" O_E="0.0" SE="0.16938028500852145" STUDY_ID="STD-Shoupe-1994-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="407" TOTAL_2="405" VAR="0.028689680949567954" WEIGHT="92.16534969659095"/>
<DICH_DATA CI_END="4.8789170698448" CI_START="0.5003992105317057" EFFECT_SIZE="1.5625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6883234361866913" LOG_CI_START="-0.3006833841544656" LOG_EFFECT_SIZE="0.19382002601611284" ORDER="1283" O_E="0.0" SE="0.5809475019311126" STUDY_ID="STD-Singh-1996-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="16" TOTAL_2="20" VAR="0.3375" WEIGHT="7.834650303409048"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="14.263441358452278" CI_START="0.6309837698927226" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.9999999999999996" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-009.05" LOG_CI_END="1.1542243209347827" LOG_CI_START="-0.19998181149545805" LOG_EFFECT_SIZE="0.4771212547196624" METHOD="MH" MODIFIED="2010-11-01 12:41:12 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.16725119829906188" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="59" TOTAL_2="59" WEIGHT="100.0" Z="1.3810902980197093">
<NAME>breakthrough bleeding</NAME>
<GROUP_LABEL_1>3rd gen.</GROUP_LABEL_1>
<GROUP_LABEL_2>1st gen.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3rd</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1st</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.263441358452278" CI_START="0.6309837698927226" DF="0" EFFECT_SIZE="2.9999999999999996" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" ID="CMP-009.05.01" LOG_CI_END="1.1542243209347827" LOG_CI_START="-0.19998181149545805" LOG_EFFECT_SIZE="0.4771212547196624" NO="1" P_CHI2="1.0" P_Z="0.16725119829906188" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="59" WEIGHT="100.0" Z="1.3810902980197093">
<NAME>monophasic</NAME>
<DICH_DATA CI_END="14.263441358452278" CI_START="0.6309837698927226" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1542243209347827" LOG_CI_START="-0.19998181149545805" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1284" O_E="0.0" SE="0.7954673856179906" STUDY_ID="STD-Rossmanith-1997-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="59" TOTAL_2="59" VAR="0.632768361581921" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2011-01-04 15:56:14 +0100" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Gestodene vs Norethindrone (triphasic)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="114" TOTAL_2="115" WEIGHT="0.0" Z="0.0">
<NAME>pregnancy</NAME>
<GROUP_LABEL_1>GSD</GROUP_LABEL_1>
<GROUP_LABEL_2>NE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NE</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1317" O_E="0.0" SE="0.0" STUDY_ID="STD-Weber_x002d_Diehl-1993-_x0028_GSD_x002d_NE_x0029_" TOTAL_1="114" TOTAL_2="115" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.048092086161374" CI_START="0.34095649922038074" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5977907732293697" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-010.02" LOG_CI_END="0.02039944176488993" LOG_CI_START="-0.4673010267367368" LOG_EFFECT_SIZE="-0.22345079248592345" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.07249420079474653" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="114" TOTAL_2="115" WEIGHT="100.0" Z="1.796001988412617">
<NAME>Discontinuation</NAME>
<GROUP_LABEL_1>GSD</GROUP_LABEL_1>
<GROUP_LABEL_2>NE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NE</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.048092086161374" CI_START="0.34095649922038074" EFFECT_SIZE="0.5977907732293697" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="27" LOG_CI_END="0.02039944176488993" LOG_CI_START="-0.4673010267367368" LOG_EFFECT_SIZE="-0.22345079248592345" ORDER="1318" O_E="0.0" SE="0.2864776693541097" STUDY_ID="STD-Weber_x002d_Diehl-1993-_x0028_GSD_x002d_NE_x0029_" TOTAL_1="114" TOTAL_2="115" VAR="0.08206945503856258" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.09188456464430389" CI_END="0.8809192481008487" CI_START="0.4388048130490476" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.621732744814201" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="65" I2="0.0" I2_Q="0.0" ID="CMP-010.03" LOG_CI_END="-0.05506390056815024" LOG_CI_START="-0.35772861749391077" LOG_EFFECT_SIZE="-0.20639625903103054" METHOD="MH" MODIFIED="2010-11-01 12:42:12 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7617948728541772" P_Q="0.7618878879876455" P_Z="0.007514983642391977" Q="0.09181058331597303" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="228" TOTAL_2="230" WEIGHT="200.0" Z="2.673117886706597">
<NAME>Cycle control</NAME>
<GROUP_LABEL_1>GSD</GROUP_LABEL_1>
<GROUP_LABEL_2>NE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NE</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9850686949766277" CI_START="0.34829006227848536" DF="0" EFFECT_SIZE="0.5857385398981324" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="31" I2="0.0" ID="CMP-010.03.01" LOG_CI_END="-0.00653348238664244" LOG_CI_START="-0.45805891704101276" LOG_EFFECT_SIZE="-0.23229619971382753" NO="1" P_CHI2="1.0" P_Z="0.04372844271378949" STUDIES="1" TAU2="0.0" TOTAL_1="114" TOTAL_2="115" WEIGHT="100.0" Z="2.0166845552483164">
<NAME>spotting</NAME>
<DICH_DATA CI_END="0.9850686949766277" CI_START="0.34829006227848536" EFFECT_SIZE="0.5857385398981324" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="31" LOG_CI_END="-0.00653348238664244" LOG_CI_START="-0.45805891704101276" LOG_EFFECT_SIZE="-0.23229619971382753" ORDER="1319" O_E="0.0" SE="0.2652282754029256" STUDY_ID="STD-Weber_x002d_Diehl-1993-_x0028_GSD_x002d_NE_x0029_" TOTAL_1="114" TOTAL_2="115" VAR="0.07034603807321013" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0439216104820492" CI_START="0.4081366706959356" DF="0" EFFECT_SIZE="0.652734778121775" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="34" I2="0.0" ID="CMP-010.03.02" LOG_CI_END="0.018667888117140208" LOG_CI_START="-0.3891943825229598" LOG_EFFECT_SIZE="-0.18526324720290976" NO="2" P_CHI2="1.0" P_Z="0.07498622734863904" STUDIES="1" TAU2="0.0" TOTAL_1="114" TOTAL_2="115" WEIGHT="100.0" Z="1.7805485739427656">
<NAME>breakthrough bleeding</NAME>
<DICH_DATA CI_END="1.0439216104820492" CI_START="0.4081366706959356" EFFECT_SIZE="0.652734778121775" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="34" LOG_CI_END="0.018667888117140208" LOG_CI_START="-0.3891943825229598" LOG_EFFECT_SIZE="-0.18526324720290976" ORDER="1320" O_E="0.0" SE="0.23958031672479557" STUDY_ID="STD-Weber_x002d_Diehl-1993-_x0028_GSD_x002d_NE_x0029_" TOTAL_1="114" TOTAL_2="115" VAR="0.057398728161953357" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2011-01-31 12:09:39 +0100" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Desogestrel vs Norethisterone (monophasic)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-011.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="59" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>Pregnancy</NAME>
<GROUP_LABEL_1>DSG</GROUP_LABEL_1>
<GROUP_LABEL_2>NE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DSG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NE</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1415" O_E="0.0" SE="0.0" STUDY_ID="STD-Rossmanith-1997-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="59" TOTAL_2="59" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.23904342725417563" CI_END="1.5550604433043627" CI_START="0.677064086315033" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0260972557270185" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-011.02" LOG_CI_END="0.1917472741881872" LOG_CI_START="-0.16937022198585652" LOG_EFFECT_SIZE="0.011188526101165322" METHOD="MH" MODIFIED="2011-01-31 12:09:39 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9710530710237578" P_Q="0.9710633712578716" P_Z="0.9033335267725164" Q="0.23898391199635113" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="236" TOTAL_2="236" WEIGHT="400.0" Z="0.12145137486111432">
<NAME>Side-effects</NAME>
<GROUP_LABEL_1>DSG</GROUP_LABEL_1>
<GROUP_LABEL_2>NE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DSG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NE</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.425737107439599" CI_START="0.35304853453077006" DF="0" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-011.02.01" LOG_CI_END="0.6459856128946216" LOG_CI_START="-0.45216558687850894" LOG_EFFECT_SIZE="0.09691001300805642" NO="1" P_CHI2="1.0" P_Z="0.7293974950745757" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="59" WEIGHT="100.0" Z="0.34592710962996515">
<NAME>breast tenderness</NAME>
<DICH_DATA CI_END="4.425737107439599" CI_START="0.35304853453077006" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6459856128946216" LOG_CI_START="-0.45216558687850894" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="1416" O_E="0.0" SE="0.6450594506828454" STUDY_ID="STD-Rossmanith-1997-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="59" TOTAL_2="59" VAR="0.4161016949152542" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9097318097332177" CI_START="0.5236337348015878" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" I2="0.0" ID="CMP-011.02.02" LOG_CI_END="0.2809723820482649" LOG_CI_START="-0.2809723820482649" LOG_EFFECT_SIZE="0.0" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="59" WEIGHT="100.0" Z="0.0">
<NAME>headache</NAME>
<DICH_DATA CI_END="1.9097318097332177" CI_START="0.5236337348015878" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.2809723820482649" LOG_CI_START="-0.2809723820482649" LOG_EFFECT_SIZE="0.0" ORDER="1417" O_E="0.0" SE="0.3300891361017461" STUDY_ID="STD-Rossmanith-1997-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="59" TOTAL_2="59" VAR="0.10895883777239708" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.258022214704372" CI_START="0.33906885194229064" DF="0" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="0.0" ID="CMP-011.02.03" LOG_CI_END="0.3537282102532838" LOG_CI_START="-0.4697121042086574" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2011-01-31 12:09:39 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.7824970191920849" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="59" WEIGHT="100.0" Z="0.27606646279856356">
<NAME>nausea/vomiting</NAME>
<DICH_DATA CI_END="2.258022214704372" CI_START="0.33906885194229064" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3537282102532838" LOG_CI_START="-0.4697121042086574" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="1418" O_E="0.0" SE="0.4836929168102393" STUDY_ID="STD-Rossmanith-1997-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="59" TOTAL_2="59" VAR="0.23395883777239707" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.391540705632641" CI_START="0.5059499916309872" DF="0" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" I2="0.0" ID="CMP-011.02.04" LOG_CI_END="0.37867777725531304" LOG_CI_START="-0.29589240693886293" LOG_EFFECT_SIZE="0.04139268515822507" MODIFIED="2011-01-31 12:09:39 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.8099171366309398" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="59" WEIGHT="100.0" Z="0.24053293203416748">
<NAME>other minor effects</NAME>
<DICH_DATA CI_END="2.391540705632641" CI_START="0.5059499916309872" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.37867777725531304" LOG_CI_START="-0.29589240693886293" LOG_EFFECT_SIZE="0.04139268515822507" ORDER="1420" O_E="0.0" SE="0.39624586537192424" STUDY_ID="STD-Rossmanith-1997-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="59" TOTAL_2="59" VAR="0.15701078582434513" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2011-01-31 12:09:56 +0100" MODIFIED_BY="[Empty name]" NO="12">
<NAME>Desogestrel vs Norethindrone (triphasic).</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.132576778902093" CI_START="0.009584529562342233" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.19901960784313727" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-012.01" LOG_CI_END="0.6162209310502" LOG_CI_START="-2.0184291987476093" LOG_EFFECT_SIZE="-0.7011041338487046" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.29688896192297687" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="430" TOTAL_2="428" WEIGHT="100.0" Z="1.0431281453382701">
<NAME>Pregnancy</NAME>
<GROUP_LABEL_1>DSG</GROUP_LABEL_1>
<GROUP_LABEL_2>NE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DSG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NE</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.132576778902093" CI_START="0.009584529562342233" EFFECT_SIZE="0.19901960784313724" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6162209310502" LOG_CI_START="-2.0184291987476093" LOG_EFFECT_SIZE="-0.7011041338487047" ORDER="1421" O_E="0.0" SE="1.54760652797171" STUDY_ID="STD-Shoupe-1994-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="407" TOTAL_2="405" VAR="2.395085965420651" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1422" O_E="0.0" SE="0.0" STUDY_ID="STD-Singh-1996-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="23" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5555540946291325" CI_END="1.4685001271825235" CI_START="0.9389423268694905" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1742388711096654" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="104" I2="0.0" I2_Q="0.0" ID="CMP-012.02" LOG_CI_END="0.16687398847180224" LOG_CI_START="-0.027361082804772622" LOG_EFFECT_SIZE="0.0697564528335148" METHOD="MH" NO="2" P_CHI2="0.45605723430374345" P_Q="1.0" P_Z="0.15919619103420837" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="430" TOTAL_2="428" WEIGHT="100.0" Z="1.4077801124625713">
<NAME>Discontinuation</NAME>
<GROUP_LABEL_1>DSG</GROUP_LABEL_1>
<GROUP_LABEL_2>NE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DSG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NE</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.44466694674789" CI_START="0.8999044424579214" EFFECT_SIZE="1.1402027027027026" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="96" LOG_CI_END="0.1597677364619111" LOG_CI_START="-0.04580360424570083" LOG_EFFECT_SIZE="0.05698206610810512" ORDER="1423" O_E="0.0" SE="0.12075362312619926" STUDY_ID="STD-Shoupe-1994-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="407" TOTAL_2="405" VAR="0.014581437498104166" WEIGHT="89.27506231107442"/>
<DICH_DATA CI_END="2.969223262919807" CI_START="0.7577739364022918" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.4726428544531005" LOG_CI_START="-0.12046033634173813" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="1424" O_E="0.0" SE="0.3483917501810324" STUDY_ID="STD-Singh-1996-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="23" TOTAL_2="23" VAR="0.12137681159420288" WEIGHT="10.724937688925586"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.96995097532009" CI_END="1.6914254787255028" CI_START="0.9867419365883453" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2918980038967751" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="106" I2="0.0" I2_Q="0.0" ID="CMP-012.03" LOG_CI_END="0.2282528682834774" LOG_CI_START="-0.005796413865302618" LOG_EFFECT_SIZE="0.11122822720908745" METHOD="MH" MODIFIED="2010-11-01 13:03:49 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6636305626499037" P_Q="0.5840494692105208" P_Z="0.062478602883340534" Q="2.845237472077566" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2127" TOTAL_2="2117" WEIGHT="500.0" Z="1.8628838968663823">
<NAME>Reasons for discontinuation</NAME>
<GROUP_LABEL_1>DSG</GROUP_LABEL_1>
<GROUP_LABEL_2>NE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DSG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NE</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.131692853946399" CI_START="0.2612877959308323" DF="0" EFFECT_SIZE="0.7463144963144963" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" I2="0.0" ID="CMP-012.03.01" LOG_CI_END="0.3287246293199797" LOG_CI_START="-0.5828808745576827" LOG_EFFECT_SIZE="-0.12707812261885143" NO="1" P_CHI2="1.0" P_Z="0.5847639938508404" STUDIES="1" TAU2="0.0" TOTAL_1="407" TOTAL_2="405" WEIGHT="100.0" Z="0.5464393150248875">
<NAME>due to cycle disturbances</NAME>
<DICH_DATA CI_END="2.131692853946399" CI_START="0.2612877959308323" EFFECT_SIZE="0.7463144963144963" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.3287246293199797" LOG_CI_START="-0.5828808745576827" LOG_EFFECT_SIZE="-0.12707812261885143" ORDER="1425" O_E="0.0" SE="0.5354815854977601" STUDY_ID="STD-Shoupe-1994-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="407" TOTAL_2="405" VAR="0.286740528407195" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.132576778902093" CI_START="0.009584529562342233" DF="0" EFFECT_SIZE="0.19901960784313727" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-012.03.02" LOG_CI_END="0.6162209310502" LOG_CI_START="-2.0184291987476093" LOG_EFFECT_SIZE="-0.7011041338487046" NO="2" P_CHI2="1.0" P_Z="0.29688896192297687" STUDIES="2" TAU2="0.0" TOTAL_1="430" TOTAL_2="428" WEIGHT="100.0" Z="1.0431281453382701">
<NAME>pregnancy</NAME>
<DICH_DATA CI_END="4.132576778902093" CI_START="0.009584529562342233" EFFECT_SIZE="0.19901960784313724" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6162209310502" LOG_CI_START="-2.0184291987476093" LOG_EFFECT_SIZE="-0.7011041338487047" ORDER="1426" O_E="0.0" SE="1.54760652797171" STUDY_ID="STD-Shoupe-1994-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="407" TOTAL_2="405" VAR="2.395085965420651" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1427" O_E="0.0" SE="0.0" STUDY_ID="STD-Singh-1996-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="23" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.029035367869439287" CI_END="2.451811037630859" CI_START="0.9070116027487418" DF="1" EFFECT_SIZE="1.4912481546941212" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="24" I2="0.0" ID="CMP-012.03.03" LOG_CI_END="0.38948699583147833" LOG_CI_START="-0.042387157286626766" LOG_EFFECT_SIZE="0.17354991927242583" NO="3" P_CHI2="0.8646974313089076" P_Z="0.11520226405970539" STUDIES="2" TAU2="0.0" TOTAL_1="430" TOTAL_2="428" WEIGHT="99.99999999999999" Z="1.5752347707678944">
<NAME>side-effects</NAME>
<DICH_DATA CI_END="2.5837697748572173" CI_START="0.8898745403841721" EFFECT_SIZE="1.5163215163215162" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="21" LOG_CI_END="0.4122538135167207" LOG_CI_START="-0.050671218365850305" LOG_EFFECT_SIZE="0.1807912975754352" ORDER="1428" O_E="0.0" SE="0.27192445524368714" STUDY_ID="STD-Shoupe-1994-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="407" TOTAL_2="405" VAR="0.07394290935957602" WEIGHT="87.03483210506607"/>
<DICH_DATA CI_END="5.304499254107467" CI_START="0.3351452592629133" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7246443926780186" LOG_CI_START="-0.47476691946141886" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="1429" O_E="0.0" SE="0.7045401419324543" STUDY_ID="STD-Singh-1996-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="23" TOTAL_2="23" VAR="0.4963768115942029" WEIGHT="12.965167894933913"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3094943892311486" CI_END="2.3591512203680094" CI_START="0.6943878312463787" DF="1" EFFECT_SIZE="1.279908551222934" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="35" I2="23.63464798141395" ID="CMP-012.03.04" LOG_CI_END="0.37275577982857666" LOG_CI_START="-0.15839789852980163" LOG_EFFECT_SIZE="0.10717894064938756" NO="4" P_CHI2="0.2524863471158916" P_Z="0.4289537021933203" STUDIES="2" TAU2="0.06872775467385488" TOTAL_1="430" TOTAL_2="428" WEIGHT="100.0" Z="0.7909833712277144">
<NAME>lost to follow-up</NAME>
<DICH_DATA CI_END="1.722713362389087" CI_START="0.6876134097650107" EFFECT_SIZE="1.088375307125307" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="32" LOG_CI_END="0.23621302237633768" LOG_CI_START="-0.16265566233670137" LOG_EFFECT_SIZE="0.03677868001981815" ORDER="1430" O_E="0.0" SE="0.2342974398322717" STUDY_ID="STD-Shoupe-1994-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="407" TOTAL_2="405" VAR="0.054895290311956974" WEIGHT="78.74376105770222"/>
<DICH_DATA CI_END="7.925554502896323" CI_START="0.6869480794630611" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.8990296568990769" LOG_CI_START="-0.163076086309888" LOG_EFFECT_SIZE="0.36797678529459443" ORDER="1431" O_E="0.0" SE="0.6238861710691669" STUDY_ID="STD-Singh-1996-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="23" TOTAL_2="23" VAR="0.3892339544513458" WEIGHT="21.25623894229778"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6920925277885712" CI_END="1.9883108744131857" CI_START="0.8809858929598945" DF="1" EFFECT_SIZE="1.3235081530450687" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="37" I2="0.0" ID="CMP-012.03.05" LOG_CI_END="0.2984842877509851" LOG_CI_START="-0.05503104579762927" LOG_EFFECT_SIZE="0.12172662097667793" MODIFIED="2010-11-01 13:03:49 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.4054539454139843" P_Z="0.17709413249753786" STUDIES="2" TAU2="0.0" TOTAL_1="430" TOTAL_2="428" WEIGHT="100.0" Z="1.349756406202606">
<NAME>method unrelated</NAME>
<DICH_DATA CI_END="2.0632499174744265" CI_START="0.9026424992547448" EFFECT_SIZE="1.3646893646893647" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="35" LOG_CI_END="0.3145518364105357" LOG_CI_START="-0.04448422238101537" LOG_EFFECT_SIZE="0.13503380701476012" ORDER="1432" O_E="0.0" SE="0.21089955819131131" STUDY_ID="STD-Shoupe-1994-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="407" TOTAL_2="405" VAR="0.04447862364529031" WEIGHT="96.9483396795753"/>
<DICH_DATA CI_END="5.13814187942225" CI_START="0.04865572143915006" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7108060922618669" LOG_CI_START="-1.3128660835898294" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="1433" O_E="0.0" SE="1.1887150534341144" STUDY_ID="STD-Singh-1996-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="23" TOTAL_2="23" VAR="1.4130434782608696" WEIGHT="3.0516603204246975"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.22899129432829" CI_END="1.2297806848288673" CI_START="0.8167153353929082" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0021879786096661" ESTIMABLE="YES" EVENTS_1="207" EVENTS_2="202" I2="0.0" I2_Q="0.0" ID="CMP-012.04" LOG_CI_END="0.0898276676498272" LOG_CI_START="-0.08792928962517513" LOG_EFFECT_SIZE="9.491890123260379E-4" METHOD="MH" MODIFIED="2011-01-31 12:09:56 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.9191759828996395" P_Q="0.9568432043480986" P_Z="0.9833001515340941" Q="0.6542961882376641" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2127" TOTAL_2="2117" WEIGHT="500.0" Z="0.02093168455625767">
<NAME>Side-effects</NAME>
<GROUP_LABEL_1>DSG</GROUP_LABEL_1>
<GROUP_LABEL_2>NE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DSG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NE</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.01166589302972093" CI_END="1.4566690274416882" CI_START="0.5622632089426904" DF="1" EFFECT_SIZE="0.9050035368642444" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="33" I2="0.0" ID="CMP-012.04.01" LOG_CI_END="0.16336088609794527" LOG_CI_START="-0.2500603331292557" LOG_EFFECT_SIZE="-0.043349723515655185" NO="1" P_CHI2="0.9139887417742738" P_Z="0.6810518329049516" STUDIES="2" TAU2="0.0" TOTAL_1="430" TOTAL_2="428" WEIGHT="100.0" Z="0.41102823405762456">
<NAME>breast tenderness</NAME>
<DICH_DATA CI_END="1.470229685755489" CI_START="0.5494506804386855" EFFECT_SIZE="0.8987873504002536" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="31" LOG_CI_END="0.1673851874447643" LOG_CI_START="-0.2600712844499742" LOG_EFFECT_SIZE="-0.04634304850260496" ORDER="1434" O_E="0.0" SE="0.25109004753463077" STUDY_ID="STD-Shoupe-1994-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="407" TOTAL_2="405" VAR="0.06304621197094315" WEIGHT="93.5409406940903"/>
<DICH_DATA CI_END="6.506556978823751" CI_START="0.15369111547852443" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8133512373159635" LOG_CI_START="-0.8133512373159634" LOG_EFFECT_SIZE="0.0" ORDER="1435" O_E="0.0" SE="0.9555330859059092" STUDY_ID="STD-Singh-1996-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="23" TOTAL_2="23" VAR="0.9130434782608696" WEIGHT="6.459059305909708"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.8952694768194644" CI_END="1.696149629040972" CI_START="0.480318835617256" DF="1" EFFECT_SIZE="0.9026032433210067" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="58" I2="47.23705455974818" ID="CMP-012.04.02" LOG_CI_END="0.2294641617181245" LOG_CI_START="-0.31847038224664515" LOG_EFFECT_SIZE="-0.044503110264260314" NO="2" P_CHI2="0.16860899761741888" P_Z="0.7502000485203923" STUDIES="2" TAU2="0.11540848661603872" TOTAL_1="430" TOTAL_2="428" WEIGHT="99.99999999999997" Z="0.31837559532867604">
<NAME>headache</NAME>
<DICH_DATA CI_END="1.600306639472845" CI_START="0.779563038766724" EFFECT_SIZE="1.1169332597904027" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="49" LOG_CI_END="0.2042032070755821" LOG_CI_START="-0.10814876016522468" LOG_EFFECT_SIZE="0.04802722345517872" ORDER="1436" O_E="0.0" SE="0.18347709172442403" STUDY_ID="STD-Shoupe-1994-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="407" TOTAL_2="405" VAR="0.03366384318765271" WEIGHT="69.4921145629721"/>
<DICH_DATA CI_END="1.4051690775553636" CI_START="0.21964757141226054" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.14772858404993594" LOG_CI_START="-0.6582735942565481" LOG_EFFECT_SIZE="-0.255272505103306" ORDER="1437" O_E="0.0" SE="0.47344966931235755" STUDY_ID="STD-Singh-1996-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="23" TOTAL_2="23" VAR="0.2241545893719807" WEIGHT="30.507885437027873"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.67381029011994" CI_END="1.539062018526228" CI_START="0.6976157869726798" DF="1" EFFECT_SIZE="1.0361823976761697" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="43" I2="0.0" ID="CMP-012.04.03" LOG_CI_END="0.18725612065086322" LOG_CI_START="-0.15638369992534196" LOG_EFFECT_SIZE="0.015436210362760678" MODIFIED="2010-11-01 13:03:53 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.4117266512885909" P_Z="0.8602294171516756" STUDIES="2" TAU2="0.0" TOTAL_1="430" TOTAL_2="428" WEIGHT="100.0" Z="0.1760821334271746">
<NAME>nausea/vomiting</NAME>
<DICH_DATA CI_END="1.68258550084329" CI_START="0.7226172940002564" EFFECT_SIZE="1.1026628594196162" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="37" LOG_CI_END="0.22597714219822837" LOG_CI_START="-0.1410916489138503" LOG_EFFECT_SIZE="0.042442746642189014" ORDER="1438" O_E="0.0" SE="0.21561802491905555" STUDY_ID="STD-Shoupe-1994-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="407" TOTAL_2="405" VAR="0.04649113266999446" WEIGHT="87.64195247637309"/>
<DICH_DATA CI_END="2.0543385040884483" CI_START="0.21634430915836506" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3126720061284497" LOG_CI_START="-0.6648545242398122" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="1439" O_E="0.0" SE="0.5742039227726821" STUDY_ID="STD-Singh-1996-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="23" TOTAL_2="23" VAR="0.32971014492753625" WEIGHT="12.358047523626915"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.11395180192935013" CI_END="1.41473865975404" CI_START="0.7465908219609646" DF="1" EFFECT_SIZE="1.027730946719871" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="63" I2="0.0" ID="CMP-012.04.04" LOG_CI_END="0.15067622140857945" LOG_CI_START="-0.1269173532741771" LOG_EFFECT_SIZE="0.01187943406720121" MODIFIED="2011-01-31 12:09:56 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.735689199895273" P_Z="0.8667793819210463" STUDIES="2" TAU2="0.0" TOTAL_1="430" TOTAL_2="428" WEIGHT="100.0" Z="0.1677507338204162">
<NAME>other minor</NAME>
<DICH_DATA CI_END="1.4103815326065328" CI_START="0.726077690389048" EFFECT_SIZE="1.0119518594094865" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="59" LOG_CI_END="0.14933661272037355" LOG_CI_START="-0.13901690725847768" LOG_EFFECT_SIZE="0.00515985273094795" ORDER="1441" O_E="0.0" SE="0.16938028500852145" STUDY_ID="STD-Shoupe-1994-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="407" TOTAL_2="405" VAR="0.028689680949567954" WEIGHT="92.67621842189878"/>
<DICH_DATA CI_END="4.071788766154415" CI_START="0.38373798095516065" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.609785239841216" LOG_CI_START="-0.41596521382510315" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="1442" O_E="0.0" SE="0.6025308940302311" STUDY_ID="STD-Singh-1996-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="23" TOTAL_2="23" VAR="0.3630434782608696" WEIGHT="7.323781578101222"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.353190894031805" CI_START="0.44583030631363324" DF="0" EFFECT_SIZE="1.393120393120393" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" ID="CMP-012.04.05" LOG_CI_END="0.6388077120475606" LOG_CI_START="-0.35083041271218757" LOG_EFFECT_SIZE="0.1439886496676865" MODIFIED="2011-01-31 12:09:56 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.568450594761791" STUDIES="1" TAU2="0.0" TOTAL_1="407" TOTAL_2="405" WEIGHT="100.00000000000001" Z="0.5703348738706542">
<NAME>serious adverse events</NAME>
<DICH_DATA CI_END="4.353190894031805" CI_START="0.44583030631363324" EFFECT_SIZE="1.393120393120393" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6388077120475606" LOG_CI_START="-0.35083041271218757" LOG_EFFECT_SIZE="0.1439886496676865" ORDER="1443" O_E="0.0" SE="0.5813183332716002" STUDY_ID="STD-Shoupe-1994-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="407" TOTAL_2="405" VAR="0.3379310045976712" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3424856284094793" CI_END="3.025086053216201" CI_START="0.21977021964543245" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8153672953716373" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-012.05" LOG_CI_END="0.48073773333737463" LOG_CI_START="-0.658031157771959" LOG_EFFECT_SIZE="-0.08864671221729219" METHOD="MH" MODIFIED="2010-11-01 13:06:59 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.7190701657289531" P_Q="0.7190764348477556" P_Z="0.7602563262676405" Q="1.34245909093372" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="92" TOTAL_2="92" WEIGHT="400.0" Z="0.30514420379806156">
<NAME>Side-effects leading to discontinuation</NAME>
<GROUP_LABEL_1>DSG</GROUP_LABEL_1>
<GROUP_LABEL_2>NE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DSG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NE</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="70.02229214079287" CI_START="0.12853049685811227" DF="0" EFFECT_SIZE="2.9999999999999996" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-012.05.01" LOG_CI_END="1.8452363230500497" LOG_CI_START="-0.8909938136107249" LOG_EFFECT_SIZE="0.4771212547196624" NO="1" P_CHI2="1.0" P_Z="0.49427533688550807" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="99.99999999999999" Z="0.6835247247516404">
<NAME>breast tenderness</NAME>
<DICH_DATA CI_END="70.02229214079287" CI_START="0.12853049685811227" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8452363230500497" LOG_CI_START="-0.8909938136107249" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1444" O_E="0.0" SE="1.6072751268321592" STUDY_ID="STD-Singh-1996-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="23" TOTAL_2="23" VAR="2.5833333333333335" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.972834728985546" CI_START="0.03737547534269649" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-012.05.02" LOG_CI_END="0.4731707658195643" LOG_CI_START="-1.4274132752588893" LOG_EFFECT_SIZE="-0.4771212547196625" NO="2" P_CHI2="1.0" P_Z="0.32508803826320287" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="100.0" Z="0.9840559062870702">
<NAME>headache</NAME>
<DICH_DATA CI_END="2.972834728985546" CI_START="0.03737547534269649" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4731707658195643" LOG_CI_START="-1.4274132752588893" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="1445" O_E="0.0" SE="1.1164124737722179" STUDY_ID="STD-Singh-1996-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="23" TOTAL_2="23" VAR="1.2463768115942029" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.042527544933725" CI_START="0.06647818971997141" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-012.05.03" LOG_CI_END="1.1773208154172594" LOG_CI_START="-1.1773208154172596" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-11-01 13:06:59 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="100.0" Z="0.0">
<NAME>nausea/vomiting</NAME>
<DICH_DATA CI_END="15.042527544933725" CI_START="0.06647818971997141" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1773208154172594" LOG_CI_START="-1.1773208154172596" LOG_EFFECT_SIZE="0.0" ORDER="1446" O_E="0.0" SE="1.3831281496162493" STUDY_ID="STD-Singh-1996-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="23" TOTAL_2="23" VAR="1.9130434782608696" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.042527544933725" CI_START="0.06647818971997141" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-012.05.04" LOG_CI_END="1.1773208154172594" LOG_CI_START="-1.1773208154172596" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-11-01 13:06:59 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="100.0" Z="0.0">
<NAME>other minor (vaginal dryness, dysmenorrhoea)</NAME>
<DICH_DATA CI_END="15.042527544933725" CI_START="0.06647818971997141" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1773208154172594" LOG_CI_START="-1.1773208154172596" LOG_EFFECT_SIZE="0.0" ORDER="1447" O_E="0.0" SE="1.3831281496162493" STUDY_ID="STD-Singh-1996-_x0028_DSG_x002d_NE_x0029_" TOTAL_1="23" TOTAL_2="23" VAR="1.9130434782608696" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" MODIFIED="2011-01-31 12:10:37 +0100" MODIFIED_BY="[Empty name]" NO="13">
<NAME>Gestodene vs Desogestrel (monophasic)</NAME>
<DICH_OUTCOME CHI2="0.7463633456488121" CI_END="5.318148717415601" CI_START="0.6405968211063797" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8457489435314338" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-013.01" LOG_CI_END="0.7257604778338123" LOG_CI_START="-0.19341522080704454" LOG_EFFECT_SIZE="0.2661726285133838" METHOD="MH" NO="1" P_CHI2="0.8622483883191303" P_Q="1.0" P_Z="0.25632377996802935" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2802" TOTAL_2="2822" WEIGHT="100.00000000000001" Z="1.1351230593410788">
<NAME>Pregnancy</NAME>
<GROUP_LABEL_1>GSD</GROUP_LABEL_1>
<GROUP_LABEL_2>DSG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DSG</GRAPH_LABEL_2>
<DICH_DATA CI_END="18.023159039570263" CI_START="0.07117620750274065" EFFECT_SIZE="1.1326164874551972" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.255830915012119" LOG_CI_START="-1.1476651563225064" LOG_EFFECT_SIZE="0.054082879344806274" ORDER="1" O_E="0.0" SE="1.4118254897993923" STUDY_ID="STD-Halbe-1998-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="279" TOTAL_2="316" VAR="1.9932512136472937" WEIGHT="14.625483578872387"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.0" STUDY_ID="STD-L.-America-1994-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="176" TOTAL_2="176" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.0" STUDY_ID="STD-Zichella-1999-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="126" TOTAL_2="115" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.0" STUDY_ID="STD-Koetsawang-1995-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="389" TOTAL_2="394" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="104.29711998406832" CI_START="0.24159092694337805" EFFECT_SIZE="5.019685039370079" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0182723161705773" LOG_CI_START="-0.6169193798705056" LOG_EFFECT_SIZE="0.7006764681500359" ORDER="2" O_E="0.0" SE="1.5479246466638052" STUDY_ID="STD-Serfaty-1998-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="507" TOTAL_2="509" VAR="2.3960707117492666" WEIGHT="12.166695561535894"/>
<DICH_DATA CI_END="7.877283540277003" CI_START="0.49622707771540286" EFFECT_SIZE="1.9770992366412214" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8963764780402801" LOG_CI_START="-0.304319541189305" LOG_EFFECT_SIZE="0.2960284684254876" ORDER="2" O_E="0.0" SE="0.7052947852366097" STUDY_ID="STD-Endrikat-1999-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="786" TOTAL_2="777" VAR="0.4974407340819555" WEIGHT="58.60449475969732"/>
<DICH_DATA CI_END="15.827940426997667" CI_START="0.06224516559554349" EFFECT_SIZE="0.9925788497217068" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1994244070049787" LOG_CI_START="-1.205894373335999" LOG_EFFECT_SIZE="-0.0032349831655102647" ORDER="3" O_E="0.0" SE="1.412896158092279" STUDY_ID="STD-GSD-Group-1999-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="539" TOTAL_2="535" VAR="1.996275553551922" WEIGHT="14.603326099894412"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.9995327814803225" CI_END="1.2438991440374" CI_START="0.99895513218762" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1147194417699677" ESTIMABLE="YES" EVENTS_1="534" EVENTS_2="477" I2="0.0" I2_Q="0.0" ID="CMP-013.02" LOG_CI_END="0.0947851689691992" LOG_CI_START="-4.540175607303739E-4" LOG_EFFECT_SIZE="0.04716557570423443" METHOD="MH" NO="2" P_CHI2="0.4232425453580413" P_Q="1.0" P_Z="0.05222466603210378" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2802" TOTAL_2="2822" WEIGHT="100.00000000000001" Z="1.9412771792490289">
<NAME>Discontinuation</NAME>
<GROUP_LABEL_1>GSD</GROUP_LABEL_1>
<GROUP_LABEL_2>DSG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DSG</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.2650419478054538" CI_START="0.94353744018586" EFFECT_SIZE="1.7551892551892552" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="13" LOG_CI_END="0.5138887652691049" LOG_CI_START="-0.025240862066605602" LOG_EFFECT_SIZE="0.2443239516012496" ORDER="1" O_E="0.0" SE="0.3166874118316924" STUDY_ID="STD-Zichella-1999-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="126" TOTAL_2="115" VAR="0.10029091681265595" WEIGHT="3.1206492423315364"/>
<DICH_DATA CI_END="1.6384349122455604" CI_START="0.4029188129879517" EFFECT_SIZE="0.8125" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.2144291934669137" LOG_CI_START="-0.3947824541650897" LOG_EFFECT_SIZE="-0.09017663034908802" ORDER="1" O_E="0.0" SE="0.35785393746533034" STUDY_ID="STD-L.-America-1994-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="176" TOTAL_2="176" VAR="0.12805944055944057" WEIGHT="2.4439648666033276"/>
<DICH_DATA CI_END="2.037012219080118" CI_START="0.9653398420946141" EFFECT_SIZE="1.4022870797064346" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="42" LOG_CI_END="0.30899363413671443" LOG_CI_START="-0.015319768973304466" LOG_EFFECT_SIZE="0.14683693258170497" ORDER="1" O_E="0.0" SE="0.1905032983640617" STUDY_ID="STD-Halbe-1998-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="279" TOTAL_2="316" VAR="0.03629150668758672" WEIGHT="8.62385726385949"/>
<DICH_DATA CI_END="1.627290199445388" CI_START="0.7942577315491959" EFFECT_SIZE="1.1368763443680814" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="49" LOG_CI_END="0.21146500885528857" LOG_CI_START="-0.1000385489240954" LOG_EFFECT_SIZE="0.05571322996559656" ORDER="1" O_E="0.0" SE="0.1829787318070897" STUDY_ID="STD-Koetsawang-1995-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="389" TOTAL_2="394" VAR="0.03348121629373086" WEIGHT="9.347712186392465"/>
<DICH_DATA CI_END="1.4917531123272019" CI_START="0.8798898552494752" EFFECT_SIZE="1.1456781529179718" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="85" LOG_CI_END="0.17369695260973014" LOG_CI_START="-0.0555716894989804" LOG_EFFECT_SIZE="0.05906263155537485" ORDER="2" O_E="0.0" SE="0.1346735352727384" STUDY_ID="STD-Serfaty-1998-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="507" TOTAL_2="509" VAR="0.018136961102857514" WEIGHT="17.256075689264197"/>
<DICH_DATA CI_END="1.1922823556300217" CI_START="0.872374525667123" EFFECT_SIZE="1.0198611446927568" ESTIMABLE="YES" EVENTS_1="228" EVENTS_2="221" LOG_CI_END="0.07637911695694977" LOG_CI_START="-0.059297024803250754" LOG_EFFECT_SIZE="0.00854104607684949" ORDER="2" O_E="0.0" SE="0.07969683727767504" STUDY_ID="STD-Endrikat-1999-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="786" TOTAL_2="777" VAR="0.006351585872064213" WEIGHT="49.274744901218874"/>
<DICH_DATA CI_END="1.7638767501279196" CI_START="0.8795922489502461" EFFECT_SIZE="1.2455891447488086" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="51" LOG_CI_END="0.2464682357791505" LOG_CI_START="-0.05571860633826955" LOG_EFFECT_SIZE="0.09537481472044052" ORDER="3" O_E="0.0" SE="0.17750604690876576" STUDY_ID="STD-GSD-Group-1999-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="539" TOTAL_2="535" VAR="0.031508396689176946" WEIGHT="9.932995850330121"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="26.982385106884063" CI_END="1.4064897133791703" CI_START="0.8987322439098144" CI_STUDY="95" CI_TOTAL="95" DF="24" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1243031869301685" ESTIMABLE="YES" EVENTS_1="259" EVENTS_2="207" I2="11.053081834945578" I2_Q="0.0" ID="CMP-013.03" LOG_CI_END="0.1481365602203805" LOG_CI_START="-0.046369676801732304" LOG_EFFECT_SIZE="0.05088344170932409" METHOD="MH" NO="3" P_CHI2="0.3052750180214263" P_Q="0.46562008308394676" P_Z="0.30514363287527113" Q="4.607578937237808" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.028681616845275305" TOTALS="SUB" TOTAL_1="9422" TOTAL_2="9585" WEIGHT="600.0" Z="1.0254654522814142">
<NAME>Reasons for discontinuation</NAME>
<GROUP_LABEL_1>GSD</GROUP_LABEL_1>
<GROUP_LABEL_2>DSG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DSG</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.6181406421814415" CI_END="1.8106424955414264" CI_START="0.47549277419525343" DF="4" EFFECT_SIZE="0.9278725253399897" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="19" I2="0.0" ID="CMP-013.03.01" LOG_CI_END="0.257832708988508" LOG_CI_START="-0.3228560784131558" LOG_EFFECT_SIZE="-0.03251168471232383" NO="1" P_CHI2="0.8055280750573048" P_Z="0.8262843572657106" STUDIES="5" TAU2="0.0" TOTAL_1="1509" TOTAL_2="1536" WEIGHT="100.0" Z="0.21946947313380702">
<NAME>cycle disturbances</NAME>
<DICH_DATA CI_END="16.13574217366747" CI_START="0.06357762422917683" EFFECT_SIZE="1.012853470437018" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2077889458487296" LOG_CI_START="-1.1966957048489968" LOG_EFFECT_SIZE="0.0055466204998663934" ORDER="1" O_E="0.0" SE="1.4124061862108246" STUDY_ID="STD-Koetsawang-1995-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="389" TOTAL_2="394" VAR="1.9948912348466066" WEIGHT="5.8323403881525016"/>
<DICH_DATA CI_END="15.861931258963535" CI_START="0.0630440255775855" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.200356063438653" LOG_CI_START="-1.200356063438653" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="1.4101901870444156" STUDY_ID="STD-L.-America-1994-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="176" TOTAL_2="176" VAR="1.9886363636363638" WEIGHT="5.850684887252117"/>
<DICH_DATA CI_END="11.53246459170444" CI_START="0.45145293202407205" EFFECT_SIZE="2.2817460317460316" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0619221298616195" LOG_CI_START="-0.34538752204544676" LOG_EFFECT_SIZE="0.35826730390808637" ORDER="1" O_E="0.0" SE="0.8266606558253387" STUDY_ID="STD-Zichella-1999-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="126" TOTAL_2="115" VAR="0.683367839889579" WEIGHT="17.025800805679243"/>
<DICH_DATA CI_END="1.656829738009814" CI_START="0.29321159949553344" EFFECT_SIZE="0.6969947615108906" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.21927788099504117" LOG_CI_START="-0.532818852935215" LOG_EFFECT_SIZE="-0.15677048597008691" ORDER="1" O_E="0.0" SE="0.44178534444950823" STUDY_ID="STD-Halbe-1998-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="279" TOTAL_2="316" VAR="0.1951742905703706" WEIGHT="59.61279369821657"/>
<DICH_DATA CI_END="7.0206925377842495" CI_START="0.14032985600959" EFFECT_SIZE="0.9925788497217068" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8463799540818876" LOG_CI_START="-0.8528499204129081" LOG_EFFECT_SIZE="-0.0032349831655102647" ORDER="3" O_E="0.0" SE="0.9981360396017779" STUDY_ID="STD-GSD-Group-1999-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="539" TOTAL_2="535" VAR="0.996275553551922" WEIGHT="11.678380220699568"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.12465866993356182" CI_END="6.092123531142989" CI_START="0.5136242741994441" DF="1" EFFECT_SIZE="1.7689156359240743" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" I2="0.0" ID="CMP-013.03.02" LOG_CI_END="0.7847687010247757" LOG_CI_START="-0.2893544594295594" LOG_EFFECT_SIZE="0.2477071207976081" NO="2" P_CHI2="0.7240357711755366" P_Z="0.3660019605492937" STUDIES="5" TAU2="0.0" TOTAL_1="1756" TOTAL_2="1778" WEIGHT="100.0" Z="0.9039876493717309">
<NAME>pregnancy</NAME>
<DICH_DATA CI_END="18.023159039570263" CI_START="0.07117620750274065" EFFECT_SIZE="1.1326164874551972" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.255830915012119" LOG_CI_START="-1.1476651563225064" LOG_EFFECT_SIZE="0.054082879344806274" ORDER="1" O_E="0.0" SE="1.4118254897993923" STUDY_ID="STD-Halbe-1998-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="279" TOTAL_2="316" VAR="1.9932512136472937" WEIGHT="19.971989492135695"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.0" STUDY_ID="STD-Koetsawang-1995-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="389" TOTAL_2="394" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.0" STUDY_ID="STD-Zichella-1999-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="126" TOTAL_2="115" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.0" STUDY_ID="STD-L.-America-1994-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="176" TOTAL_2="176" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.877283540277003" CI_START="0.49622707771540286" EFFECT_SIZE="1.9770992366412214" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8963764780402801" LOG_CI_START="-0.304319541189305" LOG_EFFECT_SIZE="0.2960284684254876" ORDER="2" O_E="0.0" SE="0.7052947852366097" STUDY_ID="STD-Endrikat-1999-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="786" TOTAL_2="777" VAR="0.4974407340819555" WEIGHT="80.02801050786431"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="11.336933176251916" CI_END="3.2251250623629995" CI_START="1.0125971623824253" DF="4" EFFECT_SIZE="1.8071393102019597" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="60" I2="64.71708937670185" ID="CMP-013.03.03" LOG_CI_END="0.5085465601623104" LOG_CI_START="0.005436706022004045" LOG_EFFECT_SIZE="0.2569916330921571" NO="3" P_CHI2="0.023027294833394496" P_Z="0.04524994879982243" STUDIES="5" TAU2="0.27357272257978765" TOTAL_1="1756" TOTAL_2="1778" WEIGHT="99.99999999999999" Z="2.0023235126231125">
<NAME>side-effects (other than cycle disturbances)</NAME>
<DICH_DATA CI_END="5.26486793408789" CI_START="0.8947304081076594" EFFECT_SIZE="2.1704002937936098" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" LOG_CI_END="0.7213874816532747" LOG_CI_START="-0.048307802570693226" LOG_EFFECT_SIZE="0.33653983954129074" ORDER="1" O_E="0.0" SE="0.4521228200062634" STUDY_ID="STD-Koetsawang-1995-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="389" TOTAL_2="394" VAR="0.20441504437041605" WEIGHT="18.271915136189303"/>
<DICH_DATA CI_END="2.3610254835147204" CI_START="0.324276466029608" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3731006746221811" LOG_CI_START="-0.48908456857755456" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="1" O_E="0.0" SE="0.5064518797413101" STUDY_ID="STD-L.-America-1994-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="176" TOTAL_2="176" VAR="0.2564935064935065" WEIGHT="16.476718256735246"/>
<DICH_DATA CI_END="5.135265262739774" CI_START="1.2903202815607218" EFFECT_SIZE="2.5741283805799933" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="11" LOG_CI_END="0.7105628820459936" LOG_CI_START="0.11069752367124405" LOG_EFFECT_SIZE="0.4106302028586188" ORDER="1" O_E="0.0" SE="0.3523638808907414" STUDY_ID="STD-Halbe-1998-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="279" TOTAL_2="316" VAR="0.12416030455638459" WEIGHT="21.958829963749956"/>
<DICH_DATA CI_END="11.100942060398488" CI_START="1.728929280032958" EFFECT_SIZE="4.380952380952381" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="5" LOG_CI_END="1.0453598359282883" LOG_CI_START="0.23777722929498388" LOG_EFFECT_SIZE="0.641568532611636" ORDER="1" O_E="0.0" SE="0.47437802073477825" STUDY_ID="STD-Zichella-1999-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="126" TOTAL_2="115" VAR="0.22503450655624568" WEIGHT="17.516296201690157"/>
<DICH_DATA CI_END="1.687192754723625" CI_START="0.6198387988002598" EFFECT_SIZE="1.0226375361937352" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="29" LOG_CI_END="0.22716470175377132" LOG_CI_START="-0.20772124258934585" LOG_EFFECT_SIZE="0.009721729582212728" ORDER="2" O_E="0.0" SE="0.2554541564272902" STUDY_ID="STD-Endrikat-1999-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="786" TOTAL_2="777" VAR="0.06525682603597845" WEIGHT="25.776240441635327"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.8836867490655855" CI_END="3.38586139747794" CI_START="0.4836515826712425" DF="3" EFFECT_SIZE="1.2796785626069034" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="26" I2="38.57099862979538" ID="CMP-013.03.04" LOG_CI_END="0.5296691759989829" LOG_CI_START="-0.31546738673016333" LOG_EFFECT_SIZE="0.10710089463440975" NO="4" P_CHI2="0.1805151357785626" P_Z="0.6193601822413366" STUDIES="5" TAU2="0.3775307693171745" TOTAL_1="1509" TOTAL_2="1536" WEIGHT="99.99999999999999" Z="0.4967573418373962">
<NAME>other medical reasons</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.0" STUDY_ID="STD-L.-America-1994-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="176" TOTAL_2="176" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="10.122023443707047" CI_START="0.6900046070025606" EFFECT_SIZE="2.642771804062127" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="1.0052673388471824" LOG_CI_START="-0.1611480095683813" LOG_EFFECT_SIZE="0.4220596646394007" ORDER="1" O_E="0.0" SE="0.6851581495083963" STUDY_ID="STD-Halbe-1998-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="279" TOTAL_2="316" VAR="0.46944168983776985" WEIGHT="29.09776934211884"/>
<DICH_DATA CI_END="2.0831984399879646" CI_START="0.00607924038616248" EFFECT_SIZE="0.11253561253561253" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3187306416649449" LOG_CI_START="-2.2161506833436726" LOG_EFFECT_SIZE="-0.9487100208393638" ORDER="1" O_E="0.0" SE="1.48900183817499" STUDY_ID="STD-Koetsawang-1995-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="389" TOTAL_2="394" VAR="2.2171264740884995" WEIGHT="9.498367970664749"/>
<DICH_DATA CI_END="7.400033613596074" CI_START="0.012526574759434233" EFFECT_SIZE="0.30446194225721784" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8692336924561298" LOG_CI_START="-1.9021676653535313" LOG_EFFECT_SIZE="-0.5164669864487008" ORDER="1" O_E="0.0" SE="1.6279348762353678" STUDY_ID="STD-Zichella-1999-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="126" TOTAL_2="115" VAR="2.6501719612634624" WEIGHT="8.139837840319103"/>
<DICH_DATA CI_END="2.9310246161771816" CI_START="0.9337015226283266" EFFECT_SIZE="1.6542980828695115" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="18" LOG_CI_END="0.46701946587106014" LOG_CI_START="-0.02979193296936785" LOG_EFFECT_SIZE="0.21861376645084613" ORDER="3" O_E="0.0" SE="0.291829474934954" STUDY_ID="STD-GSD-Group-1999-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="539" TOTAL_2="535" VAR="0.08516444244081092" WEIGHT="53.2640248468973"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8472378446178503" CI_END="1.3654288670039851" CI_START="0.5872554313756746" DF="3" EFFECT_SIZE="0.8954638565041159" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="45" I2="0.0" ID="CMP-013.03.05" LOG_CI_END="0.13526908018258157" LOG_CI_START="-0.23117295785290823" LOG_EFFECT_SIZE="-0.04795193883516334" NO="5" P_CHI2="0.8381382201561137" P_Z="0.6079830480310255" STUDIES="4" TAU2="0.0" TOTAL_1="1383" TOTAL_2="1421" WEIGHT="100.00000000000001" Z="0.5129546468502362">
<NAME>lost to follow-up</NAME>
<DICH_DATA CI_END="2.9778291189272084" CI_START="0.4307903699046025" EFFECT_SIZE="1.1326164874551972" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.4738997723831614" LOG_CI_START="-0.3657340136935489" LOG_EFFECT_SIZE="0.054082879344806274" ORDER="1" O_E="0.0" SE="0.4932050421957319" STUDY_ID="STD-Halbe-1998-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="279" TOTAL_2="316" VAR="0.24325121364729368" WEIGHT="19.047183598543295"/>
<DICH_DATA CI_END="1.7290197411204413" CI_START="0.5406130399379335" EFFECT_SIZE="0.9668146763262444" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" LOG_CI_END="0.23779995186890823" LOG_CI_START="-0.2671134830457495" LOG_EFFECT_SIZE="-0.0146567655884206" ORDER="1" O_E="0.0" SE="0.29658865103068194" STUDY_ID="STD-Koetsawang-1995-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="389" TOTAL_2="394" VAR="0.08796482792019963" WEIGHT="52.67162610846802"/>
<DICH_DATA CI_END="3.9412112935124006" CI_START="0.11276848951895607" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5956297185871635" LOG_CI_START="-0.947812236698526" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="1" O_E="0.0" SE="0.9066254446957116" STUDY_ID="STD-L.-America-1994-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="176" TOTAL_2="176" VAR="0.8219696969696968" WEIGHT="5.636765617990045"/>
<DICH_DATA CI_END="1.6058457554840122" CI_START="0.272673973837382" EFFECT_SIZE="0.6617192331478046" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.2057038281411713" LOG_CI_START="-0.5643563125835545" LOG_EFFECT_SIZE="-0.1793262422211915" ORDER="3" O_E="0.0" SE="0.4523371385208773" STUDY_ID="STD-GSD-Group-1999-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="539" TOTAL_2="535" VAR="0.20460888688525536" WEIGHT="22.644424674998646"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1941882297269224" CI_END="1.5936866475106375" CI_START="0.7638288630853065" DF="4" EFFECT_SIZE="1.1033149414751364" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="53" I2="0.0" ID="CMP-013.03.06" LOG_CI_END="0.20240293397668074" LOG_CI_START="-0.11700393480553613" LOG_EFFECT_SIZE="0.04269949958557227" NO="6" P_CHI2="0.8790545734540851" P_Z="0.6002572815634912" STUDIES="5" TAU2="0.0" TOTAL_1="1509" TOTAL_2="1536" WEIGHT="100.00000000000001" Z="0.5240305674369651">
<NAME>method unrelated</NAME>
<DICH_DATA CI_END="2.187566145175616" CI_START="0.19148222606962115" EFFECT_SIZE="0.6472094214029698" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.33996119360313737" LOG_CI_START="-0.7178715322861137" LOG_EFFECT_SIZE="-0.18895516934148818" ORDER="1" O_E="0.0" SE="0.6213761795437901" STUDY_ID="STD-Halbe-1998-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="279" TOTAL_2="316" VAR="0.38610835650443653" WEIGHT="9.117053547308629"/>
<DICH_DATA CI_END="2.3769756145087544" CI_START="0.6214855090194901" EFFECT_SIZE="1.2154241645244217" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.376024726305963" LOG_CI_START="-0.20656899321098054" LOG_EFFECT_SIZE="0.08472786654749125" ORDER="1" O_E="0.0" SE="0.34221843472967495" STUDY_ID="STD-Koetsawang-1995-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="389" TOTAL_2="394" VAR="0.11711345706882878" WEIGHT="30.057780287754955"/>
<DICH_DATA CI_END="3.4922955349285694" CI_START="0.3434836694842628" EFFECT_SIZE="1.0952380952380953" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5431109886869598" LOG_CI_START="-0.46409390611961254" LOG_EFFECT_SIZE="0.03950854128367365" ORDER="1" O_E="0.0" SE="0.591637140954019" STUDY_ID="STD-Zichella-1999-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="126" TOTAL_2="115" VAR="0.35003450655624574" WEIGHT="10.056638689559122"/>
<DICH_DATA CI_END="2.9297974948633922" CI_START="0.21844513182978245" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4668376033224636" LOG_CI_START="-0.6606576293385763" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="1" O_E="0.0" SE="0.6622962808565088" STUDY_ID="STD-L.-America-1994-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="176" TOTAL_2="176" VAR="0.43863636363636366" WEIGHT="8.025259310768302"/>
<DICH_DATA CI_END="2.156725340974986" CI_START="0.7002341688717845" EFFECT_SIZE="1.2289071472744941" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="21" LOG_CI_END="0.3337948412110354" LOG_CI_START="-0.15475670106825862" LOG_EFFECT_SIZE="0.08951907007138842" ORDER="3" O_E="0.0" SE="0.2869775943039946" STUDY_ID="STD-GSD-Group-1999-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="539" TOTAL_2="535" VAR="0.08235613963250812" WEIGHT="42.743268164609"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.49964597115942" CI_END="0.995575267626736" CI_START="0.7716345463820883" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8764817568120756" ESTIMABLE="YES" EVENTS_1="423" EVENTS_2="475" I2="15.786335361468115" I2_Q="0.0" ID="CMP-013.04" LOG_CI_END="-0.001925900800536616" LOG_CI_START="-0.11258833705815081" LOG_EFFECT_SIZE="-0.05725711892934374" METHOD="MH" MODIFIED="2010-11-01 12:42:32 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.30191309591343185" P_Q="0.7852307700152412" P_Z="0.04254147290602036" Q="2.441818092223616" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.009027658505231713" TOTALS="SUB" TOTAL_1="4153" TOTAL_2="4121" WEIGHT="600.0" Z="2.028183993686815">
<NAME>Cycle control</NAME>
<GROUP_LABEL_1>GSD</GROUP_LABEL_1>
<GROUP_LABEL_2>DSG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DSG</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.025529747165736" CI_START="0.7638942325212729" DF="0" EFFECT_SIZE="0.8850967512870584" ESTIMABLE="YES" EVENTS_1="231" EVENTS_2="258" I2="0.0" ID="CMP-013.04.01" LOG_CI_END="0.01094826230805242" LOG_CI_START="-0.11696676892721135" LOG_EFFECT_SIZE="-0.05300925330957946" NO="1" P_CHI2="1.0" P_Z="0.10427833249368522" STUDIES="1" TAU2="0.0" TOTAL_1="786" TOTAL_2="777" WEIGHT="100.00000000000001" Z="1.624456896594873">
<NAME>spotting EE&lt; 30mcg</NAME>
<DICH_DATA CI_END="1.025529747165736" CI_START="0.7638942325212729" EFFECT_SIZE="0.8850967512870584" ESTIMABLE="YES" EVENTS_1="231" EVENTS_2="258" LOG_CI_END="0.01094826230805242" LOG_CI_START="-0.11696676892721135" LOG_EFFECT_SIZE="-0.05300925330957946" ORDER="2" O_E="0.0" SE="0.07513792253721051" STUDY_ID="STD-Endrikat-1999-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="786" TOTAL_2="777" VAR="0.005645707403207846" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.466064218648222" CI_END="1.3228250651959006" CI_START="0.36521611298629264" DF="1" EFFECT_SIZE="0.6950662043803352" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="43" I2="31.790163945066094" ID="CMP-013.04.02" LOG_CI_END="0.12150241543212083" LOG_CI_START="-0.4374500700570599" LOG_EFFECT_SIZE="-0.15797382731246956" NO="2" P_CHI2="0.2259680107389227" P_Z="0.2679184958035884" STUDIES="2" TAU2="0.08568531997576039" TOTAL_1="565" TOTAL_2="570" WEIGHT="100.00000000000001" Z="1.107868808424445">
<NAME>spotting EE = 30mcg</NAME>
<DICH_DATA CI_END="0.9292783918794765" CI_START="0.3466484818430434" EFFECT_SIZE="0.5675675675675675" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="37" LOG_CI_END="-0.03185416119998245" LOG_CI_START="-0.4601106974661691" LOG_EFFECT_SIZE="-0.24598242933307576" ORDER="1" O_E="0.0" SE="0.25156000930680195" STUDY_ID="STD-L.-America-1994-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="176" TOTAL_2="176" VAR="0.06328243828243829" WEIGHT="72.36568960180811"/>
<DICH_DATA CI_END="3.4844466523271485" CI_START="0.400731055680973" EFFECT_SIZE="1.181662382176521" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5421338197592603" LOG_CI_START="-0.3971469994983011" LOG_EFFECT_SIZE="0.07249341013047961" ORDER="1" O_E="0.0" SE="0.5517382027469333" STUDY_ID="STD-Koetsawang-1995-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="389" TOTAL_2="394" VAR="0.30441504437041605" WEIGHT="27.634310398191904"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1840826708005963" CI_START="0.5568709074327647" DF="0" EFFECT_SIZE="0.8120229007633588" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="56" I2="0.0" ID="CMP-013.04.03" LOG_CI_END="0.07338202520710549" LOG_CI_START="-0.25424547033334544" LOG_EFFECT_SIZE="-0.09043172256311995" MODIFIED="2010-11-01 12:42:32 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.27926218976923356" STUDIES="1" TAU2="0.0" TOTAL_1="786" TOTAL_2="777" WEIGHT="100.0" Z="1.0819782936182154">
<NAME>breakthrough bleeding EE &lt; 30 mcg</NAME>
<DICH_DATA CI_END="1.1840826708005963" CI_START="0.5568709074327647" EFFECT_SIZE="0.8120229007633588" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="56" LOG_CI_END="0.07338202520710549" LOG_CI_START="-0.25424547033334544" LOG_EFFECT_SIZE="-0.09043172256311995" ORDER="2" O_E="0.0" SE="0.19245001266271958" STUDY_ID="STD-Endrikat-1999-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="786" TOTAL_2="777" VAR="0.03703700737388092" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.30199226827271664" CI_END="1.4717898979948845" CI_START="0.3916301402521159" DF="1" EFFECT_SIZE="0.7592083272550321" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="20" I2="0.0" ID="CMP-013.04.04" LOG_CI_END="0.16784581770938367" LOG_CI_START="-0.4071238918396246" LOG_EFFECT_SIZE="-0.1196390370651205" MODIFIED="2010-11-01 12:42:32 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5826362281412013" P_Z="0.4146979990771452" STUDIES="2" TAU2="0.0" TOTAL_1="565" TOTAL_2="570" WEIGHT="100.00000000000001" Z="0.8156541115065535">
<NAME>breakthrough bleeding EE = 30mcg</NAME>
<DICH_DATA CI_END="1.9173789342447896" CI_START="0.17030051098037674" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.28270795157834455" LOG_CI_START="-0.7687840489509336" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="1" O_E="0.0" SE="0.6176516060802453" STUDY_ID="STD-L.-America-1994-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="176" TOTAL_2="176" VAR="0.3814935064935065" WEIGHT="29.900467981832147"/>
<DICH_DATA CI_END="1.8895659290090223" CI_START="0.38871370877868827" EFFECT_SIZE="0.8570298596005537" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.27636204952389787" LOG_CI_START="-0.4103701428213886" LOG_EFFECT_SIZE="-0.06700404664874536" ORDER="1" O_E="0.0" SE="0.4033898891627979" STUDY_ID="STD-Koetsawang-1995-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="389" TOTAL_2="394" VAR="0.1627234026787744" WEIGHT="70.09953201816786"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="25.952660941794058" CI_START="0.2888784910994007" DF="0" EFFECT_SIZE="2.738095238095238" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-013.04.05" LOG_CI_END="1.4141818929394656" LOG_CI_START="-0.5392847930280431" LOG_EFFECT_SIZE="0.43744854995571125" MODIFIED="2010-11-01 12:42:32 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.3800484536288763" STUDIES="1" TAU2="0.0" TOTAL_1="126" TOTAL_2="115" WEIGHT="100.0" Z="0.8778070382887762">
<NAME>absence of withdrawal bleed EE = 30mcg</NAME>
<DICH_DATA CI_END="25.952660941794058" CI_START="0.2888784910994007" EFFECT_SIZE="2.738095238095238" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4141818929394656" LOG_CI_START="-0.5392847930280431" LOG_EFFECT_SIZE="0.43744854995571125" ORDER="1" O_E="0.0" SE="1.147476001153363" STUDY_ID="STD-Zichella-1999-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="126" TOTAL_2="115" VAR="1.3167011732229124" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.4466818629902543" CI_END="1.8339603102708337" CI_START="0.6367620201726" DF="1" EFFECT_SIZE="1.0806462289225018" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="97" I2="70.9865882680444" ID="CMP-013.04.06" LOG_CI_END="0.2633899326334125" LOG_CI_START="-0.19602284809915754" LOG_EFFECT_SIZE="0.03368354226712744" MODIFIED="2010-11-01 12:42:32 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.06337899380092882" P_Z="0.7738030181493543" STUDIES="2" TAU2="0.10430537948574088" TOTAL_1="1325" TOTAL_2="1312" WEIGHT="100.0" Z="0.2874039751790567">
<NAME>other menstrual problems (dysmenorrhoea)</NAME>
<DICH_DATA CI_END="1.1794028930406701" CI_START="0.6058158039075561" EFFECT_SIZE="0.8452815576944352" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="69" LOG_CI_END="0.07166218875470788" LOG_CI_START="-0.2176594014219173" LOG_EFFECT_SIZE="-0.07299860633360473" ORDER="2" O_E="0.0" SE="0.16994893423471868" STUDY_ID="STD-Endrikat-1999-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="786" TOTAL_2="777" VAR="0.02888264024751674" WEIGHT="54.67844915739258"/>
<DICH_DATA CI_END="2.3147511697550884" CI_START="0.9125935021530904" EFFECT_SIZE="1.4534190299496421" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="28" LOG_CI_END="0.3645043122392915" LOG_CI_START="-0.03972262781527948" LOG_EFFECT_SIZE="0.162390842212006" ORDER="3" O_E="0.0" SE="0.23744490554367928" STUDY_ID="STD-GSD-Group-1999-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="539" TOTAL_2="535" VAR="0.05638008316864678" WEIGHT="45.32155084260742"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.945847860114249" CI_END="1.1310268204611802" CI_START="0.9186509090189662" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0193227245291328" ESTIMABLE="YES" EVENTS_1="705" EVENTS_2="699" I2="19.71014215911957" I2_Q="0.0" ID="CMP-013.05" LOG_CI_END="0.05347290363472597" LOG_CI_START="-0.036849490886980765" LOG_EFFECT_SIZE="0.008311706373872607" METHOD="MH" MODIFIED="2011-01-31 12:10:37 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.24441135660437596" P_Q="0.4173155550144072" P_Z="0.7183071493670693" Q="3.917288197299742" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.00838735507726277" TOTALS="SUB" TOTAL_1="6456" TOTAL_2="6423" WEIGHT="500.0" Z="0.36072217148643587">
<NAME>Side-effects</NAME>
<GROUP_LABEL_1>GSD</GROUP_LABEL_1>
<GROUP_LABEL_2>DSG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DSG</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.726274527071489" CI_END="1.179836190324874" CI_START="0.5028714874325724" DF="3" EFFECT_SIZE="0.7702635782350409" ESTIMABLE="YES" EVENTS_1="149" EVENTS_2="167" I2="61.17145476143082" ID="CMP-013.05.01" LOG_CI_END="0.0718217135972692" LOG_CI_START="-0.29854298796575585" LOG_EFFECT_SIZE="-0.11336063718424332" NO="1" P_CHI2="0.05202090736356757" P_Z="0.2302149866993083" STUDIES="4" TAU2="0.09852083750466298" TOTAL_1="1890" TOTAL_2="1882" WEIGHT="100.0" Z="1.1998053011421779">
<NAME>breast tenderness</NAME>
<DICH_DATA CI_END="2.255340644614225" CI_START="0.028428969117872068" EFFECT_SIZE="0.2532133676092545" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3532121466145637" LOG_CI_START="-1.5462388882707554" LOG_EFFECT_SIZE="-0.596513370828096" ORDER="1" O_E="0.0" SE="1.1157469403258997" STUDY_ID="STD-Koetsawang-1995-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="389" TOTAL_2="394" VAR="1.2448912348466066" WEIGHT="3.5231013309921817"/>
<DICH_DATA CI_END="0.9068423260335975" CI_START="0.23164935999762937" EFFECT_SIZE="0.4583333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="24" LOG_CI_END="-0.04246821777595147" LOG_CI_START="-0.6351688953308106" LOG_EFFECT_SIZE="-0.338818556553381" ORDER="1" O_E="0.0" SE="0.3481553119113957" STUDY_ID="STD-L.-America-1994-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="176" TOTAL_2="176" VAR="0.12121212121212122" WEIGHT="21.539676559273474"/>
<DICH_DATA CI_END="1.4684598451894644" CI_START="0.8376890145462184" EFFECT_SIZE="1.1091044498231242" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="82" LOG_CI_END="0.1668620753048055" LOG_CI_START="-0.07691717985811569" LOG_EFFECT_SIZE="0.044972447723344945" ORDER="2" O_E="0.0" SE="0.14319714120947483" STUDY_ID="STD-Endrikat-1999-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="786" TOTAL_2="777" VAR="0.020505421250566272" WEIGHT="39.76414036422686"/>
<DICH_DATA CI_END="1.136842179019498" CI_START="0.5401385465986723" EFFECT_SIZE="0.7836148813592423" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="57" LOG_CI_END="0.05570017837437227" LOG_CI_START="-0.2674948284996882" LOG_EFFECT_SIZE="-0.10589732506265796" ORDER="3" O_E="0.0" SE="0.18984634687890908" STUDY_ID="STD-GSD-Group-1999-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="539" TOTAL_2="535" VAR="0.03604163542326708" WEIGHT="35.17308174550749"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4990469292402424" CI_END="1.2453960423735468" CI_START="0.946999846740165" DF="2" EFFECT_SIZE="1.0859971736881073" ESTIMABLE="YES" EVENTS_1="327" EVENTS_2="296" I2="0.0" ID="CMP-013.05.02" LOG_CI_END="0.09530748128415988" LOG_CI_START="-0.023650091281738214" LOG_EFFECT_SIZE="0.03582869500121088" NO="2" P_CHI2="0.47259181080273593" P_Z="0.2377463378667608" STUDIES="3" TAU2="0.0" TOTAL_1="1714" TOTAL_2="1706" WEIGHT="100.0" Z="1.180638614268001">
<NAME>headache</NAME>
<DICH_DATA CI_END="2.964347911160146" CI_START="0.6945434473369625" EFFECT_SIZE="1.4348757497857756" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="12" LOG_CI_END="0.4719291733390045" LOG_CI_START="-0.15830058167797348" LOG_EFFECT_SIZE="0.1568142958305155" ORDER="1" O_E="0.0" SE="0.3702000777845739" STUDY_ID="STD-Koetsawang-1995-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="389" TOTAL_2="394" VAR="0.13704809759170458" WEIGHT="3.5627584564250374"/>
<DICH_DATA CI_END="1.4537161593923869" CI_START="0.9365320627768772" EFFECT_SIZE="1.1668126642472783" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="122" LOG_CI_END="0.16247961804762415" LOG_CI_START="-0.028477349683608502" LOG_EFFECT_SIZE="0.06700113418200782" ORDER="2" O_E="0.0" SE="0.11216906809756115" STUDY_ID="STD-Endrikat-1999-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="786" TOTAL_2="777" VAR="0.012581899837875311" WEIGHT="38.80727671682551"/>
<DICH_DATA CI_END="1.2181699875434486" CI_START="0.8491966753733087" EFFECT_SIZE="1.0170869694679219" ESTIMABLE="YES" EVENTS_1="166" EVENTS_2="162" LOG_CI_END="0.08570789544053643" LOG_CI_START="-0.07099171477670863" LOG_EFFECT_SIZE="0.00735809033191391" ORDER="3" O_E="0.0" SE="0.09204612671719029" STUDY_ID="STD-GSD-Group-1999-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="539" TOTAL_2="535" VAR="0.008472489443637052" WEIGHT="57.62996482674944"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.14879249207229" CI_END="1.208673613633159" CI_START="0.8311109849073309" DF="3" EFFECT_SIZE="1.0022683859416885" ESTIMABLE="YES" EVENTS_1="195" EVENTS_2="193" I2="0.0" ID="CMP-013.05.03" LOG_CI_END="0.08230904119582019" LOG_CI_START="-0.08034097752225461" LOG_EFFECT_SIZE="9.840318367827768E-4" MODIFIED="2010-11-01 12:43:35 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.542105014998957" P_Z="0.9810795059758599" STUDIES="4" TAU2="0.0" TOTAL_1="1890" TOTAL_2="1882" WEIGHT="100.0" Z="0.023715545499911977">
<NAME>nausea/vomiting</NAME>
<DICH_DATA CI_END="1.2700521402469265" CI_START="0.4320270228326707" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="27" LOG_CI_END="0.10382155068564597" LOG_CI_START="-0.3644890876756583" LOG_EFFECT_SIZE="-0.13033376849500614" ORDER="1" O_E="0.0" SE="0.27508798714847704" STUDY_ID="STD-L.-America-1994-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="176" TOTAL_2="176" VAR="0.07567340067340068" WEIGHT="12.062579486159164"/>
<DICH_DATA CI_END="2.508882150716354" CI_START="0.7043874399727965" EFFECT_SIZE="1.3293701799485862" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="16" LOG_CI_END="0.39948026175477397" LOG_CI_START="-0.1521883965990522" LOG_EFFECT_SIZE="0.12364593257786088" ORDER="1" O_E="0.0" SE="0.3240529007209381" STUDY_ID="STD-Koetsawang-1995-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="389" TOTAL_2="394" VAR="0.10501028246565418" WEIGHT="8.692638370051256"/>
<DICH_DATA CI_END="1.3315493953969204" CI_START="0.8177147948543979" EFFECT_SIZE="1.0434690415606447" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="108" LOG_CI_END="0.12435728174034692" LOG_CI_START="-0.08739814451828837" LOG_EFFECT_SIZE="0.01847956861102929" ORDER="2" O_E="0.0" SE="0.12438618559058766" STUDY_ID="STD-Endrikat-1999-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="786" TOTAL_2="777" VAR="0.015471923165776117" WEIGHT="58.99825127299077"/>
<DICH_DATA CI_END="1.4332219241405926" CI_START="0.6235022033472053" EFFECT_SIZE="0.9453131902111493" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="42" LOG_CI_END="0.1563134429914589" LOG_CI_START="-0.20516200746235563" LOG_EFFECT_SIZE="-0.024424282235448354" ORDER="3" O_E="0.0" SE="0.21233246892890842" STUDY_ID="STD-GSD-Group-1999-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="539" TOTAL_2="535" VAR="0.045085077361445854" WEIGHT="20.24653087079881"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.247295744431326" CI_START="0.473956589884022" DF="0" EFFECT_SIZE="0.768871925360475" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="36" I2="0.0" ID="CMP-013.05.04" LOG_CI_END="0.09596944060464192" LOG_CI_START="-0.3242614339317652" LOG_EFFECT_SIZE="-0.11414599666356166" MODIFIED="2010-11-01 12:43:35 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.2869855801101163" STUDIES="1" TAU2="0.0" TOTAL_1="786" TOTAL_2="777" WEIGHT="100.0" Z="1.0647577605373097">
<NAME>nervousness</NAME>
<DICH_DATA CI_END="1.247295744431326" CI_START="0.473956589884022" EFFECT_SIZE="0.768871925360475" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="36" LOG_CI_END="0.09596944060464192" LOG_CI_START="-0.3242614339317652" LOG_EFFECT_SIZE="-0.11414599666356166" ORDER="2" O_E="0.0" SE="0.2468456958790632" STUDY_ID="STD-Endrikat-1999-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="786" TOTAL_2="777" VAR="0.06093279757401895" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.499445573044745" CI_START="0.2939427389315141" DF="0" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="0.0" ID="CMP-013.05.05" LOG_CI_END="0.39784368416374777" LOG_CI_START="-0.5317372634249743" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2011-01-31 12:10:37 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.7777086265339397" STUDIES="1" TAU2="0.0" TOTAL_1="176" TOTAL_2="176" WEIGHT="100.0" Z="0.2823063379191259">
<NAME>others (vaginal discharge)</NAME>
<DICH_DATA CI_END="2.499445573044745" CI_START="0.2939427389315142" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.39784368416374777" LOG_CI_START="-0.5317372634249742" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="1" O_E="0.0" SE="0.5460404501135179" STUDY_ID="STD-L.-America-1994-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="176" TOTAL_2="176" VAR="0.2981601731601732" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.844260143018522" CI_END="2.479694637840068" CI_START="0.6082140522682252" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2280818881770452" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="24" I2="19.160672984811708" I2_Q="0.0" ID="CMP-013.06" LOG_CI_END="0.3943982028962662" LOG_CI_START="-0.21594355007145316" LOG_EFFECT_SIZE="0.08922732641240645" METHOD="MH" MODIFIED="2010-11-01 12:43:39 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.2500642450880375" P_Q="0.9187705405007117" P_Z="0.5666015791002156" Q="2.0100657684829586" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.30804583603368285" TOTALS="SUB" TOTAL_1="3177" TOTAL_2="3121" WEIGHT="700.0" Z="0.5730636822887182">
<NAME>Side-effects leading to discontinuation</NAME>
<GROUP_LABEL_1>GSD</GROUP_LABEL_1>
<GROUP_LABEL_2>DSG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DSG</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.211175721108088" CI_END="186.48896068981372" CI_START="0.007626073012971057" DF="1" EFFECT_SIZE="1.1925512275510888" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" I2="83.89998858667617" ID="CMP-013.06.01" LOG_CI_END="2.270653128619795" LOG_CI_START="-2.1176990410530845" LOG_EFFECT_SIZE="0.07647704378335511" NO="1" P_CHI2="0.012694712658695373" P_Z="0.9455359314067999" STUDIES="2" TAU2="11.149969699641748" TOTAL_1="665" TOTAL_2="650" WEIGHT="99.99999999999999" Z="0.06831368389043499">
<NAME>breast tenderness</NAME>
<DICH_DATA CI_END="266.04175597737907" CI_START="0.9062678500388528" EFFECT_SIZE="15.527559055118111" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.424949805681318" LOG_CI_START="-0.042743426382846915" LOG_EFFECT_SIZE="1.1911031896492354" ORDER="1" O_E="0.0" SE="1.4495352197929947" STUDY_ID="STD-Zichella-1999-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="126" TOTAL_2="115" VAR="2.1011523534203254" WEIGHT="50.14475290241001"/>
<DICH_DATA CI_END="1.6278513779312895" CI_START="0.0050019798506784376" EFFECT_SIZE="0.09023569023569024" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.21161475148024725" LOG_CI_START="-2.3008580620570944" LOG_EFFECT_SIZE="-1.0446216552884235" ORDER="3" O_E="0.0" SE="1.4758389676128418" STUDY_ID="STD-GSD-Group-1999-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="539" TOTAL_2="535" VAR="2.1781006583245386" WEIGHT="49.855247097589974"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.032061018676637" CI_END="2.1031685499517234" CI_START="0.3230433980665782" DF="2" EFFECT_SIZE="0.8242661676201217" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" I2="1.5777586589164667" ID="CMP-013.06.02" LOG_CI_END="0.322874078858793" LOG_CI_START="-0.49073913006895276" LOG_EFFECT_SIZE="-0.08393252560507991" NO="2" P_CHI2="0.3620292918628587" P_Z="0.6859328133284792" STUDIES="3" TAU2="0.011154710958345417" TOTAL_1="841" TOTAL_2="826" WEIGHT="100.00000000000003" Z="0.4043806701079546">
<NAME>headache</NAME>
<DICH_DATA CI_END="7.020230187063325" CI_START="0.14244547163749285" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8463513524905522" LOG_CI_START="-0.8463513524905522" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.9943019479194253" STUDY_ID="STD-L.-America-1994-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="176" TOTAL_2="176" VAR="0.9886363636363635" WEIGHT="22.845566413820105"/>
<DICH_DATA CI_END="6.223520647244298" CI_START="0.371805624250396" EFFECT_SIZE="1.5211640211640212" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7940361347088514" LOG_CI_START="-0.42968404500404106" LOG_EFFECT_SIZE="0.18217604485240516" ORDER="1" O_E="0.0" SE="0.7188192910759369" STUDY_ID="STD-Zichella-1999-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="126" TOTAL_2="115" VAR="0.5167011732229124" WEIGHT="43.27088904204544"/>
<DICH_DATA CI_END="1.631934847655127" CI_START="0.0670787109158927" EFFECT_SIZE="0.3308596165739023" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.2127028162630164" LOG_CI_START="-1.1734152920333618" LOG_EFFECT_SIZE="-0.4803562378851727" ORDER="3" O_E="0.0" SE="0.8142126382085878" STUDY_ID="STD-GSD-Group-1999-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="539" TOTAL_2="535" VAR="0.6629422202185886" WEIGHT="33.88354454413447"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="73.14413347914392" CI_START="0.12304472788055147" DF="0" EFFECT_SIZE="2.9999999999999996" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-013.06.03" LOG_CI_END="1.8641794992951504" LOG_CI_START="-0.9099369898558256" LOG_EFFECT_SIZE="0.4771212547196624" NO="3" P_CHI2="1.0" P_Z="0.5001906786197396" STUDIES="1" TAU2="0.0" TOTAL_1="176" TOTAL_2="176" WEIGHT="100.0" Z="0.6741897675647365">
<NAME>migraine</NAME>
<DICH_DATA CI_END="73.14413347914392" CI_START="0.12304472788055147" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8641794992951504" LOG_CI_START="-0.9099369898558256" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1" O_E="0.0" SE="1.629529757825373" STUDY_ID="STD-L.-America-1994-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="176" TOTAL_2="176" VAR="2.6553672316384183" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.5104855994141655" CI_END="9.034799782132342" CI_START="0.20513828189860067" DF="2" EFFECT_SIZE="1.361390210264669" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" I2="55.658876280199955" ID="CMP-013.06.04" LOG_CI_END="0.9559185327155924" LOG_CI_START="-0.6879532861653879" LOG_EFFECT_SIZE="0.1339826232751022" MODIFIED="2010-11-01 12:37:50 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.10484820795709737" P_Z="0.7493542242709184" STUDIES="3" TAU2="1.5514466820923187" TOTAL_1="841" TOTAL_2="826" WEIGHT="100.0" Z="0.31949098847884216">
<NAME>nausea/vomiting</NAME>
<DICH_DATA CI_END="15.06566786453815" CI_START="0.6773330860865092" EFFECT_SIZE="3.1944444444444446" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.177988388810869" LOG_CI_START="-0.16919770963822023" LOG_EFFECT_SIZE="0.5043953395863244" ORDER="1" O_E="0.0" SE="0.7913437829077334" STUDY_ID="STD-Zichella-1999-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="126" TOTAL_2="115" VAR="0.6262249827467219" WEIGHT="42.817243475355276"/>
<DICH_DATA CI_END="28.563192786688465" CI_START="0.31509082570749375" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.455806751148267" LOG_CI_START="-0.5015642417089424" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1" O_E="0.0" SE="1.149769410347004" STUDY_ID="STD-L.-America-1994-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="176" TOTAL_2="176" VAR="1.321969696969697" WEIGHT="32.44983865277225"/>
<DICH_DATA CI_END="2.0434454991279862" CI_START="0.005952425681388404" EFFECT_SIZE="0.1102880658436214" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.31036305910481016" LOG_CI_START="-2.225306018243857" LOG_EFFECT_SIZE="-0.9574714795695234" ORDER="3" O_E="0.0" SE="1.4894645677989722" STUDY_ID="STD-GSD-Group-1999-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="539" TOTAL_2="535" VAR="2.2185046987285792" WEIGHT="24.73291787187247"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="21.856384956534562" CI_START="0.18301288195439164" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-013.06.05" LOG_CI_END="1.3395783312980352" LOG_CI_START="-0.7375183399700725" LOG_EFFECT_SIZE="0.3010299956639812" NO="5" P_CHI2="1.0" P_Z="0.5699614216365716" STUDIES="1" TAU2="0.0" TOTAL_1="176" TOTAL_2="176" WEIGHT="99.99999999999999" Z="0.5681083195876874">
<NAME>nervousness</NAME>
<DICH_DATA CI_END="21.856384956534562" CI_START="0.18301288195439164" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3395783312980352" LOG_CI_START="-0.7375183399700725" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="1" O_E="0.0" SE="1.2200968664972318" STUDY_ID="STD-L.-America-1994-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="176" TOTAL_2="176" VAR="1.4886363636363638" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0015470276288011612" CI_END="27.399780964717593" CI_START="0.2999930259753703" DF="1" EFFECT_SIZE="2.867009452838965" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-013.06.06" LOG_CI_END="1.437747091061457" LOG_CI_START="-0.5228888413323993" LOG_EFFECT_SIZE="0.4574291248645288" MODIFIED="2010-11-01 12:43:39 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.9686254821027621" P_Z="0.3604307063935711" STUDIES="2" TAU2="0.0" TOTAL_1="302" TOTAL_2="291" WEIGHT="100.0" Z="0.9145447101130169">
<NAME>acne</NAME>
<DICH_DATA CI_END="73.14413347914392" CI_START="0.12304472788055147" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8641794992951504" LOG_CI_START="-0.9099369898558256" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1" O_E="0.0" SE="1.629529757825373" STUDY_ID="STD-L.-America-1994-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="176" TOTAL_2="176" VAR="2.6553672316384183" WEIGHT="49.95103918578241"/>
<DICH_DATA CI_END="66.60030252236464" CI_START="0.11273917283490806" EFFECT_SIZE="2.7401574803149606" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8234762018954545" LOG_CI_START="-0.9479251559142066" LOG_EFFECT_SIZE="0.43777552299062406" ORDER="1" O_E="0.0" SE="1.6279348762353678" STUDY_ID="STD-Zichella-1999-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="126" TOTAL_2="115" VAR="2.6501719612634624" WEIGHT="50.04896081421758"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="73.14413347914392" CI_START="0.12304472788055147" DF="0" EFFECT_SIZE="2.9999999999999996" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-013.06.07" LOG_CI_END="1.8641794992951504" LOG_CI_START="-0.9099369898558256" LOG_EFFECT_SIZE="0.4771212547196624" MODIFIED="2010-11-01 12:43:39 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.5001906786197396" STUDIES="1" TAU2="0.0" TOTAL_1="176" TOTAL_2="176" WEIGHT="100.0" Z="0.6741897675647365">
<NAME>weight gain</NAME>
<DICH_DATA CI_END="73.14413347914392" CI_START="0.12304472788055147" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8641794992951504" LOG_CI_START="-0.9099369898558256" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1" O_E="0.0" SE="1.629529757825373" STUDY_ID="STD-L.-America-1994-_x0028_GSD_x002d_DSG_x0029_" TOTAL_1="176" TOTAL_2="176" VAR="2.6553672316384183" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" MODIFIED="2011-01-04 15:59:42 +0100" MODIFIED_BY="[Empty name]" NO="14">
<NAME>Gestodene vs Norgestimate (monophasic)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-014.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="91" TOTAL_2="83" WEIGHT="0.0" Z="0.0">
<NAME>Pregnancy</NAME>
<GROUP_LABEL_1>GSD</GROUP_LABEL_1>
<GROUP_LABEL_2>NGM</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NGM</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1403" O_E="0.0" SE="0.0" STUDY_ID="STD-Affinito-1993-_x0028_GSD_x002d_NGM_x0029_" TOTAL_1="91" TOTAL_2="83" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6351682531087994" CI_START="0.2261145115380189" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.608058608058608" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-014.02" LOG_CI_END="0.2135624466826595" LOG_CI_START="-0.6456715646840615" LOG_EFFECT_SIZE="-0.21605455900070097" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.324296733362737" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="91" TOTAL_2="83" WEIGHT="100.0" Z="0.9856666489807416">
<NAME>Discontinuation</NAME>
<GROUP_LABEL_1>GSD</GROUP_LABEL_1>
<GROUP_LABEL_2>NGM</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NGM</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6351682531087994" CI_START="0.2261145115380189" EFFECT_SIZE="0.608058608058608" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.2135624466826595" LOG_CI_START="-0.6456715646840615" LOG_EFFECT_SIZE="-0.21605455900070097" ORDER="1404" O_E="0.0" SE="0.5047183115537641" STUDY_ID="STD-Affinito-1993-_x0028_GSD_x002d_NGM_x0029_" TOTAL_1="91" TOTAL_2="83" VAR="0.25474057401768246" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9376201647471181" CI_END="2.0053856711426867" CI_START="0.23409227584347642" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6851607809132751" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-014.03" LOG_CI_END="0.3021979075008167" LOG_CI_START="-0.6306129161363478" LOG_EFFECT_SIZE="-0.1642075043177655" METHOD="MH" NO="3" P_CHI2="0.3328907875670848" P_Q="0.33289298364964803" P_Z="0.490165796521851" Q="0.9376116464293849" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="546" TOTAL_2="498" WEIGHT="200.0" Z="0.6900451544915015">
<NAME>Reasons for discontinuation</NAME>
<GROUP_LABEL_1>GSD</GROUP_LABEL_1>
<GROUP_LABEL_2>NGM</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NGM</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-014.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="91" TOTAL_2="83" WEIGHT="0.0" Z="0.0">
<NAME>cycle disturbances</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1405" O_E="0.0" SE="0.0" STUDY_ID="STD-Affinito-1993-_x0028_GSD_x002d_NGM_x0029_" TOTAL_1="91" TOTAL_2="83" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-014.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="91" TOTAL_2="83" WEIGHT="0.0" Z="0.0">
<NAME>pregnancy</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1406" O_E="0.0" SE="0.0" STUDY_ID="STD-Affinito-1993-_x0028_GSD_x002d_NGM_x0029_" TOTAL_1="91" TOTAL_2="83" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.9863689908268976" CI_START="0.23437244268927696" DF="0" EFFECT_SIZE="1.3681318681318682" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-014.03.03" LOG_CI_END="0.9023493718460398" LOG_CI_START="-0.6300934536247167" LOG_EFFECT_SIZE="0.13612795911066156" NO="3" P_CHI2="1.0" P_Z="0.7276825386798984" STUDIES="1" TAU2="0.0" TOTAL_1="91" TOTAL_2="83" WEIGHT="100.0" Z="0.34820992041106236">
<NAME>side-effects (other than cycle disturbances)</NAME>
<DICH_DATA CI_END="7.9863689908268976" CI_START="0.23437244268927696" EFFECT_SIZE="1.3681318681318682" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9023493718460398" LOG_CI_START="-0.6300934536247167" LOG_EFFECT_SIZE="0.13612795911066156" ORDER="1407" O_E="0.0" SE="0.9001645013958492" STUDY_ID="STD-Affinito-1993-_x0028_GSD_x002d_NGM_x0029_" TOTAL_1="91" TOTAL_2="83" VAR="0.8102961295732379" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-014.03.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="91" TOTAL_2="83" WEIGHT="0.0" Z="0.0">
<NAME>lost to follow-up</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1408" O_E="0.0" SE="0.0" STUDY_ID="STD-Affinito-1993-_x0028_GSD_x002d_NGM_x0029_" TOTAL_1="91" TOTAL_2="83" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-014.03.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="91" TOTAL_2="83" WEIGHT="0.0" Z="0.0">
<NAME>other medical reasons</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1409" O_E="0.0" SE="0.0" STUDY_ID="STD-Affinito-1993-_x0028_GSD_x002d_NGM_x0029_" TOTAL_1="91" TOTAL_2="83" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7654999597925929" CI_START="0.11780011021277752" DF="0" EFFECT_SIZE="0.45604395604395603" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="0.0" ID="CMP-014.03.06" LOG_CI_END="0.2468677120085154" LOG_CI_START="-0.9288543032265172" LOG_EFFECT_SIZE="-0.3409932956090009" NO="6" P_CHI2="1.0" P_Z="0.2555833834621153" STUDIES="1" TAU2="0.0" TOTAL_1="91" TOTAL_2="83" WEIGHT="100.0" Z="1.1368921729847146">
<NAME>method unrelated</NAME>
<DICH_DATA CI_END="1.7654999597925929" CI_START="0.11780011021277752" EFFECT_SIZE="0.45604395604395603" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2468677120085154" LOG_CI_START="-0.9288543032265172" LOG_EFFECT_SIZE="-0.3409932956090009" ORDER="1410" O_E="0.0" SE="0.690624931666896" STUDY_ID="STD-Affinito-1993-_x0028_GSD_x002d_NGM_x0029_" TOTAL_1="91" TOTAL_2="83" VAR="0.4769627962399047" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.577793006514581" CI_END="1.4980600726599396" CI_START="0.3893056083248426" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7636774108837027" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="20" I2="34.46623742640285" I2_Q="34.43870836934699" ID="CMP-014.04" LOG_CI_END="0.175529229052116" LOG_CI_START="-0.4097093398035752" LOG_EFFECT_SIZE="-0.11709005537572965" METHOD="MH" MODIFIED="2010-11-01 13:02:55 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.20545546547864868" P_Q="0.20562186241839997" P_Z="0.4328821760779916" Q="4.57587080025946" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.2603427768620304" TOTALS="SUB" TOTAL_1="364" TOTAL_2="332" WEIGHT="400.0" Z="0.7842691978860988">
<NAME>Side-effects</NAME>
<GROUP_LABEL_1>GSD</GROUP_LABEL_1>
<GROUP_LABEL_2>NGM</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NGM</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.246421699967761" CI_START="0.09385792187379326" DF="0" EFFECT_SIZE="0.34203296703296704" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" I2="0.0" ID="CMP-014.04.01" LOG_CI_END="0.09566500137969196" LOG_CI_START="-1.0275290658142937" LOG_EFFECT_SIZE="-0.46593203221730084" NO="1" P_CHI2="1.0" P_Z="0.10392949522879054" STUDIES="1" TAU2="0.0" TOTAL_1="91" TOTAL_2="83" WEIGHT="100.0" Z="1.6260947757156314">
<NAME>breast tenderness</NAME>
<DICH_DATA CI_END="1.246421699967761" CI_START="0.09385792187379326" EFFECT_SIZE="0.34203296703296704" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.09566500137969196" LOG_CI_START="-1.0275290658142937" LOG_EFFECT_SIZE="-0.46593203221730084" ORDER="1411" O_E="0.0" SE="0.6597697549700486" STUDY_ID="STD-Affinito-1993-_x0028_GSD_x002d_NGM_x0029_" TOTAL_1="91" TOTAL_2="83" VAR="0.435296129573238" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="11.437370163217736" CI_START="0.4545977066324807" DF="0" EFFECT_SIZE="2.2802197802197806" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-014.04.02" LOG_CI_END="1.0583261770007877" LOG_CI_START="-0.3423727595467517" LOG_EFFECT_SIZE="0.357976708727018" NO="2" P_CHI2="1.0" P_Z="0.3164323757638198" STUDIES="1" TAU2="0.0" TOTAL_1="91" TOTAL_2="83" WEIGHT="100.0" Z="1.0018162191777">
<NAME>headache</NAME>
<DICH_DATA CI_END="11.437370163217732" CI_START="0.45459770663248067" EFFECT_SIZE="2.28021978021978" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0583261770007875" LOG_CI_START="-0.3423727595467518" LOG_EFFECT_SIZE="0.3579767087270179" ORDER="1412" O_E="0.0" SE="0.8227774888995837" STUDY_ID="STD-Affinito-1993-_x0028_GSD_x002d_NGM_x0029_" TOTAL_1="91" TOTAL_2="83" VAR="0.6769627962399046" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.70105841737017" CI_START="0.34301591582515395" DF="0" EFFECT_SIZE="1.8241758241758241" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-014.04.03" LOG_CI_END="0.986819119807176" LOG_CI_START="-0.4646857283692529" LOG_EFFECT_SIZE="0.26106669571896146" MODIFIED="2010-10-25 11:36:32 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.4807880651681381" STUDIES="1" TAU2="0.0" TOTAL_1="91" TOTAL_2="83" WEIGHT="100.0" Z="0.7050356350030562">
<NAME>nausea/vomiting</NAME>
<DICH_DATA CI_END="9.70105841737017" CI_START="0.34301591582515395" EFFECT_SIZE="1.8241758241758241" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.986819119807176" LOG_CI_START="-0.4646857283692529" LOG_EFFECT_SIZE="0.26106669571896146" ORDER="1413" O_E="0.0" SE="0.8526211328837121" STUDY_ID="STD-Affinito-1993-_x0028_GSD_x002d_NGM_x0029_" TOTAL_1="91" TOTAL_2="83" VAR="0.7269627962399047" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6736385961152633" CI_START="0.19416535991454645" DF="0" EFFECT_SIZE="0.570054945054945" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" I2="0.0" ID="CMP-014.04.04" LOG_CI_END="0.22366168265479697" LOG_CI_START="-0.7118282478566861" LOG_EFFECT_SIZE="-0.2440832826009445" NO="4" P_CHI2="1.0" P_Z="0.30641770667683454" STUDIES="1" TAU2="0.0" TOTAL_1="91" TOTAL_2="83" WEIGHT="100.0" Z="1.0227677017637147">
<NAME>other minor</NAME>
<DICH_DATA CI_END="1.6736385961152633" CI_START="0.19416535991454645" EFFECT_SIZE="0.570054945054945" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.22366168265479697" LOG_CI_START="-0.7118282478566861" LOG_EFFECT_SIZE="-0.2440832826009445" ORDER="1414" O_E="0.0" SE="0.5495114159322849" STUDY_ID="STD-Affinito-1993-_x0028_GSD_x002d_NGM_x0029_" TOTAL_1="91" TOTAL_2="83" VAR="0.3019627962399047" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" MODIFIED="2011-03-03 15:42:48 +0100" MODIFIED_BY="[Empty name]" NO="15">
<NAME>Drospirenone vs Levonorgestrel (monophasic)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-015.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-10-22 11:40:44 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="58" TOTAL_2="57" WEIGHT="0.0" Z="0.0">
<NAME>Pregnancy</NAME>
<GROUP_LABEL_1>DRSP</GROUP_LABEL_1>
<GROUP_LABEL_2>LNG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DRSP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LNG</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-10-22 11:37:33 +0200" MODIFIED_BY="[Empty name]" ORDER="584" O_E="0.0" SE="0.0" STUDY_ID="STD-Suthipongse2004_x0028_DRSP_x002d_LNG_x0029_" TOTAL_1="58" TOTAL_2="57" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.04954698941271739" CI_END="1.058068290740546" CI_START="0.621743031241745" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8110774231513285" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="58" I2="0.0" I2_Q="0.0" ID="CMP-015.02" LOG_CI_END="0.02451369920639602" LOG_CI_START="-0.20638907378656182" LOG_EFFECT_SIZE="-0.09093768729008289" METHOD="MH" MODIFIED="2010-10-22 11:41:14 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8238534299468872" P_Q="1.0" P_Z="0.12263523504950212" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="342" TOTAL_2="202" WEIGHT="99.99999999999999" Z="1.5438064222066676">
<NAME>Discontinuation</NAME>
<GROUP_LABEL_1>DRSP</GROUP_LABEL_1>
<GROUP_LABEL_2>LNG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DRSP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LNG</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0662737419393398" CI_START="0.6226792476773471" EFFECT_SIZE="0.814829142488717" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="55" LOG_CI_END="0.027868714401558727" LOG_CI_START="-0.20573560797283005" LOG_EFFECT_SIZE="-0.08893344678563567" MODIFIED="2010-10-20 11:38:06 +0200" MODIFIED_BY="[Empty name]" ORDER="275" O_E="0.0" SE="0.13722033532276132" STUDY_ID="STD-Kelly-2010-_x0028_DRSP_x002d_LNG_x0029_" TOTAL_1="282" TOTAL_2="142" VAR="0.018829420426091054" WEIGHT="97.7004465208037"/>
<DICH_DATA CI_END="3.8481017433944946" CI_START="0.11549706168953583" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5852465462167757" LOG_CI_START="-0.9374290643281383" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2010-10-22 11:38:50 +0200" MODIFIED_BY="[Empty name]" ORDER="585" O_E="0.0" SE="0.8944271909999157" STUDY_ID="STD-Suthipongse2004_x0028_DRSP_x002d_LNG_x0029_" TOTAL_1="60" TOTAL_2="60" VAR="0.7999999999999998" WEIGHT="2.2995534791962977"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.46476930613746914" CI_END="0.911374246683955" CI_START="0.3413408238766738" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5577537415590182" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-015.03" LOG_CI_END="-0.040303247731924084" LOG_CI_START="-0.4668117676132143" LOG_EFFECT_SIZE="-0.2535575076725692" METHOD="MH" MODIFIED="2011-02-15 10:47:09 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9265604265121371" P_Q="0.9391003965712542" P_Z="0.019786045973575323" Q="0.1256657902609331" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="682" TOTAL_2="402" WEIGHT="300.0" Z="2.3303805663075314">
<NAME>Reasons for discontinuation</NAME>
<GROUP_LABEL_1>DRSP</GROUP_LABEL_1>
<GROUP_LABEL_2>LNG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DRSP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LNG</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.017186793054035" CI_START="0.013859114671916584" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-015.03.01" LOG_CI_END="0.9040220023759301" LOG_CI_START="-1.8582645118152552" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2010-10-22 11:36:09 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.49835704004838544" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="58" WEIGHT="99.99999999999999" Z="0.6770771031207925">
<NAME>Pregnancy or desire for pregnancy</NAME>
<DICH_DATA CI_END="8.017186793054035" CI_START="0.013859114671916584" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9040220023759301" LOG_CI_START="-1.8582645118152552" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2010-10-22 11:36:09 +0200" MODIFIED_BY="[Empty name]" ORDER="583" O_E="0.0" SE="1.6225807719746714" STUDY_ID="STD-Suthipongse2004_x0028_DRSP_x002d_LNG_x0029_" TOTAL_1="58" TOTAL_2="58" VAR="2.632768361581921" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.33957027000008827" CI_END="1.1559832536514556" CI_START="0.29634699345678117" DF="1" EFFECT_SIZE="0.5852966441950581" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" I2="0.0" ID="CMP-015.03.02" LOG_CI_END="0.06295154264900481" LOG_CI_START="-0.5281994744710337" LOG_EFFECT_SIZE="-0.23262396591101447" MODIFIED="2011-02-15 10:47:09 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5600775502481136" P_Z="0.12294443798550773" STUDIES="2" TAU2="0.0" TOTAL_1="342" TOTAL_2="202" WEIGHT="100.0" Z="1.5425317116011323">
<NAME>loss to follow-up</NAME>
<DICH_DATA CI_END="1.1224317805740227" CI_START="0.26199191182110065" EFFECT_SIZE="0.5422804146208402" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.05015995482405525" LOG_CI_START="-0.5817121159538619" LOG_EFFECT_SIZE="-0.2657760805649033" MODIFIED="2010-10-20 11:39:17 +0200" MODIFIED_BY="[Empty name]" ORDER="276" O_E="0.0" SE="0.37116478219214366" STUDY_ID="STD-Kelly-2010-_x0028_DRSP_x002d_LNG_x0029_" TOTAL_1="282" TOTAL_2="142" VAR="0.13776329553974145" WEIGHT="87.52629861068594"/>
<DICH_DATA CI_END="6.869017391942697" CI_START="0.14558122988201952" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8368946159855735" LOG_CI_START="-0.8368946159855735" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-10-22 11:34:27 +0200" MODIFIED_BY="[Empty name]" ORDER="582" O_E="0.0" SE="0.983192080250175" STUDY_ID="STD-Suthipongse2004_x0028_DRSP_x002d_LNG_x0029_" TOTAL_1="60" TOTAL_2="60" VAR="0.9666666666666666" WEIGHT="12.473701389314058"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1224317805740227" CI_START="0.26199191182110065" DF="0" EFFECT_SIZE="0.5422804146208402" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" I2="0.0" ID="CMP-015.03.03" LOG_CI_END="0.05015995482405525" LOG_CI_START="-0.5817121159538619" LOG_EFFECT_SIZE="-0.2657760805649033" MODIFIED="2011-02-15 10:47:09 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.09919107295142471" STUDIES="1" TAU2="0.0" TOTAL_1="282" TOTAL_2="142" WEIGHT="100.0" Z="1.648788006148511">
<NAME>side effects (including cycle disturbance)</NAME>
<DICH_DATA CI_END="1.1224317805740227" CI_START="0.26199191182110065" EFFECT_SIZE="0.5422804146208402" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.05015995482405525" LOG_CI_START="-0.5817121159538619" LOG_EFFECT_SIZE="-0.2657760805649033" MODIFIED="2010-10-20 11:40:24 +0200" MODIFIED_BY="[Empty name]" ORDER="277" O_E="0.0" SE="0.37116478219214366" STUDY_ID="STD-Kelly-2010-_x0028_DRSP_x002d_LNG_x0029_" TOTAL_1="282" TOTAL_2="142" VAR="0.13776329553974145" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.703744222696268E-31" CI_END="1.4816630901561307" CI_START="0.5162376649634648" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8745800671892497" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="19" I2="100.0" I2_Q="0.0" ID="CMP-015.04" LOG_CI_END="0.17074946226666124" LOG_CI_START="-0.28715031228915344" LOG_EFFECT_SIZE="-0.058200425011246094" METHOD="MH" MODIFIED="2010-10-22 11:42:13 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="1.0" P_Z="0.6183187569559897" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="282" TOTAL_2="142" WEIGHT="100.0" Z="0.49823451875520464">
<NAME>Cycle control</NAME>
<GROUP_LABEL_1>DRSP</GROUP_LABEL_1>
<GROUP_LABEL_2>LNG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DRSP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LNG</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.703744222696268E-31" CI_END="1.4816630901561307" CI_START="0.5162376649634648" DF="0" EFFECT_SIZE="0.8745800671892497" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="19" I2="100.0" ID="CMP-015.04.01" LOG_CI_END="0.17074946226666124" LOG_CI_START="-0.28715031228915344" LOG_EFFECT_SIZE="-0.058200425011246094" MODIFIED="2010-10-20 13:03:23 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.6183187569559897" STUDIES="1" TAU2="0.0" TOTAL_1="282" TOTAL_2="142" WEIGHT="100.0" Z="0.49823451875520464">
<NAME>intermenstrual bleeding</NAME>
<DICH_DATA CI_END="1.4816630901561307" CI_START="0.5162376649634648" EFFECT_SIZE="0.8745800671892497" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="19" LOG_CI_END="0.17074946226666124" LOG_CI_START="-0.28715031228915344" LOG_EFFECT_SIZE="-0.058200425011246094" MODIFIED="2010-10-20 13:03:23 +0200" MODIFIED_BY="[Empty name]" ORDER="283" O_E="0.0" SE="0.2689725942145255" STUDY_ID="STD-Kelly-2010-_x0028_DRSP_x002d_LNG_x0029_" TOTAL_1="282" TOTAL_2="142" VAR="0.07234625643849181" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6391371762264301" CI_END="1.8197841692831154" CI_START="0.724077463852417" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1478957731664037" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-015.05" LOG_CI_END="0.2600198826841456" LOG_CI_START="-0.14021496926691002" LOG_EFFECT_SIZE="0.059902456708617796" METHOD="MH" MODIFIED="2011-03-03 15:42:48 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.726462425075694" P_Q="0.7266448825469255" P_Z="0.5574127165829555" Q="0.6386349208092241" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1128" TOTAL_2="568" WEIGHT="99.99999999999999" Z="0.5866888261331034">
<NAME>Side-effects</NAME>
<GROUP_LABEL_1>DRSP</GROUP_LABEL_1>
<GROUP_LABEL_2>LNG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DRSP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LNG</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-015.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-10-20 13:06:20 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="282" TOTAL_2="142" WEIGHT="0.0" Z="0.0">
<NAME>breast tenderness</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-10-20 13:06:20 +0200" MODIFIED_BY="[Empty name]" ORDER="284" O_E="0.0" SE="0.0" STUDY_ID="STD-Kelly-2010-_x0028_DRSP_x002d_LNG_x0029_" TOTAL_1="282" TOTAL_2="142" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.078116786958611" CI_START="0.6642966955791265" DF="0" EFFECT_SIZE="1.1749408983451537" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="15" I2="0.0" ID="CMP-015.05.02" LOG_CI_END="0.3176699505871188" LOG_CI_START="-0.1776379078705392" LOG_EFFECT_SIZE="0.07001602135828978" MODIFIED="2010-10-20 11:41:50 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5794998071803554" STUDIES="1" TAU2="0.0" TOTAL_1="282" TOTAL_2="142" WEIGHT="65.29491646497331" Z="0.5541154975023129">
<NAME>headache</NAME>
<DICH_DATA CI_END="2.078116786958611" CI_START="0.6642966955791265" EFFECT_SIZE="1.1749408983451537" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="15" LOG_CI_END="0.3176699505871188" LOG_CI_START="-0.1776379078705392" LOG_EFFECT_SIZE="0.07001602135828978" MODIFIED="2010-10-20 11:41:50 +0200" MODIFIED_BY="[Empty name]" ORDER="278" O_E="0.0" SE="0.29094628787147003" STUDY_ID="STD-Kelly-2010-_x0028_DRSP_x002d_LNG_x0029_" TOTAL_1="282" TOTAL_2="142" VAR="0.08464974242618832" WEIGHT="65.29491646497331"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.417956799666933" CI_START="0.268454012831607" DF="0" EFFECT_SIZE="0.8056737588652483" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" I2="0.0" ID="CMP-015.05.03" LOG_CI_END="0.38344853728824824" LOG_CI_START="-0.5711300998490079" LOG_EFFECT_SIZE="-0.0938407812803798" MODIFIED="2011-03-03 15:42:48 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.6999763956036611" STUDIES="1" TAU2="0.0" TOTAL_1="282" TOTAL_2="142" WEIGHT="17.579494620925704" Z="0.38535233124895285">
<NAME>migraine</NAME>
<DICH_DATA CI_END="2.417956799666933" CI_START="0.268454012831607" EFFECT_SIZE="0.8056737588652483" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.38344853728824824" LOG_CI_START="-0.5711300998490079" LOG_EFFECT_SIZE="-0.0938407812803798" MODIFIED="2010-10-20 12:49:25 +0200" MODIFIED_BY="[Empty name]" ORDER="281" O_E="0.0" SE="0.5607242166948857" STUDY_ID="STD-Kelly-2010-_x0028_DRSP_x002d_LNG_x0029_" TOTAL_1="282" TOTAL_2="142" VAR="0.3144116471880931" WEIGHT="17.579494620925704"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.59974344516046" CI_START="0.4961207280809624" DF="0" EFFECT_SIZE="1.5106382978723405" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" I2="0.0" ID="CMP-015.05.04" LOG_CI_END="0.6627336091906294" LOG_CI_START="-0.3044126276239138" LOG_EFFECT_SIZE="0.17916049078335783" MODIFIED="2010-10-25 11:26:34 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.46774493741799317" STUDIES="1" TAU2="0.0" TOTAL_1="282" TOTAL_2="142" WEIGHT="17.12558891410097" Z="0.7261530801059957">
<NAME>nausea/vomiting</NAME>
<DICH_DATA CI_END="4.59974344516046" CI_START="0.4961207280809624" EFFECT_SIZE="1.5106382978723405" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="0.6627336091906294" LOG_CI_START="-0.3044126276239138" LOG_EFFECT_SIZE="0.17916049078335783" MODIFIED="2010-10-20 12:50:06 +0200" MODIFIED_BY="[Empty name]" ORDER="282" O_E="0.0" SE="0.568106486955946" STUDY_ID="STD-Kelly-2010-_x0028_DRSP_x002d_LNG_x0029_" TOTAL_1="282" TOTAL_2="142" VAR="0.3227449805214264" WEIGHT="17.12558891410097"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-016" MODIFIED="2011-01-31 12:12:11 +0100" MODIFIED_BY="[Empty name]" NO="16">
<NAME>Drospirenone vs Desogestrel (monophasic)</NAME>
<DICH_OUTCOME CHI2="1.8971118332665031" CI_END="2.325924029482358" CI_START="0.38948007717393085" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9517883538389661" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-016.01" LOG_CI_END="0.366595525476084" LOG_CI_START="-0.40951475261199866" LOG_EFFECT_SIZE="-0.021459613567957343" METHOD="MH" MODIFIED="2010-10-25 10:34:45 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7546756061630429" P_Q="1.0" P_Z="0.9136888409335797" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3013" TOTAL_2="1402" WEIGHT="100.0" Z="0.10838683857906585">
<NAME>Pregnancy</NAME>
<GROUP_LABEL_1>DRSP</GROUP_LABEL_1>
<GROUP_LABEL_2>DSG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DRSP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DSG</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.573575089280207" CI_START="0.010668859887194541" EFFECT_SIZE="0.2208955223880597" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6602558137572025" LOG_CI_START="-1.9718819883689405" LOG_EFFECT_SIZE="-0.6558130873058691" MODIFIED="2010-10-18 13:30:51 +0200" MODIFIED_BY="[Empty name]" ORDER="249" O_E="0.0" SE="1.5461307742611508" STUDY_ID="STD-Anttila-2009-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="200" TOTAL_2="221" VAR="2.3905203711173857" WEIGHT="8.694199968296285"/>
<DICH_DATA CI_END="5.0276719639959975" CI_START="0.20798317458790216" EFFECT_SIZE="1.0225806451612902" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7013669339156862" LOG_CI_START="-0.6819717971487286" LOG_EFFECT_SIZE="0.009697568383478768" ORDER="1480" O_E="0.0" SE="0.8125800182643933" STUDY_ID="STD-Foidart-2000-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="310" TOTAL_2="317" VAR="0.6602862860825617" WEIGHT="31.476743607819877"/>
<DICH_DATA CI_END="3.9689452874070787" CI_START="0.11300080972250093" EFFECT_SIZE="0.6696969696969697" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5986751121243534" LOG_CI_START="-0.9469184445099068" LOG_EFFECT_SIZE="-0.17412166619277678" MODIFIED="2010-10-19 12:21:22 +0200" MODIFIED_BY="[Empty name]" ORDER="260" O_E="0.0" SE="0.9078893059784605" STUDY_ID="STD-Gruber-2006-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="220" TOTAL_2="221" VAR="0.8242629919100507" WEIGHT="25.21484324635123"/>
<DICH_DATA CI_END="9.75769959480736" CI_START="0.10682060777698416" EFFECT_SIZE="1.0209424083769634" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="0.9893474435850457" LOG_CI_START="-0.9713449553554647" LOG_EFFECT_SIZE="0.009001244114790483" MODIFIED="2010-10-22 10:14:57 +0200" MODIFIED_BY="[Empty name]" ORDER="571" O_E="0.0" SE="1.1517204207215603" STUDY_ID="STD-Guang_x002d_Sheng2010_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="573" TOTAL_2="195" VAR="1.3264599275070479" WEIGHT="15.668518666705044"/>
<DICH_DATA CI_END="19.382131757387057" CI_START="0.31939819578786977" EFFECT_SIZE="2.488095238095238" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.2874015415256408" LOG_CI_START="-0.4956675414272961" LOG_EFFECT_SIZE="0.39586700004917236" ORDER="1481" O_E="0.0" SE="1.047383605660865" STUDY_ID="STD-Huber-2000-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="1680" TOTAL_2="418" VAR="1.0970124174071543" WEIGHT="18.945694510827565"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-10-25 10:34:45 +0200" MODIFIED_BY="[Empty name]" ORDER="322" O_E="0.0" SE="0.0" STUDY_ID="STD-Kriplani-2010-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.43794059357084514" CI_END="1.2021728107657679" CI_START="0.9295105861676392" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0570867296535735" ESTIMABLE="YES" EVENTS_1="632" EVENTS_2="294" I2="0.0" I2_Q="0.0" ID="CMP-016.02" LOG_CI_END="0.07996690141672375" LOG_CI_START="-0.03174565969734393" LOG_EFFECT_SIZE="0.024110620859689916" METHOD="MH" MODIFIED="2010-10-25 10:35:22 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9942198721365085" P_Q="1.0" P_Z="0.3975374204556147" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3174" TOTAL_2="1531" WEIGHT="100.0" Z="0.8460274844408986">
<NAME>Discontinuation</NAME>
<GROUP_LABEL_1>DRSP</GROUP_LABEL_1>
<GROUP_LABEL_2>DSG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DRSP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DSG</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6313580126120248" CI_START="0.6179675022480691" EFFECT_SIZE="1.0040548970679974" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="28" LOG_CI_END="0.2125492803779311" LOG_CI_START="-0.20903436304295617" LOG_EFFECT_SIZE="0.0017574586674874747" MODIFIED="2010-10-18 13:35:57 +0200" MODIFIED_BY="[Empty name]" ORDER="250" O_E="0.0" SE="0.24764031901812078" STUDY_ID="STD-Anttila-2009-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="229" TOTAL_2="222" VAR="0.06132572760339663" WEIGHT="7.0216068893811245"/>
<DICH_DATA CI_END="1.289803696317863" CI_START="0.8606765740102238" EFFECT_SIZE="1.0536146480058928" ESTIMABLE="YES" EVENTS_1="135" EVENTS_2="129" LOG_CI_END="0.11052361720370402" LOG_CI_START="-0.0651600175485104" LOG_EFFECT_SIZE="0.02268179982759681" ORDER="1482" O_E="0.0" SE="0.10319743670146826" STUDY_ID="STD-Foidart-2000-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="442" TOTAL_2="445" VAR="0.010649710941753548" WEIGHT="40.43350601640065"/>
<DICH_DATA CI_END="1.5884619234541635" CI_START="0.5907093463326983" EFFECT_SIZE="0.9686688311688312" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="28" LOG_CI_END="0.2009768089447589" LOG_CI_START="-0.22862615758541371" LOG_EFFECT_SIZE="-0.013824674320327444" MODIFIED="2010-10-19 12:24:37 +0200" MODIFIED_BY="[Empty name]" ORDER="261" O_E="0.0" SE="0.2523509091088046" STUDY_ID="STD-Gruber-2006-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="220" TOTAL_2="221" VAR="0.06368098132804015" WEIGHT="6.761911365940508"/>
<DICH_DATA CI_END="1.4937785683570426" CI_START="0.663743695250989" EFFECT_SIZE="0.9957339538491371" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="27" LOG_CI_END="0.17428622420764575" LOG_CI_START="-0.17799959115448147" LOG_EFFECT_SIZE="-0.0018566834734178458" MODIFIED="2010-10-22 10:16:17 +0200" MODIFIED_BY="[Empty name]" ORDER="572" O_E="0.0" SE="0.20693443178662388" STUDY_ID="STD-Guang_x002d_Sheng2010_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="573" TOTAL_2="195" VAR="0.04282185905885289" WEIGHT="10.05573230355345"/>
<DICH_DATA CI_END="1.3760376559796421" CI_START="0.8936100560965708" EFFECT_SIZE="1.1088918283362728" ESTIMABLE="YES" EVENTS_1="361" EVENTS_2="81" LOG_CI_END="0.13863031875443604" LOG_CI_START="-0.04885195260207502" LOG_EFFECT_SIZE="0.044889183076180506" ORDER="1483" O_E="0.0" SE="0.11012801424702527" STUDY_ID="STD-Huber-2000-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="1680" TOTAL_2="418" VAR="0.012128179521993002" WEIGHT="35.5045166222572"/>
<DICH_DATA CI_END="15.259760455310136" CI_START="0.0655318281652329" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1835477162038213" LOG_CI_START="-1.1835477162038213" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-10-25 10:35:22 +0200" MODIFIED_BY="[Empty name]" ORDER="323" O_E="0.0" SE="1.390443574307614" STUDY_ID="STD-Kriplani-2010-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="30" TOTAL_2="30" VAR="1.9333333333333331" WEIGHT="0.22272680246706206"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="17.370879367191364" CI_END="1.2485632645930451" CI_START="0.8501170684883683" CI_STUDY="95" CI_TOTAL="95" DF="20" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0302547948532472" ESTIMABLE="YES" EVENTS_1="509" EVENTS_2="177" I2="0.0" I2_Q="10.629496384281918" ID="CMP-016.03" LOG_CI_END="0.09641055290887869" LOG_CI_START="-0.07052126405319348" LOG_EFFECT_SIZE="0.012944644427842622" METHOD="MH" MODIFIED="2010-10-25 10:36:49 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.628776323768655" P_Q="0.34767489066736046" P_Z="0.7611516174848386" Q="5.594687058606462" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="11760" TOTAL_2="5170" WEIGHT="600.0" Z="0.3039688578602488">
<NAME>Reasons for discontinuation</NAME>
<GROUP_LABEL_1>DRSP</GROUP_LABEL_1>
<GROUP_LABEL_2>DSG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DRSP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DSG</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.147158408551045" CI_END="2.1408987003867783" CI_START="0.5161429768299338" DF="2" EFFECT_SIZE="1.0511944769208827" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" I2="0.0" ID="CMP-016.03.01" LOG_CI_END="0.33059611853038406" LOG_CI_START="-0.28722997773878467" LOG_EFFECT_SIZE="0.02168307039579966" MODIFIED="2010-10-19 12:53:57 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5635051004972154" P_Z="0.8905780431843706" STUDIES="3" TAU2="0.0" TOTAL_1="891" TOTAL_2="886" WEIGHT="100.0" Z="0.13757281314805095">
<NAME>cycle disturbances</NAME>
<DICH_DATA CI_END="27.49798893462984" CI_START="0.302075827279626" EFFECT_SIZE="2.8820960698689957" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4393009328655324" LOG_CI_START="-0.519884026461571" LOG_EFFECT_SIZE="0.45970845320198067" MODIFIED="2010-10-18 13:39:24 +0200" MODIFIED_BY="[Empty name]" ORDER="251" O_E="0.0" SE="1.1508349432306983" STUDY_ID="STD-Anttila-2009-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="229" TOTAL_2="220" VAR="1.3244210665608045" WEIGHT="9.944469516303114"/>
<DICH_DATA CI_END="2.2166940818120744" CI_START="0.4572668537364033" EFFECT_SIZE="1.006787330316742" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.3457057617891918" LOG_CI_START="-0.3398302785255125" LOG_EFFECT_SIZE="0.002937741631839686" ORDER="1484" O_E="0.0" SE="0.4026872635389859" STUDY_ID="STD-Foidart-2000-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="442" TOTAL_2="445" VAR="0.16215703221651667" WEIGHT="81.22166977980784"/>
<DICH_DATA CI_END="5.499048936125164" CI_START="0.045876640759583406" EFFECT_SIZE="0.5022727272727273" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7402875844926738" LOG_CI_START="-1.3384083900948274" LOG_EFFECT_SIZE="-0.29906040280107665" MODIFIED="2010-10-19 12:53:57 +0200" MODIFIED_BY="[Empty name]" ORDER="271" O_E="0.0" SE="1.2210363051837227" STUDY_ID="STD-Gruber-2006-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="220" TOTAL_2="221" VAR="1.4909296585767173" WEIGHT="8.833860703889048"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0946789839992885" CI_END="1.7027947464887694" CI_START="0.5140597071887688" DF="3" EFFECT_SIZE="0.9355950880496278" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="15" I2="0.0" ID="CMP-016.03.02" LOG_CI_END="0.23116230160936374" LOG_CI_START="-0.2889864354859279" LOG_EFFECT_SIZE="-0.028912066938282015" MODIFIED="2010-10-22 10:18:47 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.778358781600042" P_Z="0.8275177976652819" STUDIES="4" TAU2="0.0" TOTAL_1="2702" TOTAL_2="1055" WEIGHT="100.00000000000001" Z="0.21788617707347294">
<NAME>pregnancy or desire for pregnancy</NAME>
<DICH_DATA CI_END="3.9984963062646792" CI_START="0.00931994971226266" EFFECT_SIZE="0.19304347826086957" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6018966991604322" LOG_CI_START="-2.0305864309663786" LOG_EFFECT_SIZE="-0.7143448659029731" MODIFIED="2010-10-18 13:44:20 +0200" MODIFIED_BY="[Empty name]" ORDER="254" O_E="0.0" SE="1.546333621638144" STUDY_ID="STD-Anttila-2009-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="229" TOTAL_2="221" VAR="2.3911476694085385" WEIGHT="3.904126699281219"/>
<DICH_DATA CI_END="15.959437562999707" CI_START="0.06322977023873662" EFFECT_SIZE="1.0045454545454546" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2030175820278863" LOG_CI_START="-1.1990783963020772" LOG_EFFECT_SIZE="0.0019695928629044983" MODIFIED="2010-10-19 12:28:31 +0200" MODIFIED_BY="[Empty name]" ORDER="262" O_E="0.0" SE="1.411003068237882" STUDY_ID="STD-Gruber-2006-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="220" TOTAL_2="221" VAR="1.9909296585767173" WEIGHT="4.688936858138734"/>
<DICH_DATA CI_END="9.75769959480736" CI_START="0.10682060777698416" EFFECT_SIZE="1.0209424083769634" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="0.9893474435850457" LOG_CI_START="-0.9713449553554647" LOG_EFFECT_SIZE="0.009001244114790483" MODIFIED="2010-10-22 10:18:47 +0200" MODIFIED_BY="[Empty name]" ORDER="573" O_E="0.0" SE="1.1517204207215603" STUDY_ID="STD-Guang_x002d_Sheng2010_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="573" TOTAL_2="195" VAR="1.3264599275070479" WEIGHT="7.0377877721544175"/>
<DICH_DATA CI_END="1.910160762054732" CI_START="0.5185421488543649" EFFECT_SIZE="0.9952380952380953" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="11" LOG_CI_END="0.28106991967452816" LOG_CI_START="-0.28521593692025865" LOG_EFFECT_SIZE="-0.0020730086228652584" ORDER="1485" O_E="0.0" SE="0.3326391153239767" STUDY_ID="STD-Huber-2000-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="1680" TOTAL_2="418" VAR="0.1106487810435179" WEIGHT="84.36914867042564"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.3110746907892077" CI_END="1.9766014064389699" CI_START="0.6600561157552044" DF="3" EFFECT_SIZE="1.142220577091124" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="20" I2="0.0" ID="CMP-016.03.03" LOG_CI_END="0.2959191000486563" LOG_CI_START="-0.18041914062958053" LOG_EFFECT_SIZE="0.05774997970953785" MODIFIED="2010-10-22 10:19:27 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5104027450521871" P_Z="0.6346147613046728" STUDIES="4" TAU2="0.0" TOTAL_1="2703" TOTAL_2="1057" WEIGHT="100.0" Z="0.47524162736735126">
<NAME>lost to follow up</NAME>
<DICH_DATA CI_END="8.62137875010705" CI_START="0.24533519064077686" EFFECT_SIZE="1.4543478260869565" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.935576724720474" LOG_CI_START="-0.6102401525479761" LOG_EFFECT_SIZE="0.162668286086249" MODIFIED="2010-10-18 13:42:07 +0200" MODIFIED_BY="[Empty name]" ORDER="253" O_E="0.0" SE="0.9080204856244386" STUDY_ID="STD-Anttila-2009-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="230" TOTAL_2="223" VAR="0.8245012023136413" WEIGHT="9.495433734785674"/>
<DICH_DATA CI_END="1.8892513536297648" CI_START="0.2086457190414416" EFFECT_SIZE="0.6278409090909091" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2762897420575922" LOG_CI_START="-0.6805905216436329" LOG_EFFECT_SIZE="-0.20215038979302033" MODIFIED="2010-10-19 12:29:04 +0200" MODIFIED_BY="[Empty name]" ORDER="263" O_E="0.0" SE="0.5620762035317964" STUDY_ID="STD-Gruber-2006-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="220" TOTAL_2="221" VAR="0.31592965857671745" WEIGHT="24.78082167432589"/>
<DICH_DATA CI_END="4.150669087721772" CI_START="0.7448395946407677" EFFECT_SIZE="1.7582897033158813" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="6" LOG_CI_END="0.6181181106117033" LOG_CI_START="-0.12793724492018915" LOG_EFFECT_SIZE="0.24509043284575707" MODIFIED="2010-10-22 10:19:27 +0200" MODIFIED_BY="[Empty name]" ORDER="574" O_E="0.0" SE="0.438236608873004" STUDY_ID="STD-Guang_x002d_Sheng2010_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="573" TOTAL_2="195" VAR="0.19205132535651026" WEIGHT="40.76512628219104"/>
<DICH_DATA CI_END="2.7966056594562336" CI_START="0.3112900959736748" EFFECT_SIZE="0.9330357142857143" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" LOG_CI_END="0.44663123219348233" LOG_CI_START="-0.5068346966396999" LOG_EFFECT_SIZE="-0.030101732223108794" ORDER="1486" O_E="0.0" SE="0.5600706063290778" STUDY_ID="STD-Huber-2000-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="1680" TOTAL_2="418" VAR="0.3136790840738209" WEIGHT="24.958618308697403"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.48855864130048693" CI_END="1.4366388769489664" CI_START="0.7271184440259748" DF="1" EFFECT_SIZE="1.0220599908196957" ESTIMABLE="YES" EVENTS_1="154" EVENTS_2="38" I2="0.0" ID="CMP-016.03.04" LOG_CI_END="0.1573476147187178" LOG_CI_START="-0.1383948389387068" LOG_EFFECT_SIZE="0.00947638789000551" MODIFIED="2010-10-25 10:36:21 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.4845710123970054" P_Z="0.9000445325115568" STUDIES="2" TAU2="0.0" TOTAL_1="1710" TOTAL_2="448" WEIGHT="100.0" Z="0.12560509144525378">
<NAME>method unrelated</NAME>
<DICH_DATA CI_END="1.4585530664723387" CI_START="0.7352749308370665" EFFECT_SIZE="1.0355855855855856" ESTIMABLE="YES" EVENTS_1="154" EVENTS_2="37" LOG_CI_END="0.16392223466231523" LOG_CI_START="-0.13355024102503443" LOG_EFFECT_SIZE="0.0151859968186404" ORDER="1487" O_E="0.0" SE="0.17473680473125225" STUDY_ID="STD-Huber-2000-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="1680" TOTAL_2="418" VAR="0.030532950927687777" WEIGHT="98.84023464801824"/>
<DICH_DATA CI_END="7.8698689779204765" CI_START="0.01411854649967386" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8959675020363438" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2010-10-25 10:36:21 +0200" MODIFIED_BY="[Empty name]" ORDER="324" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Kriplani-2010-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="1.1597653519817563"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.425770178195767" CI_END="1.760064393689287" CI_START="0.8741604665400039" DF="4" EFFECT_SIZE="1.2403945789658533" ESTIMABLE="YES" EVENTS_1="222" EVENTS_2="65" I2="26.277747331160985" ID="CMP-016.03.05" LOG_CI_END="0.24552855719616226" LOG_CI_START="-0.05840883814807558" LOG_EFFECT_SIZE="0.09355985952404336" MODIFIED="2010-10-25 10:36:49 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.24633199554342577" P_Z="0.2275646368211498" STUDIES="5" TAU2="0.04150319667462441" TOTAL_1="2732" TOTAL_2="1086" WEIGHT="100.0" Z="1.2066560934896702">
<NAME>side effects (including cycle disturbances)</NAME>
<DICH_DATA CI_END="4.223516706545" CI_START="0.8900630233254625" EFFECT_SIZE="1.9388646288209608" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="9" LOG_CI_END="0.6256742164175522" LOG_CI_START="-0.05057924086808834" LOG_EFFECT_SIZE="0.2875474877747319" MODIFIED="2010-10-18 13:41:29 +0200" MODIFIED_BY="[Empty name]" ORDER="252" O_E="0.0" SE="0.3972346283181867" STUDY_ID="STD-Anttila-2009-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="229" TOTAL_2="222" VAR="0.1577953499350879" WEIGHT="15.993346526322101"/>
<DICH_DATA CI_END="3.7449063040095045" CI_START="0.748506762941441" EFFECT_SIZE="1.6742424242424243" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.5734409563049944" LOG_CI_START="-0.12580427134647262" LOG_EFFECT_SIZE="0.22381834247926083" MODIFIED="2010-10-19 12:31:38 +0200" MODIFIED_BY="[Empty name]" ORDER="264" O_E="0.0" SE="0.41074010804217204" STUDY_ID="STD-Gruber-2006-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="220" TOTAL_2="221" VAR="0.16870743635449514" WEIGHT="15.163127916940063"/>
<DICH_DATA CI_END="1.2874237152954604" CI_START="0.4442356893993378" EFFECT_SIZE="0.7562536358347877" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="18" LOG_CI_END="0.10972150489167118" LOG_CI_START="-0.3523865536521025" LOG_EFFECT_SIZE="-0.12133252438021563" MODIFIED="2010-10-22 10:21:19 +0200" MODIFIED_BY="[Empty name]" ORDER="575" O_E="0.0" SE="0.27144456106039433" STUDY_ID="STD-Guang_x002d_Sheng2010_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="573" TOTAL_2="195" VAR="0.07368214972927015" WEIGHT="27.672363001321095"/>
<DICH_DATA CI_END="1.8629859428227595" CI_START="0.8654696786363061" EFFECT_SIZE="1.2697865353037767" ESTIMABLE="YES" EVENTS_1="148" EVENTS_2="29" LOG_CI_END="0.27020957793567413" LOG_CI_START="-0.06274814284532682" LOG_EFFECT_SIZE="0.10373071754517366" ORDER="1488" O_E="0.0" SE="0.19558101335405914" STUDY_ID="STD-Huber-2000-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="1680" TOTAL_2="418" VAR="0.038251932784600665" WEIGHT="39.96546353486986"/>
<DICH_DATA CI_END="70.82882080128427" CI_START="0.12706691849706478" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8502100114756685" LOG_CI_START="-0.895967502036344" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2010-10-25 10:36:49 +0200" MODIFIED_BY="[Empty name]" ORDER="325" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Kriplani-2010-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="1.2056990205468736"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0885815675543902" CI_END="0.9928900020155436" CI_START="0.2570981947304359" DF="2" EFFECT_SIZE="0.5052427407534869" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="24" I2="0.0" ID="CMP-016.03.06" LOG_CI_END="-0.0030988624449733064" LOG_CI_START="-0.5899009728373519" LOG_EFFECT_SIZE="-0.2964999176411625" MODIFIED="2010-10-22 10:23:25 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.5802532803404838" P_Z="0.04762886996358796" STUDIES="3" TAU2="0.0" TOTAL_1="1022" TOTAL_2="638" WEIGHT="99.99999999999999" Z="1.9806648602786578">
<NAME>Reason not specified</NAME>
<DICH_DATA CI_END="0.9451876408216364" CI_START="0.12682383667591937" EFFECT_SIZE="0.34622582657517154" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.024481965793431405" LOG_CI_START="-0.8967991126695058" LOG_EFFECT_SIZE="-0.46064053923146864" MODIFIED="2010-10-19 12:41:16 +0200" MODIFIED_BY="[Empty name]" ORDER="266" O_E="0.0" SE="0.5124034101145236" STUDY_ID="STD-Anttila-2009-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="229" TOTAL_2="222" VAR="0.2625572546969927" WEIGHT="45.25166000804387"/>
<DICH_DATA CI_END="1.8892513536297648" CI_START="0.2086457190414416" EFFECT_SIZE="0.6278409090909091" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2762897420575922" LOG_CI_START="-0.6805905216436329" LOG_EFFECT_SIZE="-0.20215038979302033" MODIFIED="2010-10-19 12:54:50 +0200" MODIFIED_BY="[Empty name]" ORDER="265" O_E="0.0" SE="0.5620762035317964" STUDY_ID="STD-Gruber-2006-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="220" TOTAL_2="221" VAR="0.31592965857671745" WEIGHT="37.606952369457844"/>
<DICH_DATA CI_END="4.349919741871604" CI_START="0.16640208055470962" EFFECT_SIZE="0.8507853403141361" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.638481244084789" LOG_CI_START="-0.7788412479504578" LOG_EFFECT_SIZE="-0.07018000193283436" MODIFIED="2010-10-22 10:23:25 +0200" MODIFIED_BY="[Empty name]" ORDER="576" O_E="0.0" SE="0.8325422476809898" STUDY_ID="STD-Guang_x002d_Sheng2010_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="573" TOTAL_2="195" VAR="0.6931265941737146" WEIGHT="17.141387622498268"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.14918501357449257" CI_END="1.1351322663317986" CI_START="0.830105678417543" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9707109456666289" ESTIMABLE="YES" EVENTS_1="523" EVENTS_2="142" I2="0.0" I2_Q="0.0" ID="CMP-016.04" LOG_CI_END="0.055046468746138236" LOG_CI_START="-0.08086661529614977" LOG_EFFECT_SIZE="-0.012910073275005766" METHOD="MH" MODIFIED="2010-10-19 13:05:32 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6993155601526763" P_Q="1.0" P_Z="0.709635998753241" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1900" TOTAL_2="639" WEIGHT="100.0" Z="0.3723450002637208">
<NAME>Cycle control</NAME>
<GROUP_LABEL_1>DRSP</GROUP_LABEL_1>
<GROUP_LABEL_2>DSG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DRSP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DSG</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.14918501357449257" CI_END="1.1351322663317986" CI_START="0.830105678417543" DF="1" EFFECT_SIZE="0.9707109456666289" ESTIMABLE="YES" EVENTS_1="523" EVENTS_2="142" I2="0.0" ID="CMP-016.04.01" LOG_CI_END="0.055046468746138236" LOG_CI_START="-0.08086661529614977" LOG_EFFECT_SIZE="-0.012910073275005766" MODIFIED="2010-10-19 13:05:32 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6993155601526763" P_Z="0.709635998753241" STUDIES="2" TAU2="0.0" TOTAL_1="1900" TOTAL_2="639" WEIGHT="100.0" Z="0.3723450002637208">
<NAME>intermenstrual bleeding</NAME>
<DICH_DATA CI_END="1.9441004646301565" CI_START="0.3474722530049855" EFFECT_SIZE="0.821900826446281" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.2887187040609994" LOG_CI_START="-0.45907986977299087" LOG_EFFECT_SIZE="-0.08518058285599568" MODIFIED="2010-10-19 13:05:32 +0200" MODIFIED_BY="[Empty name]" ORDER="275" O_E="0.0" SE="0.439260583932726" STUDY_ID="STD-Gruber-2006-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="220" TOTAL_2="221" VAR="0.1929498605969194" WEIGHT="3.303339948416264"/>
<DICH_DATA CI_END="1.1446333081388116" CI_START="0.8326284905367379" EFFECT_SIZE="0.9762450018175209" ESTIMABLE="YES" EVENTS_1="514" EVENTS_2="131" LOG_CI_END="0.05866637946370087" LOG_CI_START="-0.07954873268633318" LOG_EFFECT_SIZE="-0.010441176611316166" ORDER="1489" O_E="0.0" SE="0.08118824105276935" STUDY_ID="STD-Huber-2000-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="1680" TOTAL_2="418" VAR="0.006591530485242584" WEIGHT="96.69666005158373"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="43.203066917642836" CI_END="1.5058107780151113" CI_START="1.0352433557019303" CI_STUDY="95" CI_TOTAL="95" DF="26" EFFECT_MEASURE="RR" EFFECT_SIZE="1.248551401779077" ESTIMABLE="YES" EVENTS_1="647" EVENTS_2="271" I2="39.819087266273726" I2_Q="0.0" ID="CMP-016.05" LOG_CI_END="0.1777704013288434" LOG_CI_START="0.015042451836818224" LOG_EFFECT_SIZE="0.09640642658283081" METHOD="MH" MODIFIED="2011-01-31 12:12:11 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.018383994240725343" P_Q="0.6899269520378098" P_Z="0.020215752318595535" Q="4.754226577745691" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.11038443734503389" TOTALS="SUB" TOTAL_1="15047" TOTAL_2="7420" WEIGHT="800.0" Z="2.3223192398158172">
<NAME>Side-effects</NAME>
<GROUP_LABEL_1>DRSP</GROUP_LABEL_1>
<GROUP_LABEL_2>DSG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DRSP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DSG</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.362918257267062" CI_END="1.8551561783665902" CI_START="1.0354672273000298" DF="4" EFFECT_SIZE="1.3859846406875411" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="63" I2="0.0" ID="CMP-016.05.01" LOG_CI_END="0.2683804770495339" LOG_CI_START="0.015136357958597307" LOG_EFFECT_SIZE="0.14175841750406556" MODIFIED="2010-10-25 10:37:47 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4990257530587736" P_Z="0.028216909191337708" STUDIES="5" TAU2="0.0" TOTAL_1="2953" TOTAL_2="1305" WEIGHT="100.0" Z="2.1942574130504635">
<NAME>breast tenderness</NAME>
<DICH_DATA CI_END="67.68138718038729" CI_START="1.1045621686851637" EFFECT_SIZE="8.646288209606986" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="1.8304692513107217" LOG_CI_START="0.04319016453256474" LOG_EFFECT_SIZE="0.9368297079216431" MODIFIED="2010-10-18 13:50:41 +0200" MODIFIED_BY="[Empty name]" ORDER="255" O_E="0.0" SE="1.0498565827476543" STUDY_ID="STD-Anttila-2009-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="229" TOTAL_2="220" VAR="1.1021988443385824" WEIGHT="2.0076776779007712"/>
<DICH_DATA CI_END="1.9054938650275526" CI_START="0.8809259118636414" EFFECT_SIZE="1.2956075488356693" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="41" LOG_CI_END="0.2800075548458036" LOG_CI_START="-0.05506061533574118" LOG_EFFECT_SIZE="0.1124734697550312" ORDER="1490" O_E="0.0" SE="0.1968207017788316" STUDY_ID="STD-Foidart-2000-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="442" TOTAL_2="443" VAR="0.03873838864871176" WEIGHT="57.1231817733386"/>
<DICH_DATA CI_END="35.40856562963611" CI_START="0.08232278084432056" EFFECT_SIZE="1.7073170731707317" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.5491083342206573" LOG_CI_START="-1.0844799676316146" LOG_EFFECT_SIZE="0.23231418329452133" MODIFIED="2010-10-22 10:25:50 +0200" MODIFIED_BY="[Empty name]" ORDER="577" O_E="0.0" SE="1.5469828049803682" STUDY_ID="STD-Guang_x002d_Sheng2010_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="573" TOTAL_2="195" VAR="2.3931557989049277" WEIGHT="0.9246619118567919"/>
<DICH_DATA CI_END="2.275745584785354" CI_START="0.8789225364228533" EFFECT_SIZE="1.4142857142857144" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="19" LOG_CI_END="0.35712370882156713" LOG_CI_START="-0.05604939965498096" LOG_EFFECT_SIZE="0.15053715458329311" ORDER="1491" O_E="0.0" SE="0.24269992915899652" STUDY_ID="STD-Huber-2000-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="1680" TOTAL_2="418" VAR="0.05890325561378193" WEIGHT="37.567703063747864"/>
<DICH_DATA CI_END="6.627129539131202" CI_START="0.1508948925919286" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8213254597385298" LOG_CI_START="-0.8213254597385299" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-10-25 10:37:47 +0200" MODIFIED_BY="[Empty name]" ORDER="326" O_E="0.0" SE="0.9649012813540154" STUDY_ID="STD-Kriplani-2010-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="29" TOTAL_2="29" VAR="0.9310344827586208" WEIGHT="2.3767755731559763"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="25.89292838328695" CI_END="3.2211085751388637" CI_START="0.6788148446748827" DF="4" EFFECT_SIZE="1.478694125610101" ESTIMABLE="YES" EVENTS_1="229" EVENTS_2="108" I2="84.55176664149786" ID="CMP-016.05.02" LOG_CI_END="0.5080053639966424" LOG_CI_START="-0.16824866887366946" LOG_EFFECT_SIZE="0.16987834756148654" MODIFIED="2010-11-01 14:06:07 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="3.3257360541383285E-5" P_Z="0.32476889370290074" STUDIES="5" TAU2="0.5475761666071651" TOTAL_1="2400" TOTAL_2="1334" WEIGHT="99.99999999999999" Z="0.9847052343939031">
<NAME>headache</NAME>
<DICH_DATA CI_END="24.528698792069406" CI_START="3.1935111360009913" EFFECT_SIZE="8.850574712643677" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="1.389674510195264" LOG_CI_START="0.5042684349124628" LOG_EFFECT_SIZE="0.9469714725538633" MODIFIED="2010-10-18 13:51:10 +0200" MODIFIED_BY="[Empty name]" ORDER="256" O_E="0.0" SE="0.5200919114518754" STUDY_ID="STD-Anttila-2009-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="29" TOTAL_2="220" VAR="0.27049559635766535" WEIGHT="19.288725719416224"/>
<DICH_DATA CI_END="1.1498298901896644" CI_START="0.5641854258321937" EFFECT_SIZE="0.8054298642533937" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="60" LOG_CI_END="0.060633594078357826" LOG_CI_START="-0.24857813683079116" LOG_EFFECT_SIZE="-0.0939722713762167" ORDER="1492" O_E="0.0" SE="0.18163250135878772" STUDY_ID="STD-Foidart-2000-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="442" TOTAL_2="445" VAR="0.03299036554985002" WEIGHT="27.179592657539363"/>
<DICH_DATA CI_END="1.1494632409696788" CI_START="0.21947451955850605" EFFECT_SIZE="0.5022727272727273" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="0.060495087393650546" LOG_CI_START="-0.6586158929958039" LOG_EFFECT_SIZE="-0.29906040280107665" MODIFIED="2010-10-19 12:46:38 +0200" MODIFIED_BY="[Empty name]" ORDER="268" O_E="0.0" SE="0.42240934953752785" STUDY_ID="STD-Gruber-2006-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="220" TOTAL_2="221" VAR="0.1784296585767174" WEIGHT="21.73475929154047"/>
<DICH_DATA CI_END="2.354250793265093" CI_START="1.0590158671535865" EFFECT_SIZE="1.5789835164835164" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="26" LOG_CI_END="0.371852725427346" LOG_CI_START="0.024902467157175364" LOG_EFFECT_SIZE="0.19837759629226065" ORDER="1493" O_E="0.0" SE="0.20380029913937509" STUDY_ID="STD-Huber-2000-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="1680" TOTAL_2="418" VAR="0.041534561929298774" WEIGHT="26.78539210078433"/>
<DICH_DATA CI_END="73.1419820989928" CI_START="0.13138829061254456" EFFECT_SIZE="3.1" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8641667252526586" LOG_CI_START="-0.8814433375841133" LOG_EFFECT_SIZE="0.4913616938342727" MODIFIED="2010-10-25 10:38:28 +0200" MODIFIED_BY="[Empty name]" ORDER="327" O_E="0.0" SE="1.6127849418993234" STUDY_ID="STD-Kriplani-2010-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="29" TOTAL_2="30" VAR="2.6010752688172043" WEIGHT="5.011530230719603"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5786432419375869" CI_END="1.6394449113633471" CI_START="0.5511893069048556" DF="2" EFFECT_SIZE="0.9506021798854954" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="19" I2="0.0" ID="CMP-016.05.03" LOG_CI_END="0.21469682808506185" LOG_CI_START="-0.25869921634945425" LOG_EFFECT_SIZE="-0.02200119413219615" MODIFIED="2010-10-19 13:04:30 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.748771372258937" P_Z="0.8554417916033807" STUDIES="3" TAU2="0.0" TOTAL_1="2342" TOTAL_2="1084" WEIGHT="100.0" Z="0.1821795877804103">
<NAME>migraine</NAME>
<DICH_DATA CI_END="2.5124976870254643" CI_START="0.4034315071096978" EFFECT_SIZE="1.006787330316742" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.4001056706225592" LOG_CI_START="-0.39423018735887977" LOG_EFFECT_SIZE="0.002937741631839686" ORDER="1494" O_E="0.0" SE="0.4665968150042092" STUDY_ID="STD-Foidart-2000-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="442" TOTAL_2="445" VAR="0.21771258777207222" WEIGHT="35.51737932996057"/>
<DICH_DATA CI_END="73.57545621163685" CI_START="0.12343290416153548" EFFECT_SIZE="3.013574660633484" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.866732963664373" LOG_CI_START="-0.9085690526939921" LOG_EFFECT_SIZE="0.4790819554851904" MODIFIED="2010-10-19 13:04:30 +0200" MODIFIED_BY="[Empty name]" ORDER="274" O_E="0.0" SE="1.6302261423754478" STUDY_ID="STD-Gruber-2006-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="220" TOTAL_2="221" VAR="2.657637275284334" WEIGHT="2.909569577729803"/>
<DICH_DATA CI_END="1.744143604734173" CI_START="0.43479831155303617" EFFECT_SIZE="0.8708333333333333" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="10" LOG_CI_END="0.24158223987181282" LOG_CI_START="-0.3617121510729168" LOG_EFFECT_SIZE="-0.06006495560055201" ORDER="1495" O_E="0.0" SE="0.3543781115963327" STUDY_ID="STD-Huber-2000-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="1680" TOTAL_2="418" VAR="0.12558384597858283" WEIGHT="61.57305109230963"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.657711858302724" CI_END="2.2122388776779" CI_START="0.9640647796593719" DF="5" EFFECT_SIZE="1.4603909018349985" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="40" I2="11.625050458119887" ID="CMP-016.05.04" LOG_CI_END="0.34483202030718996" LOG_CI_START="-0.015893783002376805" LOG_EFFECT_SIZE="0.16446911865240654" MODIFIED="2010-11-01 14:05:58 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.34096201505815393" P_Z="0.07389713329026745" STUDIES="6" TAU2="0.032261820311494174" TOTAL_1="3173" TOTAL_2="1528" WEIGHT="100.0" Z="1.7872497402195826">
<NAME>nausea/vomiting</NAME>
<DICH_DATA CI_END="5.6579153532296145" CI_START="0.2899982815463365" EFFECT_SIZE="1.2809315866084425" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7526564457897102" LOG_CI_START="-0.537604575608474" LOG_EFFECT_SIZE="0.1075259350906182" MODIFIED="2010-10-25 10:40:49 +0200" MODIFIED_BY="[Empty name]" ORDER="258" O_E="0.0" SE="0.7579057108643558" STUDY_ID="STD-Anttila-2009-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="229" TOTAL_2="220" VAR="0.5744210665608045" WEIGHT="7.400616127958781"/>
<DICH_DATA CI_END="2.498372223942252" CI_START="0.6989030963133458" EFFECT_SIZE="1.321408371040724" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="16" LOG_CI_END="0.39765714290975634" LOG_CI_START="-0.15558303549008795" LOG_EFFECT_SIZE="0.12103705370983422" MODIFIED="2010-10-25 10:51:32 +0200" MODIFIED_BY="[Empty name]" ORDER="1496" O_E="0.0" SE="0.3249760193751189" STUDY_ID="STD-Foidart-2000-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="442" TOTAL_2="445" VAR="0.10560941316889763" WEIGHT="32.565365840309774"/>
<DICH_DATA CI_END="7.887134021464172" CI_START="0.7996500752853646" EFFECT_SIZE="2.5113636363636362" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.8969192206013293" LOG_CI_START="-0.09710001753144525" LOG_EFFECT_SIZE="0.39990960153494204" MODIFIED="2010-10-25 10:51:34 +0200" MODIFIED_BY="[Empty name]" ORDER="269" O_E="0.0" SE="0.5838918209537769" STUDY_ID="STD-Gruber-2006-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="220" TOTAL_2="221" VAR="0.3409296585767174" WEIGHT="12.030894088256073"/>
<DICH_DATA CI_END="2.4501423422450634" CI_START="0.3195327367437819" EFFECT_SIZE="0.8848167539267016" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.38919131565263493" LOG_CI_START="-0.49548464092074296" LOG_EFFECT_SIZE="-0.053146662634054" MODIFIED="2010-10-25 10:51:50 +0200" MODIFIED_BY="[Empty name]" ORDER="578" O_E="0.0" SE="0.5196630361078144" STUDY_ID="STD-Guang_x002d_Sheng2010_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="573" TOTAL_2="195" VAR="0.27004967109679157" WEIGHT="14.851658917192813"/>
<DICH_DATA CI_END="5.445190723821471" CI_START="1.1696112084594925" EFFECT_SIZE="2.523639455782313" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="7" LOG_CI_END="0.7360130960022813" LOG_CI_START="0.06804152150570049" LOG_EFFECT_SIZE="0.4020273087539908" ORDER="1497" O_E="0.0" SE="0.39236980937191207" STUDY_ID="STD-Huber-2000-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="1680" TOTAL_2="418" VAR="0.15395406730655062" WEIGHT="24.11087053083783"/>
<DICH_DATA CI_END="2.2813851788805" CI_START="0.15779886857012715" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3581986158071433" LOG_CI_START="-0.801896115039856" LOG_EFFECT_SIZE="-0.22184874961635637" MODIFIED="2010-10-25 10:53:19 +0200" MODIFIED_BY="[Empty name]" ORDER="328" O_E="0.0" SE="0.6814453874610599" STUDY_ID="STD-Kriplani-2010-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="29" TOTAL_2="29" VAR="0.464367816091954" WEIGHT="9.040594495444719"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5715263521379492" CI_END="1.4378677127595658" CI_START="0.5751229916725806" DF="3" EFFECT_SIZE="0.9093683415380659" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="31" I2="0.0" ID="CMP-016.05.05" LOG_CI_END="0.1577189317622266" LOG_CI_START="-0.24023927027926906" LOG_EFFECT_SIZE="-0.0412601692585212" MODIFIED="2011-01-31 12:11:52 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.6658631650320239" P_Z="0.6844363926519617" STUDIES="4" TAU2="0.0" TOTAL_1="2724" TOTAL_2="1087" WEIGHT="100.0" Z="0.40641678109851337">
<NAME>other minor (abdominal pain)</NAME>
<DICH_DATA CI_END="1.5775806810059017" CI_START="0.3614152142190298" EFFECT_SIZE="0.7550904977375565" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.19799157927569502" LOG_CI_START="-0.4419935692286156" LOG_EFFECT_SIZE="-0.12200099497646028" ORDER="1500" O_E="0.0" SE="0.3759304442090097" STUDY_ID="STD-Foidart-2000-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="442" TOTAL_2="445" VAR="0.14132369888318333" WEIGHT="38.666523671849994"/>
<DICH_DATA CI_END="78.4374535752626" CI_START="0.2512184758557071" EFFECT_SIZE="4.439024390243903" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="1.8945234861155449" LOG_CI_START="-0.5999484235848662" LOG_EFFECT_SIZE="0.6472875312653393" MODIFIED="2010-10-22 10:30:28 +0200" MODIFIED_BY="[Empty name]" ORDER="581" O_E="0.0" SE="1.465265147593118" STUDY_ID="STD-Guang_x002d_Sheng2010_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="573" TOTAL_2="195" VAR="2.1470019527510815" WEIGHT="2.545175211069568"/>
<DICH_DATA CI_END="2.1025773310310054" CI_START="0.4976230074288121" EFFECT_SIZE="1.022883597883598" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="9" LOG_CI_END="0.3227519777505368" LOG_CI_START="-0.3030995483968519" LOG_EFFECT_SIZE="0.009826214676842493" ORDER="1501" O_E="0.0" SE="0.3676282844739947" STUDY_ID="STD-Huber-2000-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="1680" TOTAL_2="418" VAR="0.13515055554529237" WEIGHT="40.432657684701255"/>
<DICH_DATA CI_END="2.4280147050707623" CI_START="0.28601327784141467" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.38525131267988755" LOG_CI_START="-0.5436138047751372" LOG_EFFECT_SIZE="-0.07918124604762482" MODIFIED="2010-10-25 11:09:26 +0200" MODIFIED_BY="[Empty name]" ORDER="331" O_E="0.0" SE="0.5456199679495678" STUDY_ID="STD-Kriplani-2010-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="29" TOTAL_2="29" VAR="0.29770114942528736" WEIGHT="18.355643432379182"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.314192024316851" CI_END="3.732585047615612" CI_START="0.24736722213906387" DF="1" EFFECT_SIZE="0.9608949966705411" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" I2="23.907619168528715" ID="CMP-016.05.06" LOG_CI_END="0.5720097119869794" LOG_CI_START="-0.6066578479050608" LOG_EFFECT_SIZE="-0.017324067959040783" MODIFIED="2011-01-31 12:11:52 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.2516371983320802" P_Z="0.9540551883403083" STUDIES="2" TAU2="0.2727846612223206" TOTAL_1="662" TOTAL_2="666" WEIGHT="100.0" Z="0.05761514174285796">
<NAME>depression</NAME>
<DICH_DATA CI_END="5.31490825564085" CI_START="0.4291036701665911" EFFECT_SIZE="1.510180995475113" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7254957722623615" LOG_CI_START="-0.36743777088731966" LOG_EFFECT_SIZE="0.17902900068752092" ORDER="1502" O_E="0.0" SE="0.6419945733544145" STUDY_ID="STD-Foidart-2000-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="442" TOTAL_2="445" VAR="0.41215703221651667" WEIGHT="69.9848864558464"/>
<DICH_DATA CI_END="3.1943489529609503" CI_START="0.03510058213940432" EFFECT_SIZE="0.33484848484848484" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5043823570333528" LOG_CI_START="-1.4546856807468687" LOG_EFFECT_SIZE="-0.47515166185675795" MODIFIED="2010-10-19 13:00:57 +0200" MODIFIED_BY="[Empty name]" ORDER="272" O_E="0.0" SE="1.150766262935289" STUDY_ID="STD-Gruber-2006-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="220" TOTAL_2="221" VAR="1.3242629919100506" WEIGHT="30.015113544153614"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="28.749140576648553" CI_START="0.31590523925463876" DF="0" EFFECT_SIZE="3.0136363636363637" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-016.05.07" LOG_CI_END="1.4586248664726778" LOG_CI_START="-0.5004431713075439" LOG_EFFECT_SIZE="0.4790908475825669" MODIFIED="2011-01-31 12:12:11 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.3377502739692473" STUDIES="1" TAU2="0.0" TOTAL_1="220" TOTAL_2="221" WEIGHT="100.0" Z="0.958619903419548">
<NAME>Alopecia</NAME>
<DICH_DATA CI_END="28.749140576648553" CI_START="0.31590523925463876" EFFECT_SIZE="3.0136363636363637" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4586248664726778" LOG_CI_START="-0.5004431713075439" LOG_EFFECT_SIZE="0.4790908475825669" MODIFIED="2010-10-19 13:02:44 +0200" MODIFIED_BY="[Empty name]" ORDER="273" O_E="0.0" SE="1.150766262935289" STUDY_ID="STD-Gruber-2006-_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="220" TOTAL_2="221" VAR="1.3242629919100506" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.685507671769489" CI_START="0.24953232757376598" DF="0" EFFECT_SIZE="1.1910994764397906" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" I2="0.0" ID="CMP-016.05.08" LOG_CI_END="0.7547692498864236" LOG_CI_START="-0.6028731823956162" LOG_EFFECT_SIZE="0.0759480337454037" MODIFIED="2011-01-31 12:12:11 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="0.8264279307149779" STUDIES="1" TAU2="0.0" TOTAL_1="573" TOTAL_2="195" WEIGHT="100.0" Z="0.21928514798615306">
<NAME>dizziness</NAME>
<DICH_DATA CI_END="5.685507671769489" CI_START="0.24953232757376598" EFFECT_SIZE="1.1910994764397906" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="0.7547692498864236" LOG_CI_START="-0.6028731823956162" LOG_EFFECT_SIZE="0.0759480337454037" MODIFIED="2010-10-22 10:28:15 +0200" MODIFIED_BY="[Empty name]" ORDER="579" O_E="0.0" SE="0.7974858851608958" STUDY_ID="STD-Guang_x002d_Sheng2010_x0028_DRSP_x002d_DSG_x0029_" TOTAL_1="573" TOTAL_2="195" VAR="0.6359837370308574" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2011-03-22 12:20:19 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2011-03-22 12:20:19 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAX4AAASeCAIAAABOxNKOAABg3UlEQVR42u2dv04kSfa2U1pnDQwM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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2011-03-07 21:37:35 +0100" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2010-10-01 12:30:19 +0200" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2010-10-01 12:30:11 +0200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-10-01 12:29:26 +0200" MODIFIED_BY="[Empty name]">Search methods of the original review</TITLE>
<APPENDIX_BODY MODIFIED="2010-10-01 12:30:11 +0200" MODIFIED_BY="[Empty name]">
<P>1. Cochrane Controlled Trials Register with the following search strategy:<BR/>CONTRACEPTIVES-ORAL*:ME<BR/>LEVONORGESTREL<BR/>NORETHISTERONE<BR/>norethyndrone<BR/>NORETHINDRONE<BR/>NORGESTIMATE<BR/>DESOGESTREL<BR/>GESTODENE<BR/>(((((((#1 or #2) or #3) or #4) or #5) or #6) or #7) or #8)<BR/>MENOPAUS*<BR/>NORPLANT<BR/>REPLACEMENT<BR/>ANIMAL<BR/>INJECT*<BR/>CANCER<BR/>IUD<BR/>INTRAUTERINE<BR/>PROSTAT*<BR/>((((((((#10 or #11) or #12) or #13) or #14) or #15) or #16) or #17) or #18)<BR/>(#9 not #19)</P>
<P>2. Letters were sent requesting information from pharmaceutical companies which have combined low-dose oestrogen OCs containing different progestogens.</P>
<P>3. Informal contact with researchers in the field were made to identify any trials.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2010-10-01 12:30:19 +0200" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-10-01 12:29:50 +0200" MODIFIED_BY="[Empty name]">Methodology of the original review</TITLE>
<APPENDIX_BODY MODIFIED="2010-10-01 12:30:19 +0200" MODIFIED_BY="[Empty name]">
<P>The reports identified with the electronic search were checked initially for two characteristics:<BR/>1. Random allocation to comparison groups<BR/>2. Clinical outcomes reported</P>
<P>If these characteristics were not clear from either the title or abstract, the full report was retrieved. Reports that met the above-mentioned criteria were fully assessed for other inclusion criteria, methodological quality and data validity. Both application of inclusion criteria and data extraction were made independently by two reviewers, and differences were resolved by discussion and consultation with other reviewers if necessary.</P>
<P>In addition to clinical outcomes, systematic data extraction was carried out for each trial for the following variables:</P>
<UL>
<LI>Methodology: Random allocation techniques, blinding, post-randomisation exclusions and loss to follow-up (intention-to-treat). Trials were given a quality score for the concealment of allocation as described in: Mulrow CD, Oxman AD (eds). Cochrane Collaboration Handbook [updated 1 March 1997]. In: The Cochrane Library [database on disk and CD ROM]. The Cochrane Collaboration. Oxford: Update Software; 1996-. Updated quarterly.</LI>
<LI>We used relative risk (RR) to report measures of effect and the random-effects model. Because of the low baseline level, RR and Odds ratio (OR) were found to be very similar for all outcomes.</LI>
<LI>Demographic characteristics: Type of health-care setting, city, country, total number of women included, and inclusion and exclusion criteria. Information on funding for the study and potential conflicts of interest were extracted if reported.</LI>
<LI>Trials were excluded if there were unexplained imbalances for loss to follow-up in numbers between the comparison groups.</LI>
<LI>Trials were searched for, regardless of their language.</LI>
<LI>When there was more than one time period reported for an outcome (e.g., pregnancy after 6 months, 1 year) the longest follow-up data were extracted. The rest of the data are discussed in the text if warranted.</LI>
<LI>For cycle-related side effects, stratification according to the dose of oestrogen used was performed when possible.</LI>
</UL>
<P>
<BR/>Definitions:<BR/>Low-dose OC is referred to the EE content of &lt;50 µg.<BR/>Regarding cycle disturbances: definitions are used as they have been given by the individual authors of the trials.</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>